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ABSTRACT 
The canine gastrointestinal tract (GIT) is home to a complex ecosystem known as the 
microbiome. The microbiota (i.e., bacteria, viruses, fungi, and protozoa) are metabolically active, 
augmenting host digestion and thereby influencing the host, depending on both community 
composition and metabolic function. The upper GIT is physiologically different from the lower 
GIT, but feces are still frequently used as a representative sample due to the ease and non-
invasiveness of collection. Previous studies in dogs as well as in humans have shown metabolic 
and microbiota changes in feces associated with various disease states. Our study aims were to 
characterize the microbiome at different sites of the canine gastrointestinal tract using sequencing 
and metabolomics; identify potential biomarkers in feces of dogs with chronic enteropathy (CE) 
by comparing their fecal composition with that in healthy dogs using sequencing and 
metabolomics; develop and analytically validate a quantitative assay for potential biomarkers; and 
use this assay to investigate altered concentrations associated with various gastrointestinal diseases 
in dogs at a single time point and over time. 
Characterization of the contents of the duodenum, ileum, colon, and rectum revealed 
shifting compositions of both the microbiota and the metabolome. Major microbiota differences 
included distally increasing Firmicutes and decreasing Proteobacteria, while the differences in the 
metabolome largely reflected absorptive processes (e.g., decreasing concentrations of amino acids 
as these are absorbed by the host). In feces of dogs with CE, relative amounts of phytosterols were 
decreased and abundances of some fatty acids were altered. Thus a quantitative assay for fecal 
sterols and fatty acids (“FASter”) was developed, analytically validated, and used to analyze 
samples from dogs diagnosed with CE, acute hemorrhagic diarrhea syndrome (AHDS), or 
exocrine pancreatic insufficiency (EPI). FASter profiles differed among the different groups of 
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dogs. The FASter profile of dogs with AHDS rapidly shifted towards that of healthy dogs, while 
in CE the profile exhibited little change over time.  
Additional studies are warranted to continue to elucidate the role of lipid metabolism in 
canine gastrointestinal diseases, and determine whether fecal metabolite profiles can be of 
diagnostic use or even lead to a novel therapeutic approach.  
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ABC ATP-binding cassette 
AHDS acute hemorrhagic diarrhea syndrome 
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CD Crohn’s disease 
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MS mass spectrometry 
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NPC1L1 Niemann-Pick C1-like 1 protein 
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PCA principal component analysis 
PCoA principal coordinates analysis 
PICRUSt phylogenetic investigation of communities by reconstruction of 
unobserved states 
PLE protein-losing enteropathy 
PLS-DA partial least squares discriminant analysis 
PPAR peroxisome proliferator-activated receptor 
PUFA poly-unsaturated fatty acid 
QIIME quantitative insights into microbial ecology 
RFA random forest analysis 
RT retention time 
RXR retinoid X receptor 
SCFA short chain fatty acid (approx. <8 carbons) 




TCA tricarboxylic acid cycle 
TIC total ion current 
TLI trypsin-like immunoreactivity 
TOF time-of-flight 
UC ulcerative colitis 
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1.1 BRIEF OVERVIEW OF CANINE GASTROINTESTINAL PHYSIOLOGY 
Gastrointestinal physiology varies significantly among mammals. Ruminants, for 
example, efficiently harvest nutrition by cultivating an ecosystem in their forestomach. The 
microbiota breaks down nondigestible plant fiber (e.g., cellulose), releasing absorbable nutrients 
and biosynthesizing digestible protein as part of their own survival, which can subsequently be 
absorbed by the host organism downstream in the GI tract. In contract to ruminants, other 
herbivores, such as the mouse, rabbit, and horse, are hind-gut fermenters. While they have a simple 
stomach, their cecum performs somewhat analogous functions as the rumen in the ruminant: the 
cecum is home to a diverse population of microbiota and nutrients are released from plant fiber 
that otherwise would not be accessible to the host. Rabbits in particular are known to practice 
coprophagia to absorb certain essential vitamins and nutrients that are generated by the microbiota 
in the hind gut, but require a second pass for more efficient extraction. The world of veterinary 
medicine exposes researchers to many blueprints for life, but dogs bear particular similarity to 
humans. Both species are omnivores, and although both lack the “fermentation vat” of ruminants, 
the presence of microbiota in the colon permits digestion of cellulose and concomitant release of 
nutrients. 
Due to the general similarities between humans and dogs, in many cases what is known 
about human physiology is extrapolated to canine physiology. However, veterinary researchers 
must also be open to differences existing even between these seemingly similar biological systems. 
Publicly-available databases such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(Kanehisa and Goto 2000) are utilized for interpretation of results, providing a contextual 
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framework of the interrelationships of metabolites and enzymes for example. While the 
interweaving networks of biochemical pathways represented by human metabolism are generally 
similar to other mammals, including the dog, it is worth noting that some biochemical relationships 
between compounds are governed by species-specific metabolic processes. For example, xylitol, 
a sugar substitute, is considered safe for people, but may cause a fatal release of insulin in dogs 
and subsequent hypoglycemia and/or liver failure. Where possible, information known to be 
applicable to the dog is presented, but the limited availability of canine-specific information must 
be kept in mind. 
Our understanding of the function of the GI tract is continuously evolving. Most obviously 
the GIT serves as the site of nutrient assimilation necessary for life. The process begins with oral 
intake of food, which is mechanically broken down through mastication and in some species, 
mixing with salivary amylase (not present in the dog). In the stomach, chewed food is mixed with 
gastric juice, rich in hydrochloric acid, and is then called chyme. The acidity of chyme is 
neutralized upon entry into the duodenum, where it mixes with pancreatic juice, rich in bicarbonate 
and digestive enzymes, as well as bile from the gall bladder. Importantly, bile is composed 
primarily of bile salts, fatty acids, cholesterol, and phospholipids (Kristiansen et al. 2007). The 
orchestration of lipase secretion from the pancreas and bile from the gall bladder is critical for the 
emulsification of dietary lipids and lipid-soluble compounds (e.g., fat-soluble vitamins) for 
absorption in the intestinal tract. The amphipathic bile salts form mixed micelles with cholesterol, 
triacylglycerides (TAGs, also known as triglycerides), and other lipids, which overcomes the 
hydrophobicity of the lipids and permits pancreatic lipase to hydrolyze TAGs to 
monoacylglycerides and free fatty acids, which are amphipathic and thus can be absorbed by the 
epithelial cells of the intestine. Once inside the enterocyte, free fatty acids and monoacylglycerides 
re-esterify to form TAGs. In addition to lipase, pancreatic enzymes also include proteases (e.g., 
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trypsin and chymotrypsin) and amylase to break down proteins and carbohydrates. Another 
important enzyme, enteropeptidase (also known as enterokinase) is produced by the 
enterochromaffin cells of the duodenum rather than the pancreas and serves to activate pancreatic 
trypsinogen to trypsin (Light and Janska 1989). Although enteropeptidase is a brush-border 
enzyme, the action of bile salts facilitates its dispersal into the intestinal lumen (Lentze et al. 1982). 
Throughout the small intestine, the mucosal surface has microscopic finger-like 
projections known as villi. The villi greatly increase the surface area, increasing opportunity for 
absorption of nutrients. Each villus also contains a lacteal, or lymphatic capillary. The TAGs 
formed by re-esterification inside enterocytes are combined with phospholipids, esterified 
cholesterol, and apolipoproteins to form chylomicrons (Kindel et al. 2010). They may also contain 
fat-soluble vitamins A, D, E, and K. The chylomicrons are secreted through the basolateral 
membrane into the lacteal, where they flow as a component of lymph to the thoracic duct and enter 
the bloodstream at the level of the subclavian artery. Since lipids are inherently hydrophobic, this 
is a critical mechanism for transporting this important group of compounds through the aqueous 
bloodstream. In contrast to proteins and complex carbohydrates, lipids can enter the bloodstream 
via lacteals without first going through the portal vein and the liver. 
The small intestine is also the site of absorption of amino acids, carbohydrates, and some 
vitamins. The last segment of the small intestine, the ileum, has some unique absorptive functions, 
particularly with regard to bile acids. After serving their function in forming micelles with dietary 
lipids within the intestinal lumen, bile acids are liberated when those lipids are absorbed by the 
enterocytes. The synthesis of bile acids de novo from cholesterol in the liver is metabolically 
expensive, so the ileum contains active transporters for recovery of bile acids from the lumen and 
only a small proportion of the bile acid pool fails to be recovered (Hofmann 1999). Resorbed bile 
acids are transported to the liver via portal circulation, eventually returning to the gall bladder for 
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re-secretion with bile. This process is known as enterohepatic circulation. Importantly, the bile 
acids that are not recovered are a means for elimination of cholesterol, since cholesterol is 
consumed in the synthesis of bile acids. Due to this relationship between bile acids and cholesterol, 
it is not surprising that bile acids play a role in regulation of cholesterol biosynthesis and overall 
whole-body cholesterol homeostasis (Vlahcevic et al. 1991). However, bile acid metabolism is a 
very active and complex field of study in its own right, and much is outside the scope of this 
current work. 
The metabolic function of the large intestine was somewhat underappreciated until fairly 
recently, when the microbial inhabitants were found to be associated with health and disease. The 
importance of the GI microbiota and the metabolites they produce is discussed at greater length in 
the next section, but it is worth mentioning that some consider the microbiome to be an organ that 
possesses its own physiology and pathology (Baquero and Nombela 2012). As mentioned, in the 
dog, the colon is the primary site of microbial action within the GI tract. Thus, as part of digestion 
and nutrient assimilation, the colon is expected to be the site of absorption of metabolites and 
nutrients that are released by microbial fermentation or other enzymatic action. The small 
proportion of bile acids that escape recovery in the terminal ileum are largely deconjugated and 
dehydroxylated by the microbiota, which enhances passive uptake by colonocytes. Fiber, or 
cellulose, is a dietary component that remains largely unchanged as it traverses the upper GIT, but 
is important for colonic health. Cellulose is the major component of plant cell walls and is made 
up of glucose monomers with 1,4-β-acetal linkages. An enzyme capable of breaking that chemical 
bond is generally unknown in the animal kingdom, so metabolic action by the microbiota is 
required to release nutrients from these molecules. Through microbial fermentation of 
carbohydrates (Topping and Clifton 2001) and amino acids to some extent (Smith and Macfarlane 
1996), short chain fatty acids (SCFAs) are released, which are the main source of energy for 
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colonocytes. SCFAs were also recently shown to influence transport and metabolism of phenolics 
by Caco-2 cells (Van Rymenant et al. 2017), suggesting that production of one group of 
metabolites may influence the host’s ability to utilize other metabolites. Beyond our incomplete 
understanding of the effects of the colonic microbiota, it is known that the colon also provides the 
function of water and electrolyte extraction from the digesta, with the remaining material passing 
into the rectum for storage until defecation.  
Another perhaps less obvious function of the GIT is as the interface between the external 
environment and the immune system. While the importance of the gastrointestinal tract as an 
immune organ cannot be overstated, and it is already established that some metabolites in the GIT 
have anti-inflammatory activity (Aldini et al. 2014; Miquel et al. 2015), the vast majority of 
immunologic mechanisms pertaining to the GI tract will not be discussed in detail herein. 
While gastrointestinal physiology overall is far more complex than can be fully described 
here, and research to enhance our understanding is ongoing, this overview aims to provide a basic 
framework for interpretation of the research presented within this dissertation.  
1.2 THE CANINE GASTROINTESTINAL MICROBIOTA 
The intestinal microbiota is comprised of bacteria, fungi, protozoa, and viruses living 
within the gastrointestinal tract. The coevolution of the gut microbiota with mammalian host 
species has resulted in an intimate commensal relationship and codependence to maintain 
homeostasis. The limits of influence that the microbiota exerts on the host have not yet been fully 
determined. Prior to the development of DNA sequencing methods and bioinformatics, exploration 
of the gastrointestinal microbiota was limited by cultivation techniques, which neglected many of 
the inhabitants and likely failed to accurately mirror metabolic behavior in vivo. DNA-based 
techniques do not require the ability to sustain the life of a given species in order to detect it, so 
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characterization of the composition of the intestinal microbiota has improved with the emergence 
of high throughput sequencing platforms. Unfortunately, these techniques applied to the bacterial 
16S rRNA gene continue to neglect non-bacterial inhabitants and like any method are not without 
inherent bias, but 16S rRNA gene sequencing seems to be the most popular method for 
characterizing the microbiota, even if it is not comprehensive. Fungal inhabitants have been 
characterized in the dog using fecal samples and 18S rRNA sequencing (Foster et al. 2013). 
Suchodolski et al. (2008) used clonal libraries to show that the composition of the microbiota 
varies at different sites within the canine GIT, yet the vast majority of studies available have used 
fecal samples as a representative surrogate for the entire GIT.  
At the taxonomic level of phylum, the composition of the fecal microbiota of humans and 
dogs exhibit similarities, with the predominant phyla being Firmicutes, Bacteroidetes, 
Proteobacteria, Fusobacteria, and Actinobacteria (Honneffer et al. 2014; Hooda et al. 2012; 
Jandhyala et al. 2015; Swanson et al. 2011; Handl et al. 2011). While the physiological function 
of the microbiota was touched upon in Section 1.1, the importance of the microbiota in maintaining 
health is most profoundly demonstrated by the plethora of literature comparing the microbiota of 
diseased patients to that of healthy controls. In dogs, several studies have shown significant 
changes associated with both acute and chronic gastrointestinal disease (Suchodolski et al. 2012a; 
Vazquez-Baeza et al. 2016; Wilke et al. 2012; Suchodolski et al. 2010; Suchodolski et al. 2012b; 
Honneffer et al. 2015). In humans, changes in the microbiota have also been associated with a 
wide range of extra-GI diseases: arthritis (Costello et al. 2015), autism (Rosenfeld 2015), 
cardiovascular disease (Z. Wang et al. 2011), and renal disease (Ramezani and Raj 2014) as well 
as potentially demonstrating behavioral influence in experimental animal models (Collins et al. 
2013; Cryan and Dinan 2012). In the vein of the GIT as an immune organ, the role of the gut 
microbiota in immune-mediated inflammatory diseases was also recently reviewed (Forbes et al. 
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2016). In spite of these associations, in many cases, a direct causal relationship has not been 
established and work is ongoing to understand the relationship between disease and changes in the 
microbiota, or dysbiosis. There are some situations where the evidence is strong that the 
microbiota plays a role in the pathogenesis of some diseases. For example, adherent-invasive 
Escherichia coli (AIEC) play a major role in the pathology of granulomatous colitis (also called 
histiocytic ulcerative colitis, HUC) of Boxer dogs, where elimination of AIEC correlated strongly 
with clinical remission of disease (Mansfield et al. 2009). Other well-known enteropathogens 
include Campylobacter jejuni and Salmonella (S. L. Marks et al. 2011). Furthermore, while 
Clostridium perfringens has been shown to inhabit the GIT of healthy dogs (Minamoto et al. 2014), 
recent work has shown a strong association between the presence of a specific genotype of C. 
perfringens (containing a pore forming cytotoxin gene called netF) and cases of necrotizing 
enterocolitis of foals as well as acute hemorrhagic diarrhea syndrome (AHDS, formerly 
hemorrhagic gastroenteritis, HGE) in dogs (Gohari et al. 2015; Unterer et al. 2014). Specific canine 
gastrointestinal diseases, including AHDS, will be discussed further in Section 1.3. 
Whether or not a causal relationship is established between the microbiota and 
pathogenesis of disease, there would be much to understand about where, why, and how the 
presence (or absence) of microbial species causes disease, and how we might eventually leverage 
our understanding in order to improve diagnostics and therapeutics for our patients. This requires 
moving beyond identification of which microbial species are present, instead considering what 
metabolic consequences they have. One of the key reasons for this is the functional redundancy of 
the microbiota. For example, the ability to ferment carbohydrates or amino acids and release 
SCFAs as described above may not be ubiquitous among GI bacteria, but several genera within 
Clostridia possess this ability in their functional repertoire (Macfarlane and Macfarlane 1997), 
allowing a change in composition without necessarily concomitant change in function. The 
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converse is also true: many bacteria can change their substrate utilization depending on what is 
available, resulting in a change in function without any change in microbial composition. A model 
has been developed for the mechanism by which E. coli can accomplish this regulation of 
metabolism based on metabolic fluxes (Kotte et al. 2010). However, if the biochemical milieu of 
a microbial ecosystem were analyzed for all of the metabolites present, perhaps a snapshot of the 
net effect of the community’s functional capacity could be determined. In Section 1.4, the field of 
metabolomics is described, which aims to capture the biochemical composition of a sample. 
1.3 GASTROINTESTINAL DISEASES IN DOGS 
Clinical signs commonly associated with gastrointestinal disease, such as vomiting, 
diarrhea, or weight loss, are nonspecific due to the wide variety of conditions that can cause these 
complaints. Gastrointestinal diseases are often further characterized by considering the time course 
of illness (acute or chronic), success of response to various treatments (i.e., antibiotic 
responsiveness, food responsiveness), as well as by quantification of biomarkers or other 
diagnostics that may or may not be pathognomonic for a disease. 
Chronic enteropathy (CE), acute hemorrhagic diarrhea syndrome (AHDS), and exocrine 
pancreatic insufficiency (EPI) are three very different diseases that affect the GIT and typically 
present with clinical signs of gastrointestinal disease. Although CE and EPI may occur 
concurrently, EPI can be excluded by a serum trypsin-like immunoreactivity (TLI) concentration 
within the reference interval. A serum cTLI concentration < 2.5 μg/L is highly suggestive of EPI, 
but concurrent CE is far more difficult to rule out. The clinical presentation of AHDS is very 
distinct due to the peracute time course and accompanying clinical signs.  
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1.3.1 Chronic enteropathy 
A discussion of chronic enteropathy cannot occur without a clarification of terminology 
in order to prevent misunderstandings due to inconsistencies in disease definitions. For dogs with 
chronic (duration > 3 weeks) gastrointestinal signs, it is largely agreed that some combination of 
genetic predisposition, environmental factors (potentially including diet), and the GI microbiota 
lead to aberrant immune function, but a precise terminology for this disease has not been 
established. Dandrieux (2016) summarized that using the term “inflammatory bowel disease”, 
which is already used in human medicine to encompass Crohn’s disease (CD) and ulcerative colitis 
(UC), may be disadvantageous because of important differences between the management of the 
disease in humans and dogs. Examples of these profound differences between dogs and humans 
include the routine use of biologics (e.g., humanized antibodies directed against tumor necrosis 
factor) and the frequent necessity of surgical therapy in humans with IBD, compared to a fairly 
high rate of success with dietary management alone in dogs. In fact, the term IBD at face value 
suggests a prominent inflammatory component, and in many cases, dogs with chronic GI signs do 
not undergo biopsy to confirm an inflammatory infiltration and rule out other potential non-
inflammatory causes. Furthermore, the clinical signs associated with disease are indicative of 
aberrant function, but the presence of inflammation is not necessarily a prerequisite to the 
pathophysiology. 
To address cases where chronicity of GI disease has been established, but inflammation 
can only be presumed due to a lack of histopathological assessment, the more general term 
“chronic enteropathy” is favored. Literally implying a gastrointestinal problem that has persisted 
beyond an acute issue, this term could be criticized as extremely broad. Fortunately, there seems 
to be agreement that a diagnosis of “chronic enteropathy” implies exclusion of other diseases that 
have more specific criteria, and nuances of the clinical signs as well as available diagnostic tests 
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may easily exclude other causes of vomiting and diarrhea. Dandrieux further describes the 
retrospective assignment of dogs with CE to different subgroups based on their response to 
treatment. Dogs with food responsive enteropathy (FRE) are recognized following improvement 
of clinical signs during a dietary intervention trial, often an exclusion diet, a hydrolyzed protein 
diet, or a novel protein diet. Unfortunately, scientific evidence is inconclusive regarding which 
diet would be most beneficial for a given patient, and failure to improve on one diet may not 
definitively rule out the possibility that a different diet would have been associated with a different 
outcome. Nonetheless, it is presumed that either approach (i.e., use of a hydrolyzed or novel 
protein) will decrease or eliminate the antigenic effect of the diet, thus assuaging the assumed pro-
inflammatory feedback loop that perpetuates CE, and improvement is often seen over a matter of 
days. Of the dogs with CE that do not improve with a faithfully executed dietary trial, endoscopy 
is generally recommended to confirm the presence of and characterize the inflammation and rule 
out other causes of chronic GI signs, such as GI lymphoma.  
Medical management of CE in dogs that do not respond adequately to diet alone often 
proceeds with an antibiotic trial, using metronidazole, or more frequently, tylosin. Recent studies 
have demonstrated a profound effect of antibiotic therapy on the composition of the microbiota as 
well as the biochemical environment (metabolome) within the GIT when metronidazole was 
administered to healthy dogs for two weeks (Suchodolski et al. 2016). It is unclear exactly how 
this or other antibiotics are improving the clinical signs of some dogs with CE, but dogs that have 
an apparent dependence on antibiotics to control clinical signs are classified as having antibiotic-
responsive enteropathy (ARE). Importantly, these dogs typically relapse when the antibiotic is 
discontinued. This is distinct from infectious causes of chronic diarrhea, including granulomatous 
colitis of Boxers mentioned in Section 1.2, wherein clinical improvement correlated with clearance 
of an enteropathogen, such as AIEC. 
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Finally, dogs with CE that have failed to respond to diet and antibiotic treatment, or relapse 
in spite of ongoing treatment, are generally treated with immunomodulatory drugs. These dogs 
arguably are most similar to the human form of IBD, and in fact some clinicians reserve the term 
“IBD” for these dogs that have failed dietary and antibiotic trials. Some of these dogs are non-
responders and continue to do poorly in spite of increasing doses of immunosuppressants, but the 
review by Dandrieux (2016) cites success rates ranging from 25-100% with variable treatments 
and duration of follow-up. 
Another important subgroup of CE is protein-losing enteropathy (PLE). This subset of 
patients is defined by the presence of hypoalbuminemia in addition to CE, without evidence of 
non-GI causes of protein loss. Because of the severity and rapid progression of this disease in 
many patients, these dogs are often treated aggressively with a multi-modal approach, so if they 
improve, categorizing them as FRE, ARE, or IRE is often impossible. 
Regardless of the subcategorization of CE, there are two published scoring systems in use 
for grading severity of disease, the canine IBD activity index (CIBDAI) (Jergens et al. 2003), and 
the canine chronic enteropathy clinical activity index (CCECAI) (Allenspach et al. 2007). Jergens 
et al. (2003) found a strong correlation between improved histology, CIBDAI score improvement, 
and decreased serum measurements of C-reactive protein (CRP) after medical therapy. Allenspach 
et al. (2007) suggested that the clinical importance of the CCECAI is the use of 
hypocobalaminemia and hypoalbuminemia as negative prognostic indicators. While both scoring 
systems may have utility to the clinician making treatment decisions and assessing response to 
therapy, these parameters do little to inform the researcher about the pathogenesis of the disease, 
and new diagnostic panels and indices are needed to better elucidate the biological changes that 
occur during disease. 
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Among those biological changes thought to be relevant to disease progression, the term 
“dysbiosis” invariably arises in discussions of CE and chronic GI disease. Dysbiosis can be defined 
as an abnormal change in the composition of the microbiota. Because folate and cobalamin are 
absorbed by the proximal and distal small intestine, respectively, and bacteria in the gut may 
produce folate and consume cobalamin, serum measurements of these B vitamins are sometimes 
used to assess small intestinal health status. Decreased serum levels could be due to mucosal 
damage of the small intestine, hindering absorption. However, an abnormal microbial composition 
could also result in increased luminal production of folate and consumption of cobalamin. 
Although serum concentrations of folate and cobalamin are used to guide treatment to an extent, 
it appears likely that basing a diagnosis of dysbiosis solely on measurement of these two 
parameters in serum would involve unwarranted assumptions in many cases. Recently, a 
quantitative polymerase chain reaction (qPCR) panel has been developed to use a few key taxa of 
the fecal microbiota to establish a dysbiosis index (AlShawaqfeh et al. 2016). The dysbiosis index 
(DI) was trained using fecal DNA from 43 healthy dogs and 64 dogs with CE and validated with 
an additional 242 healthy dogs and 108 diseased dogs. Thus the DI may be particularly useful for 
assessing the shift in the microbiota that occurs most commonly with CE, but it may under- or 
over-estimate the degree of microbial dysbiosis in diseases with shifts in microbial populations 
other than those included in the panel. However, if the bacterial groups in the panel are core 
components of a healthy canine gut microbiota, the interconnectedness of the entire gut ecosystem 
would suggest that some shift in the DI should be detected. The clinical utility of the DI in guiding 
treatment decisions has not yet been determined. Unfortunately, the DI may also be heavily 
swayed by a recent history of antimicrobial use. While this gives credence to the idea that an upset 
microbial composition (known to occur with antibiotic usage) results in an increased DI, it also 
means that dogs with CE who have received antibiotics recently are not good candidates for a 
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meaningful assessment of dysbiosis. An additional condition known to increase DI is exocrine 
pancreatic insufficiency (EPI) (Isaiah et al. 2017). This disease is discussed in greater detail in 
Section 1.3.3. 
1.3.2 Acute hemorrhagic diarrhea syndrome 
Acute hemorrhagic diarrhea syndrome (AHDS) is a severe, sudden-onset syndrome 
affecting the canine gastrointestinal tract, and is characterized by vomiting and bloody diarrhea, 
but is also often associated with lethargy, anorexia, and abdominal pain. This syndrome was 
previously known as hemorrhagic gastroenteritis (HGE), but recent work has revealed that the 
stomach is not involved (Unterer et al. 2014), and the more appropriately descriptive AHDS 
terminology is now preferred. The etiology of AHDS is unknown, though there is a strong 
suspicion for a role of a strain of Clostridium perfringens, either as a causative agent or as a 
frequent opportunist secondary to the disease, since it was detected much more frequently in 
diseased dogs than control dogs (Suchodolski et al. 2012b). However, this is complicated by the 
prevalence of C. perfringens among healthy dogs (Minamoto et al. 2014) and the fact that samples 
are collected after the onset of diarrhea, so proof of induction of disease is difficult. Furthermore 
the enterotoxin cpe, proposed as the relevant agent for diarrhea in dogs, may also be present in 
healthy dogs (Silva and Lobato 2015; S. L. Marks et al. 2011), and the clinical course of infection 
may vary from self-limiting to fatal. In short, the presence or absence of enterotoxins does not 
appear to be a relevant factor in choosing therapy or determining prognosis of the disease (Busch 
et al. 2015). 
The histopathological changes associated with AHDS suggest that the initial insult 
invokes a massive peracute increase in intestinal permeability with acute mucosal hemorrhagic 
necrosis, subsequent extravasation of fluid, plasma proteins, and red blood cells into the intestinal 
lumen. For an excellent article summarizing the clinical course of a large cohort (n=108) of dogs 
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with AHDS, the reader is referred to a recent paper by Mortier et al. (2015). In regards to the 
intestinal microbiome, the potential prevalence of bacteremia and a corresponding necessity for 
antibiotic therapy was recently studied (Unterer et al. 2015), and it was ultimately determined that 
bacteremia based on blood culture was equivocal between patients with AHDS and control dogs. 
While this does not mean that dogs with sepsis should not be treated with antibiotics, it does 
suggest that antibiotics are not an appropriate prophylactic treatment in dogs with AHDS. This is 
largely based on the fact that animals with positive blood cultures and those with negative blood 
cultures were equivocal in terms of outcome and clinical parameters, so bacteremia (in the absence 
of signs of sepsis) does not necessarily suggest any benefit of antibiotic therapy, and in fact, 
considering the previously described disturbance to the microbiome induced by antibiotic therapy, 
their injudicious use may be detrimental to the patients. 
One additional aspect regarding AHDS is that patients typically recover very quickly, 
often only with supportive care. Although not yet confirmed, this may suggest that the 
physiological responses to such a severe mucosal insult in a normal dog may be intact, and perhaps 
this is distinct from a dog with chronic enteropathy, who may have an underlying genetic 
predisposition. On the other hand, the fact that a given animal develops AHDS may indicate some 
other predisposition or inciting factor that parallels, or mimics the process that is ongoing in 
chronic enteropathy. However, another possibility is that the comparison of histopathology is 
misleading, and the etiology of mucosal damage (and perhaps the sequelae in terms of the effect 
of the luminal contents) is completely dissimilar between AHDS and chronic enteropathies. Thus, 
comparison of the microbiome and metabolome may yield additional insight into these diseases. 
1.3.3 Exocrine pancreatic insufficiency 
In contrast to AHDS and CE, exocrine pancreatic insufficiency (EPI) is characterized by 
a functional defect rather than a clinical presentation or histopathological finding, and the 
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pathogenesis generally is better understood. The pancreas consists of both endocrine and exocrine 
functions. The endocrine pancreas is responsible for critical functions such as insulin production 
for regulation of body-wide glucose homeostasis. The exocrine pancreas is the primary source of 
digestive enzymes that are secreted into the GI tract for digestion of dietary components, as briefly 
described in Section 1.1. Exocrine pancreatic function is quantitatively assessed by measuring the 
serum concentration of trypsin-like immunoreactivity (TLI). During health, a small amount of 
trypsinogen and other enzymes and zymogens leak into the vascular space. The exocrine pancreas 
also synthesizes and secretes pancreatic lipase, an important enzyme for fat digestion and 
assimilation.  
Causes of EPI include pancreatic fibrosis, atrophy (most likely due to immune-mediated 
destruction), or much less frequently, hypoplasia. Clinical signs usually do not ensue until more 
than 90% of exocrine pancreatic function has been lost. Regardless of the cause of the decreased 
exocrine pancreatic tissue, the result is impaired secretion of pancreatic enzymes into the lumen, 
and subsequent maldigestion of dietary lipids, carbohydrates, and proteins by virtue of the 
decreased lipases, amylase, and proteases entering the proximal duodenum. Without adequate 
lipase being present, small dietary lipids may still be solubilized by bile acids, but lipid 
assimilation is greatly impaired, also affecting assimilation of lipid-soluble vitamins and essential 
fatty acids. The composition of the luminal digesta then is greatly altered from normal, which 
provides an abnormal substrate for the GI microbiota, and subsequent dysbiosis develops, adding 
to the dysfunction.  
Fortunately, although treatment is lifelong and the cost of exogenous enzymes may be a 
consideration for some owners, many dogs with EPI clinically respond well to enzyme 
replacement therapy. While all owners and clinicians would be happy to have resolution of clinical 
signs, it is not clear whether this corresponds to normalization of all metabolic disruptions caused 
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by the disease. Enzyme replacement therapy is expected to supply the enzymes to the lumen, but 
importantly, this will not change the serum TLI concentration. Thus, assessing efficacy of 
treatment is limited to resolution of clinical signs. It is possible that analysis of fecal metabolites 
may be helpful in assessing the extent of both dysbiosis and dysmetabolism that are part of the 
pathogenesis of EPI. 
1.4 METABOLOMICS 
Metabolites can loosely be defined as biochemicals that result from anabolic and catabolic 
processes within an organism. While this includes amino acids and even short peptides, it does not 
encompass large biomolecules such as proteins. A metabolomics approach, then, is an attempt to 
survey a sample broadly for the presence and abundance of metabolites. Urinalyses and serum 
chemistry panels could be considered targeted metabolomics panels – measuring the 
concentrations of compounds such as creatinine, glucose, cholesterol, and blood urea nitrogen. In 
the past two decades, a much broader approach has been utilized: untargeted metabolomics (Kell 
and Oliver 2016). In comparison to analysis for a specific set of metabolites, untargeted 
metabolomics aims to detect signals from compounds both known and unknown, and regardless 
of whether or not they are expected. This makes untargeted metabolomics an excellent approach 
for biomarker discovery, as it isn’t limited by what is currently known about a given phenotype or 
how a phenotype is expected to affect a biological sample.  
1.4.1 Untargeted metabolomics platforms 
The breadth and quality of coverage of a given sample type by untargeted metabolomics 
may depend on the platform(s) used, and each platform has limitations in the types and/or sizes of 
molecules it can detect. The two most common approaches for the characterization of the 
metabolome are nuclear magnetic resonance (NMR) analysis and mass spectrometry (MS). NMR 
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has the advantage of being non-destructive, so the sample can be recovered after analysis and used 
for additional testing. NMR also has the advantage of being quantitative; for example, every proton 
generates the same integrated peak area regardless of the molecule it is part of. MS, on the other 
hand, consumes the sample being analyzed, and the magnitude of signal does not correlate to the 
quantity of different compounds (but importantly does allow comparison of signal for the same 
compound across different samples). However, the sensitivity of MS greatly surpasses that of 
NMR, making it by far the more popular choice for metabolomics experiments and the only 
method that will be discussed here further. 
Mass spectrometry is a method of detection, and there are many different types of MS that 
can be used, as well as different front-end components. Quantifying any target out of a complex 
matrix requires both a way to separate the target from matrix and other interfering components, 
and a method to detect and quantify a signal specifically from the target. Chromatography is a 
term generally used to describe a process of separating a mixture into distinct components, usually 
by using a variety of chemical properties of the components to spend variable time periods in a 
stationary or mobile phase. For metabolomics, the two most common types of chromatography 
are liquid chromatography (LC) or gas chromatography (GC). Components that spend more time 
in the movement phase will move over a distance more quickly, while components that spend 
more time in the stationary phase will take longer to pass the same distance. The stationary phase 
in most types of chromatography is called a column, and the movement phase is a solvent (for 
liquid chromatography) or carrier gas (for gas chromatography). GC-MS-SIM is the abbreviation 
for gas chromatography-mass spectrometry-selected ion monitoring, and this technique will be 
described in greater detail to demonstrate the concepts of chromatography and detection that are 
critical to metabolomics. GC is a method to physically stratify the mixture, while MS serves as the 
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detection method. The sensitivity of detection is enhanced if the instrument is set only to quantitate 
ions relevant to the target, so SIM is an approach to limit the ions that are being monitored. 
Gas chromatography stratifies components of a mixture on the basis of volatility and 
interaction with the stationary phase of the capillary column versus the gas phase (typically helium 
flowing at a rate that allows interaction of the compounds with both the column and the gas). As 
a generalization, compounds that are smaller or more volatile spend more time in the gas phase of 
the column and thus are carried through more quickly, while larger, less volatile compounds spend 
more time interacting with the solid phase and move through more slowly, though the specific 
properties of the column used can affect the affinity of different compounds to the stationary phase. 
The entire column is housed within an oven, so after the sample is injected, the oven can be 
programmed to run a gradient. This can help increase separation of different compounds that come 
off early and speed the process of eluting slower compounds. With various parameters on the GC, 
the analyst can fairly well devise a protocol to separate different compounds from each other, with 
the caveat that certain differences (e.g., conformation differences of chemical isomers) are much 
more difficult to separate with simple gas chromatography. Also, large molecules may not become 
volatile enough to move appreciably in the gas phase, so larger/heavier compounds do not reach 
the detector. 
Liquid chromatography operates on the same principles as GC, but with an important 
difference that the solvent controlling the movement phase can be altered over time. This provides 
an additional dimension for separation of compounds since the relative affinity of the compounds 
to the column at the beginning of the run (e.g., when 100% solvent A is passing through) can be 
changed (e.g., by switching to 70% solvent A and 30% solvent B). The properties of the 
chromatography column can also be changed, yielding additional options such as reverse phase 
(RPLC) and hydrophilic interaction (HILIC). There are other advantages associated with LC such 
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as not requiring volatility as is required with GC, which often obviates the need to derivatize 
compounds prior to analysis. This process in the context of GC is described later. 
As the compounds separate from each other and reach the end of the column (theoretically 
in a series rather than mixed together), they flow into the mass spectrometer. For GC, 
perpendicular to the flow of the sample, there is an electron beam generated from a filament and 
these electrons impact the molecules, causing the vast majority to ionize and fragment. For LC, 
the desolvation of compounds as they enter the detector results in ionization, and a portion of the 
compound enters the detector without fragmentation. Knowing the molecular ion peak, or [M+], 
is one of the most useful pieces of information for identifying an unknown compound. With either 
GC or LC, some of the molecules will fragment. The fragmentation is not random; rather the nature 
of the chemical bonds within the molecule dictates which are most likely to break, and potentially 
subsequent rearrangement within the residual fragments. A single molecule may break in any 
number of ways, but across a population of molecules of the same compound, a characteristic 
pattern of fragments will be associated with a given compound. This fragmentation pattern is 
called the mass spectrum. These fragments, each of which has a certain mass-to-charge ratio (m/z), 
are referred to as daughter ions, then flow into the quadrupole, which is a series of magnets that 
together can filter certain m/z fragments. In scan mode, the quadrupole scans over the entire mass 
range (typically 50-600 m/z) very rapidly. Although no m/z fragments are specifically excluded, 
at any instant only one m/z is allowed through. As the fragments pass the filter they reach the 
detector, which utilizes an electron multiplier to generate a signal proportionate to the number of 
fragments hitting the detector. Coordination of the quadrupole with the detector allows rough 
quantification of every m/z in the scan range. The signal over time will trace a total ion current 
chromatogram (TIC), which represents the sum of all fragments that have reached the detector. 
The peaks on the chromatogram correspond to compounds moving through, and the time it takes 
 20 
 
to elute after injection is called the retention time (RT). If two compounds still co-elute, the mass 
spectrum at their RT will reflect the superimposition of the characteristic fragmentation patterns 
of both compounds. 
Because biological matrices can be complex, and several distinct compounds could have 
the same nominal mass and similar mass spectra, more advanced MS instruments use time-of-
flight (TOF) to gain much higher mass accuracy for the molecular ions and the fragments. It is 
expected that relatively few chemical formulas are consistent with a specific, extremely accurate 
mass determination, and by predicting the fragmentation structure of those compounds, a “best-
fit” decision can be made to assign the unknown to a specific metabolite. Another advanced 
approach, though utilized when targeting certain compounds, harnesses repeated MS filtering 
steps. These instruments, sometimes referred to as “triple quad” for having three quadrupoles 
rather than a single quadrupole, or “tandem MS” for the sequential MS steps, can be operated in 
different modes. As an example, they use the first quadrupole to fragment compounds, a second 
quadrupole to select only certain fragments emitting from the first quadrupole and further fragment 
them, and a third quadrupole to detect the subsequent fragments. For two co-eluting compounds, 
even if their initial fragmentation pattern is similar, it is likely that secondary fragmentation of one 
of the primary fragments can be used to distinguish the two compounds. An additional instrument 
type has combined the triple quad with TOF and is referred to as a Q-TOF. These instruments are 
capable of the highly sensitive tandem MS quantitation, but also access high mass accuracy 
analyses. Importantly, even with high mass accuracy or tandem MS methods, there is always a 
possibility of incorrect assignment of metabolite identity. Thus once untargeted metabolomics has 
potentially revealed some metabolites of interest, it is critical to validate the findings with authentic 
standards (if available). Finally, if it is desired to use the metabolite as a biomarker, a targeted, 
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quantitative method may be required so a reference interval can be established and individual 
samples can be compared to this reference interval.  
1.4.2 Targeted metabolomics and quantitation 
For untargeted metabolomics, the most ideal analysis may involve multiple platforms. 
Analyzing the same sample by LC-MS and GC-MS may enhance both the mass range that is 
accessible as well as the diversity of compounds that can be accurately detected. However, once 
there is a specific subset of molecules that are of interest, the focus becomes accurate and sensitive 
quantification of those specific compounds. Analysis for a specific subset of molecules is a type 
of targeted metabolomics. Since the targets are known, their fragmentation spectra can be 
characterized and the relationship between signal and quantity can be calibrated if a pure standard 
can be obtained. Additional techniques can then be employed to enhance detection of desired 
compounds. 
In highly complex matrices, complete chromatographic resolution of all compounds may 
be difficult to obtain. Once the fragmentation pattern of an isolated compound of interest is known, 
certain fragments can be chosen that are unique to the target compound and generate a strong 
signal. With access to a triple quad or Q-TOF instrument, the secondary fragmentation pattern 
associated with a primary fragment can also be characterized. However, subsequent descriptions 
will assume use of a single quadrupole instrument. The quadrupole is used to filter out ions except 
for those associated with the target compounds, or “selected ion monitoring” (SIM). Instead of 
scanning repeatedly over the entire possible mass range, the quadrupole only cycles through all 
the ions of interest. To further enhance sensitivity, the set of ions being monitored can be changed 
at different times after injection of the sample. These periods are referred to as “SIM windows” 
and as long as the target compounds elute during their designated SIM window, the relevant ions 
will be detected. Maintaining the SIM windows relative to elution time after cutting the column 
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requires “retention time locking” (RTLock). This involves a one-time calibration of the 
relationship between carrier gas pressure and retention time. From that equation, when the column 
length is changed, the pressure can be adjusted to maintain consistent RTs. 
When using SIM, selection of ions is extremely critical. For each compound of interest, a 
target ion must be selected. This is the ion that will be used to quantify the compound relative to 
a calibration curve. Additional ion(s) are selected as qualifying ions. Since the relative quantity of 
fragments in the mass spectrum from a compound are characteristic for that compound, the ratio 
of different fragments can be used to confirm the identity of the compound, particularly in 
conjunction with the characteristic retention time. Failure to match the expected ratio may indicate 
another compound co-eluting in the sample and quantitation may be incorrect. Proper mass 
assignment is also critical: while publications typically report the nominal mass of a fragment (e.g., 
a CH3 group has m/z = 15), the actual mass of the fragment is slightly greater. Of note is that this 
is distinct from the concept of “molar mass,” which takes into consideration the isotopic 
composition of a very large number of molecules. Interestingly, this is a manifestation of 
Einstein’s famous equation E=mc2 – meaning that the energy of these fragments results in a mass 
greater than simply the sum of protons and neutrons. As an example, typical fragments for sterols 
may be nominally 219 or 334, but the quadrupole selects for 219.3 and 334.4 (±0.2). An example 
of a TIC from a GC-MS-SIM analysis on a fecal sample is shown in Figure 1. 
A calibration curve and internal standard (ISTD) are used to transform the signal generated 
by a specific target ion into a concentration. The target ion for the ISTD and the target ion for an 
analyte of interest have a fundamental relationship in terms of relative response of the detector. 
Once the calibration is established to define that relationship in terms of a concentration, it is quite 
stable over time so recalibration only needs to be done infrequently (as needed, though the 
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Figure 1. Total ion current (TIC) chromatogram for a typical canine fecal sample. Inset shows 
individual ion currents for a subset of fragments associated with fatty acids. Compounds 
identified by letters (retention time in minutes) are a: palmitic acid (6.9); b: linoleic acid (7.6); 
c: α-linolenic acid (7.6); d: oleic acid (7.7); e: cis-vaccenic acid (7.7); f: stearic acid (7.8); 
g: gondoic acid (8.7); h: erucic acid (10.2); i: d4-cholestane (11.4); j: coprostanol (14.2); 
k: cholesterol (15.7); l: cholestanol (15.8); m: campesterol (18.0); n: stigmasterol (18.8); 
o: fucosterol (20.3); p: β-sitosterol (20.3); q: sitostanol (20.7). Obtained under parameters 
described in Section 6. 
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1.4.3 Metabolomics and feces 
Fecal matter represents the net result of diet, host GI function, and the metabolic effects 
of the microbiota. Given the relative ease and non-invasiveness of collection, using feces as a 
diagnostic sample holds great potential, while also presenting some significant challenges. First, 
it is critical to note that the composition of biochemicals within the gastrointestinal tract is the 
result of the collective metabolic activity of the microbiota as well as the host, and may be 
significantly shaped by dietary intake. For example, when comparing the fecal metabolite profile 
of dogs with chronic enteropathy to that of healthy control dogs as described in Section 5, a 
metabolite identified as famotidine was detected in a subset of diseased dogs. Frequently 
prescribed to dogs with gastrointestinal disease, this finding is not surprising, but it demonstrates 
that oral intake of metabolites (or their precursors) does in fact have an effect on the fecal 
metabolomic profile. This must always be considered a confounding variable when diet is not 
standardized, which is nearly always the case for clinical research where dietary choice is largely 
driven by patient and owner factors. To further complicate this facet of research, information 
pertaining to diet is often scarce in clinical work. Within an owner questionnaire, a query of the 
dietary history for their pet may result in answers such as “dry” or “dog food”. Although honest, 
it is unlikely that this level of detail will allow researchers to distinguish the effect of corn- versus 
soy-containing diets, nor have the data to consider whether concentrations of some metabolites are 
largely driven by the ingredients of the diet. This may become especially relevant with regard to 
questions being raised in the research community about the efficacy of novel-protein versus 
hydrolyzed protein diets.As a further demonstration of how the metabolomic composition of feces 
can be affected, measurements on material taken from the human colon has shown a relationship 
between the presence of starch and the bacterial propensity to ferment amino acids (Smith and 
Macfarlane 1996). Bacteria require a nitrogen source, and mucus, dietary protein, and enterocyte 
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turnover are all nitrogen sources for the gut microbiota. Using culture techniques where 
carbohydrate sources were excluded, Smith and Macfarlane (1996) showed a preference on the 
part of the fecal microbiota for peptides over free amino acids, with SCFAs and branched chain 
fatty acids (BCFAs) as the products. While SCFAs are usually considered to be the product of 
carbohydrate fermentation, it demonstrates the resourcefulness of the microbiota that SCFAs can 
also be produced from peptides and amino acids. In addition, these data demonstrated that adding 
fermentable carbohydrate altered the profile of SCFAs produced, and decreased net ammonia 
production (which suggests decreased bacterial amino acid degradation). This highlights the 
potential utility of using feces as a surrogate sample for the entire GI tract. Since the metabolomic 
composition of feces involves tremendously complex biochemical interrelationships, and the 
different locations within the GI tract carry out different metabolic reactions in physiologically 
normal organisms, it is very likely that an abnormal process at a proximal point of the GI tract will 
result in material of abnormal composition arriving at the next distal point, such that the net 
metabolic result in the feces very well may be an altered concentration of a given metabolite 
compared to that of healthy feces. Furthermore, comparing concentrations of multiple compounds 
simultaneously may better reveal the changes to the metabolic processes occurring, as the 
deviation from normal may be the combination of many small changes.  
1.4.4 Metabolomics and data analysis 
Untargeted metabolomics invariably produces large data sets, with many features 
(metabolites) detected in each biological sample. The number of features in a targeted 
metabolomics assay may vary greatly, but by definition is more than one feature. With multiple 
features to explore, multivariate analyses become a useful tool for data exploration. In subsequent 
sections, some of these methods are used, especially to help visualize complex data sets. One 
example is principal components analysis (PCA). A PCA plot is a way to easily see the spread of 
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data and check for outliers in the global profile. The composition of a sample in a data set is 
summarized in relation to all other samples – creating a spatial arrangement such that samples 
most similar to each other are in close proximity, while samples that are very dissimilar are far 
from each other. PCA is unsupervised – which means it does not take into consideration what 
group the sample belongs to (e.g., healthy versus diseased), rather the pattern of separation must 
be found purely by the data themselves. This also requires that the within-group variation is 
sufficiently less than between-group variation (Worley and Powers 2013). Therefore, if one plots 
a two-group data set with PCA and the two groups are completely distinct, the combined features 
of the data set successfully distinguish the two groups. On the other hand, where there is overlap 
between the two groups, it would suggest that there is still enough variability that the features in 
the data set are not adequate to completely distinguish sample groups. 
In comparison, partial least squares projections to latent structures (PLS-DA) produces 
similar-looking plots, but the algorithm begins with the classification into groups as assigned by 
the data set, which makes this a supervised method. The algorithm can further be queried to 
determine which of the features in the data set are most important to establishing the separation, 
or the variable importance in projection (VIP) score. 
Random forest analysis (RFA) is another form of multivariate analysis. This method uses 
the different features in the data set in a random way to classify and determines the error in 
classification. Repeating this over many permutations (bootstrapping), certain features will 
eventually be observed as having a greater impact on the accuracy of classification. Therefore, this 
method also produces a ranking of the importance of the features, defined by the mean decrease 
in accuracy. Since PLS-DA and RFA both aim to rank the importance of features in the data set, 
but have very distinct algorithms to achieve this, comparing the results of the two methods can 
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provide greater support for features that are ranked as highly important using both methods rather 
than only one of the two methods. 
An interesting feature of multivariate analyses is that different data sets associated with 
the same samples can be combined. This method is utilized in Section 2, where the 16S rRNA 
sequencing data were combined with the metabolomics data from samples along the canine GIT 
to search for correlations between microbial composition and metabolites. However, multivariate 
analyses are particularly sensitive to the scale of data. In other words, the most abundant (highest 
concentration) compounds or sequences will inherently carry more weight than low abundance 
compounds or sequences. Since the biological relevance of a compound does not correlate with 
abundance, it is very important to scale the features in a data set before performing multivariate 
analyses. This is always a necessary step, but becomes especially important when combining 
metabolomics data (which may have values into the millions associated with a given compound) 
with sequencing data (where an OTU table may show proportions of sequences, by definition < 
1). For a more complete description of these methods and their application using the online 
software MetaboAnalyst, the reader is referred to an excellent recent tutorial by Xia and Wishart 
(2016). 
1.5 FATTY ACIDS 
The group of compounds known as fatty acids is tremendously diverse, representing a 
variety of chemicals and physiologically relevant compounds. Chemically, fatty acids are defined 
by some as “compounds synthesized in nature via condensation of malonyl coenzyme A units by 
a fatty acid synthase complex” (Christie 2013). More loosely, fatty acids can be described as a 
carboxylic acid with an aliphatic chain. In many cases, they are grouped with sterols and some 
other groups of hydrophobic compounds and simply called “lipids”, but for the purpose of this 
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work, a much smaller subset of these compounds will be explored, but first their context within 
the realm of lipids should be mentioned.  
Among the simplest lipids are triacylglycerols (TAGs), also known in nutrition and 
medicine by the older term triglycerides. TAGs consist of a glycerol backbone, with a fatty acid 
esterified to each of the three hydroxyl groups. The specific fatty acid at each position of glycerol 
can vary in terms of length (number of carbons), units of unsaturation, and type of unsaturated 
bonds (cis or trans). TAGs were mentioned previously in terms of dietary intake and absorption 
of lipids, where lipase is required to hydrolyze them in the GI lumen for absorption by enterocytes 
and subsequent reassembly and packaging into chylomicrons for transport within the 
cardiovascular system. TAGs functionally are primarily considered an energy source, including 
storage in cells, but their component fatty acids are multifunctional. 
Similar in structure to TAGs are the phospholipids. These molecules also usually have a 
glycerol backbone, and two of the three hydroxyl groups of the glycerol are esterified to fatty 
acids: typically a saturated fatty acid at carbon 1 (C1) and an unsaturated fatty acid at 2. The C3 
of glycerol, however, is bound to a phosphate group, which in turn can be bound to one of several 
small molecules such as choline, serine, or ethanolamine. The phosphate group is extremely 
hydrophilic compared to the fatty acid tails, creating the amphiphilic character of the phospholipid 
that permits self-assembly into micelles, liposomes, or bilayers, and ultimately provides for the 
general character of cell membranes. When the phosphate group is modified, additional chemical 
properties become accessible (such as the emulsifying ability of lecithin, which is primarily 
phosphatidylcholine but can be a mix of phospholipids). Another important and structurally similar 
group is the sphingolipids. In these molecules, a sphingosine backbone plays a role similar to the 
glycerol backbone of the previously described glycerophospholipids, providing sites for a fatty 
acid and phosphate group to bond. Again, the identity of the specific fatty acid residue has 
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important consequences for the final properties of the molecule. These compounds are very 
important in cell signaling pathways, and include ceramides, sphingomyelins, cerebrosides, and 
gangliosides, depending on the substituents on the sphingosine backbone. 
The genetic regulation of lipid metabolism is quite complicated. The regulation of de novo 
lipogenesis is thought to involve the liver X receptors (LXRα and LXRβ), which are ligand-
activated nuclear receptors that particularly respond to cholesterol and oxysterols (Calkin and 
Tontonoz 2012). Also critical in lipid homeostasis are peroxisome proliferator-activated receptors 
(PPARs), which are also nuclear receptors, and bind unsaturated fatty acids and other lipids 
(Kidani and Bensinger 2012). Both PPAR and LXR form a heterodimer with retinoid X receptor 
(RXR), requiring their endogenous ligand to bind at the same time as 9-cis-retinoic acid (or other 
RXR ligand) to activate transcription of target genes. This is mentioned because farnesoid X 
receptor (FXR), which is a receptor for bile acids, also forms a heterodimer with RXR, and also 
requires 9-cis-retinoic acid to bind RXR while bile acids are bound to the FXR ligand to activate 
transcription of FXR target genes. In a gene expression study, FXR (also known as NR1H4) was 
significantly downregulated, exhibiting a more than 2-fold decrease in expression in duodenal 
biopsies from dogs with chronic enteropathy relative to healthy control dogs (Wilke et al. 2012). 
Interestingly, in the same data set NR1H2 (which is LXRβ) was very slightly, but significantly, 
upregulated (1.17-fold change, q=0.007), and PPARγ, a specific member of the PPAR family with 
a wide range of effects, was significantly upregulated (4.02-fold change, q=0.001). The important 
take-home message from this is that metabolism of fatty acids, sterols, and bile acids do not occur 
independently, and collectively these metabolites interact with nuclear receptors that exert 
tremendous influence over host metabolism of lipids and carbohydrates, potentially playing a 
significant role in the pathogenesis of chronic enteropathy and/or IBD in dogs. 
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Returning to the diversity of fatty acids that can be components of phospholipids, 
sphingolipids, TAGs, or free fatty acids, a more basic understanding of the biosynthesis and 
modification of fatty acids is warranted. A descriptive schematic, adapted from the text Lipid 
Biochemistry (Gurr et al. 2002), is shown in Figure 2. 
Among some key features shown in Figure 2 is the fact that long-chain fatty acids are 
“built” from two-carbon units, and the LCFAs are an important branching point for subsequent 
conversion to unsaturated fatty acids via desaturases, and VLCFAs via elongases. In other words, 
palmitic and stearic acids (saturated fatty acids with carbon chain lengths of 16 and 18, 
respectively) may be considered the precursors for a tremendous library of fatty acids accessible 
through all the possible variations. Short chain fatty acids (SCFAs) are generally less than eight 
carbons in length, while medium chain fatty acids (MCFAs) are eight to fourteen carbons. LCFAs 
Figure 2. Schematic showing de novo biosynthesis and basic transformations leading to the 




are longer than fourteen carbons, with inconsistent distinction given to those longer than 18 
carbons as VLCFAs. It is important to note that these divisions are not entirely arbitrary; the 
chemical properties associated with different lengths of aliphatic chains have biological 
consequences. Units of unsaturation introduce three types of variability: the number of unsaturated 
bonds, their location(s), and their conformation (cis or trans). Regarding conformation, the 
important point is that a cis bond introduces a kink in the carbon chain, while a trans bond does 
not, and this has the effect of lowering the melting point by introduction of disorder – and in a 
phospholipid bilayer, the kinks help maintain membrane fluidity. The location of the unsaturated 
bonds is usually specified in relation to the terminal carbon of the aliphatic chain (the methyl 
group) rather than the carboxyl end, as this better conveys the chemical relationship between two 
fatty acids. For example, erucic acid and nervonic acid are 22 and 24 carbons in length, 
respectively, and both have one unit of unsaturation that is 9 carbons from the methyl end. Their 
shorthand notations are 22:1(n-9) and 24:1(n-9) respectively, and erucic acid is the precursor to 
nervonic acid, with the former undergoing an enzymatically driven elongation step (Bourre et al. 
1976). Arachidonic acid, consisting of a twenty-carbon chain with four units of unsaturation, has 
the notation 20:4(n-6). Arachidonic acid is a representative of an important classification of fatty 
acids, the polyunsaturated fatty acids (PUFAs), and is also a key player in the ongoing debate over 
the importance of the ratio of dietary omega-6 to omega-3 fatty acids (Simopoulos 2002) and 
subsequent formation of prostaglandins, thromboxanes, and prostacyclins. A wide range of PUFAs 
are accessible by modification of oleic acid – 18:1(n-9), linoleic acid – 18:2(n-6), and linolenic 
acid – 18:3(n-3). Fatty acids of the omega-9 series can be synthesized endogenously, while omega-
3 and -6 fatty acids start with dietary intake of linoleic and linolenic acids (also referred to as 
essential fatty acids, EFAs). The question may arise whether unsaturated fatty acids can be restored 
to saturated fatty acids, and it is worth mentioning that this enzymatic transformation is quite rare 
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in nature. However, there are ruminal microorganisms (e.g., Butyrivibrio fibrisolvens) that can 
hydrogenate PUFAs to stearic acid (Gurr et al. 2002). This accounts at least in part for the 
particularly high stearic acid content of beef and dairy fat. 
Just as important as biosynthesis of fatty acids is the degradation of fatty acids. As 
mentioned, dietary TAGs are largely considered a source of energy, but accessing the energy 
requires breaking of bonds. For a complete discussion of the underlying biochemistry, the reader 
is referred to the text Lipid Biochemistry (Gurr et al. 2002). In brief, there are three main forms of 
oxidation, creatively named α, β, and ω. While mitochondria have been historically credited as the 
“power house” of the eukaryotic cell, VLCFAs must first be oxidized to shorter fatty acid products 
in order to be accessible to mitochondrial β-oxidation, and this occurs in the peroxisome. Both 
organelles primarily utilize β-oxidation for fatty acid degradation, and β-oxidation is the most 
common pathway for fatty acid degradation in mammals. In β-oxidation, the carbon chain is 
cleaved two carbons at a time, releasing acetyl-CoA into the tricarboxylic acid (TCA) cycle. The 
rate of β-oxidation is affected by the availability of fatty acids and the accumulation of β-oxidation 
products. In contrast, α-oxidation occurs only in the peroxisome. This pathway is particularly 
important in plants, where branched fatty acids are common and structurally cannot undergo β-
oxidation, and also can be used to install additional hydroxyl groups on fatty acids. ω-Oxidation 
generates dicarboxylic acid products from saturated fatty acids, where the terminal methyl group 
is converted to a second carboxylic acid. Between the requirements of location within the cell and 
activities of multiple enzymes, these reactions are under many levels of control to maintain 
homeostasis. 
The main focus on fatty acids has been their utility for energy and as a component of larger 
molecules such as TAGs and phospholipids. Although the variability of the fatty acid composition 
of phospholipids has been mentioned in terms of affecting structural properties of the phospholipid 
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bilayer in cell membranes, there is a particularly interesting example of this related to the 
microbiota. Saito et al. (2014) showed that Enterococcus faecalis can incorporate exogenous fatty 
acids into their membrane from the growth medium, and in doing so, could withstand a wider 
range of known membrane stressors, including high concentrations of bile salts and the antibiotic 
daptomycin. Another facet of their research showed that the fatty acid composition of the 
membrane also changed from the exponential growth phase to the stationary phase, also observed 
in other Gram-positive bacteria. Therefore, the composition of fatty acids in the lumen of the GI 
tract in animals may have a direct connection to the physiology of the resident microbiota.  
Another physiological function of fatty acids not yet mentioned is related to detoxification 
in cases of excess cholesterol. Although cholesterol is a very important compound, as will be 
described in the next section, too much cholesterol presents a problem for cells, and the excess 
cholesterol must be excreted via the bile. The esters of cholesterol have less of an effect than free 
cholesterol, so fatty acids may be esterified to cholesterol to mitigate the effect of high cholesterol 
concentrations while the organism excretes the excess via bile or by conversion to bile acids. The 
esterification products, O-acyl-cholesterol, formed within intestinal cells via the enzyme acyl 
CoA:cholesterol acyltransferase, ACAT) can then be stored as neutral lipid. This again 
underscores the importance of fatty acids to sterols, and vice versa, when considering the overall 
metabolism and homeostasis of lipids. 
1.6 STEROLS 
Defined by their structure, sterols are a class of compounds with a characteristic four-ring 
backbone (conventionally identified from left to right, A-D), and a hydroxyl group on the A-ring. 
The four-ring backbone, also called sterane, is also characteristic of steroids and bile acids, but the 
hydroxyl group on carbon 3 identifies these as “steroid alcohols” or sterols. Sterols are found in 
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eukaryotic cells, although plants, animals, and fungi each are associated with a different 
predominant sterol: β-sitosterol, cholesterol, and ergosterol, respectively. In comparison, 
prokaryotes are associated with a structurally similar group of molecules, called hopanoids. 
Hopanoids have a five-ring backbone, and like sterols, are synthesized from squalene. Unlike 
sterols, the hydrophilic portion of hopanoids is at the equivalent of the alkyl chain on sterol C-17. 
However, synthesis of hopanoids is anaerobic, while sterol synthesis requires oxygen. This fact is 
often used to associate evolution of the first eukaryote life with the oxygenation of the atmosphere 
approximately 2.7 billion years ago. Example structures of these compounds are shown in Figure 
3, and the similarity of structure across these varying molecular classes is readily apparent. 
The fused ring structure common to all sterols may have one or more units of unsaturation, 
typically at carbon 5 or 7 (Δ5 or Δ7). The stereochemistry of the hydroxyl group at carbon three 
may distinguish between two sterols, such as cholesterol and epicholesterol. The alpha 
configuration projects backwards (axially, relative to the six-carbon ring) and the beta 
configuration projects forwards (equatorially). Similarly, the stereochemistry of the hydrogen on 
carbon five has a significant effect on the three-dimensional shape of the molecule overall, where 
cholestanol (5-alpha) is overall a flatter molecule than the isomer coprostanol (5-beta) since the 
inversion of the C5 stereocenter forces inversion of the six-carbon ring. A final characteristic of 
sterols is a variable alkyl chain attached to C17 on the D-ring. While the structural variations may 
seem small, they may result in significantly different physiological function.  
Physiologically, sterols play a critical role in cell structure, making up a large portion of 
the cell membrane and controlling fluidity and permeability of the membrane. Compared to a 
simple phospholipid bilayer, the presence of sterols makes the membrane more resilient to variable 
temperatures (Dufourc 2008). The effects of sterols on membrane characteristics has been studied 
using model membranes (Vist and Davis 1990). At low temperatures, a model phospholipid bilayer 
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forms a solid-ordered (so) phase, which is rigid and possesses a high degree of order. With 
increasing temperatures, the bilayer undergoes a phase transition and enters the liquid-disordered 
(ld) phase, which is analogous to ice melting to form water. The ld phase has very little structural 
integrity, corresponding to virtually unlimited permeability. Importantly, like other phase 
transitions, the so-ld transition was shown to occur at a specific temperature, meaning the 
membrane nearly instantaneously went from impermeable and rigid to completely permeable and 
flaccid at approximately 25°C. However, when model membranes were prepared with at least 20 
mol% cholesterol, a distinct phase was observed, the liquid-ordered (lo) phase. Not only did the 
Figure 3. Chemical structures of sterane and related molecules.  On sterane (top left), numbering 
of carbons and letters on rings identifies features used for all sterols. Cholesterol is representative 
of sterols; cholic acid is representative of bile acids; vitamin D3 is drawn to show its structural 
relationship to cholesterol as its precursor; cortisol and prednisone are endogenous and exogenous 





lo phase demonstrate the possibility of controlled permeability across the membrane, but the 
sudden transition between phases at a certain temperature no longer occurred: the cholesterol 
served to disrupt the tight packing of the phospholipids at low temperatures to create a liquid state 
rather than solid, and at high temperatures, the cholesterol provided increased stability and 
cohesion, maintaining order. Therefore, although the membrane characteristics still changed with 
increasing temperature, the degree of change was smaller and it occurred on a steady slope with 
variation of physiologically-relevant temperatures. Clearly this temperature tolerance for cell 
membranes is advantageous, even for animals that possess the ability to thermoregulate or move 
to find compatible temperatures. Combining the effect of cholesterol incorporation with the fatty 
acid composition of the phospholipid bilayer, the tunability of membrane dynamics for a cell is 
tremendously vast. One implication of this was explored by Mason et al. (2007), who showed that 
the sterol composition confers protection to cell membranes when challenged with antimicrobial 
peptides known to target membrane integrity. Interestingly, they also showed that ergosterol, the 
principal sterol of fungi, conferred less protection than cholesterol, but demonstrated an 
intermediate effect compared to membranes lacking sterols. 
Also in the cell membrane, cholesterol is a key component in “lipid rafts”, which are 
important for assembling cell signaling machinery on the cell surface (Lingwood and Simons 
2010). Cholesterol is the precursor to bioactive molecules such as vitamin D, hormones (including 
cortisol), and bile acids. Cholesterol is a constituent of all lipoproteins as a mechanism to get 
cholesterol to all tissues in the body, as described in Section 1.1. The liver synthesizes cholesterol 
de novo, but much of the body’s need for cholesterol is met by dietary intake and every cell is 
capable of synthesizing cholesterol, which arguably demonstrates that cholesterol is as important 
as glucose for cell survival. An interesting tissue variation is the brain, where the blood-brain 
 37 
 
barrier prevents importation of cholesterol via lipoproteins, so all cholesterol in the brain must be 
synthesized de novo. Fortunately, the turnover of cholesterol in this tissue is also very slow. 
In spite of the necessity of cholesterol for homeostasis, it is detrimental in excess. The 
primary method for elimination of cholesterol from the total body pool is via conversion to bile 
acids, which are subsequently excreted into the gastrointestinal tract. The toxicity of excess 
cholesterol can be mitigated by forming cholesteryl esters – typically phenolic acids or long chain 
fatty acids are enzymatically esterified at the sterol C3 hydroxyl group. Interestingly, Wilke et al. 
(2012) showed by microarray analysis that duodenal biopsies of dogs with IBD (relative to healthy 
dogs) exhibited a 1.6-fold increased expression of cholesterol 7-alpha-hydroxylase, which is the 
rate-limiting step of conversion of cholesterol to bile acids. This may suggest that a component of 
the pathogenesis of IBD includes aberration in cholesterol homeostasis and warrants further 
investigation. 
The physiology of cholesterol has been well studied, yet the relevance of other sterols to 
mammalian health is poorly understood, though an active area of research. Due to consumption of 
plant material, it can be assumed that phytosterols (plant-origin sterols) enter the gastrointestinal 
tract. The intestinal absorption of sterols is thought to occur via Niemann-Pick C1-like 1 protein 
(NPC1L1), and this enzyme does not exclusively absorb cholesterol (though may be less active 
towards phytosterols). Enterocytes subsequently use transporters ABCG5 and ABCG8 to export 
phytosterols back into the lumen, and mutations in these transporters in humans are associated 
with sitosterolemia due to the inability to eliminate sitosterol, the most common phytosterol. In a 
mouse model that lacks ABCG5 and ABCG8, blood and tissues accumulated sitosterol and 
campesterol. However, a triple-knock-out mouse model that additionally lacks NPC1L1 did not 
develop sitosterolemia, suggesting that NPC1L1 is responsible for absorption of phytosterols and 
the G5/G8 transporters are responsible for selectively expelling non-cholesterol sterols. Based on 
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experiments in mice, NPC1L1 expression is indirectly decreased by LXR activation, with a 
concurrent increase in G5 and G8 (Calkin and Tontonoz 2012). As mentioned previously, LXR 
activation is also tied to de novo biosynthesis of fatty acids. 
While the function of phytosterols in mammalian cells is unclear, there is evidence that 
phytosterols are not entirely inert. F. Xu et al. (2005) demonstrated that a mutant cell line with 
minimal ability to synthesize cholesterol incorporated phytosterols into the cells >90% after 60 
days in culture, but also that a small amount of cholesterol was required for continued growth, 
concluding that phytosterols can substitute for cholesterol as a structural component in the plasma 
membrane but cannot perform all necessary functions of cholesterol. Given that sterols play an 
important role in membrane stability, it is conceivable that this incorporation of noncholesterol 
sterols in the membrane may also impact membrane stability. Some evidence for this in vivo was 
demonstrated by showing that a phytosterol-supplemented diet resulted in decreased severity of 
disease in a murine model of colitis (Aldini et al. 2014). However, phytosterols are also appreciated 
as antioxidants, so the mechanism by which the phytosterols exerted the perceived preventative 
effect is uncertain. In serum, phytosterols may have more negative effects. In pediatric total 
parenteral nutrition where intravenous lipid emulsions derived from soy lecithin contain relatively 
high concentrations of phytosterols, a correlation to cholestatic liver disease was observed 
(Clayton et al. 1998). By comparison to intravenous lipid administered to adults, it was 
hypothesized that pediatric patients lacked sufficient phytosterol clearance capacity, ultimately 
affecting function of transporters and resulting in a cascade of dysfunction. Nonetheless, oral 
administration of phytosterols is still considered beneficial for people with hypercholesterolemia, 
even as adjunct treatment to statins, with the proposed mechanism being competitive interference 
of NPC1L1 activity towards cholesterol, thus simply decreasing gastrointestinal absorption (X. 
Lin et al. 2011). 
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The physiology of sterols in the context of the microbiota is also relevant, and introduces 
an interesting host species variation. In humans, the fate of a variable portion of unabsorbed 
cholesterol in the GI tract is microbial conversion to coprostanol, where the Δ5 bond of cholesterol 
is hydrogenated (Veiga et al. 2005). A specific strain of Bacteroides has been isolated from an 
individual human and has been shown to convert cholesterol to coprostanol in vitro, but the 
specific strain was not ubiquitous among other individuals known to have a large capacity for 
reducing cholesterol (Gerard et al. 2007). Other isolated cholesterol-reducing bacteria from non-
human animals have been from the genus Eubacterium (Gerard 2013). In comparison to humans, 
the dog is considered in general to be poor at converting cholesterol to coprostanol, to the extent 
that the sterol composition of fecal pollution in water can be sourced to different animals (Leeming 
et al. 1996). An interesting study by Antharam et al. (2016) used an integrative approach to 
combine targeted metabolomics with 16S rRNA sequencing data for fecal samples from humans 
with Clostridium difficile infection (n=7) versus healthy controls (n=6). Although their sample 
size was small and further subdivided by history of antibiotics usage, they did identify two OTUs 
with a significant negative correlation to coprostanol and 63 OTUs with a positive correlation. The 
majority of OTUs positively correlated with coprostanol concentration were taxonomically 
classified in the order Clostridiales, which has repeatedly been a bacterial group of interest in 
health and disease in both humans and dogs. A broader and more extensive computational search 
for relationships between the microbiota and lipid metabolism was performed by Fu et al. (2015), 
who showed that a model that takes the microbiota into consideration performed better than one 
that did not when examining risk factors for cardiovascular disease. Neither C. difficile nor 
atherosclerotic cardiovascular disease are as concerning for the canine patient population as for 
humans (a notable exception is a research colony of cholesterol-sensitive dogs, (Starr 2007)). 
However, this motif of gastrointestinal protection associated with the microbiota and a correlation 
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to lipid metabolism may exist among dogs as well. It is clear that the physiology of sterols is quite 
complicated, and that the role of cholesterol versus other sterols in the dog still requires much 
investigation.  
1.7 HYPOTHESES AND SPECIFIC OBJECTIVES 
Though not reviewed in this work, there are several potential biomarkers for IBD in dogs. 
The specific objectives of this study are not to replace those biomarkers, nor to use molecular 
techniques to distinguish between diseases that clinically are easily distinguished (i.e., AHDS, 
IBD, and EPI). As is often joked, clinicians do not need a test to determine whether a dog has 
diarrhea. Rather, in spite of many ongoing advances in our comprehension of gastrointestinal 
physiology in health and disease, we are still deficient in a complete understanding of the 
underlying biochemistry and etiopathophysiology of gastrointestinal diseases. If we attained that 
complete understanding, decisions of how to diagnose, treat, and track response to therapy would 
become much less controversial. Thus the objective of this study is to add to the general body of 
knowledge about canine gastrointestinal physiology in a broad and descriptive sense. 
The hypotheses of this project are that 
1. The canine gastrointestinal metabolome will be altered in gastrointestinal disease, and 
2. These differences in metabolites are associated with changes in the gastrointestinal 
microbiome. 
The specific aims of this study are: 
1. to characterize the healthy canine microbiota and metabolome at multiple sites along 
the gastrointestinal tract 
2. to employ untargeted metabolomics approaches on fecal samples to broadly explore 
potential alterations between dogs with chronic enteropathy and healthy control dogs, 
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using that information to identify metabolites that may elucidate gastrointestinal 
physiology and disease pathogenesis 
3. to develop and validate a quantitative assay for a subset of relevant metabolites  
4. to apply the assay to a broader range of samples from diseased dogs to facilitate 
additional hypothesis generation and eventually further our understanding of canine 





2. VARIATION OF THE MICROBIOTA AND METABOLOME ALONG THE 
HEALTHY CANINE GASTROINTESTINAL TRACT*
 
OVERVIEW 
The fecal microbiota is relevant to the health and disease of many species. The importance 
of the fecal metabolome has more recently been appreciated, but our knowledge of the microbiota 
and metabolome at other sites along the gastrointestinal tract remains deficient. Therefore, we 
aimed to analyze the gastrointestinal microbiota and metabolome of healthy domestic dogs at four 
anatomical sites. 
Samples of the duodenal, ileal, colonic, and rectal contents were collected from six adult 
dogs after humane euthanasia for an unrelated study. The microbiota was characterized using 
Illumina sequencing of 16S rRNA genes. The metabolome was characterized by mass 
spectrometry-based methods.  
Prevalent phyla throughout the samples were Proteobacteria, Firmicutes, Fusobacteria, 
and Bacteroidetes, consistent with previous findings in dogs and other species. A total of 530 
unique metabolites were detected; 199 of these were identified as previously named compounds, 
but 141 of them had at least one significantly different site-pair comparison. Noteworthy examples 
include relative concentrations of amino acids, which decreased from the small to large intestine; 
pyruvate, which peaked in the ileum; and several phenol-containing carboxylic acid compounds 
that increased in the large intestine.  
                                                     
 
* Reprinted with permission from “Variation of the microbiota and metabolome along the canine 
gastrointestinal tract” by Honneffer, J. B., Steiner, J. M., Lidbury, J. A., & Suchodolski, J. S., 2017. 
Metabolomics, 13, 26, Copyright 2017 Springer. 
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In conclusion, the microbiota and metabolome vary significantly at different sites along 
the canine gastrointestinal tract. 
2.1 INTRODUCTION 
Eukaryotes co-evolved with prokaryotes over millennia. It is not surprising that 
coevolution of the gut microbiota with mammalian host species has resulted in commensalism and 
codependence to maintain homeostasis. The importance of the microbiota has been documented 
in humans (Cho and Blaser 2012; Shreiner et al. 2015) and companion animals (Hooda et al. 2012; 
Suchodolski 2011; Kil and Swanson 2011), yet underlying mechanisms of interaction are poorly 
understood. Bacteria are known to communicate via compounds called auto-inducers (Papenfort 
and Bassler 2016). Ismail et al. (2016) showed that mammalian epithelial cells produce a 
compound that mimics a bacterial auto-inducer, suggesting bidirectional communication via 
metabolites and potential mechanisms that mediate the relationship between the microbiota and 
the host. Bacterial metabolic activities are also known to respond to changing availability of 
substrates. Therefore, when considering the gastrointestinal ecosystem, identifying microbiota 
present is part of characterization, but the biochemical environment – the metabolome – should 
also be considered. 
Investigations into the gastrointestinal metabolome are still relatively new (Saric et al. 
2008; Di Cagno et al. 2011; McHardy et al. 2013). This biochemical environment represents the 
core of symbiosis between host and microbiota: the host provides a nutrient-rich environment, and 
the microbiota performs functions and produce metabolites for the host that otherwise would be 
limited or inaccessible. These bacterial metabolites include short chain fatty acids, which provide 
nutrition for enterocytes (Macfarlane and Macfarlane 1997; Flint et al. 2012); vitamin K, 
cobalamin, folate, biotin, and thiamine (Hill 1997; LeBlanc et al. 2013); and enzymes to 
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dehydroxylate and deconjugate endogenous and exogenous metabolites (Winter and 
Bokkenheuser 1987). The complete repertoire of metabolic assistance provided by the microbiota 
is far from fully catalogued. Non-targeted metabolomics, which aims to characterize the chemical 
environment by broadly analyzing samples to identify molecules present, offers another key to 
describing the gastrointestinal tract (GIT).  
Human diseases are often studied through induction of the disease phenotype in a rodent 
model. However, the veterinary world offers opportunities to study spontaneously occurring 
diseases that sometimes parallel the disease in man – often both in phenotype and pathogenesis 
(Honneffer et al. 2014). This is particularly beneficial when the organ of interest is relatively 
inaccessible in vivo, as are some segments of the GIT. To broaden our understanding of 
mammalian gastrointestinal physiology, the goal of this study was to sample multiple sites along 
the canine GIT, confirm findings of previous microbiota studies with high throughput sequencing, 
and investigate the metabolome in conjunction with the microbiota at each site.  
2.2 MATERIALS AND METHODS 
2.2.1 Study population and sampling 
From a colony of apparently healthy adult hound-type dogs (mean age 3.5 years, range 1-
11 years), maintained on a commercial adult canine maintenance diet (24% protein, 20% fat), a 
random subset of six dogs (2 female, 4 male) were sampled. Subjects were fasted at least 8 hours 
before being humanely euthanized by intravenous injection of a pentobarbital sodium solution at 
the College of Veterinary Medicine (Texas A&M University, College Station, TX) in accordance 
with animal use protocol 2015-0164 for reasons unrelated to this study. Carcasses were held at 
room temperature for up to 3 hours after death while samples were collected. A ventral midline 
approach was used to access the GIT. At each site, the serosal surface was cut longitudinally to 
 45 
 
expose the contents, which were collected using disposable spatulae with as little disruption to the 
mucosa as possible while collecting material representative of the entire transverse section. 
Duodenal contents were collected aborally to the cranial flexure. The ileum was identified by 
presence of the antimesenteric artery. The colon was identified by location in situ and samples 
were taken from the transverse colon or proximal descending colon. Rectal samples were collected 
as caudally as possible from within the abdominal cavity. Aliquots of approximately 100 mg were 
collected and stored at -80°C. 
2.2.2 DNA extraction and sequencing 
Approximately 100 mg of each sample was used for DNA extraction according to the 
manufacturer’s protocol (PowerSoil®, Mo Bio, Carlsbad, CA, USA). Amplification and 
sequencing of the V4 variable region 16S rRNA gene was performed at MR DNA 
(www.mrdnalab.com, Shallowater, TX, USA). Briefly, samples were barcoded and PCR primers 
515F/806R were used in a 28-cycle PCR using the HotStarTaq Plus Master Mix Kit (Qiagen, 
USA) under the following conditions: 94°C for 3 minutes, followed by 28 cycles of 94°C for 30 
seconds, 53°C for 40 seconds, and 72°C for 1 minute, with final elongation at 72°C for 5 minutes. 
A DNA library was prepared according to the Illumina TruSeq DNA library preparation protocol. 
Sequencing was performed on a MiSeq (Illumina) following the manufacturer’s guidelines. 
Sequence data were uploaded into the NCBI GenBank database under submission number 
SRP086847.  
2.2.3 Analysis of sequences 
Quantitative Insights Into Microbial Ecology (QIIME, v. 1.8) was used for processing and 
analysis of sequences (Caporaso et al. 2010b). Raw sequence data were de-multiplexed, and low 
quality reads were filtered using default parameters. Chimeric sequences were detected using 
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USEARCH (Edgar 2010) and removed prior to further analysis. Sequences were assigned to 
operational taxonomic units (OTUs) using an open-reference picking protocol in QIIME against 
the Greengenes database (v. 13.8) filtered at ≥97% similarity (Caporaso et al. 2010a; DeSantis et 
al. 2006; Q. Wang et al. 2007).  
2.2.3.1 Diversity metrics 
Without filtering rare sequences, samples were rarefied to an even depth of 2,840 reads. 
Alpha rarefaction plots, coverage and alpha diversity metrics (Goods coverage, Chao1, Shannon, 
and Observed Species), and beta diversity (weighted and unweighted UniFrac distance matrices) 
were determined using QIIME scripts (Lozupone and Knight 2005). PRIMER 7 (PRIMER-E Ltd, 
Ivybridge, UK) was used to compare beta diversity between sites. Variation in community 
distributions was visualized with Principal Coordinates Analysis (PCoA) plots based on weighted 
and unweighted UniFrac distances (Vazquez-Baeza et al. 2013). PCoA was chosen for its aptness 
to representing the phylogenetic similarity distance matrix. 
2.2.3.2 Taxonomic summaries 
To simplify taxonomic summaries, OTUs present in three or fewer of the samples (to 
conservatively minimize OTUs that were not consistently represented in a given GI site) were 
filtered out of the original unrarefied OTU table. Samples were rarefied to an even depth of 1800 
reads per sample and QIIME was used to summarize taxa at all phylogenetic levels. Taxa present 
in at least four samples (again to minimize representation of rare taxa) were analyzed in JMP (SAS, 
Durham, NC, USA), treating each dog as a block and testing for significant differences with 
Kruskal-Wallis tests. P-values were adjusted using the Benjamini-Hochberg Step-up method, 
allowing a False Discovery Rate (FDR) of 0.05. A Dunn post-test was used to calculate corrected 
p-values for the six possible site-pair comparisons (duodenum to ileum, colon, or rectum; ileum 
to colon or rectum, and colon to rectum).  
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2.2.3.3 Predicted community functional potential 
The original OTU table was filtered against the Greengenes database (v. 13.5) to generate 
a closed-reference OTU table, then rarefied to an even depth of 2,600 reads per sample. The 
software PICRUSt (Phylogenetic Investigation of Communities through Reconstruction of 
Unobserved States) (Langille et al. 2013; Paradis et al. 2004) was used to generate a new OTU 
table comprised of predicted KEGG Orthologs (KOs; Kyoto Encyclopedia of Genes and 
Genomes) (Kanehisa and Goto 2000; Kanehisa et al. 2016). KOs were categorized into three 
hierarchical levels of KEGG pathway categories (L1, L2, and L3). The resultant tables were 
analyzed in JMP in the same method described for the taxonomic summaries. 
To explore individual KOs, the uncategorized OTU table was filtered to exclude KOs 
present in fewer than six of the samples prior to statistical analysis. This cutoff was chosen to 
conservatively minimize inclusion of KOs that were not represented in all six subjects. Kruskal-
Wallis tests and Benjamini-Hochberg corrections were applied to identify predicted KOs that were 
significantly altered between the gastrointestinal sites. These KOs were cross-referenced using the 
KEGG mapping tool (http://www.kegg.jp/kegg/tool/map_pathway1.html) to identify pathways 
with large numbers of significantly altered KOs for further manual investigation. 
Further analysis of individual KOs was driven by a large number of hits for a specific 
pathway, or exploration of specific themes (e.g., to view expression of specific KOs in the bile 
acid synthesis pathways) rather than comprehensive analysis across all KOs. Particular KOs of 
interest were analyzed in JMP with a Dunn post-test to identify the site and significance of 
alteration.  
2.2.4 Metabolomics data acquisition 
Fecal samples were stored at -80°C until shipped on dry ice for preparation and analysis 
by the West Coast Metabolomics Core (University of California, Davis, CA, USA) via gas 
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chromatography time-of-flight mass spectrometry (GC-TOF-MS) in accordance with published 
methods (Fiehn et al. 2008). Briefly, 10±0.3 mg sample underwent homogenization and extraction, 
followed by centrifugation. Dried supernatant was resuspended in methanol/chloroform and 
internal standards were added, followed by drying and derivatization by methoxyamine 
hydrochloride and N-methyl-N-trimethylsilyltrifluoroacetamide. A volume of 0.5 μL was injected 
in splitless mode onto a Restek rtx5Sil-MS column on a temperature-gradient programmed GC 
(oven 50°C to 330°C at 20°C/min, injector 50°C to 250°C at 12°C/sec) coupled with a Leco 
Pegasus IV mass spectrometer (scanning 70 spectra/sec from 80-500 Da, -70 eV ionization energy, 
1,800 V detector voltage) with helium carrier gas (1 mL/min). Raw data files were processed using 
ChromaTOF v. 2.32. BinBase algorithm matched spectra to database compounds, and 
quantification was reported by peak height of an ion at the specific retention index characteristic 
of the compound across all samples. Peak heights were normalized by average total peak-sums for 
identified compounds across each sample group. Metabolomics data were uploaded to 
metabolomicsworkbench.org (submission ST000495). 
2.2.5 Analysis of metabolites 
The peak height data table was filtered to exclude metabolites of unknown identity and 
uploaded to MetaboAnalyst 3.0 (Xia Lab, McGill University, Canada) (Xia et al. 2015). The data 
were log transformed and Pareto scaled before statistical analysis (Xia and Wishart 2011). JMP 
was used for univariate analysis as described previously. 
Multivariate analyses were performed within MetaboAnalyst and included principal 
components analysis (PCA), partial least squares-dimensional analysis (PLS-DA), and random 
forest analysis (RFA). Based on ranking of features by variable importance in projection (VIP) 
from PLS-DA, the top 50 features were used to generate a heatmap to visualize metabolomic 
variability. Cutoffs based on rank were chosen over a specific significance threshold since 
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different statistical approaches will yield different absolute scores of significance, but most of the 
top-ranked features are expected to be consistent. For a heatmap, 50 features subjectively provides 
the ability to visualize both the trends and variability of the features across samples. 
2.2.6 Inter-omics analysis 
The L5 (family-level) taxonomic summary was concatenated with the metabolite 
normalized peak intensity table. This was uploaded to MetaboAnalyst, log-transformed and 
Pareto-scaled, and the Pearson correlation matrix was calculated.  
Figure 4. PCoA plot representing beta diversity of microbial communities, based on unweighted 








2.3.1 Sequencing data 
2.3.1.1 Diversity metrics 
Unweighted UniFrac distances demonstrated significantly different beta diversity at all 
pairwise comparisons (p=0.002) except colon-rectum (p=0.86). Weighted UniFrac identified 
significantly different beta diversity between duodenum-colon (p=0.0 02), duodenum-rectum 
(p=0.002), ileum-colon (p=0.035), and ileum-rectum (p=0.006), but not between duodenum-ileum 
(p=0.31) or colon-rectum (p=0.75). A Principal Coordinates Analysis (PCoA) plot using PCs 1 
and 3 is shown in Figure 4, and a chao1 rarefaction curve is shown in Figure 5. Additional diversity 






Figure 5. Alpha rarefaction curves of intestinal sites as determined by chao1. 
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Duodenum Ileum Colon Rectum 
Median Range Median Range Median Range Median Range 
Chao1 271 a [175-313] 334 a [242-442] 461 b [424-573] 566 b [438-656] 
Observed OTUs 157 a [85-210] 145 a [100-238] 212 
 
[199-283] 280 b [232-309] 





Good’s coverage 0.97 a [0.97-0.98] 0.97 a,b [0.95-0.98] 0.96 b,c [0.95-0.96] 0.95 c [0.94-0.96] 





Figure 6. Coverage and alpha diversity plots.  These are a visual representation of the sequencing 
coverage and characteristic diversity of the different GI sites with increasing sequencing depth. 
The coverage quickly plateaus over 90%, suggesting adequate coverage of the OTUs present. The 
horizontal line approximated by the Shannon diversity index indicates that the depth of sequencing 
was adequate. However, the trajectories of the observed species rarefaction curves suggest that 




2.3.1.2 Taxonomic summary 
Predominant phyla sequenced from the four sites were Proteobacteria, Firmicutes, 
Fusobacteria, Bacteroidetes, and Actinobacteria. All except Fusobacteria demonstrated 
significantly altered abundances across the different sites after the Benjamini-Hochberg correction 
for multiple comparisons. However, only Actinobacteria and Proteobacteria reached a significance 
that persisted after the Dunn post-test identified which site-pair comparison was altered 
(ileum<rectum, q=0.02; and duodenum>rectum, q=0.03, respectively).  
Few significant differences were observed at taxonomic levels of class and order. Only 
the class Coriobacteriia exhibited a difference across sites (ileum<rectum, q=0.008), largely driven 
by Coriobacteriales, the only order showing a significant difference (ileum<rectum, q=0.008). 
Variation of the microbiota was more apparent at the family level. The proportion of 
Corynebacteriaceae was significantly greater in the duodenum relative to ileum, colon, and rectum 
(q=0.04, 0.03, and 0.02, respectively). The proportion of Coriobacteriaceae was also significantly 
altered (ileum<rectum, q=0.008). Bacteroidaceae increased from duodenum to rectum (q=0.02), 
Prevotellaceae increased from ileum to rectum (q=0.02), and Weeksellaceae was observed only in 
the duodenum (q=0.049). Lachnospiraceae, Ruminococcaceae, and a poorly defined family also 
within the order Clostridiales exhibited altered proportions, increasing at distal sites. Altered 
proportions displayed by families within Proteobacteria included Enterobacteriaceae 
(ileum>rectum, q=0.02), Helicobacteraceae (duodenum>colon, q=0.02), and Alcaligenaceae 
(duodenum<rectum, q=0.008).  
The median and range of the proportion of OTUs assigned to each taxon are provided in 








Duodenum Ileum Colon Rectum   
Taxon Median Range Median Range Median Range Median Range p-value q-value 
Phylum Actinobacteria 0.02083 
 
[0.00056-0.08444] 0.00083 a [0.00056-0.06] 0.00833 
 
[0.00222-0.10056] 0.01944 b [0.00444-0.09333] 0.023 0.043 








[0-0.05944] 0.108 0.144 








[0-0] 0.009 0.060 
Family Corynebacteriaceae 0.00639 a [0-0.08056] 0.00000 b [0-0.00944] 0.00000 b [0-0.00056] 0.00000 b [0-0] 0.007 0.044 
Corynebacterium 0.00639 a [0-0.08056] 0.00000 b [0-0.00944] 0.00000 b [0-0.00056] 0.00000 b [0-0] 0.007 0.035 








[0-0.05944] 0.447 0.498 

















[0-0.05944] 0.447 0.464 
Class Coriobacteriia 0.00167 
 
[0.00056-0.01833] 0.00028 a [0-0.00278] 0.00750 
 
[0.00111-0.05611] 0.01833 b [0.00444-0.03389] 0.002 0.022 
Order Coriobacteriales 0.00167 
 
[0.00056-0.01833] 0.00028 a [0-0.00278] 0.00750 
 
[0.00111-0.05611] 0.01833 b [0.00444-0.03389] 0.002 0.034 
Family Coriobacteriaceae 0.00167 
 
[0.00056-0.01833] 0.00028 a [0-0.00278] 0.00750 
 
[0.00111-0.05611] 0.01833 b [0.00444-0.03389] 0.002 0.031 
Collinsella 0.00167 
 
[0.00056-0.01833] 0.00028 a [0-0.00222] 0.00639 
 









[0-0.00278] 0.073 0.119 
   
 
   
 
   
 
   
 
   








[0.00278-0.25667] 0.034 0.043 








[0.00278-0.25667] 0.016 0.066 








[0.00278-0.25667] 0.016 0.062 


























[0-0.00444] 0.269 0.322 




[0-0.08444] 0.06750 b [0.00222-0.22833] 0.015 0.044 




[0-0.08444] 0.06750 b [0.00222-0.22833] 0.015 0.035 
Family Prevotellaceae 0.00056 
 
[0-0.01] 0.00000 a [0-0.00167] 0.00250 
 
[0-0.12278] 0.01583 b [0.00056-0.05833] 0.013 0.044 
Prevotella 0.00056 
 
[0-0.01] 0.00000 a [0-0.00167] 0.00250 
 
[0-0.12278] 0.01583 b [0.00056-0.05833] 0.013 0.035 

















[0-0.00167] 0.381 0.419 








[0-0] 0.013 0.066 








[0-0] 0.013 0.060 
Family [Weeksellaceae] 0.00111 a [0-0.06056] 0.00000 b [0-0] 0.00000 b [0-0] 0.00000 b [0-0] 0.013 0.044 
   
 
   
 
   
 
   
 





Table 2. (Continued.) 
 
 
Duodenum Ileum Colon Rectum   
Taxon Median Range Median Range Median Range Median Range p-value q-value 








[0.54056-0.86833] 0.028 0.043 








[0.04722-0.65667] 0.147 0.160 








[0-0.00056] 0.177 0.225 

















[0-0.00056] 0.209 0.267 








[0-0] 0.134 0.181 

















[0-0] 0.134 0.193 








[0.00111-0.32167] 0.498 0.498 

















[0-0.00056] 0.198 0.260 

















[0-0.01778] 0.169 0.231 

















[0.00056-0.32111] 0.256 0.313 

















[0-0.07] 0.254 0.313 








[0.04556-0.54056] 0.030 0.081 

















[0.04556-0.54056] 0.030 0.056 








[0.16944-0.565] 0.034 0.068 








[0.16944-0.565] 0.034 0.081 
f__ 0.00028 
 
[0-0.00444] 0.00000 a [0-0.00056] 0.00472 b [0.00278-0.00667] 0.00444 b [0.00167-0.005] 0.003 0.037 
g__ 0.00028 
 
[0-0.00444] 0.00000 a [0-0.00056] 0.00472 b [0.00278-0.00667] 0.00444 b [0.00167-0.005] 0.003 0.030 








[0.02333-0.18167] 0.095 0.153 
g__ 0.00111 a [0-0.00333] 0.00250 
 
[0-0.01111] 0.01333 b [0.00278-0.01889] 0.01389 b [0.00167-0.02111] 0.006 0.035 








[0-0.00056] 0.108 0.165 
Clostridium 0.00056 
 
[0-0.00167] 0.00056 a [0-0.00222] 0.00361 b [0.00167-0.00444] 0.00111 
 
[0-0.01111] 0.012 0.035 
SMB53 0.00056 a [0-0.00333] 0.00056 a [0-0.00222] 0.00972 b [0.00056-0.01389] 0.00528 
 
[0-0.00722] 0.011 0.035 
Other 0.02417 
 
[0.00222-0.07944] 0.01722 a [0.00111-0.05667] 0.13722 b [0.005-0.37278] 0.11333 
 





Table 2. (Continued.) 
 
 
Duodenum Ileum Colon Rectum   
Taxon Median Range Median Range Median Range Median Range p-value q-value 
Family Lachnospiraceae 0.01000 
 
[0.00111-0.11056] 0.00361 a [0.00167-0.00778] 0.12833 b [0.06278-0.21056] 0.11694 b [0.075-0.30333] 0.001 0.031 
g__ 0.00111 a,b [0-0.01] 0.00028 a [0-0.00167] 0.01278 b,c [0.00556-0.01833] 0.01444 c [0.00722-0.01833] 0.001 0.021 
[Ruminococcus] 0.00222 a [0-0.00556] 0.00083 a [0.00056-0.00111] 0.01361 b [0.00389-0.04833] 0.01667 b [0.01167-0.03167] 0.001 0.021 
Blautia 0.00333 
 
[0-0.04] 0.00056 a [0-0.00333] 0.05167 b [0.01833-0.12222] 0.06361 b [0.02611-0.17778] 0.002 0.021 
Coprococcus 0.00028 
 
[0-0.00056] 0.00000 a [0-0] 0.00111 b [0.00056-0.00444] 0.00194 b [0-0.005] 0.004 0.033 
Dorea 0.00278 
 
[0-0.05167] 0.00111 a [0-0.00222] 0.02250 b [0.01056-0.06722] 0.01139 
 
[0.00556-0.03944] 0.012 0.035 
Other 0.00056 
 
[0-0.00278] 0.00028 a [0-0.00111] 0.00389 b [0.00056-0.01722] 0.00417 
 
[0.00056-0.04333] 0.006 0.035 

















[0-0.03111] 0.022 0.045 


























[0.00056-0.00667] 0.069 0.118 
Family Ruminococcaceae 0.00056 
 
[0-0.00389] 0.00028 a [0-0.00056] 0.00000 
 
[0-0.01389] 0.01083 b [0.00167-0.06722] 0.014 0.044 
g__ 0.00000 
 
[0-0.00333] 0.00000 a [0-0.00056] 0.00000 
 
[0-0.00611] 0.00417 b [0.00056-0.01778] 0.025 0.050 
Faecalibacterium 0.00056 
 
[0-0.00056] 0.00000 a [0-0.00056] 0.00000 
 
[0-0.00722] 0.00639 b [0-0.04833] 0.015 0.035 


























[0-0.03889] 0.293 0.336 
Phascolarctobacterium 0.00139 a [0-0.00333] 0.00000 a [0-0.00667] 0.00250 
 


















[0.005-0.01556] 0.355 0.398 








[0.005-0.02389] 0.086 0.129 








[0.005-0.02389] 0.086 0.136 

















[0-0.005] 0.105 0.165 
[Eubacterium] 0.00000 
 
[0-0.00056] 0.00000 a [0-0.00056] 0.00111 b [0-0.00556] 0.00056 
 









[0.00111-0.01667] 0.172 0.231 
Catenibacterium 0.00000 a [0-0.00056] 0.00000 a [0-0.00056] 0.00361 b [0.00111-0.02333] 0.00528 
 





Table 2. (Continued.) 
 
 
Duodenum Ileum Colon Rectum   
Taxon Median Range Median Range Median Range Median Range p-value q-value 








[0.00889-0.32556] 0.478 0.478 








[0.00889-0.32556] 0.478 0.478 








[0.00889-0.32556] 0.478 0.498 

















[0.00722-0.31167] 0.282 0.329 
Other 0.00000 
 
[0-0.00222] 0.00000 a [0-0.00278] 0.00444 b [0-0.015] 0.00278 
 
[0-0.01389] 0.007 0.035 

















[0-0.00056] 0.022 0.045 
   
 
   
 
   
 
   
 
   




[0.00667-0.255] 0.04806 b [0.01278-0.12556] 0.007 0.033 








[0-0] 0.074 0.126 








[0-0] 0.074 0.127 

















[0-0] 0.074 0.119 








[0.00389-0.02611] 0.123 0.147 








[0.00389-0.02611] 0.262 0.311 




[0.00056-0.01444] 0.00917 b [0.00389-0.02611] 0.011 0.044 




[0.00056-0.01444] 0.00917 b [0.00389-0.02611] 0.011 0.035 








[0-0.00278] 0.034 0.068 








[0-0.00278] 0.034 0.081 

















[0-0.00056] 0.591 0.602 
Family Helicobacteraceae 0.00194 a [0.00056-0.93278] 0.00056 
 
[0-0.00111] 0.00000 b [0-0] 0.00028 
 
[0-0.00222] 0.011 0.044 
Helicobacter 0.00194 a [0.00056-0.93278] 0.00028 
 
[0-0.00111] 0.00000 b [0-0] 0.00028 
 
[0-0.00222] 0.010 0.035 








[0.00389-0.11667] 0.034 0.068 








[0.00056-0.11111] 0.099 0.145 








































Table 2. (Continued.) 
 Duodenum Ileum Colon Rectum   
Taxon Median Range Median Range Median Range Median Range p-value q-value 








[0.00056-0.06556] 0.011 0.060 
Family Enterobacteriaceae 0.11611 
 
[0.00778-0.85] 0.49778 a [0.00278-0.90722] 0.00583 
 
[0.00056-0.24667] 0.00361 b [0.00056-0.06556] 0.011 0.044 
g__ 0.10056 
 
[0.00667-0.79667] 0.43750 a [0.00278-0.82] 0.00472 
 









[0-0] 0.407 0.431 
Other 0.01556 
 
[0.00111-0.08611] 0.05944 a [0-0.11389] 0.00139 
 
[0-0.02778] 0.00056 b [0-0.00778] 0.018 0.040 








[0-0.00056] 0.039 0.082 

















[0-0.00056] 0.039 0.072 








[0-0] 0.074 0.127 








[0-0] 0.074 0.134 
         
     
     







2.3.1.3 PICRUSt analysis results 
At the L1 hierarchy, pathway categories Cellular Processes and Human Diseases were 
predicted to have differential metagenomic potential between sites (both q=0.015). Within Cellular 
Processes, the difference was largely driven by KOs categorized into pathways of Cell Motility 
(q=0.027). Within Human Diseases, significance was driven by categories of Cardiovascular 
Diseases, Infectious Diseases, and Neurodegenerative Diseases (all q=0.027). Other differences at 






































Figure 7. Taxonomic summary of bacterial orders by intestinal segment. Orders within Firmicutes 






There were 85 L3 pathway categories that reached significance. All significant categorized 
alterations of community functional potential at all hierarchical levels are presented in the 
Appendix, Table A-1. 
Among uncategorized KOs, 4,558 were present in at least six of the 24 samples. Of these, 
2,945 exhibited differential abundance in at least one pairwise comparison of sites. Only 1,428 
were mapped to existing KEGG pathway maps.  
Because the functional potential of the microbiota with regard to bile acid processing 
would depend on the gastrointestinal site, the KOs categorized into the L3 pathway categories 
Primary Bile Acid Biosynthesis (KEGG map00120) and Secondary Bile Acid Synthesis (KEGG 
map00121) were extracted from KEGG. These contained 18 and 8 KOs respectively. Cross-
referencing with individual KOs from PICRUSt output, K01796 and K01442 exhibited significant 
alterations (q=0.031 and 0.017, respectively).  
The data for these two KOs are shown in Table 3. K01442 is identified in KEGG as the 
enzyme choloylglycine hydrolase [EC:3.5.1.24] and is responsible for hydrolytic deconjugation 
of bile acids. K01796 is identified as orthologous to alpha-methylacyl-CoA racemase 
[EC:5.1.99.4], an enzyme responsible for inversion of the C25 stereocenter during synthesis of 
cholate and chenodeoxycholate from cholesterol. 
The pathway “Flagellar Assembly” (KEGG map02040) has obvious relevance to the 
gastrointestinal microbiota and was an altered L3 pathway (q=0.013). Querying KEGG revealed 
this pathway contains 37 KOs; all were present in the data set, and 34 were among those 
significantly different at sites in the GIT (Table 4). 
 60 
 
Table 3. Abundance of KOs associated with bile acid synthesis. P- and q-values <0.05 are shown in bold; superscripts identify which 
comparisons are statistically significantly different. 
KEGG Ortholog 
Duodenum Ileum Colon Rectum     
Median Range Median Range Median Range Median Range p-value q-value 
K01442 E3.5.1.24; choloylglycine hydrolase 182.5 a [26-307] 251.5 a,b [177-389] 465.5 b,c [365-923] 648.5 c [434-933] 0.001 0.017 




[0-6] 0.016 0.031 




Table 4. Abundance of KOs associated with the flagellar assembly pathway. P- and q-values <0.05 are shown in bold; superscripts identify 
which comparisons are statistically significantly different. 
KEGG Ortholog 
Duodenum Ileum Colon Rectum     
Median Range Median Range Median Range Median Range p-value q-value 
K02386 flgA; flagellar basal-body P-ring formation protein FlgA 420.5 a [105-1134] 307.5 
 
[4-456] 3.5 b [1-115] 1.5 b [0-33] 0.002 0.019 
K02387 flgB; flagellar basal-body rod protein FlgB 436 a [266-1149] 477 a,b [256-793] 143 b,c [40-266] 87.5 c [41-125] 0.001 0.017 
K02388 flgC; flagellar basal-body rod protein FlgC 444 a [271-1306] 485.5 a,b [257-796] 144 b,c [40-266] 88 c [41-125] 0.001 0.017 
K02389 flgD; flagellar basal-body rod modification protein FlgD 442.5 a [265-1149] 426 a,b [256-796] 143.5 b,c [36-265] 87 c [37-124] 0.001 0.017 
K02390 flgE; flagellar hook protein FlgE 440.5 a [258-2422] 435.5 
 
[204-621] 79.5 b [29-232] 68 b [33-83] 0.004 0.020 
K02391 flgF; flagellar basal-body rod protein FlgF 120.5 
 
[14-447] 309.5 a [3-464] 2 
 
[1-119] 1.5 b [0-35] 0.004 0.020 








[209-499] 0.106 0.136 
K02393 flgH; flagellar L-ring protein precursor FlgH 433.5 a [168-1135] 318 
 
[4-477] 43 b [5-139] 16 b [10-36] 0.002 0.017 
K02394 flgI; flagellar P-ring protein precursor FlgI 433.5 a [168-1140] 318 
 
[4-477] 43 b [5-139] 16 b [10-36] 0.002 0.017 




[176-289] 201.5 b [155-343] 0.008 0.023 
K02397 flgL; flagellar hook-associated protein 3 FlgL 438.5 a [204-1138] 431.5 a,b [203-620] 67.5 b,c [18-139] 43.5 c [14-63] 0.001 0.017 
K02398 flgM; negative regulator of flagellin synthesis FlgM 139.5 
 
[15-483] 413.5 a [202-636] 77 b [18-155] 47.5 b [13-69] 0.002 0.019 
K02399 flgN; flagella synthesis protein FlgN 106 
 
[10-444] 309.5 a [2-462] 2 b [1-119] 1.5 b [0-35] 0.005 0.020 
K02400 flhA; flagellar biosynthesis protein FlhA 474 a [266-1151] 536 a [256-815] 149.5 b [40-266] 89.5 b [41-126] 0.001 0.017 
K02401 flhB; flagellar biosynthetic protein FlhB 423 a [187-1097] 309.5 
 
[7-460] 69 b [23-155] 37.5 b [23-69] 0.002 0.018 
K02402 flhC; flagellar transcriptional activator FlhC 89 
 
[10-436] 305 a [2-453] 2 b [1-115] 1.5 b [0-33] 0.005 0.020 
K02403 flhD; flagellar transcriptional activator FlhD 89 
 




Table 4. (Continued.) 
KEGG Ortholog 
Duodenum Ileum Colon Rectum     
Median Range Median Range Median Range Median Range p-value  q-value 








[310-817] 0.409 0.440 
K02407 fliD; flagellar hook-associated protein 2 435.5 a [215-1139] 427 
 
[204-618] 175.5 b [131-257] 159 b [137-286] 0.004 0.020 
K02408 fliE; flagellar hook-basal body complex protein FliE 264.5 
 
[146-450] 476.5 a [256-793] 143 b [40-266] 87.5 b [41-125] 0.000 0.017 
K02409 fliF; flagellar M-ring protein FliF 436 a [265-1143] 476 a,b [256-792] 138 b,c [31-260] 81 c [36-119] 0.001 0.017 
K02410 fliG; flagellar motor switch protein FliG 436 a [266-1152] 477 a,b [256-793] 143 b,c [40-266] 87.5 c [41-125] 0.001 0.017 
K02411 fliH; flagellar assembly protein FliH 430.5 a [262-1139] 407 a,b [254-789] 122.5 b,c [28-251] 72.5 c [27-104] 0.000 0.017 
K02412 fliI; flagellum-specific ATP synthase 425.5 a [265-1148] 468 a,b [251-781] 127.5 b,c [37-258] 79 c [32-112] 0.001 0.017 
K02413 fliJ; flagellar FliJ protein 172.5 
 
[18-447] 408 a [248-789] 129 b [31-164] 70.5 b [29-111] 0.001 0.017 
K02414 fliK; flagellar hook-length control protein FliK 128 
 
[13-438] 354 a [199-602] 65.5 b [9-128] 30.5 b [7-61] 0.002 0.018 
K02416 fliM; flagellar motor switch protein FliM 430.5 a [266-1149] 477 a,b [256-785] 143 b,c [40-266] 87 c [41-125] 0.001 0.017 




[70-425] 180 b [60-262] 0.006 0.021 
K02418 fliOZ, fliO; flagellar protein FliO/FliZ 148 
 
[14-445] 416 a [202-614] 69.5 b [26-131] 48 b [21-69] 0.001 0.017 
K02419 fliP; flagellar biosynthetic protein FliP 436 a [266-1149] 477 a,b [256-793] 143 b,c [40-266] 87.5 c [41-125] 0.001 0.017 
K02420 fliQ; flagellar biosynthetic protein FliQ 431 a [266-1149] 470 a,b [255-789] 141 b,c [40-266] 84.5 c [41-125] 0.001 0.017 
K02421 fliR; flagellar biosynthetic protein FliR 423 a [187-1146] 309.5 
 
[7-460] 69.5 b [23-155] 37.5 b [24-69] 0.002 0.018 








[189-448] 0.036 0.055 
K02423 fliT; flagellar protein FliT 108 
 
[10-436] 305 a [2-453] 2 
 
[1-115] 1.5 b [0-33] 0.005 0.020 
K02556 motA; chemotaxis protein MotA 460 a [295-1220] 535.5 a [268-1037] 224 
 
[74-417] 172.5 b [57-251] 0.001 0.017 
K02557 motB; chemotaxis protein MotB 511.5 a [370-1318] 607.5 a [318-1058] 247.5 
 
[157-520] 249 b [84-312] 0.001 0.017 




[3-42] 0.018 0.033 
   






A total of 533 unique metabolites were identified in the samples. Of these, 334 exhibited 
spectra that did not match known entries and were subsequently excluded from analysis, while 
199 were matched to known compounds.  
2.3.2.1 Univariate analysis 
After correcting for multiple comparisons, 141 known metabolites were significantly 
different (q<0.05). The median peak heights and ranges for named metabolites are shown in Table 
5. 
2.3.2.2 Multivariate analysis 
With either PCA or PLS-DA methods, the biochemical composition of the duodenum and 
ileum were clearly distinct from each other and from that of the large intestinal sites; however, the 
metabolomic composition of colonic and rectal samples overlapped (Figure 8). 
Figure 8. PCA plot showing clustering and variation of the metabolome by location. Shading 












PC1 (43.7 %) 
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Table 5. Median peak height and range for each named metabolite. P and q values < 0.05 are shown in bold and are calculated from the 
transformed and scaled data. Different letters indicate statistically significant differences. 
Compound (BinBase name) 
Duodenum Ileum Colon Rectum   




































[111-1157] 0.0480 0.0658 
1-monostearin 3321.5 
 
[672-11437] 9300 a [6841-11992] 1044 b [442-2493] 584.5 b [218-3978] 0.0009 0.0030 
2,4-diaminobutyric acid 2514.5 a [1668-3162] 2099 a [1332-6593] 497 b [157-1261] 1226.5 
 
[275-2171] 0.0020 0.0051 
2,5-dihydroxypyrazine NIST 2725.5 a [441-10082] 310 b [162-1844] 294.5 b [67-467] 516.5 
 
[280-780] 0.0048 0.0104 




[101-212] 0.0006 0.0023 




[467-2932] 1356 b [163-2528] 0.0096 0.0174 
2-deoxytetronic acid 187 a [103-266] 146.5 a [69-1371] 551 
 
[133-996] 1158 b [415-3626] 0.0013 0.0040 
2-hydroxybutanoic acid 16664.5 
 
[9031-31150] 48357.5 a [8234-86137] 2647.5 b [1327-75320] 4267 
 
[2406-78540] 0.0088 0.0161 




[156-3312] 1062.5 b [793-4396] 0.0056 0.0115 
2-hydroxyhexanoic acid 72.5 a [56-195] 880.5 b [319-2790] 662.5 
 
[258-1524] 1786.5 b [272-7599] 0.0015 0.0042 
2-ketobutyric acid 13286.5 a [9973-15702] 13451 a,b [6187-14373] 1035 c,d [668-1358] 1033.5 b,d [735-1266] 0.0006 0.0023 








[571-1225] 0.0644 0.0817 




[78-86228] 16686 b [123-253166] 0.0049 0.0106 
3-(4-hydroxyphenyl)propionic acid 145.5 a [90-264] 171 a [89-1303] 6483 
 
[823-40448] 23939.5 b [3025-76364] 0.0003 0.0023 




[114-1982] 1029.5 b [412-1847] 0.0214 0.0328 




[53-816] 705.5 b [51-6343] 0.0180 0.0287 
3,6-anhydro-D-galactose 284.5 a [163-519] 810.5 b [395-5318] 1056 
 
[598-1847] 1175.5 b [777-2363] 0.0031 0.0072 








[931-55693] 0.5519 0.5811 
3-phenyllactic acid 53 a [22-140] 549 
 
[217-1264] 791 b [289-5010] 1753.5 b [551-15517] 0.0011 0.0035 








[451-21463] 0.0828 0.1030 




[428-4882] 2797.5 b [830-13501] 0.0026 0.0065 








[428-15397] 0.0600 0.0780 
4-hydroxyphenylacetic acid 46.5 a [23-86] 669.5 a,b [133-1699] 5591.5 b,c [1295-18626] 18122 c [11680-25549] 0.0001 0.0023 
5-aminovaleric acid 13059 a [2926-20179] 80418.5 
 









[73-537] 0.7674 0.7792 
5-methoxytryptamine 817.5 
 
[268-2879] 2518 a [1454-3766] 734.5 b [334-1542] 901 
 
[355-2318] 0.0105 0.0180 
6-deoxyglucose 996 a [529-18084] 1497 a [513-9179] 7981.5 
 
[1422-31447] 11444.5 b [6274-31511] 0.0071 0.0138 
7-methylguanine NIST 285.5 a [183-559] 355 
 













Table 5. (Continued.) 
Compound (BinBase name) 
Duodenum Ileum Colon Rectum   
Median Range Median Range Median Range Median Range p-value q-value 








[568-1859] 0.1264 0.1489 
alanine 4111125 a [3418094-4971035] 4005396 a,b [3199208-4698134] 298524 c [221832-462232] 364662 b,c [165935-602591] 0.0006 0.0023 




[6854-25667] 15866 b [3950-23329] 0.0189 0.0296 
allantoic acid 1369.5 
 
[376-1752] 2358 a [694-21843] 958 
 
[237-1891] 826.5 b [290-1078] 0.0165 0.0264 




[94-246] 0.0017 0.0045 
aminomalonate 28591.5 a [16837-42089] 9876.5 
 
[3553-35962] 673 b [248-1244] 709.5 b [93-1649] 0.0003 0.0023 








[222-3851] 0.0103 0.0178 
arachidonic acid 3896 a [1433-10136] 2835.5 a,b [490-107237] 343.5 a,c [148-2404] 210 c [108-2772] 0.0005 0.0023 
asparagine 172340.5 a [151905-319135] 46847 
 
[27761-207050] 7907.5 b [3009-11993] 10255.5 b [8045-12762] 0.0002 0.0023 
aspartic acid 1266340.5 a [1037877-1834455] 611972.5 a,b [169383-1794428] 26537 b,c [13263-64661] 13254.5 c [3749-42421] 0.0001 0.0023 




[48-443] 503.5 b [210-1053] 0.0078 0.0147 








[643-2377] 0.2053 0.2295 

















[790-12012] 0.1665 0.1904 




[68-430] 0.0324 0.0457 
beta-glycerolphosphate 1074 a [501-2770] 222 
 
[125-4064] 272.5 b [67-321] 267 
 
[194-348] 0.0202 0.0311 
beta-sitosterol 47.5 a [25-109] 259 
 
[87-637] 362 b [33-4655] 543 
 









[371-1675] 0.0871 0.1070 








[590-4508] 0.6685 0.6929 








[356-1217] 0.5821 0.6097 
caprylic acid 4499.5 a [1309-9324] 1678.5 
 
[1162-17249] 1342 b [410-3717] 1540.5 
 









[35-1018] 0.2007 0.2256 
cholesterol 1975.5 
 
[720-4294] 1651 a [1179-27408] 805.5 
 
[406-3273] 531.5 b [286-2869] 0.0037 0.0082 
citric acid 272 
 
[104-1479] 2079 a [903-11853] 148 b [49-607] 106 b [45-419] 0.0003 0.0023 
citrulline 18504.5 a,b [14239-24836] 18871 b [18127-23464] 1989 c [1313-9651] 2803 a,c [2128-7512] 0.0004 0.0023 
creatinine 103298.5 a [49704-195215] 23067.5 a,b [8256-205774] 2141.5 c [868-12850] 5036 b,c [1035-21389] 0.0006 0.0023 








[1298-15718] 0.0845 0.1045 
cysteine 224942.5 a [50059-459113] 41293.5 
 
[12193-75133] 4065.5 b [2723-9372] 4207 b [2192-9777] 0.0002 0.0023 
cysteine-glycine 2544 a [405-7118] 648 
 
[232-1959] 468 b [234-1158] 567 
 
[382-715] 0.0252 0.0372 
cystine 161825 a [88272-316694] 55098 
 
[25563-165395] 370.5 b [241-730] 377.5 b [235-681] 0.0003 0.0023 
cytidine 19997.5 a [9190-30522] 1319.5 
 
[351-6689] 219.5 b [101-864] 202 b [75-695] 0.0002 0.0023 
cytosine 12466 a [7952-33374] 2565 
 
[1282-6934] 695.5 b [352-1469] 606 b [410-1163] 0.0002 0.0023 
dehydroascorbic acid 28296.5 a [8389-45183] 8530.5 
 




Table 5. (Continued.) 
Compound (BinBase name) 
Duodenum Ileum Colon Rectum   
Median Range Median Range Median Range Median Range p-value q-value 
D-erythro-sphingosine 459.5 
 
[167-571] 737.5 a [312-2684] 192 b [94-1583] 213 b [137-339] 0.0081 0.0152 








[60-177] 0.0546 0.0719 
dihydroxyacetone 2507.5 a [945-7797] 561 
 
[504-7606] 841 b [320-1851] 1145 
 









[312-11471] 0.5074 0.5371 
ethanolamine 1992733 a [1148597-4029936] 647912 
 
[352641-3309640] 21534 b [6351-46816] 18174 b [10122-32607] 0.0004 0.0023 








[169-1812] 0.1020 0.1222 




[382-947] 0.0099 0.0176 
fucose 6346 a [3536-21041] 8979 
 
[933-104119] 48706.5 b [17241-234088] 25924.5 
 
[7635-43896] 0.0103 0.0178 
fumaric acid 15645.5 a [8822-39110] 10845.5 
 
[1590-96261] 1767.5 b [719-2953] 1604 b [1329-2177] 0.0010 0.0033 
galactinol 239 a [88-868] 1452 b [732-5552] 517.5 
 









[3037-24432] 0.1485 0.1718 




[67-6687] 302.5 b [163-352] 0.0056 0.0115 
glucoheptulose 208 a [78-452] 1534.5 b [322-3892] 249 
 
[104-583] 174.5 a [63-599] 0.0023 0.0060 
gluconic acid 304.5 a [189-778] 121.5 
 









[4547-40026] 0.0195 0.0303 
glucose-1-phosphate 1786.5 
 
[491-2991] 5004 a [2027-10521] 1305.5 b [259-1772] 880.5 b [506-2192] 0.0028 0.0068 
glutamic acid 1709486 a [1026840-2226949] 1794420 a,b [1514715-2259318] 117028 a,c [59336-491284] 99331 c [48763-441273] 0.0005 0.0023 
glutamine 211543 a [150014-978152] 171473 a,b [106889-455724] 3992.5 c [1658-50339] 6121.5 b,c [2561-41768] 0.0006 0.0023 
glutamyl-valine 2019 a [752-3049] 1913.5 a [185-8761] 304 
 
[97-1617] 223 b [82-310] 0.0010 0.0033 




[151-612] 902 b [123-1476] 0.0094 0.0171 








[1572-10006] 0.8511 0.8597 
glycerol 790358 a [335204-1175073] 266781.5 
 
[258859-3323888] 17329 b [9333-38553] 15393 b [10718-37086] 0.0005 0.0023 
glycerol-3-galactoside 2328.5 a,b [1046-4574] 3703 b [1866-11110] 699.5 c [264-935] 807 a,c [418-958] 0.0005 0.0023 
glycerol-alpha-phosphate 21013 a [10192-34413] 3392.5 
 
[987-57006] 2121 b [716-2966] 831.5 b [461-2073] 0.0009 0.0030 
glycine 930615 a [640214-1895054] 934944.5 a,b [661892-1777776] 19043.5 c [10515-33287] 24799.5 b,c [8896-58494] 0.0005 0.0023 




[3242-14855] 8381.5 b [4160-16002] 0.0061 0.0121 
glycyl tyrosine 2001 a [933-3209] 2777.5 a,b [801-5316] 515.5 a,c [380-1299] 321 c [126-949] 0.0007 0.0026 




[238-1141] 0.0037 0.0082 
guanine 229 a [133-297] 1590 b [647-2857] 861 b [545-1433] 606.5 
 
[403-873] 0.0004 0.0023 




[180-4696] 1564.5 b [86-4273] 0.0185 0.0292 




[1217-7012] 0.0028 0.0068 
hexitol 3458 
 
[1466-12244] 14338.5 a [6714-56112] 328 b [177-1717] 752 b [182-1139] 0.0003 0.0023 












Table 5. (Continued.) 
Compound (BinBase name) 
Duodenum Ileum Colon Rectum   
Median Range Median Range Median Range Median Range p-value q-value 
hexuronic acid 28037 a [3163-48933] 38113.5 a [14434-88434] 2835 
 
[356-28849] 386 b [342-2931] 0.0006 0.0023 









[139-1746] 0.1515 0.1743 
homoserine 248.5 a [109-349] 634 
 
[249-2120] 1187 b [394-8132] 1372 b [633-7995] 0.0014 0.0042 


























[1073-11674] 0.0416 0.0578 


















[57-283] 0.3122 0.3395 
isoleucine 1111779.5 a [801644-1841393] 2005640.5 a,b [651199-2179639] 88500.5 a,c [41500-162526] 66291.5 c [23537-127145] 0.0004 0.0023 








[297-1230] 0.8763 0.8808 




[24-644] 60 b [34-645] 0.0052 0.0110 




[54-1443] 169 b [58-260] 0.0065 0.0128 
leucine 2601243 a [889141-3265881] 3151465.5 a,b [1956352-4195069] 145389.5 a,c [72205-500255] 122537 c [48012-265958] 0.0003 0.0023 
levoglucosan 516 
 
[289-666] 1420 a [599-2761] 257 b [59-873] 479 
 
[139-1578] 0.0033 0.0075 
linoleic acid 1780.5 a [506-4231] 935.5 a [190-31061] 155.5 b [69-1160] 648 
 
[104-1141] 0.0059 0.0118 


















[1127-6938] 0.3449 0.3710 
maleimide 16299 a [10712-22560] 6799 
 
[1143-36119] 2681.5 b [1362-3495] 2340 b [1887-3740] 0.0055 0.0114 









[1738-7158] 0.0620 0.0801 






















[155-3944] 0.0525 0.0696 
methionine 452897.5 a [287428-824338] 402933.5 a,b [179735-452617] 14872.5 b,c [8732-27359] 13138 c [6987-21476] 0.0004 0.0023 
methionine sulfoxide 8268.5 
 
[4834-15240] 11720 a [6700-32470] 4177 b [2312-10378] 4981.5 b [2637-7333] 0.0085 0.0158 
methyl O-D-galactopyranoside 2413.5 a [1421-3351] 4468 
 
[1682-14430] 8643 b [2720-73587] 13001 b [3420-22998] 0.0024 0.0060 








[449-1230] 0.4494 0.4782 








[7604-24637] 0.0951 0.1147 








[235-2376] 0.0396 0.0555 
N-acetyl-D-galactosamine 3704.5 
 
[1583-10732] 3117 a [67-4188] 6296 b [3317-29693] 5145 
 




Table 5. (Continued.) 
Compound (BinBase name) 
Duodenum Ileum Colon Rectum   
Median Range Median Range Median Range Median Range p-value q-value 
N-acetyl-D-hexosamine 2957 a [796-5610] 914 
 


















[1847-8834] 0.0305 0.0436 
n-epsilon-trimethyllysine 1141 a [803-2166] 977 
 
[267-1613] 295.5 b [98-917] 298 b [206-723] 0.0031 0.0072 
nicotinamide 10850 a [4185-24701] 627.5 
 
[83-15106] 406 b [233-1568] 1402 
 
[347-2355] 0.0035 0.0078 
nicotinic acid 629.5 a [168-1755] 8385.5 b [5003-25499] 11928.5 b [3061-33017] 14785.5 b [3120-25906] 0.0046 0.0100 













[1110-36677] 0.0496 0.0667 
ornithine 312532 a [77883-491450] 264649.5 a [110411-555802] 9798 b [7208-50796] 19651 
 
[7067-29179] 0.0005 0.0023 
orotic acid 274 
 
[129-550] 448 a [99-7143] 65 b [35-186] 82.5 b [24-166] 0.0011 0.0035 








[39-3713] 0.0600 0.0780 
oxoproline 924410.5 a [631837-1174316] 882320.5 a [545482-1082347] 36417 b [30843-144935] 35600.5 b [22273-187653] 0.0006 0.0023 








[14890-48100] 0.2565 0.2835 








[738-3902] 0.7642 0.7792 








[5830-28692] 0.0511 0.0682 








[1718-4339] 0.1075 0.1281 
phenylacetic acid 538.5 a [444-945] 561 a [426-975] 2790 
 
[107-11906] 3227.5 b [1810-13417] 0.0140 0.0230 
phenylalanine 1066226.5 a [574792-1621399] 1450835 a,b [544207-1852113] 114471.5 a,c [29019-249126] 100982 c [30988-187156] 0.0005 0.0023 
phenylethylamine 915 
 
[470-2468] 380 a [63-1255] 4050.5 b [798-25688] 3479.5 b [729-26899] 0.0005 0.0023 




[226-2742] 987 b [491-8261] 0.0130 0.0215 
phosphate 413261 a [276526-1009730] 205953 a,b [74456-1001565] 1926 b,c [847-8363] 1357.5 c [1104-1947] 0.0003 0.0023 
phosphoethanolamine 637 a [236-958] 119.5 
 









[51-1421] 0.1468 0.1709 




[205-4031] 4171.5 b [1190-11932] 0.0015 0.0042 
piperidone 633 a [319-1017] 953.5 a,b [411-3842] 4619 b,c [1032-9167] 11369.5 c [2108-22865] 0.0002 0.0023 
proline 1938180.5 a [1239458-3016264] 2445473 a [1416201-2837691] 34900 b [25082-94877] 34712 b [16540-99534] 0.0006 0.0023 








[1000-4830] 0.7270 0.7496 




[1090-7556] 3293 b [896-5488] 0.0109 0.0184 
putrescine 1297 a [602-2774] 30871.5 
 
[2191-167327] 267989 b [130599-935794] 341061.5 b [107769-1161861] 0.0002 0.0023 
pyruvic acid 1051.5 a,b [593-2807] 9536.5 c [5745-16720] 2228.5 b,d [884-3342] 4824 c,d [2811-5646] 0.0002 0.0023 




[57-719] 849 b [416-1190] 0.0015 0.0042 
ribitol 22574.5 a [6715-45932] 2386 
 
[1894-23764] 1572 b [662-10142] 1422 b [288-2606] 0.0026 0.0065 

















[2888-47200] 0.1419 0.1661 
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Table 5. (Continued.) 
Compound (BinBase name) 
Duodenum Ileum Colon Rectum   
Median Range Median Range Median Range Median Range p-value q-value 
serine 1417440 a [1081314-1900474] 444285 
 
[164381-923030] 21513 b [12005-38304] 16968 b [10785-32899] 0.0002 0.0023 













[732-8973] 0.1087 0.1288 




[1271-22057] 15487.5 b [3882-41319] 0.0017 0.0045 
spermine 2413 a [1153-8803] 2001 
 
[1302-5025] 683.5 b [160-2765] 1027.5 
 
[385-2453] 0.0153 0.0247 








[68694-235232] 0.0292 0.0421 
succinate semialdehyde 1182.5 a [544-2503] 799.5 a,b [284-1315] 151 c [70-281] 222 b,c [117-336] 0.0004 0.0023 








[1245-196187] 0.0664 0.0836 
sulfuric acid 491.5 
 
[101-8309] 5451 a [481-9004] 390.5 
 
[35-3231] 68 b [24-179] 0.0007 0.0025 
taurine 80674.5 
 
[40417-132110] 329901 a [54489-919201] 72561 
 









[159-1050] 0.3476 0.3719 
threonic acid 479 a,b [344-1859] 749.5 b [329-9807] 190 c [90-486] 283 a,c [122-454] 0.0012 0.0038 
threonine 808060 a [528852-877182] 421047.5 a,b [296471-987264] 22659 b,c [10481-44287] 18257.5 c [7458-49781] 0.0003 0.0023 
thymidine 16430 a [9935-34923] 10133 a,b [2195-26498] 3083.5 b,c [610-4266] 1269 c [322-3189] 0.0004 0.0023 
thymine 21868.5 a [12468-51948] 29266.5 a [10831-49208] 10000.5 
 









[409-6277] 0.0427 0.0590 
tryptophan 471778.5 a,b [297445-923000] 686598 b [329824-1005368] 71302.5 c [23990-135134] 110766 a,c [24544-161584] 0.0005 0.0023 
tyrosine 1791955.5 a [1104069-2345118] 2090782 a [803070-2293451] 168617.5 b [74737-293816] 146435 b [57832-312115] 0.0006 0.0023 








[62-106] 0.0249 0.0369 
UDP-glucuronic acid 2873.5 
 
[186-11309] 6474 a [1682-25163] 1512 
 









[8229-126885] 0.0951 0.1147 
urea 113154 a [65856-213498] 31410 
 
[12777-91404] 2173.5 b [32-3041] 2136.5 b [1685-5171] 0.0002 0.0023 
uric acid 154943.5 a [122073-191054] 53608 
 
[7743-641297] 911.5 b [166-2478] 1007 b [222-2198] 0.0005 0.0023 




[435-5984] 834.5 b [352-4457] 0.0272 0.0394 








[152-914] 0.1757 0.1998 
valine 2424533 a [1689230-2930533] 2351440.5 a,b [1645335-3448589] 145794.5 a,c [77598-252763] 135537 c [40757-243482] 0.0005 0.0023 




[72-1028] 555.5 b [386-2474] 0.0014 0.0042 
xanthine 89616 a [15556-159664] 43978 a,b [31998-50746] 8642 b,c [2162-21217] 7788.5 c [2247-14368] 0.0007 0.0026 
xanthosine 1954.5 a [288-4128] 704.5 
 
[370-1708] 188.5 b [64-346] 180.5 b [37-482] 0.0015 0.0042 
xanthurenic acid 110.5 a [26-627] 654 b [222-1193] 87 a [25-1419] 159 
 
[96-428] 0.0097 0.0174 
xylitol 15052.5 a [7131-39878] 3056.5 
 
[2129-27663] 365 b [61-1395] 308 b [89-1389] 0.0004 0.0023 








[165-3767] 0.2523 0.2804 
xylose 3455 a [1508-6118] 6530 
 
[2848-15955] 29602 b [9960-73627] 43137.5 b [8057-102445] 0.0003 0.0023 
xylulose NIST 6299  [4766-8723] 3727  [1021-22548] 2036  [1271-5940] 2274  [764-3955] 0.0491 0.0667 
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PLS-DA, a supervised method, can also be used to identify which metabolites contribute 
most significantly to the separation of groups. The significance is graphed by VIP scores and the 
highest scoring metabolites were subsequently used to generate a heatmap to visually highlight the 
patterns across samples within and between gastrointestinal sites (Figure 9). The top fifteen 
features identified by VIP scores were cystine, phosphate, 4-hydroxyphenylacetic acid, uric acid, 
putrescine, ethanolamine, aspartic acid, 3-(4-hydroxyphenyl)propionic acid, serine, proline, 
aminomalonate, threonine, cytidine, glycine, and 5-aminovaleric acid (Figure 10A).  
duodenum ileum colon rectum 
Figure 9. Heatmap showing the relative distribution of the top 50 metabolites, as identified by VIP 
scores in PLS-DA. Each column represents an individual sample and samples are grouped by 
organ site along the x-axis. 
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Random Forest Analysis is another supervised method for finding the most significant 
features. The importance of each feature is determined by how significantly the classification 
accuracy is lost when that feature is not used in the model. The top fifteen metabolites identified 
using this method were cytidine, pyruvic acid, 4-hydroxyphenylacetic acid, cytosine, serine, 
xylitol, 2-hydroxyhexanoic acid, aminomalonate, aspartic acid, nicotinic acid, phosphate, 
ethanolamine, 3-phenyllactic acid, guanine, and valine (Figure 10B). 
2.3.2.3 Examples of metabolite profiles 
Although untargeted metabolomics does not provide quantitative results for any given 
metabolite, the normalized peak height for any specific metabolite across all of the samples can 
be considered semi-quantitative. Individual metabolites that did significantly change along the 
GIT were subjectively found to exhibit one of four patterns: incrementally increasing or decreasing 
along the length, abruptly decreasing from ileum to colon, and rarely, an increase with a 







































Figure 11. Examples of semi-quantitative metabolite profiles observed in the metabolomics data 
set. Lines are fit subjectively. 
A B 





2.3.3 Inter-omics results 
Prior to filtering correlation scores, the table consisted of 199 named metabolites and 34 
bacterial families. At a stringent threshold of rho ≥0.8, 19 metabolites and four bacterial families 
were included (Table 6). The bacterial families were Lachnospiraceae, Peptococcaceae, 
Veillonellaceae, and an unspecified family-level taxon within Clostridiales. The metabolites were 
2-ketobutyric acid, 3-(3-hydroxyphenyl)propionic acid, 3-(4-hydroxyphenyl)propionic acid, 
alanine, cystine, ethanolamine, glutamic acid, glycerol, glycine, hexitol, histidine, isoleucine, 
leucine, methionine, oxoproline, phosphate, proline, threonine, and valine. With the exception of 
3-(3-hydroxyphenyl)propionic acid and 3-(4-hydroxyphenyl)propionic acid, all were negatively 




Table 6. Pearson correlation matrix between named metabolites and bacterial families with at least 
one absolute rho ≥ ±0.8. 
Metabolite unspecified Clostridiales Lachnospiraceae Peptococcaceae Veillonellaceae 
2-ketobutyric acid -0.79 -0.85 -0.49 -0.65 
3-(3-hydroxyphenyl)propionic acid 0.36 0.45 0.83 0.63 
3-(4-hydroxyphenyl)propionic acid 0.66 0.74 0.64 0.80 
alanine -0.79 -0.85 -0.59 -0.69 
cystine -0.76 -0.82 -0.52 -0.63 
ethanolamine -0.74 -0.82 -0.48 -0.55 
glutamic acid -0.80 -0.81 -0.52 -0.75 
glycerol -0.74 -0.81 -0.37 -0.49 
glycine -0.79 -0.84 -0.43 -0.57 
hexitol -0.76 -0.84 -0.54 -0.65 
histidine -0.78 -0.84 -0.45 -0.69 
isoleucine -0.76 -0.81 -0.58 -0.76 
leucine -0.79 -0.82 -0.65 -0.74 
methionine -0.76 -0.80 -0.55 -0.71 
oxoproline -0.78 -0.81 -0.54 -0.72 
phosphate -0.78 -0.83 -0.54 -0.66 
proline -0.85 -0.87 -0.51 -0.73 
threonine -0.75 -0.80 -0.53 -0.69 
valine -0.73 -0.81 -0.58 -0.75 




2.4.1 Microbiota composition 
Suchodolski et al. (2008) sampled contents of duodenum, jejunum, ileum, and colon and 
identified four predominant phyla within the healthy canine GIT using 16S rRNA gene clone 
libraries: Firmicutes, Fusobacteria, Bacteroidetes, and Proteobacteria. Percentages of 
Proteobacteria were driven primarily by Enterobacteriales, and decreased from 32% in the 
duodenum to 1.4% in the colon. The order Clostridiales was a major constituent at all four sites, 
and the overall most abundant order in the duodenum and jejunum. Sequences assigned to 
Clostridium cluster XI were more abundant in the small intestine, while sequences of Clostridium 
cluster XIVa were more abundant in the colon. Although the current study sampled duodenum, 
ileum, colon, and rectum, the results are consistent with the previous findings. Sequences 
belonging to Actinobacteria were identified in addition to the four previously mentioned phyla, 
but contributed minimally at each site. Proteobacteria predominated in the duodenum with 59% of 
sequences, and decreased to 5% in the rectum. The proportionate increase in Lachnospiraceae and 
Ruminococcaceae in the large intestine versus small intestine is also consistent with Suchodolski 
et al. (2008), describing increased Clostridium cluster XIVa in the colon. Firmicutes, 
Proteobacteria, and Bacteroidetes have previously been reported as predominant phyla in the GIT 
of other mammals, including cattle, sheep, pigs, and humans (Mao et al. 2015; J. Wang et al. 2017; 
H. Yang et al. 2016; M. Wang et al. 2005; G. Li et al. 2015). 
2.4.2 Community metabolic potential 
While PICRUSt was originally validated for human-derived data sets, the applicability of 
this tool for use with canine-derived sequencing data compared to human-derived data has been 
described by Vazquez-Baeza et al. (2016). PICRUSt analysis identified significant differences in 
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KEGG pathway categories that appear irrelevant to the microbiota. It is likely that each of these 
categories was driven to significance by relatively few KOs that are associated with human 
diseases but also are present in bacteria, hence originating from the 16S rRNA sequencing data. 
This limitation also manifests in the reduction of KOs that successfully mapped to KEGG 
pathways, where any given KO of bacterial origin may not be completely annotated to a specific 
KEGG pathway. 
PICRUSt also revealed significant differences in bile acid synthesis pathways. This was 
expected since the role of microbiota in deconjugating and dehydroxylating bile acids is well 
established. The abundance of predicted gene copies orthologous to choloylglycine hydrolase 
significantly increased along the GIT, consistent with deconjugation of bile acids occurring 
primarily in the large intestine. The second significantly altered KO associated with bile acid 
synthesis encodes alpha-methylacyl-CoA racemase. The function of this enzyme is described as 
inversion of a stereocenter during synthesis of primary bile acids from cholesterol; however, as 
bacteria modify bile acids but do not synthesize them, it may be suggested that this enzyme in 
bacteria may bind to the same substrate, and perform the same biochemical conversion, but for an 
alternative purpose than synthesis of primary bile acids. 
The flagellar assembly pathway consists of proteins of bacterial origin, yet flagellum is 
also relevant to the host immune system (Cullender et al. 2013; Haiko and Westerlund-Wikstrom 
2013). The data showed increased abundance of KOs associated with the flagellar assembly in the 
small versus large intestine. Although metabolic capacity of the community is not equivalent to 
expression, these results highlight the differing ecosystems between sites in the gut. 
2.4.3 Metabolomics profiling 
The simplest analysis of metabolites one-by-one is represented in Table 5. As with any 
large data set, different statistical methods have different biases. Therefore, multivariate analysis 
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encompassed both PLS-DA and RFA to identify metabolites that consistently demonstrated 
significance. Also, findings in this study may partially depend on diet (as some metabolites may 
only be present in the GIT if certain ingredients are incorporated in the diet). An exhaustive 
discussion of the overlap of all significant metabolites by both methods is likely not warranted 
given the limitations of this study, so only the top fifteen metabolites identified by each method 
(an arbitrary cutoff) were considered for further discussion. This resulted in seven metabolites 
appearing in both lists: phosphate, 4-hydroxyphenylacetic acid, ethanolamine, aspartic acid, 
serine, aminomalonate, and cytidine. The GIT is credited with a critical role in phosphate 
homeostasis in partnership with the renal system (J. Marks et al. 2013), and phosphate decreased 
distally. 4-hydroxyphenylacetic acid is a phenolic compound believed to be associated with 
microbial degradation of aromatic amino acids, and thus the increase along the GIT was not 
surprising. Garsin (2012) reviewed the function of ethanolamine in the GIT and specifically its 
relevance to enterohemorrhagic Escherichia coli O157:H7. In this study, it decreased along the 
GIT. Aspartic acid and serine are both amino acids that decreased along the GIT. Aminomalonate 
also generally decreased; this compound was identified by Van Buskirk et al. (1984) in proteins 
from Escherichia coli and in atherosclerotic plaque. Cytidine is a nucleoside component of RNA; 
the observed decrease may be due to degradation of dietary cytidine during normal digestion. 
While these seven compounds were consistently significantly different between sites using both 
PLS-DA and RFA, there are many compounds relevant to disease states or microbial metabolism 
that may not differentiate between sites within the canine GIT. The breadth of findings from an 
untargeted metabolomics approach in this study suggests we are only scratching the surface of the 
interactions between the microbiota and the host that may be metabolite mediated. 
Complexity of the data prevented systematic investigation of all metabolite profile shapes 
across the four sites, but representative examples are shown in Figure 11 and application of more 
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objective methods to define these profile shapes would be warranted in future studies. The varied 
profiles observed are suggestive of underlying physiology dependent on the metabolite and 
location within the GIT. From the host perspective, the gut’s primary function is absorption. 
However, this is not a linear process: many nutrients must be released from the whole-food matrix 
through enzymatic action (e.g., pancreatic enzymes or bacterial fermentation). As metabolites are 
liberated, they may spontaneously react further. The fate of each metabolite is somewhat unique, 
and changes in relative quantity at different locations of the GIT highlight this. The complexity of 
amino acid absorption has been reviewed and some species distinctions have been noted (Broer 
2008). Studies specifically in the dog are scarce and focus on the jejunum as the site of absorption 
(Weber et al. 1977; Pytkowski and Michalowski 1977; Annegers 1969), yet the current study 
suggests several amino acids remain at high concentrations in the ileum. Additional studies are 
required to determine specific locations of amino acid transporters in the canine intestine. 
The profile of pyruvate is also noteworthy. Only three other metabolites exhibited this 
profile where ileal abundances were significantly increased relative to duodenum and large 
intestine: xanthurenic acid, galactinol, and glucoheptulose. Proposing biochemical interpretations 
of this pattern would require imprudent conjecture, but it is worth highlighting that fecal 
concentrations of these compounds may be poor surrogate markers for concentrations elsewhere 
in the GIT. 
2.4.4 Inter-omics correlations 
Correlations between metabolites and bacterial families are not intended to suggest finding 
causality. Depletion of amino acids is likely partially coincidental to the relationships with the four 
bacterial families since the host actively absorbs amino acids. However, persistence of correlation 
across four sites within the GIT suggests the possibility of a stronger relationship, and Clostridia 
have long been appreciated as fermenters of amino acids (Mead 1971). The two metabolites that 
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showed strong positive correlations with bacterial families are closely related isomers, and are 
purported microbial degradation products of proanthocyanidins (Ward et al. 2004; Rios et al. 
2003). Across samples, both bacterial families and both metabolites followed the same trajectory; 
thus it is interesting that the correlations (based on each individual sample) suggest more specific 
associations of 3-(3-hydroxyphenyl)propionic acid with Peptococcaceae and 3-(4-
hydroxyphenyl)propionic acid with Veillonellaceae. Additional studies in vitro are required to 
determine if this correlation has relevance beyond coincidence. 
Relationships between the gastrointestinal microbiota and metabolome in humans and 
animal models are also being explored in other labs (H. Lin et al. 2016; McHardy et al. 2013; Di 
Cagno et al. 2011; Sridharan et al. 2014), but rarely do these studies investigate multiple sites 
within the GIT. In comparison to single-site studies, such as looking at microbiota-metabolome 
correlations only within feces, the data in the present study demonstrated correlation across a 
greater breadth of environments.  
2.4.5 Limitations 
Samples were collected within three hours post mortem and it is unclear how rapidly the 
active biochemistry of the metabolites and the ecology of the microbiome might change after 
death. All six subjects were apparently healthy but the unavailability of complete medical histories 
leaves the possibility of antibiotic usage or other medications that could have affected the results. 
Furthermore, samples from only six dogs, all of hound-type breeding and with similar diet history, 
are unlikely to represent the entire breadth of diversity of the canine population. The influence of 
composition and timing of the last meal, as well as complete dietary history, should be considered 
in future studies exploring variation along the GIT. A naturally-passed fecal sample from each 
subject would also more directly allow correlation of fecal results to corresponding sites along the 
GIT. With regard to collection of samples, in the dog, the duodenum and ileum are somewhat 
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collapsed in vivo, so all contents from these sites are in close proximity to the mucosal surface. 
However, a distinction of mucosal and luminal sampling may be more relevant with regard to 
colonic and rectal contents; for the purposes of this study, we attempted to collect material 
representative of a transverse section, incorporating mid-luminal material as well as material 
adjacent to the mucosal surface, but the potential variation of these biogeographical regions is 
worth considering for future studies. Percent dry matter is known to vary in different samples of 
the GIT, and the decision to compare samples on the basis of wet-weight or dry-matter deserves 
careful thought. It may be considered that increased water content of a sample represents a 
physiological dilution of the concentration of metabolites within a sample (which has an effect on 
the biochemical kinetics), and therefore samples should be compared on the basis of wet weight. 
However, as water content can be highly variable and the dilution effect may be considered 
confounding (e.g., if comparing diarrheic to healthy fecal samples), the argument to normalize by 
dry matter (or some other method) is equally valid. Both approaches may introduce an inherent 
bias. Specifically for this study, none of the samples were overtly liquid upon collection, but 
clearly this is a subjective assessment and future studies should consider determination of dry 
matter content of different sites. 
2.5 CONCLUSIONS 
The data analyses in this work have explored two distinct but related data sets, 16S rRNA 
sequencing and metabolomics, from multiple angles. The application of PICRUSt allowed 
inferences of the predicted community functional potential, yielding an additional data set of 
KEGG Orthologs but which is completely dependent on the 16S rRNA sequencing results. Each 
of these data sets taken by itself provided descriptive information about the four sampled sites of 
the canine GIT, and subsequent inter-omics analysis demonstrated a potential approach to explore 
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the relationships between the data sets. To our knowledge, this is the first study of the metabolome 
in healthy dogs that included small and large intestinal sampling sites. Since a majority of 
microbiome studies use feces to represent the gut microbiome, it is important to elucidate and 
appreciate differences and similarities of the microbiota and metabolome along the GIT. 
Additional studies are required to elucidate the functional capability of the microbiota in vivo, 
explore the effect of dysbiosis on those functional capabilities, and improve our understanding of 




3. VARIATION OF CONCENTRATIONS OF STEROLS AND FATTY ACIDS 
ALONG THE HEALTHY CANINE GASTROINTESTINAL TRACT 
 
OVERVIEW  
As a brief addendum to the previous section, and to provide context for upcoming sections 
about the concentrations of fatty acids and sterols in various diseases, this section reports the 
quantitative results from analysis of the same samples as those used in Section 2, using the targeted 
assay described in Section 6. 
3.1 INTRODUCTION 
A critical part of interpreting data is understanding normal physiology. As described in 
Section 2, metabolites may exhibit different patterns of concentrations within different segments 
along the GIT. Lipid metabolism is a tremendously broad and complex topic, and understanding 
the mechanisms of absorption of lipids and their transport throughout the body are crucial for 
interpreting alterations in lipid metabolism during various disease states. In an effort to understand 
a small part of canine lipid metabolism and provide a framework for interpreting fecal results in 
the context of gastrointestinal diseases, the concentrations of fatty acids and sterols were 
determined in healthy dogs in duodenal, ileal, colonic, and rectal contents (n=6 dogs), as well as 
gall bladder content (n=8 dogs). 
3.2 MATERIALS AND METHODS 
Samples were collected as described in 2.2. The samples from duodenum, ileum, colon, 
and rectum are the same samples from the same animals reported in Section 2. However, bile 
samples were taken from an additional eight dogs at a different time. All samples were prepared 
and analyzed by GC-MS using the assay described in Section 6. Because the bile samples were 
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collected from an entirely distinct group of dogs, statistics were performed without consideration 
of dependence of samples (i.e., each sample site was treated as an independent group rather than 
repeated measures from individuals), using Kruskal-Wallis tests to determine which metabolites 
were significantly altered after a Benjamini-Hochberg correction for multiple comparisons, 
followed by a Dunn post-test to identify significant pairwise comparisons. Statistical significance 
was set at p<0.05. 
3.3 RESULTS 
With the exception of gondoic acid, all quantified metabolites exhibited a significant 
change in concentration in at least one site-pair comparison. The medians and ranges of 
concentrations of compounds in μg/mg lyophilized sample are presented in Table 7. Figure 12 
shows the fatty acid concentrations of individual samples graphically, along with the sum of 
quantified fatty acids in each sample. Figure 13 shows the corresponding data for sterols, along 
with the total quantified sterols and the ratio of phytosterols to zoosterols. 
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Table 7. Concentrations of fatty acids and sterols in contents of the gastrointestinal tract. Superscripts identify which comparisons are 
statistically significantly different. 
Compound 
Bile Duodenum Ileum Colon Rectum     
Median Range Median Range Median Range Median Range Median Range   
 (μg/mg)  (μg/mg)  (μg/mg)  (μg/mg)  (μg/mg) p-value q-value 
Fatty Acids                       
α-linolenic acid 0.407 
a,c [0.274-1.246] 0.188 b [0.155-0.571] 0.159 b [0.091-0.663] 0.551 c [0.333-0.768] 0.619 c [0.468-0.849] 0.0049 0.0051 
arachidonic acid 25.30 
a [20.69-29.7] 15.18 b [12.81-20.46] 5.59 c [3.13-17.79] 0.95 d [0.61-9.99] 0.71 d [0.27-1.34] 0.0000 0.0001 
behenic acid 0.151 
a [0.122-0.213] 0.287 b [0.214-0.311] 0.385 c [0.304-0.411] 0.415 d [0.392-0.653] 0.340 c,d [0.322-0.477] 0.0000 0.0001 
cis-vaccenic acid 5.38 
a [3.66-7.24] 1.53 b [1.28-1.82] 0.94 b,c [0.47-2.07] 0.92 b,c [0.35-2.63] 0.99 c [0.69-1.05] 0.0002 0.0003 
erucic acid 0.019 
a [0.001-0.03] 0.044 b [0.033-0.049] 0.036 
 
[0.015-0.092] 0.070 c [0.043-0.159] 0.040 b,d [0.03-0.067] 0.0015 0.0017 










[0.142-0.252] 0.8197 0.8197 
linoleic acid 17.96 
a [13.45-26.42] 13.51 b [12.23-14.21] 5.78 c [3.21-11.15] 4.03 c [2.54-7.88] 4.13 c [2.78-4.75] 0.0001 0.0001 
nervonic acid 0.192 
a [0.135-0.384] 0.359 b [0.315-0.388] 0.476 c [0.332-0.637] 0.333 b,c [0.295-0.715] 0.224 a,d [0.169-0.301] 0.0004 0.0005 
oleic acid 10.38 
a [8.3-17.7] 4.99 b [4.24-6.13] 3.06 b,c [1.62-6.57] 3.71 c [2.07-4.78] 3.74 c [2.55-4.47] 0.0003 0.0004 
palmitic acid 16.24 
a [13.55-26.96] 6.43 b [5.54-7.37] 5.14 b,c [2.91-8.46] 4.27 b,c [2.5-8.05] 4.16 c [2.76-4.94] 0.0003 0.0004 
stearic acid 13.20 
a [11.4-18.98] 11.89 a [10.22-15.2] 6.19 b [5.1-11.22] 3.41 c [1.73-10.71] 3.29 c [1.77-3.91] 0.0000 0.0001 
Sterols  
 
   
 
   
 
   
 
   
 
    
β-sitosterol 0.111 
a [0.068-0.208] 0.089 a [0.049-0.214] 0.728 b [0.097-2.498] 4.443 c [3.664-7.952] 4.250 c [3.765-5.653] 0.0000 0.0001 
brassicasterol 0.030 
a [0.015-0.065] 0.018 b [0.014-0.021] 0.041 a,c [0.021-0.055] 0.058 c [0.038-0.084] 0.044 a,c [0.029-0.068] 0.0022 0.0024 
campesterol 0.312 
a [0.129-0.512] 0.247 a [0.125-0.374] 1.356 b [0.304-1.62] 2.953 c [2.129-4.294] 2.190 c [1.92-3.34] 0.0000 0.0001 
cholestanol 0.091 
a [0.064-0.205] 0.072 a [0.054-0.086] 0.205 b [0.115-0.351] 0.330 b [0.228-0.592] 0.173 b [0.114-0.384] 0.0002 0.0003 
cholesterol 1.83 
a [1.45-4.31] 15.20 b [14.57-20.61] 15.23 b [9.09-23.43] 7.89 b [5.85-23.32] 3.98 c [2.44-12.47] 0.0001 0.0001 
coprostanol 0.015 
a [0.011-0.024] 0.011 a [0.01-0.018] 0.047 b [0.014-0.105] 0.138 c [0.087-0.202] 0.130 c [0.076-0.139] 0.0000 0.0001 
fucosterol 0.016 
a [0.012-0.025] 0.015 a [0.011-0.022] 0.054 b [0.016-0.134] 0.243 c [0.204-0.395] 0.217 c [0.201-0.311] 0.0000 0.0001 
lathosterol 0.026 
a [0.01-0.028] 0.039 b [0.025-0.066] 0.141 c [0.055-0.258] 0.162 c,d [0.09-0.467] 0.051 b,c [0.032-0.455] 0.0001 0.0002 
sitostanol 0.008 
a [0.004-0.015] 0.005 a [0.002-0.04] 0.055 b [0.004-0.74] 1.200 c [0.838-1.811] 1.152 c [1.057-1.303] 0.0001 0.0001 
stigmasterol 0.036 



















































































































































































































































































































































































Figure 12. Concentrations of eleven fatty acids in bile and in samples taken at different sites along the GIT. The mean concentration is 





























































































































































































































































































































































































Figure 13. Concentrations of ten sterols in bile and in samples taken at different sites along the GIT. The total concentration of sterols and 




The purpose of quantifying these compounds in samples from multiple sites within the 
GIT was largely to provide some context for interpretation of altered concentrations seen in feces 
of diseased animals, discussed in later sections. Based on the absorptive action of the GIT, it would 
be expected that concentrations of some metabolites would change. One may apply a concept that 
in a biological system, there are three causes for decreased concentrations of a given parameter 
(e.g., hematocrit on a complete blood count): destruction, loss, or failure to synthesize. Conversely, 
reasons for increased concentrations would be a decrease in physiological degradation or 
excretion, or increased synthesis. These guidelines are not as readily applied to concentrations in 
intestinal contents, where secretion by the host increases luminal concentration and absorption 
decreases it, but generally the changes in concentration at different sites of the GIT can be 
interpreted based on similar principles. Given the increasing concentrations of several of the 
phytosterols from duodenum to rectum (i.e., β-sitosterol, campesterol, fucosterol, sitostanol, and 
stigmasterol), the factors that contribute to this increase must be explored. First, the quantity of 
material consumed on a dry matter basis is significantly greater than the quantity excreted as feces. 
Actual values from the literature are not readily available, but one article reported fecal outputs 
(i.e., wet-weight) from humans in Westernized populations as only 80-120 g/day (Cummings et 
al. 1992). Specifics of the mass of dietary intake vary tremendously and are highly dependent on 
water content of the diet, especially for the diverse diets of humans, but based on data from the 
National Health and Nutrition Examination Survey (NHANES) the average American may 
consume quantities on the order of 2.5 kilograms of food per day, a 20-fold factor relative to the 
0.12 kg fecal output. Even considering these values are for humans and without correcting for 
water content, it should be apparent that among healthy individuals, any compound that has zero 
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net absorption and excretion would show increased concentrations more distally because of the 
decreasing total mass of the digesta, which should be very important for interpretation of all results 
from samples taken at different segments along the GIT. However, while this may alter the 
interpretation of increasing concentrations to instead mean no net absorption, it does not diminish 
the importance to biochemical equilibrium dynamics caused by concentration gradients, nor does 
it reduce the significance of altered concentrations when comparing two groups of same-site 
samples (i.e., feces from diseased dogs compared to healthy dogs).  
Specifically with regard to phytosterols, there is a second mechanism that may contribute 
to the apparent increase of concentrations observed in healthy animals. As described in Section 
1.6, the NPC1L1 transporter is preferential for cholesterol but does not completely exclude other 
sterols (Tang et al. 2009). Selectivity for absorption of cholesterol is secondarily accomplished via 
ABCG5 and ABCG8 transporters, which preferentially expel phytosterols rather than cholesterol. 
Therefore, over the length of the intestines, it would make sense that the concentrations of 
phytosterols are further increased by the selective expulsion of phytosterols from the enterocytes 
with concurrent absorption of cholesterol, as supported by the decreasing luminal concentrations 
of cholesterol from duodenum to rectum. 
The composition of bile includes water, bile salts, cholesterol, and lecithin. Lecithin is 
usually a mix of phospholipids, whether phosphatidylcholine, phosphatidylethanolamine, or a 
glycerophospholipid. As discussed in Section 1.5, phospholipids usually have a saturated fatty 
acid at carbon 1 and an unsaturated fatty acid at carbon 2. Interestingly, the choline in phosphatidyl 
choline has been implicated in cardiovascular disease in humans, in a microbiota-mediated 
pathway involving metabolism of choline to trimethylamine oxide (TMAO). 
Due to the concentrating effect of general absorption and decrease of luminal contents, 
the magnitude of decrease of compounds along the GIT may in fact be underestimated. 
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Cholesterol, for example, appears to decrease from 15 μg/mg in the duodenum to 5 μg/mg in the 
rectum. If the 100-fold overall dry-matter mass decrease is mathematically reversed for the 
purpose of demonstrating this concept, the rectal contents would instead be 5 μg per 100 mg, or 
0.05 μg/mg, which is a 300-fold decrease in concentration. If equilibrium dynamics are then 
considered, it is interesting that additional extraction of a compound at such low concentrations 
would be thermodynamically disfavored, but by concentrating the compounds in the lumen, there 
is increased opportunity for both passive and active transport across enterocyte membranes. 
3.5 CONCLUSIONS 
Lipid metabolism is a complicated and multifaceted topic. While some lipids (e.g., 
cholesterol) clearly undergo net absorption, it is more difficult to interpret the metabolites that 
appeared to increase in concentration on a μg/mg basis (i.e., phytosterols) since the absorptive 
processes in the GI tract have a concentrating effect on the luminal contents. Nonetheless, 
understanding how fecal concentrations of sterols and fatty acids relate to concentrations in more 
proximal segments of the gastrointestinal tract provides an important context for interpretation of 




4. BIOMOLECULAR PATHWAYS OF BACTERIA IN THE DUODENUM OF 
DOGS WITH IDIOPATHIC INFLAMMATORY BOWEL DISEASE 
 
OVERVIEW 
The present understanding of canine idiopathic inflammatory bowel disease (IBD) assigns 
a significant role to the interplay between the gastrointestinal microbiota, the immune system, and 
host genetic factors in the pathogenesis of the disease. Sequencing of the 16S rRNA gene has 
shown significant alterations in microbial groups among dogs with IBD compared to healthy 
control dogs, but the functional effect of the resident microbiota in health and disease has not been 
elucidated. The aim of this study was to utilize a computational approach to explore possible 
alterations in microbial biomolecular pathways between dogs with idiopathic IBD and healthy 
control dogs.  
Previously published 16S rRNA gene sequencing data describing alterations in the 
microbiota of duodenal biopsies from dogs with moderate to severe IBD (n=14) and healthy 
control dogs (n=6) were used for this study. The data were analyzed using the bioinformatics 
software PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
States) to predict the functional capabilities of bacteria within each sample. The relative abundance 
of genes associated with a given pathway may indicate an increased metabolic capacity of the 
enteric microbiota with regard to that pathway. Inferences of the functional gene content were 
grouped by function according to the three-level KO (Kyoto Encyclopedia of Genes and Genomes 
Ortholog) hierarchy and compared using Linear Discriminant Analysis (LDA) through LEfSe 
(LDA Effect Size) with the significance threshold set to an LDA score of log 2.5.  
Among pathway categories, lipid metabolism was increased in dogs with IBD (LDA=3.4), 
while pathways associated with carbohydrate, nucleotide, and energy metabolism were relatively 
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decreased when compared to healthy control dogs (LDA=3.7, 3.5, and 3.5; respectively). Pathways 
categorized into translation or replication and repair, which are subcategories of genetic 
information processing, were decreased in abundance among dogs with IBD (LDA=3.6 and 3.8, 
respectively) while the category of environmental information processing was more abundant in 
the dogs with IBD compared to healthy control dogs (LDA=4.0). At the individual KO level, the 
iron complex outer membrane receptor protein was significantly increased in dogs with IBD 
(LDA=3.2), along with two KOs associated with the NitT/TauT family transport system 
(LDA=2.7, 2.5), which is involved in osmoprotection. The abundances of three KOs associated 
with the multiple sugar transport system were decreased in dogs with IBD (LDA=3.0, 2.9, and 
2.7). The abundance of the KO corresponding to 6-phosphofructokinase 1 was also decreased 
relative to the healthy control dogs (LDA=2.5). 
These predictions of the functional metagenomic milieu provide insights into the changes 
occurring in the duodenum in dogs with idiopathic IBD. Future studies are warranted to evaluate 
these pathways and related metabolites for potential diagnostic and/or therapeutic targets.  
4.1 INTRODUCTION 
Idiopathic inflammatory bowel disease (IBD) is an important disease in dogs and has been 
associated with gastrointestinal dysbiosis (Suchodolski et al. 2010; Minamoto et al. 2015; 
Vazquez-Baeza et al. 2016). The functional effects of the shift in microbial populations, including 
production of metabolites and interaction with host systems, have not yet been well-characterized. 
In addition, samples used to characterize the microbiota associated with IBD are typically naturally 
passed feces, while the histologic evidence of inflammatory lesions is often observed in the 
duodenum. There is a clear need for improved understanding of the changes occurring at the sites 
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within the GI tract that are affected by the disease, which would require endoscopy or laparotomy 
to obtain samples from the patients. 
Upon obtaining samples from sites of disease, specific experiments and analyses must be 
chosen from an array of available tests. Based on the presumed interplay between host and 
microbiota implicated in disease, it is also relevant to consider which organisms are desirable to 
target in the analysis. Tissue biopsies are primarily comprised of host cells, but the mucosa is 
known to harbor bacteria as well, though much more sparsely in the proximal than the distal GI 
tract. Experimentally determining metabolic activity through transcriptomics is expensive, and 
performed on biopsies primarily captures the effects of gene regulation on the part of the host, not 
the microbiota. Whole-genome sequencing (WGS) on a sample of the microbiota (excluding host 
cells) is also costly, but in theory would characterize the microbial metagenome. 16S rRNA 
sequencing is quite affordable and is frequently used to determine the composition of the bacterial 
microbiota in a sample. The resulting data set does not directly speak to the function (actual or 
potential) of the microbiota. However, computational methods have been shown to effectively 
predict a more complete microbial composition from 16S rRNA sequencing data, that is, beyond 
what can be directly observed (Langille et al. 2013). The identities of the predicted microbiota can 
then be used to predict the metagenomic composition of the microbial community as a whole using 
public databases. Finally, the predicted metagenome can be translated into gene sequences 
associated with specific proteins, where the gene function may be known to play a role in one or 
more metabolic or structural pathways, using a database such as the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) (Kanehisa et al. 2016). The pathways can subsequently be grouped into 
categories to observe more general themes. In other words, relative changes in the abundances of 
pathways are suggestive of up- or down-regulation of biosynthesis or degradation of specific 
metabolites or host-microbe interaction signaling molecules. Importantly, since the data for the 
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pathways originates exclusively as 16S rRNA sequencing data, the predicted metagenome and 
associated pathways must be associated specifically with the bacterial microbiota, not the host 
metagenome. Although the method involves predictive steps in silico, it is an interesting tool for 
viewing the microbial composition as a functional organ, and that comparing samples from 
diseased and healthy dogs may help elucidate how the disease state shapes the metabolic capacity 
of the microbiota. The objective of this study was to identify significant functional differences 
between the microbiota of dogs with idiopathic IBD and healthy control dogs, as evidenced by 
predicted alterations in bacterial biomolecular pathways, using a computational approach. 
Previously published data sets related to this study include host gene expression data (Wilke et al. 





















Count of individual KOs







Figure 14. PICRUSt project workflow. OTU: operational taxonomic unit; KEGG: Kyoto 
encyclopedia of genes and genomes; KO: KEGG ortholog 
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4.2 MATERIALS AND METHODS 
The overall flow of the study is depicted in Figure 14.  
4.2.1 Sequencing data 
The associated 16S rRNA sequencing data obtained from duodenal mucosal biopsies from 
dogs with IBD (severe, n=7; moderate, n=7) and healthy control dogs (n=6) has previously been 
published (Suchodolski et al. 2012a). In brief, RNA was extracted from endoscopically-obtained 
biopsies and transcribed into cDNA according to kit instructions. 454-pyrosequencing of the 16S 
rRNA gene resulted in raw data that was initially processed using QIIME version 1.4.0, and 
chimera removal was performed using B2C2 to yield the data set for the current study (Caporaso 
et al. 2010b; Gontcharova et al. 2010). 
4.2.2 Data analysis 
The GreenGenes database version 13.5 was used as the reference for picking Operational 
Taxonomic Units (OTUs) of ≥97% match to known OTUs (DeSantis et al. 2006). This closed-
reference strategy is appropriate for matching 16S rRNA sequencing data to appropriate taxonomy 
and applying established phylogenetic relationships in downstream analysis. Although the closed-
reference strategy does exclude OTUs that are not in the database, and version 13.5 is not the most 
up to date version, it is the only version that can be interfaced with the bioinformatics software 
PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) 
at the time of this writing. Data processing steps were carried out within the software PICRUSt 
using scripts. Unequal sampling depth was accounted for by random selection of 683 sequences, 
the minimum number in any single sample. The OTU table was normalized by copy number, the 
metagenome predicted, and assignment of predicted gene sequences was made to one or more 
KEGG Orthologs (KO; Kyoto Encyclopedia of Genes and Genomes) (Langille et al. 2013; 
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Kanehisa et al. 2014; Kanehisa and Goto 2000). KOs were categorized according to the three-level 
KO hierarchy to look for broader trends. An individual KO, representing a single gene sequence 
that may encode a structural protein or enzyme, in whole or in part, may be included in more than 
one category if merited by the function of the protein in the organism. 
Pathway abundances (categorized and uncategorized) were compared between the 
predicted metagenome of dogs with IBD and healthy control dogs using Linear Discriminant 
Analysis (LDA) and the online data analysis package LEfSe (LDA Effect Size), where the 
significance threshold was set to log 2.5 (Segata et al. 2011). 
4.3 RESULTS 
Previously published results of average proportion of bacterial phyla and the clustering in 




Figure 15. Average proportion of phyla in healthy control dogs and dogs with IBD. Values are the 




4.3.1 Categorized by function according to KEGG hierarchy 
The cladogram in Figure 17 displays increased and decreased abundances of pathways 
within hierarchies. The structure of the cladogram is determined by the relationships of 
subcategories to categories; for example, environmental information processing is a level 1 
category that was significantly increased in dogs with IBD. The level 1 alteration was likely driven 
by the level 3 subcategory of signal transduction, which in turn likely drove the significance of the 
two component system category, from level 2. Within a hierarchical level, the cladogram also 
attempts to co-locate more similar functions together. For example, DNA repair and recombination 
proteins are adjacent to DNA replication proteins, while the category for ribosome is somewhat 
farther away, though all three subcategories are in the same level 1 group of genetic information 
Figure 16. Principal coordinates analysis (PCoA) of unweighted UniFrac distances of 16S rRNA 
genes based on clinical severity of disease. Each spot represents the microbiome of a single sample 
and distances between spots correspond to similarity of the microbiome. Healthy control dogs (red 
squares) clustered separately from dogs with disease (blue = moderate; orange = severe). 






processing. The data can be visualized independently of this clustering strategy in the bar chart in 
Figure 18, which simply displays the LDA score for each category. Since the cladogram displays 
all significant features but does not display the LDA score, the two figures are complementary in 
terms of how they visualize the data. 
Among some of the findings of interest, the total predicted abundance of genes associated 
with lipid metabolism is increased in the metagenome of dogs with IBD (LDA=3.4). Pathways 
categorized as energy metabolism or carbohydrate metabolism were decreased (LDA=3.5 and 3.7, 
respectively), with significant subcategories of methane metabolism (LDA=3.1), amino sugar and 
nucleotide sugar metabolism (LDA=3.2), and starch and sucrose metabolism (LDA=3.2). As seen 
in the cladogram, pathways associated with the two component system, nested within the signal 
transduction subcategory of environmental information processing, are increased in abundance 
among dogs with IBD (LDA=3.4, 3.4, and 4.0, respectively). Genetic information processing 
pathways, through subcategories of both translation and replication and repair, are relatively 
decreased in abundance among dogs with IBD (LDA=4.0, 3.6, and 3.8). Importantly, significant 
features can be masked by the nature of the hierarchical structure of the categories/subcategories. 
If an enzyme responsible for microbial lipid transport were decreased in abundance, while a 
different enzyme responsible for lipid degradation were increased, there may be no net effect to 
the abundance of the category of lipid metabolism. For this reason, it is also important to explore 
the data as individual KOs, irrespective of their categorization into the hierarchical structure. 
4.3.2 Individual KEGG orthologous genes 
When the data were analyzed as individual KOs, 23 exceeded the significance threshold 
of LDA=log 2.5 (Table 8). For illustrative purposes, an example of the distribution across all of 
the samples of a particular KO is shown in Figure 19, in this case showing K02014, iron complex 
outer membrane receptor protein. This KO was significantly increased in dogs with IBD 
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(LDA=3.2). Other uncategorized KO findings included two KOs associated with the NitT/TauT 
family transport system, which is involved in osmoprotection through transport of nitrate and 
taurine, and were significantly increased in the microbiome of dogs with IBD (LDA=2.7, 2.5). 
The abundances of three KOs associated with the multiple sugar transport system were decreased 
in dogs with IBD (LDA=3.0, 2.9, and 2.7). The abundance of the KO corresponding to the enzyme 
6-phosphofructokinase 1 was also decreased relative to the healthy dogs (LDA=2.5). 
 
a: Two component system
b: Signal transduction
c: Environmental information processing
d: DNA repair and recombination proteins
e: DNA replication proteins
f: Replication and repair
g: Ribosome
h: Translation
i: Genetic information processing
j: Flavone and flavonol biosynthesis
k: Amino sugar and nucleotide sugar metabolism
















Figure 17. Cladogram of pathways organized by KEGG hierarchy. Relative changes in abundances 
of pathway categories may allow inference of selective pressure within the gastrointestinal tract 
or suggest components playing a role in the pathophysiology of IBD. Individual pathways are not 
















2.98 K02025: multiple sugar transport system permease protein 
2.91 K02026: multiple sugar transport system permease protein 
2.87 K06147: ATP-binding cassette, subfamily B, bacterial 
2.74 K02027: multiple sugar transport system substrate-binding protein 
2.69 K01190: beta-galactosidase 
2.68 K07024: K07024 (hypothetical protein; hydrolase) 
2.65 K03497: chromosome partitioning protein, ParB family 
2.64 K03530: DNA-binding protein HU-beta 
2.59 K07133: K07133 
2.59 K05349: beta-glucosidase 
2.57 K03169: DNA topoisomerase III 
2.56 K01990: ABC-2 type transport system ATP-binding protein 
2.53 K00850: 6-phosphofructokinase 1 
2.53 K03091: RNA polymerase sporulation-specific sigma factor 
2.52 K06180: 23S rRNA pseudouridine1911/1915/1917 synthase 






3.18 K02014: iron complex outer membrane receptor protein 
2.69 K02051: NitT/TauT family transport system substrate-binding protein 
2.68 K02029: polar amino acid transport system permease protein 
2.60 K03293: amino acid transporter, AAT family 
2.55 K00140: malonate-semialdehyde dehydrogenase (acetylating) / methylmalonate-semialdehyde dehydrogenase 
2.51 K02050: NitT/TauT family transport system permease protein 
2.51 K06911: K06911 
LDA Score (log 10)
0 1 2 3 4
1_Unclassified | 2_Genetic Information Processing
1_Unclassified | 2_Cellular Processes and Signaling | 3_Sporulation
1_Metabolism | 2_Energy Metabolism | 3_Methane Metabolism
1_Metabolism | 2_Enzyme Families | 3_Peptidases
1_Genetic Information Processing | 2_Replication and Repair | 3_DNA replication proteins
1_Metabolism | 2_Carbohydrate Metabolism | 3_Starch and sucrose metabolism
1_Metabolism | 2_Nucleotide Metabolism | 3_Purine metabolism
1_Metabolism | 2_Carbohydrate Metabolism | 3_Amino sugar and nucleotide sugar metabolism
1_Metabolism | 2_Nucleotide Metabolism | 3_Pyrimidine metabolism
1_Metabolism | 2_Metabolism of Cofactors and Vitamins
1_Genetic Information Processing | 2_Translation | 3_Ribosome
1_Metabolism | 2_Energy Metabolism
1_Metabolism | 2_Nucleotide Metabolism
1_Genetic Information Processing | 2_Translation
1_Metabolism | 2_Carbohydrate Metabolism
1_Genetic Information Processing | 2_Replication and Repair
1_Genetic Information Processing
1_Unclassified | 2_Cellular Processes and Signaling | 3_Pores ion channels
1_Metabolism | 2_Metabolism of Terpenoids and Polyketides | 3_Geraniol degradation
1_Unclassified | 2_Poorly Characterized
1_Unclassified | 2_Poorly Characterized | 3_Function unknown
1_Environmental Information Processing | 2_Signal Transduction
1_Environmental Information Processing | 2_Signal Transduction | 3_Two component system
1_Metabolism | 2_Lipid Metabolism
1_Environmental Information Processing
Increased in IBD Decreased in IBD
Figure 18. Linear discriminant analysis effect size (LEFSe) of categories. LEfSe identifies 
significant differences between groups using nonparametric factorial Kruskal-Wallis sum-rank 






It has previously been shown in humans that the rectal mucosa-associated microbiota is a 
better indicator of disease than the fecal microbiota (Gevers et al. 2014), potentially indicating that 
the organisms more closely interfacing with the host immune system have greater impact on 
disease status. The sequencing data generated from duodenal mucosal biopsies in this study may 
thus be of greater relevance to disease status compared to that generated from canine feces. The in 
silico conversion of sequencing data to predicted metagenomic community potential is an 
interesting alternative approach to viewing the sequencing data from a functional perspective. It 
has been established that the breadth and diversity of metabolic potential of the gut microbiota 
greatly exceeds the metabolic functions encoded by the host genome. Furthermore, the microbiota 
Figure 19. KO abundance of iron complex outer membrane receptor protein. Each bar represents 
an individual sample; the samples from dogs with IBD are also grouped by disease severity. Solid 






as a community represent a highly adaptive metabolic repertoire that when altered may play a role 
in either the onset or perpetuation of gastrointestinal diseases. This is reflected in the observation 
that a population shift of the gastrointestinal microbiota (dysbiosis) occurs among dogs with IBD, 
possibly reflecting selective pressure by the inflamed gastrointestinal environment and/or some 
other underlying facet of the etiopathogenesis of IBD. 
The two component system pathways, which were significantly more abundant in the 
predicted bacterial metagenome of dogs with IBD, may suggest an instability of the 
gastrointestinal environment, necessitating enhanced sense-and-response capabilities among 
resident microbiota. Concurrently, the significant decrease in genetic information processing 
pathways and subcategories could be suggestive of a microbial composition that is less prepared 
for replication, though assigning such specific functions to such broad categories is likely an 
overstatement of the data. 
Also observed were relative increases of lipid metabolism pathways and decreased 
carbohydrate metabolism. This may suggest a role of lipid-associated metabolites, including 
sterols, fatty acids, or bile acids, or could reflect an effect of the higher median (and range) fat 
content of diets fed to study dogs with IBD compared to the standard ration fed to all control dogs 
(4.1 (2.9-5.0) versus 2.5 g of fat/100 kcal ME). Additionally, the importance of the intestinal 
mucosa in the assimilation of lipids has been briefly discussed in Section 1.1, and altered function 
of the mucosa in a diseased state (due to inflammation) could be implicated in an altered 
composition of lipids in the lumen, which in turn may exert a selective pressure on the microbiota 
and thus drive changes in the metabolic capacity represented by the microbiota in dogs with IBD 
compared to healthy control dogs. 
Among individual KOs, the increased abundance of K02014 (iron complex outer 
membrane receptor protein) may occur with gastrointestinal bleeding, which increases the 
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concentration of iron in the lumen. It is also interesting to point out that there were several KOs 
listed that had limited or no description: K07133, K06911, and K07024. In these cases, the 
predicted gene sequence was recognized as encoding a relevant (that is, putatively functional) 
protein, but the function of said protein is unknown. However, the database of KOs is continuing 
to expand as new sequences are identified in a broader range of organisms. K07024 has since been 
further identified to be sucrose-6-phosphatase, an enzyme that plays a role in starch and sucrose 
metabolism. K06911 and K07133 remain uncharacterized proteins. To take complete advantage 
of the expanding databases, the components of PICRUSt will also require updating, as the vast 
range of metabolic functions attributed to the GI microbiota continues to expand.  
4.5 CONCLUSIONS 
Exploring how the abundances of metabolic functions or pathways changes in different 
disease states may help elucidate how bacterial species and their metabolites play a critical 
functional role in disease pathogenesis. The computational approach employed in this study allows 
reanalysis of existing data from a new perspective, highlighting differences at a functional level 
that might not have been observed when looking at the data purely based on bacterial identities. 
An in depth examination of these data compared to the host gene expression data (Wilke et al. 
2012) might also yield interesting correlations, though methods to combine different dependent 
data sets in meaningful ways (that is, beyond purely mathematical correlations) remain relatively 
unproven. Further studies are needed to evaluate metabolites involved in the identified categories 




5. DISCOVERY OF POTENTIAL FECAL BIOMARKERS FOR CHRONIC 
ENTEROPATHY USING UNTARGETED METABOLOMICS 
 
OVERVIEW 
Intestinal dysbiosis in dogs is defined as a relative shift in composition of bacterial 
populations in the gastrointestinal tract (GIT) and has been associated with chronic enteropathy 
(CE). Our group has previously reported small intestinal or fecal dysbiosis and decreased species 
richness in canine spontaneous inflammatory bowel disease. However, due to functional 
redundancy between bacterial groups, determining the biochemical changes in the GIT requires 
direct analysis of the biomolecules that are present. The aim of this study was to evaluate 
differences in fecal metabolite profiles between dogs with chronic gastrointestinal inflammation 
and healthy control dogs. 
Fecal samples were collected from dogs with histopathological evidence of 
gastrointestinal inflammation (n=15) and from healthy control dogs (n=15). The fecal 
metabolome, comprised of metabolic products from both the host and the microbiota, was assessed 
using an untargeted approach combining LC-MS and GC-MS platforms. Random Forest Analysis 
was used to rank differentiating power of metabolites, and the Mann-Whitney U-test followed by 
the Benjamini-Hochberg adjustment of p-values for multiple comparisons was used to test for 
statistical significance (q<0.05). 
A total of 787 named biochemical compounds were identified. Of these, 145 were 
significantly altered after adjusting for multiple comparisons (q<0.05). Among major metabolic 
pathways, some metabolites associated with GIT redox homeostasis were altered, including 
significantly increased concentrations of precursors of glutathione: 5-oxoproline (q=0.004), 
cysteine (q=0.024), glycine (q=0.003), and γ-glutamyl amino acid derivatives of lysine, 
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phenylalanine, valine, and leucine (all q≤0.015). Primary bile acids were generally increased in 
dogs with disease (cholate, q=0.013; chenodeoxycholate, q=0.055), while secondary bile acids 
were generally decreased in dogs with chronic enteropathy (deoxycholate, q=0.045; lithocholate, 
q=0.059), suggesting impaired bacterial conversion from primary to secondary bile acids. 
Metabolites within the aromatic amino acid biosynthesis pathway exhibited some of the most 
significant alterations. The tryptophan metabolites indoleacetate and indolepropionate were 
significantly decreased in dogs with disease (q=0.008 and 0.030, respectively). 2-oxindole-3-
acetate, an oxidative degradation product of indoleacetate, was 100-fold decreased in diseased 
animals (q=0.001) and was highly ranked for discriminating power. 
This study demonstrates that feces are a rich sample matrix for biomolecules, representing 
both the host and microbial metabolite profiles. Several metabolites were identified that may be 
investigated as future biomarkers and may help elucidate the etiopathogenesis of canine chronic 
enteropathy.  
5.1 INTRODUCTION 
Chronic enteropathy (CE) is a complex group of diseases. It is characterized by clinical 
signs of gastrointestinal disease of at least three weeks of duration. The most frequent presenting 
complaint is diarrhea, but vomiting and weight loss are also commonly reported. For both CE in 
dogs and IBD in humans, changes in the gut microbiota have been strongly associated with the 
disease, although conclusive evidence is lacking as to whether this is a direct cause or effect, or 
simply part of the perpetuation of chronic abnormal immune activation. The microbiota are now 
considered by some to be an organ, inextricably linked to host health but having a somewhat 
independent physiology and can develop unique pathology. One means of pathology of the 
microbiota is an abnormal composition, or dysbiosis. A 454-pyrosequencing study in dogs based 
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on fecal 16S rRNA genes revealed decreased bacterial diversity, with increased 
Gammaproteobacteria and decreased Erysipelotrichia, Clostridia, and Bacteroidia in the fecal 
microbiota of dogs with IBD compared to healthy control dogs (Minamoto et al. 2015). The study 
also investigated the serum metabolite profiles of the dogs. Multivariate analyses suggested 
changes of the global serum metabolite composition, but few individual compounds were 
statistically significantly altered in the serum of dogs with IBD. Considering the location of lesions 
of IBD being the mucosa of the GI tract, and the capacity for control and correction that the host 
may have on the circulatory system, it would make sense that more profound changes might be 
observed by analyzing the composition of the digesta or feces. A study of a very large cohort of 
treatment-naïve pediatric Crohn’s disease (CD) patients included samples from the ileum, rectum, 
and feces (Gevers et al. 2014). The dysbiosis they reported in CD was not dissimilar to that 
reported in dogs, with decreases observed in Bacteroidales, Clostridiales, Erysipelotrichaceae, 
though they found that the mucosa-associated rectal microbiota correlated better to disease status 
than the fecal microbiota. The study also employed PICRUSt to interpret the sequencing data as a 
predicted collective functional capacity, finding what the authors described as associations 
between disease severity and oxidative stress, benzoate metabolism, loss of basic biosynthesis, 
and a “switch toward pathobiont-like auxotrophy,” implying a developing dependence on the host 
and concurrent change from symbiont to pathogen. However, PICRUSt is dependent on the 16S 
rRNA sequencing data, and is purely predictive of functional capacity but not actual metabolic 
activity. The actual biochemical composition of feces in disease versus health, shaped by both the 
metabolic effects of the host and the microbiota, could potentially highlight relevant alterations 
that are integral to disease status. The current study aim was to evaluate differences in fecal 
microbiota and metabolite compositions between dogs with chronic gastrointestinal inflammation 
and healthy control dogs. 
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5.2 MATERIALS AND METHODS 
5.2.1 Study population and sampling 
A subset of patients from an ongoing research project at the Gastrointestinal Laboratory 
(College of Veterinary Medicine, Texas A&M University, College Station, TX, USA) with a 
tentative diagnosis of chronic enteropathy and histopathological evidence of gastrointestinal 
inflammation and where surplus naturally-passed fecal samples were available (n=15) were 
retrospectively identified. Animals with reported immunomodulatory drug usage for treatment of 
the GI signs were excluded. A combination of banked and prospectively collected fecal samples 
from healthy control dogs (n=15) were also assembled.  
5.2.2 DNA extraction and sequencing 
Approximately 100 mg of each sample was taken for DNA extraction according to 
manufacturer’s protocol (ZR Fecal DNA MiniPrep, Zymo Research, Irvine, CA, USA). 
Amplification and sequencing of the V4 variable region 16S rRNA gene was performed at MR 
DNA (www.mrdnalab.com, Shallowater, TX, USA). Briefly, samples were barcoded and PCR 
primers 515F/806R were used in a 28-cycle PCR using the HotStarTaq Plus Master Mix Kit 
(Qiagen, USA) under the following conditions: 94°C for 3 minutes, followed by 28 cycles of 94°C 
for 30 seconds, 53°C for 40 seconds and 72°C for 1 minute, with final elongation at 72°C for 5 
minutes. A DNA library was prepared according to the Illumina TruSeq DNA library preparation 
protocol. Sequencing was performed on a MiSeq (Illumina) following the manufacturer’s 
guidelines. Sequence data were uploaded into the NCBI GenBank database under submission 
number SRP090443.  
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5.2.3 Analysis of sequences 
Quantitative Insights Into Microbial Ecology (QIIME, v. 1.8) was used for processing and 
analysis of sequences (Caporaso et al. 2010b). Raw sequence data were de-multiplexed, and low 
quality reads were filtered using default parameters. Chimeric sequences were detected using 
USEARCH (Edgar 2010) and removed prior to further analysis. Sequences were assigned to 
operational taxonomic units (OTUs) using an open-reference picking protocol in QIIME against 
the Greengenes database (v. 13.8) filtered at ≥97% similarity (Caporaso et al. 2010a; DeSantis et 
al. 2006; Q. Wang et al. 2007).  
5.2.3.1 Diversity metrics 
Without filtering rare sequences, samples were rarefied to an even depth of 66,000 reads. 
Alpha rarefaction plots, coverage and alpha diversity metrics (Goods coverage, Chao1, Shannon, 
and Observed Species), and beta diversity (weighted and unweighted UniFrac distance matrices) 
were determined using QIIME scripts (Lozupone and Knight 2005). Variation in community 
distributions was visualized with Principal Coordinates Analysis (PCoA) plots based on weighted 
and unweighted UniFrac distances and groups were compared using ANOSIM (Vazquez-Baeza 
et al. 2013). 
5.2.3.2 Taxonomic summaries 
To simplify taxonomic summaries, OTUs present in eight or fewer of the samples were 
filtered out of the original unrarefied OTU table (this cut-off was chosen to conservatively 
eliminate taxa that are very unlikely to be core members of the microbiota or relevant to disease 
status). Samples were then rarefied to an even depth of 60,000 reads per sample and QIIME was 
used to summarize taxa at all phylogenetic levels. Taxa were analyzed in JMP (SAS, Durham, NC, 
USA) to the level of genus, and tested for significant differences with a Mann-Whitney U test. P-
 106 
 
values were adjusted using the Benjamini-Hochberg step-up method, allowing a False Discovery 
Rate (FDR) of 0.05. 
5.2.4 Metabolomics data acquisition 
Samples were analyzed on a fee-for-service basis by Metabolon (Durham, NC, USA) 
using multiple mass spectrometry platforms. Briefly, samples were lyophilized, deproteinized with 
methanol, centrifuged, and the supernatant was divided for analysis on four platforms. The four 
analyses were UPLC-MS/MS in both positive and negative ion modes, LC polar (HILIC), and 
GC-MS. The aliquot for GC-MS was dried, derivatized using bistrimethyl-silyltrifluoroacetamide, 
and injected on a GC fitted with a 5% diphenyl / 95% dimethyl polysiloxane fused silica column 
(20 m x 0.18 mm ID; 0.18 μm film thickness) with helium as carrier gas and a temperature ramp 
from 60° to 340°C over 17.5 min. The detector was a Thermo-Finnigan Trace DSQ fast-scanning 
single quadrupole MS, using electron impact ionization and scanning from 50-750 m/z. The two 
aliquots for UPLC-MS/MS were analyzed under acidic (water and methanol containing 0.1% 
formic acid) or basic (water and methanol with 6.5 mM ammonium bicarbonate) conditions, using 
dedicated C18 columns (Waters UPLC BEH C18-2.1 x 100 mm, 1.7 μm) for each set of conditions. 
The LC polar aliquot was eluted from a HILIC column (Waters UPLC BEH Amide 2.1 x 150 mm, 
1.7 μm) using water and acetonitrile with 10 mM ammonium formate. The detector for all three 
LC-MS components was a Thermo Scientific Q-Exactive high resolution/accurate mass 
spectrometer interfaced with a heated electrospray ionization source and Orbitrap mass analyzer, 
scanning from 80-1000 m/z. Quantification for a given signal was determined by peak area. 
Metabolon applied a proprietary software algorithm and library for identification of metabolites 
and only data for known metabolites based on their assignments were curated and reported for 
further analysis (Dehaven et al. 2010; Evans et al. 2009; Evans et al. 2012). 
 107 
 
5.2.5 Analysis of metabolites 
JMP was used for univariate analysis, using a Mann-Whitney U test to determine 
significance. P-values were adjusted using the Benjamini-Hochberg step-up method, allowing a 
False Discovery Rate (FDR) of 0.05. Peak area values for known metabolites were uploaded to 
MetaboAnalyst 3.0 (Xia Lab, McGill University, Canada) (Xia et al. 2015). The data were log 
transformed and Pareto scaled before statistical analyses (Xia and Wishart 2011). Multivariate 
analyses were performed within MetaboAnalyst and included Principal Components Analysis 
(PCA), Partial Least Squares-Dimensional Analysis (PLS-DA), and Random Forest Analysis 
(RFA). Based on ranking of features by a simple t-test, the top 50 features were used to generate 
a heatmap to visualize metabolomic variability across individuals within groups and between 
groups.  
5.3 RESULTS 
5.3.1 Sample population demographics 
The diseased (median [range]) and healthy (median [range]) animals were not 
significantly different in terms of age (5.5 years [2-10] vs. 5 years [1-11], p=0.63), weight (18.2 kg 
[5.8-38.4] vs. 13.6 kg [5.0-30.2], p=0.43), or sex (9/15 male vs. 6/15 male, p=0.47). 
5.3.2 Sequencing data 
5.3.2.1 Diversity metrics 
Alpha diversity was significantly decreased in feces of dogs with CE based on the metric 
observed_species (p=0.001). ANOSIM revealed that samples from diseased and healthy dogs were 
significantly different (p=0.001). Alpha diversity plots are shown in Figure 20 and a PCoA plot 
based on unweighted UniFrac is shown in Figure 21. 
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5.3.2.2 Taxonomic summary 
Summary data for taxa from phylum to genus levels are shown in Table 9. Reported values are the 
median percentage of total reads and the range for the samples within the group. At the level of 
phylum, Bacteroidetes and Fusobacteria were significantly decreased in dogs with CE (q=0.0020 
and 0.0006, respectively), while the phylum Firmicutes was significantly increased (q=0.0007). 
While the increase in Firmicutes appears to be driven by increased Bacilli (q=0.0032), classes 
Clostridia and Erysipelotrichi were significantly decreased in disease (q=0.0451 and 0.0012). 
Although Proteobacteria were not significantly altered between groups, Betaproteobacteria 
significantly decreased in samples from dogs with CE while Gammaproteobacteria were 
significantly increased (q=0.0044 and 0.0206, respectively). 
Healthy 
CE 
Figure 20. Alpha diversity plots comparing sequences from feces of dogs with CE to those from 










Figure 21. PCoA plot based on unweighted UniFrac distances showing slightly overlapping 
clustering of samples from diseased and healthy dogs. 
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Table 9. Taxonomic summary of bacteria sequenced from fecal DNA from dogs with chronic 
enteropathy and healthy control dogs. Values are the percentage of reads. P- and q-values < 0.05 
are identified in boldface. “g__” indicates a genus of unknown identity; “f__” represents a family 
of unknown identity.  
Taxon 
Healthy Chronic Enteropathy 
p-value q-value 
Median Range Median Range 
% of reads % of reads 
Phylum Actinobacteria 1.83 [0.07-5.16] 0.42 [0.05-6.09] 0.0465 0.0760 
Class Actinobacteria 0.02 [0.01-0.03] 0.02 [0-5.01] 0.5323 0.6294 
Order Bifidobacteriales 0.02 [0.01-0.03] 0.02 [0-5.01] 0.5323 0.6294 
Family Bifidobacteriaceae 0.02 [0.01-0.03] 0.02 [0-5.01] 0.5323 0.6294 
Bifidobacterium 0.02 [0.01-0.03] 0.02 [0-5.01] 0.5323 0.6294 
Class Coriobacteriia 1.82 [0.06-5.13] 0.06 [0.04-6.07] 0.0016 0.0050 
Order Coriobacteriales 1.82 [0.06-5.13] 0.06 [0.04-6.07] 0.0016 0.0050 
Family Coriobacteriaceae 1.82 [0.06-5.13] 0.06 [0.04-6.07] 0.0016 0.0050 
Adlercreutzia 0.00 [0-0.07] 0.00 [0-0.01] 0.1971 0.2641 
Collinsella 1.63 [0.05-4.68] 0.06 [0.03-6.07] 0.0016 0.0050 
Slackia 0.01 [0-0.48] 0.01 [0-0.01] 0.4504 0.5640 
          
Phylum Bacteroidetes 15.07 [0.18-37.52] 0.23 [0.15-28.66] 0.0004 0.0020 
Class Bacteroidia 15.07 [0.18-37.52] 0.23 [0.15-28.66] 0.0004 0.0020 
Order Bacteroidales 15.07 [0.18-37.52] 0.23 [0.15-28.66] 0.0004 0.0020 
Family [Paraprevotellaceae] 0.29 [0.02-1.74] 0.03 [0.01-0.91] 0.0360 0.0661 
g__ 0.01 [0-0.01] 0.01 [0-0.21] 0.9662 0.9663 
[Prevotella] 0.29 [0.02-1.73] 0.02 [0.01-0.9] 0.0341 0.0635 
Family Bacteroidaceae 9.47 [0.13-37.45] 0.17 [0.1-27.71] 0.0006 0.0026 
Bacteroides 9.47 [0.13-37.45] 0.17 [0.1-27.71] 0.0006 0.0026 
Family Porphyromonadaceae 0.00 [0-1.82] 0.00 [0-0.03] 0.2050 0.2694 
Parabacteroides 0.00 [0-1.82] 0.00 [0-0.03] 0.2050 0.2694 
Family Prevotellaceae 0.12 [0.02-30.38] 0.03 [0.01-0.37] 0.0378 0.0676 
Prevotella 0.12 [0.02-30.38] 0.03 [0.01-0.37] 0.0378 0.0676 
Family S24-7 0.00 [0-0.03] 0.00 [0-0.01] 0.7930 0.8345 
g__ 0.00 [0-0.03] 0.00 [0-0.01] 0.7930 0.8345 
          
Phylum Firmicutes 78.40 [48.48-94.89] 98.32 [55.18-99.31] 0.0001 0.0007 
Class Bacilli 1.19 [0.62-80.54] 87.81 [0.73-96.96] 0.0008 0.0032 
Order Bacillales 0.00 [0-0.02] 0.00 [0-0.01] 0.8327 0.8583 
Family Planococcaceae 0.00 [0-0.01] 0.00 [0-0.01] 0.5900 0.6700 
g__ 0.00 [0-0] 0.00 [0-0] 0.3495 0.4461 
Sporosarcina 0.00 [0-0] 0.00 [0-0.01] 0.7765 0.8345 
Family Staphylococcaceae 0.00 [0-0.02] 0.00 [0-0.01] 0.7177 0.7819 
Staphylococcus 0.00 [0-0.02] 0.00 [0-0.01] 0.7177 0.7819 
Order Lactobacillales 0.63 [0.48-80.4] 87.53 [0.61-96.8] 0.0002 0.0012 
f__ 0.00 [0-0.01] 0.05 [0-2.27] 0.0001 0.0008 
g__ 0.00 [0-0.01] 0.05 [0-2.27] 0.0001 0.0008 
Family Enterococcaceae 0.14 [0.1-0.41] 1.17 [0.12-89.89] 0.0001 0.0006 
Enterococcus 0.02 [0.01-0.06] 0.20 [0.01-5.46] 0.0001 0.0010 
Other 0.12 [0.08-0.35] 0.97 [0.11-84.43] 0.0000 0.0006 
Family Lactobacillaceae 0.25 [0.18-3.63] 0.50 [0.21-90.43] 0.0006 0.0026 
Lactobacillus 0.24 [0.18-3.63] 0.47 [0.21-90.43] 0.0006 0.0026 




Table 9. (Continued.) 
Taxon 
Healthy Chronic Enteropathy 
p-value q-value 
Median Range Median Range 
% of reads % of reads 
Family Leuconostocaceae 0.01 [0-0.02] 0.02 [0-21.37] 0.0431 0.0740 
g__ 0.01 [0-0.02] 0.02 [0-21.37] 0.0431 0.0740 
Family Streptococcaceae 0.23 [0.16-76.34] 4.07 [0.21-82.59] 0.0054 0.0130 
Streptococcus 0.23 [0.16-76.34] 4.07 [0.21-82.59] 0.0054 0.0130 
Other 0.01 [0-0.02] 0.02 [0-0.3] 0.0457 0.0760 
Other 0.01 [0-0.02] 0.02 [0-0.3] 0.0457 0.0760 
Order Turicibacterales 0.22 [0.1-3.1] 0.16 [0.11-2.33] 0.8034 0.8345 
Family Turicibacteraceae 0.22 [0.1-3.1] 0.16 [0.11-2.33] 0.8034 0.8345 
Turicibacter 0.22 [0.1-3.1] 0.16 [0.11-2.33] 0.8034 0.8345 
Other 0.00 [0-0] 0.00 [0-0.01] 0.0881 0.1243 
Other 0.00 [0-0] 0.00 [0-0.01] 0.0881 0.1243 
Other 0.00 [0-0] 0.00 [0-0.01] 0.0881 0.1243 
Class Clostridia 59.15 [12.08-83.06] 6.47 [2.04-95.99] 0.0225 0.0451 
Order Clostridiales 59.15 [12.08-83.06] 6.47 [2.04-95.99] 0.0225 0.0451 
f__ 0.90 [0.13-1.36] 0.06 [0.02-1.32] 0.0048 0.0124 
g__ 0.90 [0.13-1.36] 0.06 [0.02-1.32] 0.0048 0.0124 
Family [Mogibacteriaceae] 0.01 [0-0.02] 0.01 [0-0.02] 0.6293 0.7028 
g__ 0.01 [0-0.02] 0.01 [0-0.02] 0.6293 0.7028 
Family [Tissierellaceae] 0.00 [0-0.01] 0.00 [0-0.01] 0.9663 0.9663 
g__ 0.00 [0-0.01] 0.00 [0-0.01] 0.9663 0.9663 
Family Clostridiaceae 14.72 [4.88-56.94] 2.56 [0.67-57.05] 0.0028 0.0077 
g__ 2.47 [0.6-41.8] 0.42 [0.13-7.3] 0.0225 0.0451 
Clostridium 0.33 [0.13-11.02] 0.19 [0.06-5.32] 0.2715 0.3533 
Sarcina 0.01 [0-0.14] 0.01 [0-0.02] 0.1436 0.1944 
SMB53 0.27 [0.05-3.33] 0.06 [0.03-0.64] 0.0487 0.0787 
Other 9.26 [0.78-19.91] 0.47 [0.3-48.61] 0.0021 0.0061 
Family Lachnospiraceae 27.36 [6.25-39.25] 4.59 [0.48-79.59] 0.0680 0.1047 
g__ 1.03 [0.12-3.81] 0.07 [0.03-5.58] 0.0019 0.0054 
[Ruminococcus] 2.98 [0.5-7.82] 0.23 [0.06-36.77] 0.0745 0.1134 
Blautia 16.23 [2.18-23.17] 0.68 [0.24-37.81] 0.0465 0.0760 
Coprococcus 0.03 [0-0.39] 0.00 [0-0.23] 0.0406 0.0716 
Dorea 3.70 [0.66-9.66] 0.24 [0.09-9.82] 0.0101 0.0219 
Epulopiscium 0.01 [0-5.38] 0.00 [0-0.04] 0.3353 0.4320 
Roseburia 0.02 [0-0.48] 0.00 [0-0.07] 0.0018 0.0054 
Other 0.30 [0.11-0.46] 0.10 [0.02-1.16] 0.1149 0.1587 
Family Peptococcaceae 0.08 [0.02-6.49] 0.05 [0.03-0.1] 0.0589 0.0919 
Peptococcus 0.08 [0.02-6.49] 0.05 [0.03-0.1] 0.0589 0.0919 
Family Peptostreptococcaceae 0.21 [0.03-7.37] 0.04 [0.02-0.51] 0.0089 0.0206 
g__ 0.17 [0.03-7.35] 0.03 [0.01-0.5] 0.0054 0.0130 
Peptostreptococcus 0.01 [0-0.02] 0.01 [0-0.02] 0.6438 0.7130 
Other 0.01 [0-0.38] 0.00 [0-0.04] 0.0341 0.0635 
Family Ruminococcaceae 2.82 [0.16-17.29] 0.13 [0.04-4.79] 0.0011 0.0040 
g__ 0.35 [0.04-1.89] 0.03 [0.01-1.7] 0.0004 0.0019 
Faecalibacterium 2.21 [0.03-15.6] 0.06 [0.02-4.39] 0.0224 0.0451 
Oscillospira 0.04 [0.01-0.1] 0.02 [0.01-0.08] 0.1190 0.1627 
Ruminococcus 0.03 [0-0.53] 0.01 [0-0.03] 0.0018 0.0054 
Family Veillonellaceae 1.23 [0.06-21.4] 0.06 [0.04-2.97] 0.0003 0.0019 
Megamonas 0.92 [0.05-21.39] 0.05 [0.03-2.96] 0.0003 0.0017 




Table 9. (Continued.) 
Taxon 
Healthy Chronic Enteropathy 
p-value q-value 
Median Range Median Range 
% of reads % of reads 
Other 0.09 [0.02-0.59] 0.06 [0.01-0.1] 0.0324 0.0622 
Other 0.09 [0.02-0.59] 0.06 [0.01-0.1] 0.0324 0.0622 
Class Erysipelotrichi 6.81 [0.66-23.16] 0.32 [0.17-9.5] 0.0002 0.0012 
Order Erysipelotrichales 6.81 [0.66-23.16] 0.32 [0.17-9.5] 0.0002 0.0012 
Family Erysipelotrichaceae 6.81 [0.66-23.16] 0.32 [0.17-9.5] 0.0002 0.0012 
g__ 1.24 [0.05-6.47] 0.07 [0.04-1.75] 0.0010 0.0040 
[Eubacterium] 1.18 [0.18-10.91] 0.10 [0.05-6.97] 0.0003 0.0017 
Allobaculum 0.78 [0.05-6.2] 0.07 [0.04-2.31] 0.0590 0.0919 
Bulleidia 0.00 [0-0] 0.00 [0-0] 0.3554 0.4492 
Catenibacterium 1.35 [0.02-17.93] 0.04 [0.02-2.54] 0.0212 0.0451 
Clostridium 0.00 [0-0.01] 0.00 [0-0.01] 0.0023 0.0065 
Coprobacillus 0.02 [0-0.72] 0.00 [0-0.02] 0.0325 0.0622 
Erysipelothrix 0.01 [0-0.02] 0.01 [0-0.02] 0.4761 0.5907 
          
Phylum Fusobacteria 4.45 [1.29-16.9] 0.28 [0.21-9.85] 0.0001 0.0006 
Class Fusobacteriia 4.45 [1.29-16.9] 0.28 [0.21-9.85] 0.0001 0.0006 
Order Fusobacteriales 4.45 [1.29-16.9] 0.28 [0.21-9.85] 0.0001 0.0006 
Family Fusobacteriaceae 4.45 [1.29-16.9] 0.28 [0.21-9.85] 0.0001 0.0006 
Fusobacterium 4.41 [1.28-16.84] 0.28 [0.21-9.78] 0.0001 0.0006 
Other 0.04 [0.01-0.09] 0.00 [0-0.06] 0.0000 0.0006 
          
Phylum Proteobacteria 0.21 [0.01-1.33] 0.20 [0.01-9.19] 0.9174 0.9384 
Class Betaproteobacteria 0.16 [0-0.59] 0.01 [0-0.19] 0.0013 0.0044 
Order Burkholderiales 0.16 [0-0.59] 0.01 [0-0.19] 0.0013 0.0044 
Family Alcaligenaceae 0.16 [0-0.59] 0.01 [0-0.19] 0.0013 0.0044 
Sutterella 0.16 [0-0.59] 0.01 [0-0.19] 0.0013 0.0044 
Class Epsilonproteobacteria 0.00 [0-0.04] 0.00 [0-0.01] 0.0792 0.1154 
Order Campylobacterales 0.00 [0-0.04] 0.00 [0-0.01] 0.0792 0.1154 
Family Helicobacteraceae 0.00 [0-0.04] 0.00 [0-0.01] 0.0792 0.1154 
Helicobacter 0.00 [0-0.04] 0.00 [0-0.01] 0.0792 0.1154 
Class Gammaproteobacteria 0.01 [0-0.72] 0.14 [0.01-9.18] 0.0092 0.0206 
Order Enterobacteriales 0.01 [0-0.72] 0.14 [0.01-9.18] 0.0092 0.0206 
Family Enterobacteriaceae 0.01 [0-0.72] 0.14 [0.01-9.18] 0.0092 0.0206 
g__ 0.01 [0-0.72] 0.13 [0.01-9.17] 0.0098 0.0215 
Other 0.00 [0-0] 0.00 [0-0.02] 0.0033 0.0089 
          
Phylum Tenericutes 0.00 [0-0.01] 0.00 [0-1.2] 0.5495 0.6294 
Class Mollicutes 0.00 [0-0.01] 0.00 [0-1.2] 0.5495 0.6294 
Order Anaeroplasmatales 0.00 [0-0.01] 0.00 [0-1.2] 0.5495 0.6294 
Family Anaeroplasmataceae 0.00 [0-0.01] 0.00 [0-1.2] 0.5495 0.6294 
Anaeroplasma 0.00 [0-0.01] 0.00 [0-1.2] 0.5495 0.6294 






5.3.3.1 Univariate analysis 
A total of 787 named biochemical compounds were identified. Of these, 269 had p<0.05, 
and 145 were significantly altered after adjusting for multiple comparisons (q<0.05). The median 
normalized peak areas and ranges for named metabolites are shown in the Appendix, Table A-2, 
along with their corresponding p- and q-values. 
5.3.3.2 Multivariate analysis 
The PCA plot comparing the unsupervised grouping of samples is shown in Figure 22 
along with the PLS-DA plot, which is a supervised method, showing much more distinct 
separation. To visualize the distribution of specific metabolites responsible for the characterization 
of the samples, a heatmap made up of the top 50 ranked features (by t-test) is shown in Figure 23.  
Figure 22. Clustering of samples using PCA and PLS-DA plots. The PCA plot (left) employs an 
unsupervised method and groups overlap slightly, while clear separation is evident in the PLS-DA 





Figure 23. Heatmap using the top 50 features as ranked by a t-test. Each column corresponds to 
an individual sample, with the left half corresponding to 15 healthy control dogs and the right 
half corresponding to 15 dogs with chronic enteropathy. Metabolites are displayed in rows, where 




As described previously, identifying metabolites as significant using more than one 
statistical analysis method adds support to the metabolite alteration being genuine. The top 50 
metabolites ranked each by PLS-DA VIP scores and RFA mean decrease accuracy are compared 
in Table 10. 
 
 
Table 10. The 24 compounds that were ranked among the top 50 metabolites by both RFA and 
PLS-DA. 
Compound RFA rank PLS-DA rank 
3-4-hydroxyphenylpropionate 1 9 
2-oxindole-3-acetate 2 1 
p-aminobenzoate PABA 3 4 
4-hydroxybenzoate 4 6 
sitostanol  5 13 
1,5-anhydroglucitol 1,5-AG 6 20 
xylose 8 22 
thiamin Vitamin B1 9 10 
N-acetylmethionine 10 25 
lactate 11 3 
5-2-Hydroxyethyl-4-methylthiazole 14 34 
N-acetylalanine 20 44 
isoferulate 21 38 
gamma-glutamyllysine 24 7 
gamma-glutamylphenylalanine 25 23 
tyramine 26 49 
aspartylaspartate 27 8 
syringic acid 31 15 
gentisate 32 41 
2-hydroxy-3-methylvalerate 33 17 
glycine 36 47 
aspartylglycine 45 26 
alpha-hydroxyisocaproate 46 16 
eriodictyol 47 18 







The results of 16S rRNA sequencing reported in this study are not vastly dissimilar from 
previously reported results comparing samples from healthy dogs to those from dogs with chronic 
enteropathy. One somewhat surprising finding was the increased percentage of sequences 
corresponding to the phylum Firmicutes in samples from diseased dogs. However, this was largely 
driven by profoundly increased groups within the order Lactobacillales, while the groups 
Bacteroidia, Clostridia, and Erysipelotrichi were decreased as has been previously reported in both 
human IBD and canine CE (Minamoto et al. 2015; Honneffer et al. 2014; AlShawaqfeh et al. 2016; 
Dandrieux 2016). This inconsistency regarding Lactobacillales has previously been reported for 
humans with IBD (W. Wang et al. 2014). In the present study, there were subjectively some 
inconsistencies between the owner and referring veterinarian questionnaires regarding the 
reporting of medications, so one possibility is that this particular cohort of dogs with CE had been 
treated more intensively with antibiotics, probiotics, or other medications that might influence the 
microbiota. Metronidazole in particular has been shown to greatly increase fecal lactate via 
increased lactic acid bacteria (Suchodolski et al. 2016). Regardless, the results of the 16S rRNA 
sequencing in the present study are not inconsistent with previously reported studies in dogs with 
CE. 
5.4.2 Metabolomics 
Alterations in the fecal microbiota have repeatedly been identified in both human patients 
with IBD and dogs with CE. However, the mechanism by which the bacteria play a role in disease 
has not been elucidated. Considering the microbiota as a metabolically active organ, a shift in the 
collective function of the host and microbiota may manifest as altered biochemical composition 
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within the lumen of the GI tract and this may play a role in the pathogenesis of disease. 
Unfortunately, this is simultaneously one of the weaknesses of metabolomics: while the 
biochemical composition can be determined without concern for the origin of the metabolite (host, 
microbiota, or both), it also means that interpretation of potential causes for an altered composition 
is greatly complicated. Some studies take care to determine which metabolites are thought to be 
of a specific origin, as done by Sridharan et al. (2014) with a focus on aromatic amino acid 
metabolites. Therefore, an attempt to summarize a biological interpretation of the entire untargeted 
metabolomics data set would quickly become an intense tangle of trans-kingdom biochemical 
webs. Instead, some metabolites can be grouped together based on a known biochemical or 
physiological relationship (e.g., redox homeostasis) for proposed interpretation. It should be noted, 
however, that even these proposed interpretations require much more rigorous experimentation 
before considering them as anything more than fanciful ideas. 
Among major metabolic pathways, some metabolites associated with GIT redox 
homeostasis were altered, including significantly increased concentrations of precursors of 
glutathione: 5-oxoproline (q=0.004), cysteine (q=0.024), glycine (q=0.003), and γ-glutamyl amino 
acid derivatives of lysine, phenylalanine, valine, and leucine (all q≤0.015). The γ-glutamyl amino 
acids are generated by gamma-glutamyl transpeptidase (GGT), which is located on the outer 
surface of the cell plasma membrane and has extracellular activity (Zhang et al. 2005). The host 
peroxisome is implicated in redox metabolism, but also plays a significant role in β-oxidation of 
fatty acids (Deb and Nagotu 2017). A schematic of the redox cycle and the distribution of samples 




Primary bile acids were generally increased in dogs with disease (cholate, q=0.013; 
chenodeoxycholate, q=0.055), while secondary bile acids were generally decreased in dogs with 
chronic enteropathy (deoxycholate, q=0.045; lithocholate, q=0.059), suggesting impaired bacterial 
conversion from primary to secondary bile acids. Recent and ongoing work in our lab has 
identified a very strong relationship between Clostridium hiranonis and bile acid profiles 
(unpublished work). Though the data in the present study were not shown since species-level 
assignment of taxa is somewhat unreliable, C. hiranonis was significantly decreased in the dogs 
with CE (Mann-Whitney U test resulted in p=0.0095, uncorrected for multiple comparisons). Also 
of interest is that there were three dogs with CE that had normal C. hiranonis sequence 




















































healthy dogs on the global metabolite profiles represented by PCA plots (see Figure 8). Although 
far from being conclusive evidence, it is interesting that out of a 787-feature metabolome 
composition and over 200-taxa microbiota composition, certain key features may account for 
classification and warrant further targeted inspection, particularly to determine if perhaps the cause 
of chronic GI signs in these individuals is of an alternative etiology. 
Other metabolites exhibiting significant alterations included those within the aromatic 
amino acid biosynthesis pathway. The tryptophan metabolites indoleacetate, 5-
hydroxyindoleacetate, and indolepropionate were significantly decreased in dogs with disease 
(q=0.008, 0.008, and 0.030, respectively), though tryptophan and indolelactate trended up in 
diseased animals (q=0.156 and 0.137, respectively). 2-oxindole-3-acetate, an oxidative 
degradation product of indoleacetate, was 100-fold decreased in diseased animals (q=0.001) and 
was very highly ranked for discriminating power out of all detected metabolites. Among the data 
for gene expression in duodenal biopsies of dogs with IBD (Wilke et al. 2012), the gene 
SLC16A10 exhibited a 4-fold increase in expression in dogs with IBD. This gene encodes a 
sodium-independent aromatic amino acid transporter. Although the gene expression data is host-
specific and the data are based on duodenal tissues, while the metabolomics data corresponds to 
feces, it is possible that the increased transporter expression is depriving the luminal contents of 
those aromatic amino acids. Conversely, the gene expression data also showed a 3.5-fold decrease 
in SLC1A1, the excitatory amino-acid transporter 3 (EAAT3). EAAT3 is a major route of neuronal 
cysteine uptake (Guitart et al. 2015), also potentially related to the previously mentioned redox 
homeostasis and potentially a partial cause for increased fecal cysteine among dogs with CE. 
Additionally, the ability of the microbiota to metabolize amino acids has also been described 
(Mead 1971; Smith and Macfarlane 1996; Sridharan et al. 2014). Regardless, the pattern of certain 
amino acids being increased while others were decreased does suggest that the cause is not just a 
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simple change in absorptive ability for the host, and further supports the idea that some metabolites 
are bioactive and their presence may influence other biochemical relationships. 
Also evident in the data and particularly relevant to our ongoing research are potential 
alterations in lipid metabolism in dogs with CE, which have been shown to some extent in human 
IBD patients (Shores et al. 2011). Several classes of lipids were altered in disease, to varying levels 
of significance. Saturated LCFAs palmitic and stearic acids were increased in disease (q=0.156 
and 0.022); monounsaturated VLCFAs erucic and eicosenoic (also known as gondoic) acids also 
were increased. Interestingly, among PUFAs there were significant increases of both n-3 and n-6 
fatty acids: docosatrienoate (22:3 n-3, q=0.020), arachidonate (20:4 n-6, q=0.045), and 
docosadienoate (22:2 n-6, q=0.060). It was mentioned previously that ω-oxidation of fatty acids 
results in conversion of the terminal methyl group on a fatty acid to a second carboxylic acid 
group. Interestingly, saturated dicarboxylic fatty acids from seven to eleven carbons in length were 
decreased among animals with disease: pimelate, suberate, azelate, sebacate, and undecanedioate 
(q=0.007, 0.049, 0.007, 0.020, and 0.005, respectively). Of the corresponding saturated MCFAs, 
only C8 (caprylic acid) and C10 (capric acid) were reported in the data, and were not significantly 
different between healthy and diseased animals. This may indicate alterations in ω-oxidation of 
fatty acids in diseased animals, but the MCFAs also could have been diverted to other products 
without necessarily an underlying defect in ω-oxidation pathways. Interestingly, the primary 
degradation of fatty acids occurs in the peroxisome by β-oxidation, and the peroxisome is also 
credited with a role in redox homeostasis along with many other functions (Deb and Nagotu 2017). 
Other altered lipids include some sterols. Interestingly, cholesterol trended to higher 
concentrations in feces of dogs with CE (q=0.128) while coprostanol (the hydrogenated form of 
cholesterol) trended to lower concentrations (q=0.190). A correlation between cholesterol-to-
coprostanol conversion and GI health has been shown in people (Antharam et al. 2016; Olejníková 
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et al. 2017), but the dog supposedly does not host the microbiota capable of biohydrogenating 
cholesterol, so it is unclear whether this trend is suggestive of a similar situation in the dog, or if 
coprophagia (ingestion of coprostanol from eating other animal’s feces) could be a confounding 
factor. Additionally, several phytosterols were decreased: β-sitosterol (q=0.003), campesterol 
(q=0.067), fucosterol (q=0.006), and sitostanol (q=0.001). Because these sterols are associated 
with plants, an association with diet should be considered, but it is also conceivable that the net 
effects of intraluminal sterol homeostasis are affected by disease, and further exploration of these 
metabolites is warranted. 
5.5 CONCLUSIONS 
This study demonstrates that feces are a rich sample matrix for biomolecules, representing 
both the host and microbial metabolite profiles. Several metabolites were identified that may be 
investigated as future biomarkers and may help elucidate the etiopathogenesis of canine chronic 
enteropathy. Specifically of interest are compounds associated with lipid metabolism: bile acids, 




6. DEVELOPMENT AND VALIDATION OF A GAS CHROMATOGRAPHY-
MASS SPECTROMETRY ASSAY FOR THE QUANTIFICATION OF STEROL 
AND FATTY ACID CONCENTRATIONS IN CANINE FECES 
 
OVERVIEW 
Cholesterol is the most abundant sterol in mammalian tissues, playing a critical role in cell 
membrane function and serving as a precursor molecule for hormones, vitamins, and bile acids. 
Structurally similar to cholesterol, phytosterols have been associated with anti-inflammatory 
effects in rodent models of colitis. Previous studies have shown altered fecal sterol concentrations 
in dogs with chronic enteropathy. Fatty acids are an important source of energy, and along with 
sterols, they are also critical for intestinal epithelial cell membrane structure and function. The aim 
of this study was to analytically validate a gas chromatography-mass spectrometry (GC-MS) assay 
for the measurement of several sterols (i.e., cholesterol, coprostanol, cholestanol, β-sitosterol, 
stigmasterol, campesterol, sitostanol, and fucosterol) and fatty acids (i.e., palmitic, oleic, linoleic, 
α-linolenic, stearic, gondoic, and erucic acids) in canine fecal samples. 
A fecal sample was collected from eight dogs, lyophilized, and used for assessment of 
intra- and inter-assay variability (%CV). Sample and standard preparation were adapted from 
published methods, using deuterated analogs of cholesterol, sitostanol, and stearic acid for internal 
standards. Validation parameters also included lower and upper limits of quantitation (LLOQ and 
ULOQ, respectively). Quality control procedure for each sample run consisted of blanks, 
continuing calibration verification of standards, and a laboratory control sample of pooled feces.  
Intra- and inter-assay variability (median %CV) were 4% and 6% for cholesterol, 5% and 
10% for coprostanol, 4% and 9% for cholestanol, 4% and 5% for β-sitosterol, 4% and 7% for 
stigmasterol, 4% and 6% for campesterol, 4% and 11% for sitostanol, 6% and 10% for fucosterol, 
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4% and 7% for palmitic acid, 4% and 8% for oleic acid, 8% and 7% for linoleic acid, 14% and 
12% for α-linolenic acid, 4% and 6% for stearic acid, 5% and 11% for gondoic acid, and 10% and 
18% for erucic acid. Limits of quantitation for each compound in μg/mL (LLOQ-ULOQ) were as 
follows: palmitic acid (7.8-2,000), linoleic acid (15.6-2,000), α-linolenic acid (3.1-200), oleic acid 
(7.8-2,000), stearic acid (3.9-2,000), gondoic acid (0.39-200), erucic acid (0.78-200), cholesterol 
(3.9-2,000), campesterol (6.3-400), stigmasterol (0.78-100), fucosterol (1.6-200), β-sitosterol 
(12.5-800), coprostanol (0.78-200), cholestanol (3.1-200), and sitostanol (3.1-200). 
In conclusion, the GC-MS method validated here is precise, reproducible, and sensitive 
for the quantification of several sterols and fatty acids in canine fecal samples. 
6.1 INTRODUCTION 
Sterols and fatty acids are two subclasses of the biochemicals known as lipids, having the 
defining feature of insolubility in water. Given the aqueous nature of most organisms, there is an 
inherent conflict in the dependence on lipids – yet the hydrophobic nature of lipids is also what 
permits formation of barriers, such as cell membranes. Cholesterol, the most abundant sterol in 
mammalian tissues, is an important precursor for bile acids, vitamins, and hormones. It also plays 
a role in formation of lipid rafts, which are part of cell signaling regulation (Lingwood and Simons 
2010). Fatty acids are critical for cell structure as well, comprising much of the phospholipid 
bilayer, and also serve as a substrate for generation of energy in mitochondria. Based on an 
untargeted metabolomics study comparing feces from dogs with chronic enteropathy to those of 
healthy control dogs (described in Section 5), sterols and fatty acids were identified as potential 
biomarkers for disease. However, untargeted metabolomics is only semi-quantitative, allowing 
comparison of abundances of a given metabolite between samples analyzed together, but not 
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allowing determination of actual concentrations so individual samples could be compared to a 
reference interval for healthy dogs.  
Fecal matter is a complex matrix for analysis, making assay development a balance 
between user practicality and chemical perfection: multiple steps of homogenization and cleanup 
are likely to improve reproducibility of the assay, but also complicate and lengthen the preparation. 
Liquid extraction methods typically produce large amounts of waste containing organic solvents 
and may not be consistently quantitative. In contrast, solid phase extraction requires selection of 
the appropriate column and elution conditions, and we had concerns that the variability of the fecal 
matrix would introduce confounding variability or require initial cleanup steps prior to extraction. 
For the assay to have future utility to clinicians, it would need to be affordable and have a short 
turnaround time, so we sought a simple sample preparation method. The most appealing method 
we found as a starting point was designed for gas chromatography with a flame ionization detector 
(GC-FID), but simultaneously quantified fatty acids, sterols, and bile acids from feces (Batta et al. 
2002; Batta et al. 1999). The general approach was to convert acid groups to their butyl esters, and 
subsequently derivatize remaining hydroxyl groups to trimethylsilyl ethers. The authors suggested 
that these steps improved volatility of the compounds and enhanced chromatographic 
characteristics of the peaks (resolution and shape) relative to the underivatized compounds. Here 
we present the adaptation, development, and validation of a quantitative assay using gas 
chromatography-mass spectrometry (GC-MS) to analyze canine fecal samples for a variety of 
sterols and fatty acids. 
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6.2 MATERIALS AND METHODS 
6.2.1 Instrumentation 
A model 6890N gas chromatograph (GC; Agilent, Santa Clara, CA, USA) coupled with a 
model 5975 mass selective detector (MSD) with inert electron impact (EI) ionization and a 7683B 
autosampler were used for all analyses. GC operating conditions were as follows: capillary column 
DB-1MS UI (Agilent, 30 m x 0.25 mm I.D. and 0.25 μm film thickness) and a split liner (taper, 
low pressure drop, with glass wool). Helium was used as the carrier gas at 1 mL/min; a 1 μL 
volume of sample was injected in a 20:1 split; inlet temperature at 250°C. Oven temperature was 
initially held at 150°C for 1 minute, ramped to 276°C at 21°C/minute, and held for 15 minutes 
with a post-run time of 3 minutes at 325°C. The relationship between retention time of d4-
cholestane and column pressure was calibrated and pressure was adjusted as needed to maintain 
consistent retention time (RTLock). The detector was tuned daily with perfluorotributylamine 
(PFTBA) using the default AutoTune algorithm, and MSD parameters included transfer line 
temperature 230°C and solvent delay of 3 minutes. Commercially-sourced compounds were 
characterized in Scan mode (50-550 m/z) to confirm purity and identify characteristic ion peaks. 
The MS was run in SIM mode (selected ion monitoring) for quantitative analysis, using ion 




Table 11. Quantified compounds and characteristics of the ion fragments used, ordered by 
increasing retention time. For fatty acids, the number of carbons and units of unsaturation are also 
specified. 
Compound Retention Time (min) 
Quantitation ion 
(nominal m/z) 
Qualifying ions  
(nominal m/z [% intensity]) 
palmitic acid (16:0) 6.9 257 312[20], 239[51] 
linoleic acid (18:2, n-6) 7.6 263 262[49], 336[32] 
alpha-linolenic acid (18:3, n-3) 7.6 261 79[1100], 334[59] 
oleic acid (18:1, n-9) 7.7 264 265[120], 22[41] 
cis-vaccenic acid (18:1, n-7) 7.7 265 264[78], 338[11], 79[16] 
d4-stearic acid (ISTD) 7.8 289 344[33], 271[49] 
stearic acid (18:0) 7.8 285 340[33] 
arachidonic acid (20:4, n-6) 8.4 292 150 [N/A] 
gondoic acid (20:1, n-9) 8.7 293 292[91], 250[23], 366[12] 
erucic acid (22:1, n-9) 10.2 321 320[94], 236[21], 394[10] 
behenic acid (22:0) 10.4 341 396[65], 323[42] 
d4-cholestane (RTLock) 11.4 361 221[239], 376[75] 
nervonic acid (24:1, n-9) 12.3 348 349[97] 
coprostanol 14.2 370 355[41], 257[16] 
d6-cholesterol (ISTD) 15.7 464 333[219], 359[169], 374[241] 
cholesterol 15.8 368 353[52], 329[130] 
cholestanol 16.0 445 460[69], 355[59] 
brassicasterol 16.6 TIC 470[31], 380[34], 341[21] 
lathosterol 16.9 458 443[24], 213[31] 
campesterol 18.0 343 382[85], 367[41] 
stigmasterol 18.8 484 394[99], 469[18] 
fucosterol 20.3 386 296[61] 
β-sitosterol 20.3 357 396[91], 381[40] 
d7-sitostanol (ISTD) 20.5 480 390[70], 405[38] 
sitostanol 20.7 473 488[87], 383[66] 
 
 
6.2.2 Chemicals and reagents 
All reagents and solvents were of analytical-reagent grade or maximum available purity. 
Fatty acids and sterols were obtained from Sigma-Aldrich (St. Louis, MO, USA), ChromaDex 
(Irvine, CA, USA), and Steraloids (Newport, RI, USA). Deuterated internal standards were 
obtained from C/D/N Isotopes Inc. (Pointe-Claire, Quebec, Canada). Sylon HTP (a 3:1:9 mixture 
of hexamethyldisilazane, trimethylchlorosilane, and anhydrous pyridine packaged in glass 
ampules) was purchased from Sigma-Aldrich. Concentrated hydrochloric acid (HCl, 37%) and 
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solvents of HPLC-grade purity were purchased from Sigma-Aldrich or VWR (Radnor, PA, USA). 
No further purification was performed. 
6.2.3 Fecal sample collection 
Naturally passed fecal samples were collected and frozen at -80°C. Samples for assay 
validation were surplus from unrelated studies. A 0.5-1.0 g aliquot of feces was frozen overnight 
at -80°C, then lyophilized overnight, and finally homogenized with a flexible disposable plastic 
spatula before weighing for analysis. 
6.2.4 Stock and standard working solutions 
Stock solutions of 2 mg/mL in chloroform were prepared of each target compound and 
stored at -20°C. Working solutions for calibration curves were prepared as a series of two-fold 
dilutions with physiologically-relevant high-concentration standards (see limits of quantitation in 
4.3.1). Internal standards were prepared at 2 mg/mL in chloroform (d6-cholesterol, d7-sitostanol, 
and d4-stearic acid) or hexane (d4-cholestane) and stored at -20°C. 
6.2.5 Preparation of standard samples 
6.2.5.1 Sterol standard samples 
Appropriate volumes of 2 mg/mL stock solutions of the sterols were combined (in groups) 
and dried under N2 gas flow, then reconstituted with 1 mL chloroform. A series of two-fold 
dilutions was prepared in chloroform and 100 μL of each transferred to glass tubes. A master-mix 
of the relevant IS (d6-cholesterol and/or d7-sitostanol as appropriate) was prepared such that a 20 
μL volume would result in the final 100 μg/mL IS concentration. Standard samples were then dried 
with heat and N2 flow before adding 100 μL Sylon-HTP. Tubes were capped and incubated at 
65°C for 30 minutes. Sterol standard samples were again dried and reconstituted in 100 μL hexane 
for injection onto the instrument. It was found that some of the sterols were subject to degradation 
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if heated with HCl (in the absence of a fecal matrix), so the calibration curves for sterols were 
prepared with omission of the butyl esterification step. 
6.2.5.2 Fatty acid standard samples 
Appropriate volumes of 2 mg/mL stock solutions of the fatty acids were combined (in 
groups) and dried under N2 gas flow, then reconstituted with chloroform. For calibration, this 
mixed stock was dried and resuspended in an equivalent volume of butanol. A series of two-fold 
dilutions was prepared in butanol and 100 μL of each transferred to glass tubes. A master-mix of 
butanol, d4-stearic acid IS, and HCl was prepared such that each tube received 5 μL IS, 20 μL 
HCl, and 95 μL butanol. Standard samples were capped and incubated at 65°C for four hours. 
Samples were subsequently dried by heating under N2 gas flow, then reconstituted in 100 μL 
hexane. Since the fatty acids analyzed were inert to trimethylsilyl derivatization after butyl 
esterification, the addition of Sylon-HTP was omitted when preparing the standard samples for 
fatty acid calibration curves. 
6.2.6 Quality control (QC) samples 
QC consisted of a set of five samples: prep blank (PB), zero blank (ZB), sterol continuing 
calibration verification (S-CCV), fatty acid continuing calibration verification (F-CCV), and 
laboratory control sample (LCS). The PB contained only butanol and hydrochloric acid. The ZB 
was equivalent to the PB with addition of IS. Both blanks were used to assess contamination 
throughout the preparation and analysis. The S-CCV and F-CCV consisted of mixes of stock 
solutions of sterols and fatty acids, respectively, of known concentrations within the limits of 
quantitation. The LCS consisted of lyophilized feces that were pooled, ground with a mortar and 
pestle, and stored frozen. With the exception of additions of HCl to the S-CCV and master mix to 




6.2.7 Sample preparation 
A sample batch consisted of the 5 QC samples and up to 22 unknown fecal samples. 
Aliquots of 10-15 mg lyophilized feces were precisely weighed into disposable glass centrifuge 
tubes. A master mix was prepared in sufficient quantity for all samples to receive 160 μL butanol 
and 10 μL each d7-sitostanol, d6-cholesterol, d4-stearic acid, and d4-cholestane. The master mix 
was thoroughly mixed, then added to each tube except the PB, which instead received 200 μL 
butanol. All tubes except the S-CCV then received 20 μL concentrated HCl. Tubes were capped 
and vortexed at least 30 seconds before incubating at 65°C for 4 hours to convert carboxylic acid 
groups to butyl esters. Samples were briefly vortexed to mix, then dried with heat under N2 until 
visibly dry. 200 μL of Sylon-HTP was added to each dried sample, which were then capped, 
vortexed, and incubated at 65°C for 30 minutes to convert sterol alcohol groups to their 
trimethylsilyl (TMS) derivatives. Samples were again vortexed briefly before drying under heat 
and N2 flow. 200 μL hexane was then added to each tube and mixed. Tubes were then centrifuged 
at 3,200 rcf and 5°C for 10 minutes. 80-100 μL of supernatant was transferred to a glass GC vial 
insert for injection and analysis. 
6.2.8 Data analysis 
Total ion current (TIC) chromatograms from each batch were overlaid to verify consistent 
retention time of the RTLock compound, d4-cholestane, and a consistent baseline. The software 
(ChemStation, Agilent) was used to automatically integrate all peaks and calculate the 
concentrations of analytes (μg/mL) in the injected hexane solution. Validity of peak assignments 
was assessed by comparing expected retention times and relative ion intensities, and manual 
reintegration of selected peaks was performed when faulty automatic assignment was suspected 
(e.g., two compounds assigned to the same retention time). These data were exported and the 
original mass of lyophilized feces for each sample was used to calculate concentrations in μg per 
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mg of lyophilized feces. The TIC of the PB was assessed for contamination subjectively, while 
the ZB was assessed for contamination exceeding the lower limit of quantitation. The validity of 
the calibration curves and sample preparation was assessed by confirming CCV concentrations 
were within 20% of the expected values, and the LCS was within 2 standard deviations of the 
mean values (based on a minimum of 20 previous analyses of the LCS). 
6.3 RESULTS 
6.3.1 Limits of detection and quantitation 
The limit of detection (LOD) was defined as the calculated concentration resulting from 
the response ratio of the mean signal of the zero blank (n=20) plus 10 times the standard deviation 
of the blank. This calculated method based on noise was used since the number of analytes in the 
panel and range of concentrations would make experimental determination using a low-
concentration sample for all analytes impractical. The lower and upper limits of quantitation 
(LLOQ and ULOQ, respectively) were defined as the lowest and highest concentrations of each 
target analyte that could be measured with acceptable accuracy (within 20% of actual 
concentration). These values are reported in Table 12. 
6.3.2 Dilutional parallelism 
The lyophilized feces were diluted with alumina powder (Al2O3, Agilent) in series by 
weight (a portion of the 1:1 mixture of feces:Al2O3 was combined with an equal weight of pure 
Al2O3 to prepare the 1:3 mixture). A 10-15 mg aliquot of each of the samples from five animals 
and their dilution series were prepared as described in Section 2.7. The results in μg/mg lyophilized 
sample and the observed-to-expected ratios are reported in Table 13. 
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6.3.3 Spiking recovery 
Spiking recovery was determined by preparing combinations of pairs of fecal samples 
from four different animals, with the expected results calculated as a weighted average of the mass 
of each fecal sample used. The results in μg/mg lyophilized sample and the observed-to-expected 
ratios are reported in Table 14 and Table 15. 
6.3.4 Precision 
Precision was assessed by intra-assay variability and reproducibility was assessed by 
evaluation inter-assay variability as determined by the coefficient of variation (%CV) of six 
replicates of each of six samples prepared and analyzed on the same (intra-assay) or different 
(inter-assay) preparation batches and instrument run dates. Values that were outside the limits of 
quantitation were used without adjustment. The median and range of the samples that were tested, 
and the resultant median and range of the %CV, are reported in Table 16. 
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Table 12. Limits of detection and quantitation.LOD: Limit of detection, calculated from the mean 
signal of the blank +10 SD. LLOQ: lower limit of quantitation. ULOQ: upper limit of quantitation. 
LOQ12.5: the equivalent LOQ for feces if 12.5 mg were used. 
Compound 
LOD LLOQ ULOQ LLOQ12.5 ULOQ12.5 
μg/mL μg/mL μg/mL μg/mg μg/mg 
palmitic acid 4.90 7.8125 2000 0.125 32 
linoleic acid 7.85 15.625 2000 0.25 32 
α-linolenic acid 1.51 3.125 200 0.05 3.2 
oleic acid 4.46 7.8125 2000 0.125 32 
cis-vaccenic acid 4.95 6.25 400 0.1 6.4 
stearic acid 4.67 7.8125 2000 0.1250 32 
arachidonic acid 13.04 25.0 800 0.4 12.8 
gondoic acid 0.13 0.3906 200 0.00625 3.2 
erucic acid 0.05 0.78125 200 0.0125 3.2 
behenic acid 4.94 6.25 800 0.1 12.8 
nervonic acid 4.48 12.5 800 0.2 12.8 
cholesterol 1.19 3.906 2000 0.0625 32 
brassicasterol 0.11 0.3906 100 0.00625 1.6 
lathosterol 0.30 0.78125 100 0.0125 1.6 
campesterol 2.39 6.25 400 0.1 6.4 
stigmasterol 0.39 0.78125 100 0.0125 1.6 
fucosterol 0.70 1.5625 200 0.025 3.2 
β-sitosterol 7.14 12.5 800 0.2 12.8 
coprostanol 1.38 1.5625 200 0.0250 3.2 
cholestanol 1.05 3.125 200 0.05 3.2 





Table 13. Dilutional parallelism. Observed and expected values are expressed in μg/mg lyophilized sample weight. 
  palmitic acid  linoleic acid  α-linolenic acid  oleic acid  cis-vaccenic acid 
Animal Feces:Al2O3 Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E 
I 
1:0 30.691      5.908      0.263      11.868      8.621     
1:1 15.534 15.345 101%  2.959 2.954 100%  0.119 0.131 91%  5.677 5.934 96%  4.847 4.311 112% 
1:3 8.422 7.673 110%  1.438 1.477 97%  0.063 0.066 96%  2.976 2.967 100%  2.666 2.155 124% 
1:7 5.239 3.836 137%  1.228 0.738 166%  0.076 0.033 230%  2.358 1.484 159%  1.760 1.078 163% 
                     
II 
1:0 6.031      4.195      0.490      5.640      3.017     
1:1 2.510 3.016 83%  2.351 2.098 112%  0.262 0.245 107%  2.335 2.820 83%  1.517 1.509 101% 
1:3 1.497 1.508 99%  1.558 1.049 149%  0.174 0.122 142%  1.455 1.410 103%  0.995 0.754 132% 
1:7 1.092 0.754 145%  1.019 0.524 194%  0.112 0.061 183%  1.019 0.705 145%  0.704 0.377 187% 
                     
III 
1:0 5.474      5.535      0.297      5.115      1.127     
1:1 2.731 2.737 100%  2.657 2.767 96%  0.134 0.149 90%  2.476 2.557 97%  0.559 0.564 99% 
1:3 1.402 1.368 102%  1.431 1.384 103%  0.072 0.074 97%  1.321 1.279 103%  0.292 0.282 104% 
1:7 0.889 0.684 130%  0.936 0.692 135%  0.052 0.037 139%  0.819 0.639 128%  0.200 0.141 142% 
                     
IV 
1:0 7.968      7.845      0.470      5.991      1.189     
1:1 3.822 3.984 96%  4.237 3.923 108%  0.214 0.235 91%  2.869 2.996 96%  0.690 0.594 116% 
1:3 2.348 1.992 118%  2.871 1.961 146%  0.169 0.118 144%  1.772 1.498 118%  0.444 0.297 150% 
1:7 1.465 0.996 147%  1.867 0.981 190%  0.122 0.059 208%  1.287 0.749 172%  0.297 0.149 200% 
                     
V 
1:0 12.961      14.087      1.467      14.260      2.098     
1:1 6.285 6.481 97%  7.663 7.043 109%  0.732 0.733 100%  6.556 7.130 92%  1.167 1.049 111% 
1:3 3.021 3.240 93%  3.572 3.522 101%  0.332 0.367 90%  2.971 3.565 83%  0.678 0.524 129% 
1:7 2.447 1.620 151%  3.634 1.761 206%  0.284 0.183 155%  2.882 1.783 162%  0.513 0.262 196% 
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Table 13. (Continued.) 
  stearic acid  gondoic acid  erucic acid  behenic acid  nervonic acid 
Animal Feces:Al2O3 Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E 
I 
1:0 24.186      0.455      0.050      0.384      0.372     
1:1 12.097 12.093 100%  0.234 0.227 103%  0.016 0.025 62%  0.223 0.192 116%  0.194 0.186 104% 
1:3 6.465 6.046 107%  0.123 0.114 108%  0.009 0.013 71%  0.134 0.096 140%  0.117 0.093 126% 
1:7 3.882 3.023 128%  0.079 0.057 138%  0.006 0.006 89%  0.104 0.048 217%  0.089 0.046 192% 
                     
II 
1:0 3.105      0.174      0.041      0.198      0.347     
1:1 1.259 1.552 81%  0.082 0.087 94%  0.016 0.020 76%  0.134 0.099 135%  0.183 0.173 105% 
1:3 0.713 0.776 92%  0.047 0.043 108%  0.007 0.010 65%  0.093 0.049 187%  0.117 0.087 135% 
1:7 0.503 0.388 130%  0.030 0.022 139%  0.004 0.005 80%  0.096 0.025 388%  0.105 0.043 242% 
                     
III 
1:0 2.126      0.139      0.014      0.245      0.187     
1:1 1.046 1.063 98%  0.073 0.070 105%  0.006 0.007 86%  0.155 0.122 127%  0.121 0.093 129% 
1:3 0.494 0.532 93%  0.030 0.035 86%  0.001 0.004 24%  0.098 0.061 161%  0.079 0.047 170% 
1:7 0.328 0.266 123%  0.019 0.017 109%  0.001 0.002 39%  0.083 0.031 272%  0.065 0.023 280% 
                     
IV 
1:0 3.380      0.189      0.019      0.235      0.164     
1:1 1.626 1.690 96%  0.088 0.095 93%  0.007 0.009 74%  0.164 0.118 139%  0.121 0.082 148% 
1:3 0.882 0.845 104%  0.062 0.047 130%  0.007 0.005 153%  0.115 0.059 196%  0.091 0.041 222% 
1:7 0.558 0.423 132%  0.037 0.024 158%  0.001 0.002 61%  0.088 0.029 301%  0.071 0.020 345% 
                     
V 
1:0 8.891      0.488      0.035      0.307      0.131     
1:1 4.277 4.446 96%  0.260 0.244 106%  0.024 0.018 136%  0.203 0.153 132%  0.113 0.066 171% 
1:3 2.071 2.223 93%  0.126 0.122 103%  0.020 0.009 225%  0.120 0.077 156%  0.072 0.033 219% 





Table 13. (Continued.) 
  cholesterol  brassicasterol  lathosterol  campesterol  stigmasterol 
Animal Feces:Al2O3 Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E 
I 
1:0 6.705      0.014      0.040      1.223      0.467     
1:1 3.253 3.352 97%  0.002 0.007 28%  0.011 0.020 53%  0.598 0.611 98%  0.223 0.234 95% 
1:3 1.788 1.676 107%  0.001 0.003 38%  0.006 0.010 63%  0.306 0.306 100%  0.109 0.117 93% 
1:7 0.991 0.838 118%  0.001 0.002 79%  0.005 0.005 95%  0.176 0.153 115%  0.057 0.058 98% 
                     
II 
1:0 2.910      0.219      0.022      1.107      0.398     
1:1 1.526 1.455 105%  0.099 0.109 90%  0.011 0.011 100%  0.555 0.553 100%  0.189 0.199 95% 
1:3 0.850 0.728 117%  0.053 0.055 96%  0.007 0.006 128%  0.314 0.277 113%  0.102 0.099 102% 
1:7 0.530 0.364 146%  0.032 0.027 117%  0.006 0.003 204%  0.216 0.138 156%  0.069 0.050 138% 
                     
III 
1:0 2.172      0.049      0.015      1.891      0.691     
1:1 0.967 1.086 89%  0.007 0.024 30%  0.008 0.007 105%  0.887 0.945 94%  0.325 0.346 94% 
1:3 0.409 0.543 75%  0.002 0.012 15%  0.005 0.004 128%  0.368 0.473 78%  0.130 0.173 75% 
1:7 0.254 0.272 93%  0.003 0.006 41%  0.004 0.002 202%  0.234 0.236 99%  0.075 0.086 87% 
                     
IV 
1:0 2.318      0.041      0.016      1.679      0.705     
1:1 1.174 1.159 101%  0.010 0.021 46%  0.009 0.008 118%  0.899 0.839 107%  0.384 0.352 109% 
1:3 0.630 0.579 109%  0.003 0.010 32%  0.006 0.004 159%  0.469 0.420 112%  0.192 0.176 109% 
1:7 0.302 0.290 104%  0.003 0.005 52%  0.004 0.002 222%  0.234 0.210 112%  0.094 0.088 107% 
                     
V 
1:0 1.333      0.007      0.016      0.862      0.425     
1:1 0.662 0.666 99%  0.003 0.004 87%  0.010 0.008 123%  0.456 0.431 106%  0.233 0.212 110% 
1:3 0.326 0.333 98%  0.001 0.002 70%  0.006 0.004 141%  0.223 0.216 103%  0.111 0.106 105% 




Table 13. (Continued.) 
  fucosterol  β-sitosterol  coprostanol  cholestanol  sitostanol 
Animal Feces:Al2O3 Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E  Obs. Exp. O/E 
I 
1:0 0.100      2.034      0.025      0.091      0.549     
1:1 0.051 0.050 102%  1.047 1.017 103%  0.018 0.013 141%  0.044 0.046 95%  0.266 0.275 97% 
1:3 0.028 0.025 111%  0.559 0.509 110%  0.012 0.006 189%  0.023 0.023 101%  0.133 0.137 97% 
1:7 0.017 0.013 135%  0.353 0.254 139%  0.011 0.003 355%  0.015 0.011 133%  0.076 0.069 111% 
                     
II 
1:0 0.063      1.413      0.062      0.121      0.172     
1:1 0.031 0.032 97%  0.751 0.707 106%  0.032 0.031 105%  0.055 0.060 92%  0.084 0.086 98% 
1:3 0.018 0.016 113%  0.441 0.353 125%  0.020 0.015 129%  0.031 0.030 103%  0.047 0.043 110% 
1:7 0.014 0.008 180%  0.344 0.177 195%  0.018 0.008 227%  0.021 0.015 142%  0.036 0.021 170% 
                     
III 
1:0 0.167      3.404      0.538      0.171      0.972     
1:1 0.081 0.084 97%  1.575 1.702 93%  0.202 0.269 75%  0.075 0.085 87%  0.443 0.486 91% 
1:3 0.034 0.042 81%  0.695 0.851 82%  0.089 0.135 66%  0.031 0.043 74%  0.181 0.243 75% 
1:7 0.022 0.021 106%  0.465 0.426 109%  0.056 0.067 84%  0.021 0.021 96%  0.117 0.121 96% 
                     
IV 
1:0 0.167      2.886      0.048      0.149      0.860     
1:1 0.089 0.083 107%  1.531 1.443 106%  0.028 0.024 117%  0.072 0.074 97%  0.443 0.430 103% 
1:3 0.045 0.042 108%  0.815 0.722 113%  0.019 0.012 153%  0.038 0.037 101%  0.222 0.215 103% 
1:7 0.024 0.021 116%  0.443 0.361 123%  0.013 0.006 222%  0.020 0.019 106%  0.113 0.107 105% 
                     
V 
1:0 0.057      1.301      0.038      0.051      0.194     
1:1 0.033 0.028 115%  0.746 0.651 115%  0.026 0.019 137%  0.028 0.025 110%  0.107 0.097 110% 
1:3 0.017 0.014 122%  0.389 0.325 120%  0.016 0.009 166%  0.015 0.013 116%  0.054 0.048 111% 






































      Observed 
A 10.8 - 3.107 2.598 0.361 2.807 1.800 1.379 0.150 0.026 0.082 0.172 
B 11.6 - 21.412 17.889 0.373 28.551 3.807 16.926 2.961 0.767 0.997 1.372 
C 11.2 - 8.301 8.844 0.757 9.171 1.653 7.366 0.511 0.046 0.347 0.095 
D 11.3 - 16.813 4.644 0.224 9.067 6.330 17.712 0.503 0.050 0.460 0.408 
AB 6.2 5.9 14.858 11.020 0.464 20.483 2.457 10.669 1.925 0.438 0.565 0.824 
AC 6.3 5.1 6.023 5.716 0.663 5.927 1.684 4.471 0.345 0.038 0.216 0.213 
AD 6.1 6.1 10.336 3.009 0.212 5.398 4.124 10.293 0.323 0.035 0.264 0.282 
BC 5.7 5.1 18.064 15.057 0.779 23.834 3.406 14.387 2.258 0.520 0.767 0.913 
BD 6.0 5.4 18.744 12.340 0.513 21.928 5.398 16.742 2.144 0.466 0.779 0.915 
CD 5.5 5.7 13.202 6.654 0.569 9.032 4.299 13.366 0.495 0.044 0.398 0.250 
                          
  Portion 1 Portion 2 Expected 
AB 0.51 0.49 12.020 10.043 0.366 15.348 2.771 8.954 1.520 0.387 0.528 0.757 
AC 0.55 0.45 5.433 5.394 0.539 5.657 1.736 4.059 0.311 0.035 0.201 0.138 
AD 0.50 0.50 9.957 3.619 0.292 5.935 4.064 9.544 0.326 0.038 0.271 0.290 
BC 0.53 0.47 15.228 13.626 0.555 19.408 2.791 12.418 1.804 0.427 0.691 0.769 
BD 0.53 0.47 19.237 11.627 0.303 19.339 5.000 17.297 1.799 0.428 0.743 0.917 
CD 0.49 0.51 12.648 6.711 0.486 9.126 4.039 12.647 0.507 0.048 0.405 0.255 
                          
    
O/E Ratios for mixed samples 
AB   81% 91% 79% 75% 113% 84% 79% 88% 93% 92% 
AC   90% 94% 81% 95% 103% 91% 90% 92% 93% 65% 
AD   96% 120% 138% 110% 99% 93% 101% 109% 103% 103% 
BC   84% 90% 71% 81% 82% 86% 80% 82% 90% 84% 
BD   103% 94% 59% 88% 93% 103% 84% 92% 95% 100% 
CD   96% 101% 86% 101% 94% 95% 102% 110% 102% 102% 
Median     93% 94% 80% 92% 96% 92% 87% 92% 94% 96% 
 138 
 




























      Observed 
A 10.8 - 1.001 0.138 0.024 0.609 0.140 0.030 1.002 0.018 0.050 0.023 
B 11.6 - 5.609 0.021 0.032 0.156 0.085 0.017 0.177 0.018 0.132 0.007 
C 11.2 - 1.533 0.027 0.030 0.831 0.393 0.054 1.404 0.051 0.071 0.190 
D 11.3 - 7.957 0.025 0.040 1.295 0.437 0.098 2.485 0.031 0.134 0.639 
AB 6.2 5.9 3.382 0.085 0.027 0.397 0.121 0.022 0.612 0.017 0.094 0.016 
AC 6.3 5.1 1.333 0.108 0.026 0.797 0.293 0.044 1.343 0.037 0.066 0.110 
AD 6.1 6.1 4.391 0.094 0.030 0.920 0.314 0.059 1.638 0.026 0.095 0.333 
BC 5.7 5.1 4.055 0.027 0.034 0.532 0.266 0.038 0.823 0.040 0.116 0.110 
BD 6.0 5.4 6.548 0.031 0.036 0.668 0.268 0.055 1.160 0.025 0.135 0.298 
CD 5.5 5.7 4.779 0.049 0.034 1.041 0.436 0.076 1.890 0.048 0.106 0.416 
                          
  Portion 1 Portion 2  Expected 
AB 0.51 0.49 3.244 0.080 0.028 0.386 0.113 0.023 0.596 0.018 0.090 0.015 
AC 0.55 0.45 1.240 0.088 0.027 0.709 0.253 0.040 1.183 0.032 0.059 0.098 
AD 0.50 0.50 4.479 0.081 0.032 0.951 0.289 0.064 1.743 0.024 0.092 0.331 
BC 0.53 0.47 3.686 0.024 0.031 0.475 0.231 0.034 0.758 0.033 0.103 0.094 
BD 0.53 0.47 6.719 0.023 0.036 0.694 0.252 0.055 1.268 0.024 0.133 0.306 
CD 0.49 0.51 4.810 0.026 0.035 1.068 0.416 0.076 1.957 0.040 0.103 0.419 
                          
    O/E Ratios for mixed samples 
AB   96% 94% 104% 97% 93% 105% 97% 102% 96% 94% 
AC   93% 82% 101% 89% 86% 92% 88% 88% 91% 89% 
AD   102% 86% 107% 103% 92% 109% 106% 91% 97% 100% 
BC   91% 87% 92% 89% 87% 90% 92% 83% 89% 85% 
BD   103% 74% 100% 104% 94% 100% 109% 94% 99% 102% 
CD   101% 53% 104% 103% 95% 101% 104% 84% 97% 101% 
Median     98% 84% 102% 100% 92% 100% 100% 90% 97% 97% 
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Table 16. Precision and reproducibility of the assay. aConcentrations of samples used (the median 
and range of the median of six replicates from six different animals). bCoefficient of variation, 
calculated from six replicates from each of six animals. 
  intra-assay inter-assay 
Compound 
median [range] median [range] median [range] median [range] 
μg/mg fecesa %CVb μg/mg fecesa %CVb 
palmitic acid 3.63 [1.8-11.62] 4 [2-8] % 3.38 [2.35-11.18] 7 [5-14] % 
linoleic acid 2.83 [0.92-7.59] 8 [4-18] % 2.73 [1.15-7.55] 10 [4-14] % 
α-linolenic acid 0.16 [0.12-0.59] 14 [7-34] % 0.27 [0.11-0.61] 12 [10-79] % 
oleic acid 2.79 [0.87-8.34] 4 [4-11] % 2.92 [0.88-8.2] 9 [4-13] % 
cis-vaccenic acid 0.77 [0.25-3.46] 5 [2-7] % 0.81 [0.28-1.82] 9 [4-12] % 
stearic acid 2.99 [1.41-10.57] 4 [2-7] % 2.07 [1.46-6.2] 6 [5-12] % 
arachidonic acid 0.72 [0.36-2.37] 6 [3-7] % 0.57 [0.32-2.24] 11 [5-21] % 
gondoic acid 0.15 [0.08-0.36] 5 [3-9] % 0.16 [0.06-0.36] 11 [9-18] % 
erucic acid 0.03 [0.02-0.06] 10 [3-47] % 0.03 [0.02-0.07] 18 [12-62] % 
behenic acid 0.32 [0.22-0.94] 6 [2-9] % 0.29 [0.13-0.97] 12 [7-16] % 
nervonic acid 0.11 [0.09-0.38] 8 [4-11] % 0.13 [0.07-0.46] 17 [8-23] % 
cholesterol 3.03 [2.01-12.84] 4 [1-7] % 2.66 [2.01-4.5] 6 [4-15] % 
brassicasterol 0.07 [0.04-0.32] 4 [2-5] % 0.1 [0.04-0.28] 9 [6-11] % 
lathosterol 0.04 [0.03-0.08] 5 [3-6] % 0.04 [0.03-0.06] 8 [5-9] % 
campesterol 1.07 [0.43-2.19] 4 [2-6] % 1.1 [0.44-1.97] 6 [5-10] % 
stigmasterol 0.4 [0.15-0.73] 4 [2-8] % 0.4 [0.16-0.6] 7 [5-13] % 
fucosterol 0.07 [0.03-0.15] 6 [3-9] % 0.07 [0.03-0.11] 10 [7-16] % 
β-sitosterol 1.63 [0.78-3.47] 4 [2-7] % 1.44 [0.82-2.31] 6 [5-10] % 
coprostanol 0.03 [0.01-0.16] 5 [3-17] % 0.01 [0.01-0.1] 11 [3-16] % 
cholestanol 0.12 [0.07-0.3] 4 [1-5] % 0.12 [0.07-0.3] 9 [5-11] % 




The assay described here quantifies eleven fatty acids and ten sterols. In comparison to 
serum samples, the potential range of concentrations for analytes in feces is expected to be much 
wider and more variable between individuals. It also may be expected that feces are more easily 
influenced by diet, but for exploring the effects of gastrointestinal diseases, it is biologically the 
most relevant sample for its relationship with the GI tract and the microbiota. 
Although the entire range of concentrations for all compounds may not fall within the 
limits of quantitation, analytes in the vast majority of samples do fall within the range of 
quantification for this assay. Sensitivity for some compounds would likely be improved if the split 
ratio for the injection were decreased, but for other compounds this might saturate the detector and 
result in poor quantification. Considering the inherent variability associated with a heterogeneous 
mixture such as fecal matter, the validation parameters are considered satisfactory. It is likely that 
homogenization and coarse filtration prior to lyophilization would improve the reproducibility of 
the assay, but the improvement may not be clinically relevant. On the other hand, aliquots for 
assessment of inter-assay variability were taken after lyophilization, so it is worth considering that 
some additional variability could occur during the lyophilization step and this has not been 
captured by this validation of the assay. 
The method used for dilutional parallelism in this validation is somewhat unconventional. 
While serum can easily be diluted with water, dilution of feces prior to lyophilization would not 
have affected the dry weight. Therefore, an inert, dry substance that could dilute the lyophilized 
feces on a mass-basis was required. In hindsight, it potentially should be tested if the presence of 
aluminum oxide has any inherent effect on the results, though this is unlikely considering the 
consistency of recoveries. 
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There are some additional limitations and remaining considerations. First, the 
characterization of compounds was based on authentic standards, prepared and analyzed in 
isolation. In fecal samples, peaks with the appropriate fragmentation spectra and retention times 
were considered positively identified. However, closely-related compounds may still co-elute and 
produce similar spectra, so it would be naïve to exclude the possibility that peaks in a highly 
complex sample matrix such as fecal matter may in fact be combinations of isomers. This is 
particularly likely for fatty acids, where the fragmentation spectra for two isomers may be nearly 
identical. 
Another factor that was not specifically evaluated is the robustness of the assay. Although 
there are several individuals trained to perform this assay, the validation parameters reported here 
were based on analyses done exclusively by one person. The use of the LCS and other quality 
control samples does support that batches prepared by different individuals do show generally 
reproducible results, but this was not explicitly assessed in this study. In addition, the tolerance for 
preparation variability (e.g., intentionally varying quantities of reagents from the stipulated 
amounts, changes to temperatures, etc.) was not tested. The confidence in the assay would be 
strengthened by exploring what degree of changes could be tolerated without significantly 
changing the resultant values. 
Beyond technical considerations, there are concerns pertaining to normal physiology, 
including day-to-day variation, or the effect of a single bolus of dietary fat (e.g., a treat). Also, 
stability of the samples has not yet been tested. Although the literature reports using sterols in soil 
and sediment to identify ancient bathrooms in archaeological excavations, suggesting a good 
degree of stability, this is far from quantitative. Since fecal matter is a biologically and chemically 




Another item for further consideration is the presence of sterol esters. An alternative 
method might include a hydrolysis step prior to butyl esterification in order to liberate sterols and 
fatty acids from their esterified forms (including triacylglycerides and phospholipids) (Keller and 
Jahreis 2004). 
6.5 CONCLUSIONS 
The FASter assay using gas chromatography-mass spectrometry was shown to be precise, 





7. FECAL CONCENTRATIONS OF STEROLS AND FATTY ACIDS IN DOGS 
WITH CHRONIC ENTEROPATHY 
 
OVERVIEW 
Diseases of chronic inflammation of the gastrointestinal tract, including idiopathic 
inflammatory bowel disease (IBD), are thought to be perpetuated by bacterial dysbiosis and 
dysregulation of the mucosal immune system in both humans and animals. Gastrointestinal (GI) 
absorption of metabolites is altered by inflammation, with concurrent changes in microbial 
metabolism within the GI tract. Cholesterol is the primary sterol in mammals; it is incorporated 
into cell membranes throughout the body and used as a building block for endogenous hormones, 
steroids, and bile acids. Some phytosterols have been shown to have anti-inflammatory properties 
and have been shown to decrease disease severity in a murine colitis model. Therefore, the aim of 
this study was to compare fecal sterol profiles of dogs with chronic enteropathy to those of healthy 
control dogs. 
Fecal samples were collected from dogs with chronic enteropathy (n=44) and from healthy 
control dogs (n=13). Sterols in lyophilized feces were subjected to trimethylsilyl ether 
derivatization and analyzed by gas chromatography-mass spectrometry (GC-MS) operating in 
selected ion monitoring (SIM) mode. Target analytes included cholesterol, cholestanol, β-
sitosterol, sitostanol, fucosterol, stigmasterol, and campesterol. Fecal concentrations of sterols 
were expressed as μg/mg of lyophilized feces. A Mann-Whitney U test was used for comparison 
between animal groups, and a Benjamini-Hochberg step-up method was used to correct for 
multiple comparisons. Statistical significance was set at p<0.05. 
Fecal cholesterol and cholestanol were not significantly altered between healthy dogs and 
dogs with chronic enteropathy. However, β-sitosterol and sitostanol were significantly decreased 
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in dogs with chronic enteropathy, and campesterol and fucosterol were also significantly decreased 
prior to adjusting p-values for multiple comparisons. 
In conclusion, this study suggests that the fecal sterol profile in dogs with chronic 
enteropathy is characterized by decreased phytosterols. Additional studies are required to explore 
the effect of dietary supplementation with phytosterols and to investigate how these sterols are 
related to specific bacterial groups that digest dietary plant material in these patients. 
7.1 INTRODUCTION 
The importance of sterols and fatty acids in host metabolism has been described in Section 
1. Aberrant lipid metabolism has been implicated to play a role in the pathogenesis of 
inflammatory bowel disease (IBD) in people (Shores et al. 2011). Gene expression studies on 
duodenal mucosal biopsies from dogs identified several genes that were differentially expressed 
between dogs with IBD and healthy control dogs, and several of those altered genes are relevant 
to lipid metabolism (Wilke et al. 2012). Examples include a 92-fold decrease in the gene encoding 
neurotensin (NTS), which in humans has been linked to obesity (J. Li et al. 2016) due to its role 
in fatty acid absorption. Wilke et al. (2012) also found a nearly 2-fold downregulation of the gene 
encoding fatty acid synthase (FASN), a 14-fold decrease in fatty acid binding protein 6 (FABP6, 
also known as gastrotropin), and a 4-fold increase in peroxisome proliferator-activated receptor 
gamma (PPARG), which regulates fatty acid storage and glucose metabolism. Another study using 
duodenal mucosal biopsies concluded that polyunsaturated fatty acid-enriched diets affected genes 
of cholesterol homeostasis, finding that caveolin-1, ABCA1, and SREBP-2 were downregulated 
in dogs with IBD on the PUFA-enriched diet (but this change was not observed for dogs with 




Based on the altered gene expression demonstrated in these studies pertaining to 
absorption and metabolism of lipids, it would be anticipated to find altered concentrations of lipids 
in the feces of dogs with chronic GI inflammation. Previous untargeted metabolomics studies (see 
Section 5) further supported that abundances of lipid metabolites are altered in dogs with chronic 
enteropathy, finding relative changes specifically among fatty acids and sterols. It was 
hypothesized that an analysis of a new cohort of dogs with chronic enteropathy would show 
quantitatively altered fecal sterol and fatty acid concentrations compared to healthy control dogs. 
The current study aimed to use the FASter assay (described in Section 6) as a targeted 
metabolomics panel to quantify eleven fecal fatty acids and ten sterols in dogs with chronic 
enteropathy compared to healthy control dogs, using the analyte results collectively to define an 
overall fecal FASter profile. 
7.2 MATERIALS AND METHODS 
7.2.1 Study population and sample collection 
Naturally-passed fecal samples were retrospectively selected from surplus samples that 
had been stored at -80°C. Included were healthy control dogs (n=13) that had undergone physical 
examination as well as bloodwork to verify health status, and a corresponding owner questionnaire 
had asserted no recent (> 8 weeks) antibiotic usage. Inclusion criteria for the diseased samples 
(n=44) was availability of a surplus fecal sample, no recent antibiotics usage reported in the 
medical history, tentative diagnosis of IBD with active disease at the time of collection, and fecal 




7.2.2 Sample preparation and instrument analysis 
Samples were prepared and analyzed by the FASter assay using gas chromatography-mass 
spectrometry (GC-MS) as described in Section 6.2. 
7.2.3 Statistical analyses 
Results in μg/mg lyophilized feces for all samples were processed in JMP (SAS, Durham, 
NC, USA) using Mann-Whitney U test to identify significantly altered fatty acids and sterols. P-
values were corrected for multiple comparisons using the Benjamini-Hochberg step-up method 
and significance was defined as a corrected p<0.05. 
Based on the physiological relationship between phytosterols and cholesterol, meaning 
the nonspecific absorption of sterols via NPC1L1 with selective expulsion of non-cholesterol by 
ABCG5/G8, a ratio of phytosterols (i.e., brassicasterol, fucosterol, campesterol, β-sitosterol, 
sitostanol, and stigmasterol) to cholesterol was calculated. The ratio of stanols (i.e., coprostanol, 
cholestanol, and sitostanol) to Δ5 sterols (i.e., cholesterol, β-sitosterol, campesterol, stigmasterol, 
and fucosterol) was also calculated. These ratios were compared between groups using Mann-
Whitney U tests with statistical significance set at as p<0.05. 
Finally, data were visually analyzed from a multivariate perspective using MetaboAnalyst 
(Xia et al. 2015; Xia and Wishart 2011, 2016). Raw concentrations were log-transformed and 
Pareto-scaled to achieve a more Gaussian distribution, then used to generate PCA and PLS-DA 
plots reflecting the distribution of samples by their collective FASter composition profiles. 
MetaboAnalyst was also used to generate a Pearson correlation matrix between metabolites. 
7.3 RESULTS 
Before correcting for multiple comparisons, ten of the twenty-one metabolites were 
potentially significant, but only three remained significant after correcting for multiple 
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comparisons: arachidonic acid, β-sitosterol, and sitostanol. A summary of the results for all 
compounds (group medians and ranges, with corresponding p- and q-values) is given in Table 17. 
The ratio of phytosterols to cholesterol was also significantly altered between groups. The 
median [range] for healthy animals was 2.398 [1.090-3.669] while for the diseased group it was 
only 0.682 [0.019-5.106], (p=0.0006). The ratio of stanols to sterols was also decreased in samples 
from dogs with IBD. The median [range] for healthy animals was 0.129 [0.073-0.205] while for 
the diseased group it was only 0.056 [0.009-0.165], (p=0.0002). 
PCA and PLS-DA plots showing the distribution of samples when their composition is 
considered from a multivariate perspective (supervised and unsupervised, respectively) are shown 
in Figure 25, and the correlation matrix is shown in Figure 26. 
 
 
Table 17. Concentrations of fatty acids and sterols in dogs with IBD compared to healthy control 
dogs. 
Compound 
Healthy IBD   
Median Range Median Range p-value q-value 
palmitic acid (16:0) (μg/mg) 4.936 [2.753-6.639] 5.037 [0.823-30.053] 0.7107 0.7537 
linoleic acid (18:2 n-6) (μg/mg) 4.576 [1.382-14.933] 3.707 [0.202-56.091] 0.4189 0.5498 
α-linolenic acid (18:3 n-3) (μg/mg) 0.356 [0.113-0.679] 0.491 [0.042-7.342] 0.2659 0.4295 
oleic acid (18:1 n-9) (μg/mg) 4.721 [1.892-7.708] 4.657 [0.322-57.061] 0.8121 0.8121 
cis-vaccenic acid (18:1 n-7) (μg/mg) 0.806 [0.583-2.223] 1.139 [0.152-11.271] 0.5491 0.6783 
stearic acid (18:0) (μg/mg) 1.894 [1.195-3.684] 3.840 [0.41-40.124] 0.0980 0.1871 
arachidonic acid (20:4 n-6) (μg/mg) 0.341 [0.19-0.484] 0.734 [0.188-7.315] 0.0000 0.0003 
gondoic acid (20:1 n-9) (μg/mg) 0.184 [0.115-0.279] 0.232 [0.021-1.969] 0.3273 0.4910 
erucic acid (22:1 n-9) (μg/mg) 0.029 [0.019-0.047] 0.044 [0.013-0.238] 0.0260 0.0890 
behenic acid (22:0) (μg/mg) 0.223 [0.154-0.391] 0.291 [0.075-1.837] 0.0382 0.0890 
nervonic acid (24:1 n-9) (μg/mg) 0.173 [0.107-0.384] 0.249 [0.059-0.965] 0.0458 0.0962 
cholesterol (μg/mg) 1.860 [1.182-5.67] 3.749 [0.648-17.46] 0.0324 0.0890 
brassicasterol (μg/mg) 0.031 [0.021-0.16] 0.046 [0.002-0.377] 0.6755 0.7537 
lathosterol (μg/mg) 0.032 [0.02-0.068] 0.035 [0.019-0.108] 0.1534 0.2685 
campesterol (μg/mg) 1.284 [0.739-2.422] 0.922 [0.163-2.672] 0.0373 0.0890 
stigmasterol (μg/mg) 0.465 [0.297-0.765] 0.429 [0.005-1.019] 0.3563 0.4988 
fucosterol (μg/mg) 0.117 [0.077-0.233] 0.067 [0.012-0.672] 0.0179 0.0890 
β-sitosterol (μg/mg) 2.012 [1.354-4.42] 1.243 [0.086-5.989] 0.0008 0.0055 
coprostanol (μg/mg) 0.087 [0.025-0.607] 0.035 [0.008-1.494] 0.0280 0.0890 
cholestanol (μg/mg) 0.182 [0.071-0.473] 0.207 [0.032-0.746] 0.7178 0.7537 





The results of this study are supportive of the hypothesis that lipid metabolism is affected 
in dogs with IBD. However, determining the cause and effect relationship for such a change is 
much more challenging, likely requiring prospective experiments under better controlled 
conditions, such as a standardized diet, and unlikely to be possible using client-owned animals 
with spontaneous disease. One of the interesting findings in this study is the strong association 
between fecal arachidonic acid and disease. Arachidonic acid is considered the precursor to pro-
inflammatory compounds, including leukotrienes with chemotactic properties for neutrophils 
(Samuelsson 1991). More recently, phospholipids containing arachidonic acid have also been 
associated with reactive microglia (macrophages specifically in the brain) after spinal cord injury 
(D. Xu et al. 2016), underscoring the potentially critical role that arachidonic acid plays in immune 
homeostasis. Unfortunately, it is difficult to interpret what increased concentrations in the feces 
Figure 25. PCA (left) and PLS-DA (right) plots showing slightly improved separation using 






may mean for the diseased dogs in this study. Since feces are a means for elimination from the 
body, higher concentrations could reflect efficient excretion of this bioactive material. On the other 
hand, the bioactivity of the compound may result in perpetuation of inflammation.  
Other fatty acids that tended to be altered but did not quite attain significance in this study 
included erucic, behenic, and nervonic acids, which are all considered very long chain fatty acids 
(VLCFAs). Accumulation of VLCFAs was observed also in the untargeted metabolomics study 














































Figure 26. Correlation matrix plot showing relationships between metabolites across all samples, 
irrespective of sample classification. The color scale indicates metabolites that positively correlate 






elongation enzyme genes (ELOVL5 and ELOVL7) observed by Wilke et al. (2012). There is a 
review by Anderson and Stahl (2013) regarding the solute carrier family 27 proteins, which are 
fatty acid transporters. Member 2 of this family (SLC27A2, encoding a very long chain acyl-CoA 
synthetase) was 4-fold downregulated in the gene expression study by Wilke et al. (2012), yet 
member 6 (SLC27A6, also known as FATP6) was 3-fold upregulated. SLC27A6 has been 
suggested as a predominant fatty acid transporter in the heart and SLC27A2 was found primarily 
in the liver and kidney in rats (Anderson and Stahl 2013). SLC27A2 also may be involved in bile 
acid synthesis, specifically activating the precursor of cholic acid by forming the coenzyme-A 
derivative. In conjunction, fatty acid binding protein 6 (FABP6, not to be confused with FATP6) 
was nearly 14-fold downregulated in the study by Wilke et al. (2012), and this protein is thought 
to bind both fatty acids and bile acids in the ileum, its predominant location. Interestingly, FABP2 
(also called intestinal-type fatty acid binding protein, I-FABP) was not reported in the gene 
expression study, but plasma levels have been reported to correlate to mucosal injury in an 
ischemia-reperfusion model (Schellekens et al. 2014). The relevance of these gene expression 
alterations in the duodenum of the dog is difficult to interpret, but certainly suggests there is much 
still to discover about these fatty acid transport and binding proteins and their role in 
gastrointestinal physiology and disease pathogenesis. Unfortunately, the fatty acids quantified in 
this assay include only one monounsaturated n-3 fatty acid, α-linolenic acid, so the correlations 
between n-3 and n-6 fatty acids cannot be discerned with much certainty from our data. There is 
active research exploring how dietary PUFAs may modify overall fatty acid distribution and 
bioavailability (Q. Yang et al. 2017) and some research specifically looking at PUFAs for treating 
canine chronic enteropathy (Ontsouka et al. 2010). 
Additional significant changes in concentrations were observed among the sterols. 
Sitostanol has consistently been strongly associated with health in the current study and the 
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untargeted metabolomics study, but there does not appear to be much literature regarding this 
phenomenon in people. Instead, sitostanol apparently has been appreciated as a nonabsorbable 
compound to use as a normalization factor for absorption of other lipids (Hassan and Rampone 
1979). Abnormal absorption of other phytosterols due to genetic disorders is also known in humans 
(Tang et al. 2009; Yoo 2016), but again, changes in fecal concentrations of phytosterols associated 
with disease appears to be a relatively novel subject. Therefore, the cause of decreased phytosterol 
concentrations (in this study, most notably β-sitosterol and sitostanol) in feces of dogs with IBD 
can only be speculated upon, with very little information available to either validate or refute.  
The origin of phytosterols in feces is presumed to be diet, but the physiology of the 
gastrointestinal absorption of sterols modifies their concentrations. As shown in Section 3, 
phytosterols represent a small portion of the total quantified lipids in duodenal samples from 
healthy dogs, and an apparent increase in concentration distally could be ascribed to the depletion 
of other materials from the lumen (i.e., normal absorption of nutrients). Under physiologic 
conditions, the intact intestinal mucosa would be expected to absorb both phytosterols and 
cholesterol via the NPC1L1 transporter. Cholesterol then should be processed for use (esterified 
into cholesteryl esters for storage, packed into chylomicrons for secretion via lacteals, or 
incorporated into the cell membrane) while phytosterols should be expelled back into the lumen 
via the ABCG5 and ABCG8 transporters. Excess cholesterol from the tissues (and presumably the 
small proportion of phytosterols that escaped expulsion at the level of the enterocytes) undergoes 
reverse cholesterol transport (RCT). This process employs the ABCA1 transporter to transfer 
cholesterol in peripheral tissues to high density lipoprotein (HDL), which then travels in the blood 
to the liver (Tall 1998; Brufau et al. 2011). Interestingly the ratio of LDL to HDL in humans is 
inverted compared to the dog, with nearly 87% of lipoprotein partitioned into HDL and only 11% 
as LDL in the dog, yet the total amount of lipid in circulation is similar between humans and dogs 
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(Maldonado et al. 2001). Hepatic cholesterol can then be disposed of directly in the bile, or 
synthesized into bile acids.  
Hypocholesterolemia is not an unusual clinical finding among dogs or humans with IBD 
(Simpson and Jergens 2011; Agouridis et al. 2011; Hrabovsky et al. 2009), though the exact 
mechanism by which this occurs is unknown. A search of the literature for research related to fecal 
cholesterol did not yield articles relevant to inflammatory bowel disease in any species or 
experimental model of IBD. However, it would not seem unwise to connect the tendency towards 
hypocholesterolemia in both humans and dogs with IBD and the finding in this study for a trend 
towards increased fecal cholesterol in dogs with IBD. Analyses of serum in people with active 
Crohn’s disease (n=24) revealed a nonsignificant decrease of sitosterol and squalene, and 
significant decreases of lathosterol and campesterol accompanying hypocholesterolemia relative 
to healthy control subjects (Hrabovsky et al. 2009). Although interpretation for elucidating a 
mechanism at the level of the intestinal mucosa is not possible, it does suggest that the mechanism 
at play results in both decreased phytosterols and cholesterol, rather than a loss of selectivity; yet 
this is not entirely in accordance with the observation in this study that the ratio of phytosterols to 
cholesterol was significantly decreased in dogs with IBD compared to healthy control dogs. 
If the normal host physiology is considered to affect concentrations of fecal metabolites, 
the microbiota certainly also must be considered. Although the relevance of plant physiology to 
mammals may be questioned, Griebel and Zeier (2010) demonstrated that inoculation of the plant 
Arabidopsis thaliana with the bacterial pathogen Pseudomonas syringae induced the plant to 
convert β-sitosterol to stigmasterol (structurally identical except for an additional desaturation at 
C22 in stigmasterol), and furthermore that this resulted in enhanced susceptibility to P. syringae. 
A means of more direct metabolic interaction by the microbiota may be evidenced by the 
conversion of cholesterol to coprostanol occurring in the GI tract of humans (Antharam et al. 2016; 
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Gerard 2013; Gerard et al. 2007; Veiga et al. 2005; Olejníková et al. 2017). Chemically this 
conversion represents the hydrogenation of the C5 bond of cholesterol to form the fully saturated 
coprostanol. Interestingly, β-sitosterol is the C5-unsaturated analog of sitostanol, which strongly 
suggests the possibility of a similar mechanism (e.g., microbiota-mediated) for conversion of β-
sitosterol to sitostanol as from cholesterol to coprostanol. Both represent the reduction of the Δ5 
sterol to form the corresponding Δ0 stanol, and the microbial biohydrogenation of Δ5 sterols is 
known (Eyssen et al. 1973). The association of GI health with being a “high converter” of 
cholesterol-to-coprostanol has been shown in people (Antharam et al. 2016), so perhaps the 
observation of a significant increase in the Δ0/Δ5 ratio in feces of dogs with IBD is representative 
of a similar microbial etiology. 
Regardless of the mechanism that underlies the difference in phytosterol concentrations, 
there is evidence that phytosterols may represent some therapeutic options. Aldini et al. (2014) 
showed that a two-week period of feeding a phytosterol-enriched diet to mice resulted in decreased 
severity and duration of dextran sodium sulfate (DSS)-induced colitis. The change in membrane 
fluidity induced by incorporation of sterols into membranes has previously been described in 
Section 1.6, and the relative effect of phytosterols versus cholesterol to membranes has also been 
reviewed (Dufourc 2008). Considering the underlying etiology of canine IBD is most certainly not 
oral intake of a detergent to disrupt cell membranes, perhaps this indicates that increased 
phytosterol concentrations exert a protective effect from whatever insult potentially incites IBD. 
However, aside from the suspicion that dog owners would happily purchase “Fidosterols” to 
protect their dogs from IBD, these relationships are merely ideas that require significantly more 
analysis before experimentation in vivo. Furthermore, a larger population of healthy animals 




This study has demonstrated that lipid metabolism is affected in dogs with IBD, resulting 
in altered concentrations of sterols (sitostanol and β-sitosterol) and fatty acids (arachidonic acid), 
as well as changes in the ratio between phytosterols and cholesterol, and the ratio between 
saturated and C5-unsaturated sterols (i.e., coprostanol to cholesterol, and sitostanol to β-sitosterol).  
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8. LONGITUDINAL ASSESSMENT OF FECAL CONCENTRATIONS OF 




Sterols and fatty acids have been found to be altered in the feces of dogs with IBD 
compared to healthy control dogs, both by untargeted (Section 5) and targeted (Section 7) 
metabolomics studies. The biological and physiological relevance of these lipids to host health 
and in the context of canine IBD have been discussed previously. However, from the results of 
previous studies, two very broad questions immediately arose. First, are the observed changes in 
the fecal FASter profile specific to chronic gastrointestinal diseases, or will similar changes be 
observed in severe, acute disease, such as acute hemorrhagic diarrhea syndrome (AHDS)? 
Secondly, will the concentrations of these metabolites change over time? We hypothesized that 
different patterns of fecal sterols and fatty acids would be associated with different gastrointestinal 
disease phenotypes, and that these concentrations would vary over time with treatment. To 
investigate these hypotheses, we aimed to compare the fecal FASter profiles over time from dogs 
with chronic enteropathy (CE) and also from dogs with AHDS to those from healthy control dogs. 
8.2 MATERIALS AND METHODS 
8.2.1 Study population and sample collection 
Naturally-passed fecal samples were retrospectively selected from available surplus 
samples from other studies, stored at -80°C. Samples from diseased dogs were categorized based 
on the diagnosis by the referring clinician. Baseline fecal samples were available from dogs with 
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acute hemorrhagic diarrhea syndrome (n=21), and follow up samples were available for a subset 
of these dogs collected on day 3 (n=10), day 7 (n=12), day 14 (n=11), day 21 (n=8), and day 90 
(n=9). Baseline fecal samples were available from dogs diagnosed with idiopathic inflammatory 
bowel disease (n=32). For a cohort of these dogs that clinically improved with treatment (n=16), 
samples were also available from day 21 (n=11), day 56 (n=11), and > 1 year (n=7) follow up. The 
diagnosis of idiopathic IBD was based on lack of response to at least one dietary trial, though the 
specific diet attempted for management varied based on preferences and requirements from the 
clinician, patient, and owner. Naturally passed fecal samples from healthy control dogs were also 
collected (n=18). Assessment of health was based on owner questionnaire indicating no recent 
antibiotic usage and no clinical signs of gastrointestinal disease. 
8.2.2 Sample preparation and instrument analysis 
Samples were prepared and analyzed by the FASter assay using gas chromatography-mass 
spectrometry (GC-MS) as described in Section 6.2. 
8.2.3 Statistical analyses 
Results in μg/mg lyophilized feces for all samples were analyzed in JMP (SAS, Durham, 
NC, USA). Kruskal-Wallis and Benjamini-Hochberg step-up method to adjust for multiple 
comparisons were used to identify overall significantly altered compounds among healthy 
controls, AHDS (baseline), AHDS (day 90), IBD (baseline), and IBD (>1 year). A Dunn’s post 
test was used to identify which pairwise comparisons were significantly different. Statistical 
significance was set at p<0.05. Multivariate evaluation of groups at baseline and the shifting 
composition over time was performed using MetaboAnalyst (Xia et al. 2015; Xia and Wishart 
2011, 2016). Raw concentrations were log-transformed and Pareto-scaled to achieve a more 
Gaussian distribution. For baseline samples, a plot was generated of the Pearson correlation matrix 
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for metabolites (across both diseases and in health), along with a PCA plot. For the samples from 
dogs with AHDS, a PCA plot and a heatmap were generated to show the distribution of samples 
by their collective FASter composition profiles over time. For samples from dogs with IBD, a 
PCA plot was generated to show sample groups over time.  
8.3 RESULTS 
8.3.1 Univariate analysis 
The summary for univariate analysis is shown in Table 18. Nearly all metabolites were 
significantly altered between at least one pairwise comparison; exceptions were oleic and palmitic 
acids. The baseline samples for dogs with AHDS were most often distinct from the other groups. 
8.3.2 Multivariate analysis 
8.3.2.1 Baseline profiles 
The Pearson correlation matrix for all baseline samples is shown in Figure 27, and Figure 
28 shows the PCA plot at baseline for the fecal FASter profile of dogs with AHDS, IBD, and 
healthy samples. 
8.3.2.2 AHDS over time 
The PCA plot showing the samples collected at each time point is shown in Figure 29. 
Samples are shown as dots; shaded areas represent the 95% confidence area for the group. 
The heatmap for the samples is shown in Figure 30. Individual sterols and fatty acids are 
in rows, and samples are in columns. The color of each cell is relative to the normalized 
concentration, with high concentrations in red and low concentrations in blue.
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Table 18. Summary of fatty acid and sterol concentrations at baseline and last time point for dogs with AHDS or IBD compared to healthy 





Healthy AHDS day 0 AHDS day 90 IBD day 0 IBD > 1 year     
Median Range Median Range Median Range Median Range Median Range p-value q-value 
 (μg/mg)  (μg/mg)  (μg/mg)  (μg/mg)  (μg/mg)     
Fatty Acids                       
α-linolenic acid 0.321 a [0.113-0.679] 0.096 b [0.064-2.6] 0.133 
 
[0.089-0.787] 0.491 a [0.08-7.342] 0.278 
 
[0.122-1.021] 0.0000 0.0000 
arachidonic acid 0.357 a [0.19-0.699] 3.372 b [0.74-10.792] 0.799 a,c [0.324-2.385] 0.705 c [0.188-4.977] 0.608 a,c [0.399-1.361] 0.0000 0.0000 




[0.224-0.599] 0.0001 0.0001 
cis-vaccenic acid 0.864 a [0.544-2.223] 2.991 b [1.078-8.829] 0.779 a [0.464-2.158] 1.010 a [0.215-11.271] 0.638 a [0.307-4.428] 0.0003 0.0003 
erucic acid 0.029 a [0.019-0.047] 0.074 b [0.039-0.198] 0.031 a,c [0.02-0.098] 0.053 c [0.014-0.238] 0.028 a,c [0.021-0.062] 0.0000 0.0000 




[0.14-0.481] 0.0010 0.0013 










[0.81-22.663] 0.0437 0.0483 
nervonic acid 0.174 a [0.085-0.384] 0.906 b [0.257-1.776] 0.199 a [0.102-0.568] 0.270 a [0.059-0.965] 0.189 a [0.102-0.38] 0.0000 0.0000 










[0.577-31.289] 0.2283 0.2283 










[2.043-14.354] 0.0479 0.0503 
stearic acid 2.037 a [1.195-4.366] 10.189 b [2.838-18.753] 2.990 
 
[0.785-13.644] 2.349 a [0.433-23.969] 3.920 
 
[0.95-10.71] 0.0001 0.0001 
Sterols  
 
   
 
   
 
   
 
   
 
    
β-sitosterol 2.394 a [1.354-4.42] 0.068 b [0.039-0.746] 0.897 b [0.385-2.815] 1.261 c [0.415-5.989] 1.449 a,c [0.975-1.887] 0.0000 0.0000 
brassicasterol 0.032 a [0.021-0.16] 0.020 b [0.016-0.08] 0.032 
 
[0.028-0.055] 0.049 a [0.016-0.377] 0.098 a [0.019-0.146] 0.0001 0.0002 
campesterol 1.372 a [0.739-2.422] 0.172 b [0.062-0.685] 0.662 a [0.313-1.529] 0.922 a [0.31-2.672] 0.876 a [0.432-1.553] 0.0000 0.0000 
cholestanol 0.191 a [0.071-0.473] 0.113 b [0.047-0.232] 0.281 a [0.152-0.798] 0.193 a [0.032-0.746] 0.148 
 
[0.125-0.48] 0.0001 0.0002 
cholesterol 1.836 a [1.182-5.67] 14.434 b [2.283-22.874] 3.052 a [1.522-11.444] 3.101 a [0.648-14.617] 3.171 a [0.877-6.193] 0.0000 0.0000 
coprostanol 0.047 a [0.022-0.607] 0.015 b [0.01-0.643] 0.057 a [0.023-5.464] 0.035 a [0.011-1.494] 0.019 
 
[0.013-0.221] 0.0001 0.0002 
fucosterol 0.135 a [0.077-0.233] 0.014 b [0.011-0.056] 0.051 a,c [0.022-0.075] 0.070 c [0.028-0.672] 0.081 a,c [0.056-0.667] 0.0000 0.0000 






[0.022-0.066] 0.0176 0.0205 
sitostanol 0.598 a [0.207-1.253] 0.003 b [0.002-0.055] 0.129 a,c [0.058-0.242] 0.102 c [0.014-1.236] 0.067 b,c [0.031-0.109] 0.0000 0.0000 



















































Figure 27. Pearson correlation matrix for baseline samples, including fecal samples from healthy 
control dogs and dogs with AHDS or IBD. The extent of correlation, by Pearson rho, is indicated 





AHDS day 0 
IBD day 0 
Healthy 
Figure 28. Principal components analysis (PCA) plot showing the similarity of fecal FASter 
profiles between dogs with AHDS, IBD, or healthy control dogs. Proximity of dots represents 





AHDS day 0 
AHDS day 3 
AHDS day 7 
AHDS day 14 
AHDS day 21 
AHDS day 90 
Healthy 
Figure 29. Principal components analysis (PCA) plot showing the progression of fecal FASter 
profiles of dogs with AHDS towards healthy control dogs. Proximity of dots represents similarity 



























Figure 30. Heatmap showing distribution of metabolite concentrations across samples over time 
for the fecal FASter profiles of dogs with AHDS compared to healthy control dogs. The 
progression is most profound for the five phytosterols sitostanol, campesterol, fucosterol, 









8.3.2.3 Idiopathic IBD over time 
The PCA plot showing the samples collected at each time point is shown in Figure 31. 
Samples are shown as dots; shaded areas represent the 95% confidence area for the group. 
IBD day 0 
IBD day 21 
IBD day 56 
IBD > 1 year 
Healthy 
Figure 31. Principal components analysis (PCA) plot showing the progression of fecal FASter 
profiles of dogs with idiopathic IBD towards healthy control dogs. Proximity of dots represents 







AHDS is an acute enteritis, while IBD is a chronic gastrointestinal disease. And although 
IBD still can be severe, the clinical presentation is usually not as dramatic as that of AHDS. Even 
more distinguishing between the two conditions is the response to treatment observed for these 
patients. With supportive therapy, most dogs with AHDS recover clinically within a few days. The 
data shown here, however, suggest that actual recovery may be incomplete even at 90 days after 
initial presentation, as the fecal FASter profiles approach but do not completely reach those seen 
in the healthy control dogs. This could in part be due to a confounding factor affecting the FASter 
profiles of the two groups, but noting the trajectory and progression of the AHDS samples even at 
day 21 to day 90, it is apparent that the compositions were continuing to shift towards a healthy 
profile. Also of note is that the shift was not directly linear along the principal components 
distinguishing healthy from day 0 of AHDS; rather, the group of samples deviated upwards and 
then back down as it trended to the right, towards the healthy population. This may translate 
physiologically to a nonlinear recovery process, which would not be surprising considering acute 
responses are often in contrast to long-term recovery. By looking at the heatmap for these samples, 
it subjectively appears that most persistent differences relate to lower concentrations on average 
of five phytosterols (sitostanol, campesterol, fucosterol, stigmasterol, and β-sitosterol). In the 
univariate analysis, stigmasterol and β-sitosterol were significantly altered between AHDS on day 
90 and healthy dog samples. 
The profiles over time from the dogs with IBD exhibited a markedly different progress 
compared to the dogs with AHDS, even though only dogs with IBD that clinically improved were 
included. While some shift and narrowing of the 95% confidence area is evident over time, it is 
remarkable that these profiles were nearly perfectly overlapping at day 21 and 56, and even after 
more than a year, the FASter profiles had barely changed, even though this group of dogs all 
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significantly improved clinically (data not shown). Importantly, a more global metabolomics view 
of these samples (unpublished data) reporting hundreds of metabolites did reflect more of a return 
towards health. The significance of the persistently altered FASter profiles may suggest either a 
permanent difference in the host metabolism (either genetics or adaptation due to disease or other 
medical history), or that clinical improvement does not necessarily translate into resolution at the 
biochemical level. More studies would be required to determine if the metabolites in the FASter 
profile may have utility in predicting relapse or long-term prognosis. 
At baseline comparing the Pearson correlations of different metabolites, there is a strong 
positive correlation among five phytosterols (sitostanol, campesterol, fucosterol, stigmasterol, and 
β-sitosterol), and these have a strong negative correlation with arachidonic and nervonic acids, and 
with cholesterol. Although correlations are notoriously hazardous to draw conclusions from, 
observing them repeatedly is suggestive of a meaningful relationship. Speculating on the profound 
changes and rapid recovery observed among dogs with AHDS, one important feature that comes 
to mind is the extent of histological damage and subsequent bleeding into the GI tract. Because 
cell membranes (including red blood cells) are composed of large quantities of cholesterol and 
fatty acids to form the lipid bilayer, it would be reasonable to suspect this accounts for those 
changes observed. However, hematochezia typically resolves within a few days, so the altered 
FASter profiles persisting on days 7, 14, 21, and 90 cannot be explained by blood contamination. 
Another effect in the early stages may be decreased absorption of nutrients due to the major 
sloughing of mucosa, causing both an increase in non-absorbed material as well as adding 
sloughed cells and blood to the mix. This could again have a “diluting” effect on concentrations, 
but as before, this is not a likely explanation after the acute phase of the disease, though some 
persisting malabsorption is feasible. 
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Another possibility to consider, though there is no experimental evidence to either support 
or refute this explanation, is that gene expression mechanisms similar to those in play in IBD are 
also invoked in recovery from the acute onset of AHDS. The host must activate the immune system 
to protect itself while the mucosal barrier is impaired, and rebuilding the mucosal layer would 
create a tremendous demand for any available fatty acids and sterols, scavenging them from the 
lumen particularly in the small intestine where the surface area is particularly large. The disruption 
to the enterocytes, which are the gatekeepers of lipid absorption, may perpetuate the abnormal 
assimilation of lipids until the mucosa has had adequate time to recover structurally. Gene 
expression studies from biopsies in dogs recovering from AHDS would potentially help elucidate 
the role of host gene regulation during the recovery process. 
Among dogs with IBD, dietary management is often ongoing. Though not shown in this 
study, unpublished work in our lab has suggested that diet can significantly alter these metabolite 
concentrations in healthy animals. However, taken subjectively from multivariate analyses, the 
observed shift in FASter profiles associated with feeding a commonly used hydrolyzed diet was 
not in the direction of the same principal components, meaning the effect of disease is likely 
distinct from the effect of dietary treatment. The significance of the altered metabolite 
concentrations induced by diet in the perpetuation of disease is an area that would require further 
studies. 
8.5 CONCLUSIONS 
The fecal FASter profile of dogs with AHDS was distinct from dogs with IBD and from 
healthy control dogs. The rapid recovery observed in AHDS patients clinically was recapitulated 
in the shifting composition of the fecal profiles towards the healthy group, yet was still abnormal 
after 90 days. Longer term follow up of dogs with AHDS would assist in determining if these 
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animals remain abnormal (similar to scarring) or if they eventually are associated with a complete 
restoration of a healthy fecal FASter profile. 
The samples from dogs with IBD demonstrated persistence of an abnormal FASter profile, 
even after more than one year of treatment. The contribution of different diets (e.g., hydrolyzed, 
novel protein, or other types of diets) should be explored systematically to assess if some of these 
altered metabolite concentrations are iatrogenic, and how the features of a therapeutic diet should 
be considered.  
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9. FECAL CONCENTRATIONS OF FATTY ACIDS IN DOGS WITH 




Exocrine pancreatic insufficiency (EPI) is a disease characterized by insufficient synthesis 
and secretion of pancreatic enzymes by the exocrine pancreas, resulting in malassimilation of 
macro-nutrients. For example, insufficient pancreatic lipase prevents normal digestion of dietary 
fat. Consequently, EPI would be expected to be associated with excessive fat (e.g., fatty acids) 
remaining in the feces. Treatment of EPI includes oral supplementation with pancreatic digestive 
enzymes and is often effective at decreasing severity of clinical signs, but fat assimilation does not 
completely normalize. The aim of this study was to evaluate fecal fatty acid (FA) concentrations 
in dogs with EPI undergoing enzyme supplementation. The hypothesis of this study was that fecal 
fatty acid concentrations would be increased in dogs with EPI compared to those of healthy dogs, 
even when being successfully treated with enzyme supplementation. 
9.2 MATERIALS AND METHODS 
9.2.1 Study population and sample collection 
Naturally-passed fecal samples from dogs with EPI (n=34) were retrospectively selected 
from surplus samples from other studies, stored at -80°C. In addition, there were samples from 
dogs with EPI who were not currently on enzyme supplementation (n=5) that were included only 
for visualizing the clustering of samples in a PCA plot. Samples from diseased dogs were 
categorized as EPI based on the diagnosis by the referring clinician in addition to a severely 
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decreased serum TLI concentration, and had to be on enzyme replacement therapy at the time of 
fecal collection. Stored samples from healthy dogs (n=72) from a variety of studies were used as 
the control group. Some control dogs were without a TLI result or other bloodwork, but all 
individuals were deemed healthy based on owner questionnaire and no reported clinical signs of 
gastrointestinal disease. 
9.2.2 Sample preparation and instrument analysis 
Samples were prepared and analyzed by the FASter assay using gas chromatography-mass 
spectrometry (GC-MS) as described in Section 6.2. 
9.2.3 Statistical analyses 
Results in μg/mg lyophilized feces for all samples were analyzed in JMP (SAS, Durham, 
NC, USA). Mann-Whitney U tests and a Benjamini-Hochberg step-up method to adjust for 
multiple comparisons were used to identify significantly altered compounds between dogs with 
EPI and healthy control dogs. Statistical significance was set at p<0.05. Multivariate analysis was 
performed using MetaboAnalyst (Xia et al. 2015; Xia and Wishart 2011, 2016). Raw 
concentrations were log-transformed and Pareto-scaled to achieve a more Gaussian distribution. 
Principal components analysis (PCA) plots were used to show the clustering/overlap among 
FASter profiles between dogs with EPI (with and without enzyme replacement therapy) and 
healthy control dogs. A plot of the Pearson correlation matrix was also prepared with all three 
groups included. 
9.3 RESULTS 
With the exception of nervonic acid, all fecal FAs were significantly increased in the feces 
of dogs with EPI. Among sterols, cholesterol was notably the same in both groups, while 
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coprostanol was decreased along with several phytosterols (i.e., sitosterol, campesterol, fucosterol, 
sitostanol, and stigmasterol). Data are summarized in Table 19.  
The PCA plot showing the distribution of samples based on their similarity in terms of 




Table 19. Summary of fecal fatty acid and sterol concentrations in dogs with EPI compared to 
healthy control dogs. 
Compound 
Healthy EPI   
Median Range Median Range p-value q-value 
Fatty acids         
α-linolenic acid (18:3 n-3) 0.337 [0.075-3.479] 1.022 [0.202-5.503] 0.0000 0.0000 
arachidonic acid (20:4 n-6) 0.413 [0.19-2.381] 0.745 [0.241-6.23] 0.0000 0.0000 
behenic acid (22:0) 0.248 [0.097-0.519] 0.344 [0.147-1.105] 0.0000 0.0000 
cis-vaccenic acid (18:1 n-7) 0.977 [0.47-4.851] 2.657 [0.225-9.477] 0.0000 0.0000 
erucic acid (22:1 n-9) 0.034 [0.014-0.089] 0.074 [0.022-0.646] 0.0000 0.0000 
gondoic acid (20:1 n-9) 0.190 [0.029-0.594] 0.690 [0.099-2.64] 0.0000 0.0000 
linoleic acid (18:2 n-6) 4.075 [0.434-29.726] 10.343 [1.653-34.451] 0.0000 0.0000 
nervonic acid (24:1 n-9) 0.182 [0.046-0.5] 0.187 [0.06-0.979] 0.1653 0.1928 
oleic acid (18:1 n-9) 4.069 [0.321-16.733] 13.710 [1.78-68.848] 0.0000 0.0000 
palmitic acid (16:0) 4.247 [1.283-13.422] 11.974 [1.57-48.4] 0.0000 0.0000 
stearic acid (18:0) 2.277 [0.935-7.477] 6.623 [1.083-43.154] 0.0000 0.0000 
Sterols         
β-sitosterol 2.108 [0.523-5.806] 1.240 [0.177-2.452] 0.0000 0.0000 
brassicasterol 0.036 [0.017-0.48] 0.052 [0.015-0.38] 0.3554 0.3732 
campesterol 1.269 [0.449-3.368] 0.793 [0.194-2.093] 0.0000 0.0000 
cholestanol 0.210 [0.058-0.473] 0.102 [0.032-0.277] 0.0000 0.0000 
cholesterol 1.928 [0.958-8.322] 2.055 [1.047-9.059] 0.8710 0.8710 
coprostanol 0.049 [0.017-0.607] 0.033 [0.011-1.499] 0.0024 0.0030 
fucosterol 0.117 [0.025-0.332] 0.066 [0.015-0.299] 0.0000 0.0000 
lathosterol 0.033 [0.02-0.264] 0.029 [0.02-0.108] 0.3242 0.3584 
sitostanol 0.461 [0.025-1.335] 0.042 [0.004-0.293] 0.0000 0.0000 






Figure 32. PCA plot showing fecal FASter profiles for healthy control dogs (green) compared to 








Figure 33. Pearson correlation matrix plot showing correlation between metabolites across the 






With enzyme supplementation, the clinical signs of EPI can usually be well-controlled. 
Although the group of untreated dogs is very small, the PCA plot does suggest that most of them 
had more severe alterations to their fecal fatty acid and sterol composition than the dogs receiving 
enzyme replacement therapy. However, clearly most of the dogs on enzyme therapy remained 
abnormal based on the nearly-distinct clustering of dogs with EPI from the healthy control dogs. 
One feature that stands out from the data is the lack of difference in nervonic acid observed 
between healthy dogs and dogs with EPI, while every other fatty acid quantified was significantly 
increased in disease. The reason for this is unclear, but may in part be due to the length of nervonic 
acid (24 carbons; the longest fatty acid in the FASter panel). This is supported somewhat by the 
more positive correlation of nervonic acid to its biosynthetic precursor, erucic acid, and also to 
gondoic and behenic acids, the other VLCFAs. Metabolically, VLCFAs are degraded via 
peroxisomal β-oxidation before they can be transferred to mitochondria for complete oxidation, 
so perhaps the mechanisms controlling VLCFA absorption and metabolism are less affected than 
those for the more common dietary fatty acids. There may be a significant difference in dietary 
intake of some of these compounds, and a detailed dietary history, which would be required to 
control for this, was not available. 
Also surprising is the lack of a difference in fecal cholesterol concentrations with 
concurrent alterations in phytosterols. This is quite distinct from the results of dogs with chronic 
enteropathy (e.g., IBD), where increased cholesterol concentrations were typically concurrent with 
decreased phytosterol concentrations. To determine whether this is related to contrasting 
mechanisms of disease certainly requires a better understanding of the underlying pathogenesis of 
CE. Importantly, our ability to understand altered fecal lipid concentrations is enhanced by 
observing the alterations occurring in a variety of different gastrointestinal diseases.  
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10. EFFECT OF CHOLESTYRAMINE ON FECAL CONCENTRATIONS OF 
STEROLS AND FATTY ACIDS IN HEALTHY DOGS 
 
10.1 INTRODUCTION 
Cholestyramine is a resin that forms insoluble complexes with bile acids, preventing 
intestinal reabsorption and enhancing fecal elimination of bile acids. By blocking enterohepatic 
circulation, feedback suppression of hepatic synthesis of bile acids is inhibited, thus increasing 
bile acid synthesis from cholesterol and decreasing serum cholesterol concentrations. While serum 
cholesterol is a well-studied parameter, recent work has also shown altered concentrations of fecal 
cholesterol and other sterols in dogs with gastrointestinal (GI) disease. Furthermore, GI 
assimilation of lipids is dependent on the formation of chylomicrons from triglycerides (i.e., 
glycerol and fatty acids) and esterified cholesterol. This study aimed to explore the effect of 
cholestyramine on lipid metabolism by assessing fecal concentrations of fatty acids and sterols in 
healthy dogs. 
10.2 MATERIALS AND METHODS 
A crossover study design was used. 12 healthy Beagle dogs from a research colony were 
randomized into groups A and B. Dogs in group A (n=6) received 11.4 g/day cholestyramine 
powder (8 g/day active ingredient) suspended in 75 mL of water for two weeks (period 1), a two 
week washout period, and nothing additional for two weeks (period 2). Dogs in group B (n=6) 
received treatments in reverse order. Fecal samples were collected two weeks prior to the start of 
period 1 and at the end of each treatment period. Samples were immediately frozen upon 
collection, and shipped as a batch on dry ice for analysis. Samples were prepared and analyzed by 
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the FASter assay using gas chromatography-mass spectrometry (GC-MS) as described in Section 
6.2. 
Effects were modeled by standard least squares (SLS) with a restricted maximum 
likelihood (REML) method in the statistical software package JMP (SAS, Durham, NC, USA). 
Carryover effect was assessed by interaction between drug and treatment period. P-values were 
corrected for multiple comparisons using the Benjamini-Hochberg step-up method and statistical 
significance was set at p<0.05. The changes in concentration were calculated as the median 
average change across individuals while on cholestyramine compared to the sample taken during 
the no-drug period. This net change value was compared to the median no-drug concentration to 
calculate the percent change. 
10.3 RESULTS 
None of the measured sterols or fatty acids exhibited a significant carryover effect. 
Concentrations of all measured sterols except lathosterol were significantly affected by 
cholestyramine. Interestingly, brassicasterol was significantly increased, while all other sterols 
quantified were decreased regardless of whether they were phytosterols (i.e., campesterol, 
stigmasterol, fucosterol, β-sitosterol, and sitostanol) or zoosterols (i.e., cholesterol, coprostanol, 
and cholestanol). Although α-linolenic acid was significantly decreased and linoleic acid was 
virtually unchanged, most fecal fatty acid concentrations were increased with cholestyramine (i.e., 
palmitic, oleic, cis-vaccenic, stearic, and arachidonic acids). However, the very long-chain fatty 
acids (VLCFAs; i.e., gondoic, erucic, behenic, and nervonic acids) were notably not significantly 




Table 20. Summary data for fecal sterol and fatty acid concentrations as affected by 
cholestyramine administration. 
Compound 
End Cholestyramine End No Drug      
Median Range Median Range Change Change  
p-value q-value (μg/mg) (μg/mg) (median) (%) 
Fatty acids            
palmitic acid 4.2159 [3.098-6.6523] 3.2664 [2.5144-4.3075] 0.6767 21% 0.0163 0.0245 
linoleic acid 1.8812 [1.4178-3.3099] 1.9574 [1.7257-4.3757] -0.2287 -12% 0.7340 0.7340 
α-linolenic acid 0.2052 [0.162-0.3182] 0.2674 [0.1949-0.3961] -0.0729 -27% 0.0201 0.0282 
oleic acid 3.4869 [2.6718-5.7879] 2.9025 [2.4548-3.6656] 0.3038 10% 0.0129 0.0210 
cis-vaccenic acid 2.1821 [0.8892-3.0069] 0.9132 [0.6164-1.5902] 1.2968 142% 0.0012 0.0032 
stearic acid 3.2991 [2.3158-5.4361] 2.0602 [1.7659-3.1147] 0.9980 48% 0.0130 0.0210 
arachidonic acid 1.4542 [0.8199-2.2534] 0.8847 [0.6337-1.2835] 0.5915 67% 0.0099 0.0207 
gondoic acid 0.2726 [0.1474-0.3571] 0.1879 [0.1334-0.2997] 0.0594 32% 0.0441 0.0579 
erucic acid 0.0428 [0.0291-0.0616] 0.0417 [0.0303-0.0499] 0.0043 10% 0.2054 0.2303 
behenic acid 0.2609 [0.2241-0.4195] 0.2943 [0.2473-0.3873] -0.0316 -11% 0.2084 0.2303 
nervonic acid 0.2085 [0.1695-0.4613] 0.2423 [0.1741-0.3636] -0.0321 -13% 0.3526 0.3702 
Sterols            
cholesterol 1.9879 [1.3585-6.0684] 3.6176 [1.7063-8.7236] -1.7386 -48% 0.0122 0.0210 
brassicasterol 0.0486 [0.0333-0.0658] 0.0265 [0.0177-0.0357] 0.0215 81% 0.0001 0.0007 
lathosterol 0.0327 [0.0226-0.1603] 0.0513 [0.0224-0.1739] -0.0152 -30% 0.1571 0.1941 
campesterol 0.4292 [0.3107-1.0009] 0.7491 [0.5391-1.0599] -0.2152 -29% 0.0007 0.0026 
stigmasterol 0.2375 [0.1896-0.375] 0.3223 [0.2712-0.3985] -0.0577 -18% 0.0009 0.0026 
fucosterol 0.0442 [0.034-0.0858] 0.0614 [0.0485-0.0792] -0.0140 -23% 0.0060 0.0141 
β-sitosterol 0.8146 [0.6833-1.594] 1.1775 [0.9233-1.5319] -0.3295 -28% 0.0008 0.0026 
coprostanol(5β) 0.0510 [0.0392-0.0758] 0.0898 [0.0613-0.1588] -0.0258 -29% 0.0003 0.0017 
cholestanol(5α) 0.1338 [0.102-0.3307] 0.2904 [0.2085-0.5027] -0.1500 -52% 0.0003 0.0017 




The administration of cholestyramine resulted in altered concentrations of fecal sterols 
and fatty acids. The physiologic interrelationship of these compounds in lipid metabolism suggests 
that cholestyramine may have a significant effect on intra-luminal homeostasis of sterols and 
assimilation of fatty acids. The mechanism of action of cholestyramine is known to be increased 
fecal excretion of bile acids. This would be expected to diminish the feedback inhibition on the 
FXR nuclear receptor, inciting a cascade of changes in lipid metabolism pathways as cholesterol 
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from the body is drawn upon and converted to bile acids. Although all cells possess the ability to 
synthesize cholesterol de novo, a very large portion of cholesterol is thought to originate from the 
diet, so increased GI absorption of cholesterol would be logical for an immediate response, most 
likely modulated by NPC1L1 receptors that do not exclude phytosterols. Simultaneously, the 
decreased availability of bile acids would impair the formation of lipid micelles during digestion, 
thus decreasing the ability of the enterocytes to absorb luminal fatty acids and resulting in a net 
increase in fecal concentrations of fatty acids. It is also thought that cholestyramine in the lumen 
can directly bind fatty acids to an extent, which also could increase luminal concentrations of fatty 
acids. Yet some selectivity appears to occur in this regard, causing particularly extreme increases 
in cis-vaccenic acid and arachidonic acid, and a decrease in α-linolenic acid. As shown in Section 
3, among the fatty acids, cis-vaccenic and arachidonic acids are particularly large components of 
bile compared to their concentrations in feces. As the body responds to try to restore bile acid 
homeostasis, it would make sense that the gall bladder contents are more completely expelled. 
However, as arachidonic acid has repeatedly been shown to be related to inflammation, the 
increase in concentration may indicate a detrimental effect overall. The only omega-3 fatty acid 
quantified, α-linolenic acid, was somewhat depleted from the lumen. Since the ratio of omega-6 
to omega-3 fatty acids is thought to be the relevant parameter for pro-inflammatory relationships, 
the physiological significance of opposing changes between arachidonic and α-linolenic acids may 
be particularly profound. The lack of changes among other VLCFAs is also appreciable. This may 
suggest that the regulation of VLCFAs is via distinct mechanisms from LCFAs. 
Although serum cholesterol measurements were not obtained, these animals were not 
hypercholesterolemic so it is unclear whether serum cholesterol would have decreased with 
cholestyramine treatment. By inducing a whole-body depletion of cholesterol, it would make sense 
that mechanisms of sterol absorption would be upregulated after two weeks of cholestyramine 
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administration. Since targeted metabolomics studies have shown detrimental effects associated 
with decreased concentrations of fecal phytosterols, and anti-inflammatory effects associated with 
oral phytosterols administration in mouse models of colitis (Aldini et al. 2014), it should be 
considered whether this may be a negative side effect of cholestyramine administration.  
Future studies are required to explore the effect of cholestyramine on fecal metabolite 





The work reported in this dissertation represents a very large body of data, much of which 
is descriptive, but provides a stepping-stone for future research projects. First, the utility of feces 
as a biological specimen has been demonstrated. Out of all possible sample types, collection of 
naturally passed feces is among the least invasive and least expensive of any (on par with a free-
catch urine sample), easily carried out by the pet owner without a visit to the veterinarian, and 
sample quantity is usually abundant. Even with the variety of dietary intake across individuals, the 
net effects of the gastrointestinal microbiota and host metabolism in disease states clearly exerts 
an effect on the biochemical composition of feces. Although future work should attempt to include 
a dietary history as initial data from our laboratory have shown that dietary changes result in a 
different shift than what is observed in disease states. An interesting study to improve our 
understanding of how different diets affect the fecal composition would be to perform 
metabolomics studies on paired samples of diet (e.g., the commercial kibble) and feces. 
The breadth of biochemical composition within the GI tract was demonstrated by 
analyzing the metabolome at different sites of the canine GI tract. Metabolomics has historically 
been used predominantly to study serum samples, but host physiology typically keeps tight control 
over the circulatory system. While that makes serum a quieter matrix, it also likely eliminates 
many of the effects that are occurring at the level of the host-microbiota interaction within the GI 
tract. 
As feces have become more appreciated as a sample for molecular analysis, the question 
arises regarding the use of feces as a surrogate for other locations within the GI tract. In this study, 
we used both untargeted and targeted metabolomics to compare the duodenal, ileal, colonic, and 
rectal contents in healthy dogs. The results provide a context for interpretation of other studies by 
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elucidating the changing concentrations of metabolites and also the composition of the microbiota 
in different intestinal segments. However, the use of fecal samples for analysis is also associated 
with unique challenges. For example, the total amount of food taken in orally versus the relatively 
small amount of feces released upon defecation, and the concentrating effect that occurs towards 
non-absorbed compounds due to absorption of nutrients. Similar to the use of creatinine or specific 
gravity to normalize for water content of urine, perhaps there is a way to normalize for percent 
absorption of digesta, but this has not been described as of yet. Ultimately, one can also argue that 
the relative concentrations of compounds are still fundamentally the important feature, especially 
when comparing samples from diseased dogs to those from healthy dogs from the same site (e.g., 
duodenal chyme, feces, or other), and that feces represent the net effect of all factors. 
A particular area of interest in veterinary research is canine chronic enteropathy. Using 
untargeted metabolomics to compare the fecal metabolome of dogs with CE to healthy control 
dogs revealed a tremendously diverse group of chemical alterations. Furthermore, by grouping the 
compounds into pathways based on what is known about metabolism and biochemical pathways, 
certain differences in metabolism are of interest. Most notably, lipid metabolism as evidenced by 
altered abundances of sterols and fatty acids. However, many other metabolic pathways appeared 
to be disturbed, including aromatic amino acid metabolism, redox, and most excitingly, pathways 
involving host-microbiota interactions and interdependence. A more complete understanding of 
these interactions is required to completely appreciate how the microbiota and metabolome can be 
leveraged for diagnostic, prognostic, and therapeutic benefits, but the potential is immense, 
especially considering the vast and malleable metabolic repertoire of the microbiota. 
Regarding lipid metabolism, there is a significant body of research exploring connections 
between regulation of host gene expression as well as involvement of the microbiota. Specific 
examples include the conversion of cholesterol to coprostanol and the association between this 
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ability and decreased risks for certain gastrointestinal diseases, and also the relationships between 
diseases and the bile acid pool (where the microbiota are credited with dehydroxylating primary 
bile acids to form secondary bile acids). Data from an extensive gene expression study on canine 
duodenal mucosal biopsies provided many suggestions of altered host gene expression related to 
lipid metabolism, including neurotensin, fatty acid binding proteins, fatty acid transport proteins, 
several members of acyl-CoA synthetases, fatty acid elongases, PPARγ, FXR, and SREBF2, 
among many others known to play a role in fatty acid, bile acid, and sterol homeostasis. By 
combining the data previously published with our work regarding the fecal metabolome, it is quite 
clear that a significant dysmetabolism of lipids occurs in the gastrointestinal diseases studied. 
A quantitative in-house assay was developed as part of this study, to allow direct 
comparison of samples with regard to their fatty acids and sterols concentrations. As this assay 
was applied to multiple cohorts of dogs with chronic enteropathy, certain findings were consistent 
between various diseases: decreased concentrations of phytosterols and increased cholesterol in 
the feces of dogs with chronic enteropathy. The study of fecal sterols in the context of IBD is quite 
novel, though there is some research regarding non-cholesterol sterols in serum. We have not yet 
proposed a molecular mechanism for these alterations, but there is ample room for applying 
techniques such as immunohistochemistry to expand upon the initial data regarding gene 
expression. Perhaps even more practical would be to expand the breadth of fatty acids included in 
the assay. Among the notable changes reported in the literature, humans with IBD are thought to 
deplete their n-3 fatty acids, which may perpetuate inflammation by changing the n-6 to n-3 ratio. 
The only n-3 fatty acid that is currently part of our assay is arachidonic acid, and although it is 
undeniably a key player in inflammation, including other polyunsaturated fatty acids would likely 
increase the yield of information gained from each sample. Another group of compounds that 
appears to be relevant but is not currently being analyzed is the group of dicarboxylic acids. These 
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were observed to be significantly decreased in abundance in feces of dogs with CE in an untargeted 
metabolomics study, suggesting potential changes in ω-oxidation of fatty acids. Among the more 
critical parts of assay development remaining is the determination of a reference interval for each 
analyte. Very stringent criteria to identify a small group of healthy control animals resulted in 
similar variability as loose criteria to obtain a large group of healthy animals, suggesting that the 
significant findings persist across the broader population. However, the purpose of the assay for 
diagnostic testing does require establishing parameters for classification of animals with clinical 
signs suggestive of gastrointestinal disease. 
This work has shown that different disease phenotypes are accompanied by different fecal 
fatty acid and sterol profiles. The changes in diseased animals relative to healthy animals are 
summarized in Table 21, along with the changes observed during cholestyramine administration. 
Since very few changes of the phytosterols were compound-specific, they were considered as a 
group for the purposes of assessing trends across conditions. 
Comparing acute and chronic gastrointestinal diseases, there was no perfect correlation 
between clinical recovery and FASter profiles, but it was clear that the fecal composition in dogs 
with acute hemorrhagic diarrhea syndrome progressed over time towards a profile resembling the 
healthy control animals. Of note, the pre-disease FASter profiles are unknown, so there is some 
chance that these animals have recovered to their pre-disease state, and the profiles would indicate 
a predisposition to disease. Continuing to follow animals after recovery from AHDS over a longer 
duration may reveal either ongoing recovery, or potentially prolonged “scarring” to their metabolic 
pathways that may affect their predisposition to other diseases. Conversely, the animals with 
chronic GI disease, specifically idiopathic IBD, exhibited very little change in fecal FASter 
composition over time when examined from a multivariate perspective. Most studies in canine 
IBD have been limited to shorter follow up periods, so the progression/remission of disease over 
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a longer period and in a more diverse group of patients would help elucidate more subtle nuances 
within these patterns. 
Fecal samples from dogs with EPI were also analyzed, showing that in spite of enzyme 
replacement therapy, their fecal fatty acids and sterols profiles still showed an abnormal 
composition. The fact that cholesterol was not altered in this group, however, highlights that there 
is a different pattern of alteration among dogs with EPI than among dogs with IBD. This suggests 
that the FASter assay has the potential to distinguish diseases and elucidate aspects of pathogenesis 
by considering which components of lipid metabolism have been affected. 
 
 
Table 21. Summary of changes in FASter assay compounds relative to healthy animals. 
Significantly increased concentrations are noted with a “+”, decreases with a “–”, and no 
significant change with a “0”. 
Condition EPI AHDS  
(day 0) 
IBD cholestyramine 
Compound         
[phytosterols] – – – – 
cholesterol 0 + + – 
nervonate (24:1 n-9) 0 + 0 0 
behenate (22:0)  + + 0 0 
erucate (22:1 n-9) + + + 0 
gondoate (20:1 n-9) + + 0 0 
arachidonate (20:4 n-6) + + + + 
cis-vaccenate (18:1 n-7) + + 0 + 
α-linolenate (18:3 n-3) + – 0 – 
linoleate (18:2 n-6) + – 0 0 
oleate (18:1 n-9) + 0 0 + 
stearate (18:0)  + + 0 + 





An additional study in our lab sought to perturb cholesterol homeostasis in healthy dogs 
by administering cholestyramine for a period, then quantifying the fecal FASter composition. The 
mechanism of action of cholestyramine is known to be increased fecal excretion of bile acids, and 
the alterations to lipid metabolism likely begin with diminished feedback inhibition of the FXR 
nuclear receptor. It is of great interest that inducing a dysmetabolism via bile acid depletion (and 
subsequent cholesterol depletion) resulted in a different pattern than the other diseases studied, 
again showing that the FASter assay has the potential to be used to assess different underlying 
etiologies on the basis of different patterns. 
To speculate about the physiology underlying each disease pattern, first we must disregard 
the confounding factor of fecal mass: in other words, we assume that a lower concentration of a 
specific analyte corresponds to an absolute decrease in the amount exiting the body, rather than a 
dilution of the concentration by decreased absorption of non-analyte material. Since we know EPI, 
AHDS, and IBD are all characterized by some loss of function, this is probably a poor assumption 
to make. Nonetheless, this does not preclude speculation regarding compounds that are increased 
in concentration, and where the magnitude of the decrease is particularly profound, also 
speculating that the decreased concentrations are genuine indicators of alterations in the 
physiology. With regard to phytosterols, it appears they exhibit decreased concentrations in EPI, 
AHDS, and IBD, as well as upon administration of cholestyramine. The exception of brassicasterol 
being increased in feces of dogs administered cholestyramine could be related to the composition 
of the cholestyramine powder, but this has not explicitly been tested. In general, direct interference 
of cholestyramine with the quantification of fecal analytes should be assessed to determine if the 
resin masks the presence of certain compounds. Further analysis into specific ratios within the 
phytosterols (i.e., investigating relative biohydrogenation of β-sitosterol and stigmasterol to 
sitostanol) is ongoing and initial results suggest the presence of more nuanced patterns within the 
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phytosterols, and obviating the concern that dilution via decreased general absorption could be 
misleading. Fecal cholesterol was more variable, decreasing upon administration of 
cholestyramine, but unchanged in dogs with EPI and increased in dogs with AHDS or IBD. The 
variation among diseases was most profound looking at the concentrations of fatty acids. Nervonic 
acid, the longest chain fatty acid quantified in the panel, was unchanged from healthy control dogs 
except in dogs with AHDS. Nervonic acid is an important component of many cerebrosides and 
sphingomyelins, which are part of the lipid content of myelin. The exact mechanism of the 
extravasation of fluid into the GI tract in dogs with AHDS is unknown, but perhaps the sloughed 
mucosa combined with fluid movement from the cardiovascular space through the submucosa and 
submucosal plexus can carry and expose an appreciable amount of myelin breakdown products to 
the lumen. Another feature of samples from dogs with AHDS was the magnitude of increased 
cholesterol concentration. As was mentioned, cell membranes are composed largely of 
phospholipids and cholesterol, so this increase in the fecal material may be due to increased 
sloughing of enterocytes or red blood cells, or potentially accompanying the fluid as plasma 
cholesterol or myelin. 
The hallmark of EPI using the FASter assay was increased fecal fatty acid concentrations, 
excepting only nervonic acid. Oleic, stearic, and palmitic acids are likely the largest contributors 
of dietary intake of fatty acids, and all three were increased in feces from dogs with EPI. This fits 
well with the understanding of the pathogenesis of the disease, primarily characterized by 
insufficient enzymes to digest and assimilate dietary fat (and other nutrients), thus leading to more 
of these macronutrients remaining in the feces. Supplementation of the diet of dogs with EPI with 
fish oil, a source of omega-3 fatty acids, is sometimes recommended along with vitamin E 
supplementation, and the direct effect of these compounds on the fecal concentrations of fatty 
acids in healthy dogs has not yet been determined.  
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The other group of dogs that also demonstrated increased C16 and C18 fatty acids was the 
group receiving cholestyramine. In this case, there is a known perturbation to lipid metabolism 
instigated by bile acid depletion in otherwise metabolically-normal animals. This may be 
explained by the ongoing demand for bile acids in the GI tract, which promotes secretion of bile 
into the duodenum. The C16 and C18 fatty acids (especially cis-vaccenic acid) are particularly 
concentrated in bile, so this would be expected to increase fecal concentrations of these 
compounds. 
Other VLCFAs (behenic, erucic, and gondoic acids) were unchanged in dogs after 
cholestyramine administration, but increased in dogs with EPI or AHDS, and moderately trended 
upwards in dogs with IBD. Since peroxisomal oxidation is required to process VLCFAs before 
they can be used as substrate by the mitochondria, the accumulation in dogs with EPI, AHDS, or 
IBD may indicate either a defect in peroxisomal oxidation or demand on the pathway that exceeds 
the enzymatic turnover capacity. The observation in the gene expression study (Wilke et al. 2012) 
of 4-fold increased PPARγ supports that this pathway is affected in IBD, but the complexity of 
functions associated with that receptor prevents a sensible interpretation of the underlying 
mechanism. It may be as simple as upregulation due to increased ligand availability, or as complex 
as part of an underlying genetic defect that predisposes animals to a cascade of pro-inflammatory 
events. In contrast, arachidonic acid appears to increase with cholestyramine administration as 
well as with EPI, AHDS, or IBD compared to healthy control dogs. Arachidonic acid holds a 
critical role in the balance between pro- and anti-inflammatory mediators. It is the precursor to 
prostaglandins, leukotrienes, and thromboxanes, with the proportioning of synthesis of these 
metabolites depending on regulation of many distinct enzymes. It can be synthesized from linoleic 
acid, or can be obtained through dietary sources. It might be presumed that increased arachidonic 
acid acts as a perpetuator of inflammation: if the metabolic pathways leading to pro-inflammatory 
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products are upregulated, increased substrate may perpetuate the inflammation. However, dietary 
arachidonic acid itself does not seem to induce a pro-inflammatory state, though it may inhibit the 
anti-inflammatory effects of omega-3 fatty acids. This may explain the decreased fecal 
concentration of the omega-3 fatty acid α-linolenate observed with cholestyramine administration 
or in dogs with AHDS as the pro-inflammatory pathways would not be chronically upregulated 
and homeostasis of the inflammatory balance may increase the absorption of omega-3 fatty acids 
from the intestinal lumen compared to healthy animals. Furthermore, arachidonic acid is 
concentrated in bile, and as discussed above, the increased bile secretion induced by luminal bile 
acid depletion with cholestyramine administration would increase luminal arachidonic acid 
concentration without necessarily inducing a pro-inflammatory effect. 
The pathogenesis of IBD is poorly understood. The results from the untargeted 
metabolomics study described in Section 5 suggest far more extensive changes to lipid metabolism 
than are evidenced by looking only at the compounds in the FASter assay, but results from all 
studies taken together strongly suggest that peroxisomal oxidation of fatty acids plays an important 
role in the dysmetabolism, whether causing or induced by changes in the role of the peroxisome 
in redox homeostasis concurrently. 
A final simplified summary regarding the most notable alterations in compounds from the 
FASter assay and a corresponding speculation of the explanation is shown in Table 22. However, 
this study has raised far more questions than it has answered, and ultimately shows profound 
patterns of altered metabolism evidenced in fecal samples. Systematic evaluations of the effect of 
diet, supplements, antibiotics and other medications, inflammation, and the relationships with the 




Table 22. Examples of the most notable changes observed in compounds of the FASter assay, 
comparing “condition” to healthy, and potential physiological explanations. 
 
condition 
notable fecal FASter 
concentration changes potential explanation 
   
AHDS increased nervonate, increased cholesterol 
cell membrane material from sloughed 
enterocytes or red blood cells; extravasation 
of lipid-rich fluid through the submucosa 
carrying plasma cholesterol solubilizes 
nervonic acid-enriched lipids from the 
submucosal plexus 
   
EPI all fatty acids increased (except nervonate) 
lack of pancreatic lipase results in a 
significant increase in undigested and/or 
unassimilated fats remaining in the intestinal 
lumen 
   
IBD increased arachidonic acid, increased cholesterol 
underlying aberration of fatty acid metabolism 
induces a chronic pro-inflammatory state, 
perpetuated by arachidonic acid; ongoing cell 
sloughing and lymphatic fluid high in 
cholesterol leaking into the intestinal lumen 
   
cholestyramine decreased cholesterol, variable fatty acid changes 
physiological response to lack of luminal bile 
acids promotes secretion of bile; fatty acids 
that were increased are components of bile; 
cellular α-linolenic acid demand is increased 
to maintain homeostasis with presence of 
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Table A-1. Significantly altered community functional potential as categorized by KEGG 
pathways. 
L1 L2 L3 
Pathway 












Cell Growth and Death 0.267 0.549 
Meiosis - yeast 0.006 0.029 
p53 signaling pathway 0.005 0.023 
Cell Motility 0.002 0.027 
Bacterial motility proteins 0.000 0.013 
Cytoskeleton proteins 0.001 0.013 
Flagellar assembly 0.001 0.013 
Transport and 
Catabolism 0.051 0.209 
Lysosome 0.001 0.016 













Membrane Transport 0.588 0.779 
Bacterial secretion system 0.011 0.043 
Secretion system 0.001 0.013 















Folding, Sorting and 
Degradation 0.253 0.549 
Protein processing in endoplasmic reticulum 0.003 0.023 
Sulfur relay system 0.008 0.034 
Ubiquitin system 0.002 0.020 
Transcription 0.383 0.655 Basal transcription factors 0.004 0.023 










Cancers 0.141 0.387 
Bladder cancer 0.005 0.025 
Colorectal cancer 0.005 0.023 
Renal cell carcinoma 0.003 0.023 
Small cell lung cancer 0.005 0.023 
Cardiovascular 
Diseases 0.005 0.027 Viral myocarditis 0.005 0.023 
Infectious Diseases 0.004 0.027 
African trypanosomiasis 0.002 0.020 
Bacterial invasion of epithelial cells 0.010 0.040 
Chagas disease (American trypanosomiasis) 0.002 0.019 
Influenza A 0.005 0.023 
Pertussis 0.013 0.049 
Shigellosis 0.010 0.041 
Toxoplasmosis 0.005 0.023 
Vibrio cholerae pathogenic cycle 0.005 0.025 
Neurodegenerative 
Diseases 0.003 0.027 
Amyotrophic lateral sclerosis (ALS) 0.000 0.013 
Huntington's disease 0.003 0.020 










Metabolism 0.832 0.898 
Lysine degradation 0.001 0.013 
Tryptophan metabolism 0.000 0.013 
Valine, leucine and isoleucine degradation 0.002 0.020 
Biosynthesis of Other 
Secondary Metabolites 0.082 0.279 
Caffeine metabolism 0.012 0.049 
Phenylpropanoid biosynthesis 0.000 0.013 
Streptomycin biosynthesis 0.005 0.023 
Carbohydrate 
Metabolism 0.761 0.865 Ascorbate and aldarate metabolism 0.004 0.023 
Glycan Biosynthesis 
and Metabolism 0.036 0.163 
Glycosaminoglycan degradation 0.002 0.019 
Glycosphingolipid biosynthesis - globo series 0.001 0.013 
Glycosyltransferases 0.007 0.029 
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L1 L2 L3 
Pathway 
Category p-value q-value Pathway Category p-value q-value Pathway Category p-value q-value 
Lipopolysaccharide biosynthesis 0.004 0.023 
Lipopolysaccharide biosynthesis proteins 0.004 0.023 
Other glycan degradation 0.001 0.013 
Lipid Metabolism 0.577 0.779 
alpha-Linolenic acid metabolism 0.001 0.013 
Biosynthesis of unsaturated fatty acids 0.001 0.015 
Fatty acid metabolism 0.012 0.049 
Linoleic acid metabolism 0.001 0.013 
Primary bile acid biosynthesis 0.000 0.013 
Secondary bile acid biosynthesis 0.000 0.013 
Sphingolipid metabolism 0.001 0.013 





Lipoic acid metabolism 0.003 0.023 
Ubiquinone and other terpenoid-quinone biosynthesis 0.002 0.019 
Metabolism of Other 
Amino Acids 0.311 0.606 
beta-Alanine metabolism 0.005 0.025 
Cyanoamino acid metabolism 0.003 0.020 





Biosynthesis of siderophore group nonribosomal peptides 0.003 0.023 
Biosynthesis of vancomycin group antibiotics 0.002 0.019 
Geraniol degradation 0.001 0.013 
Limonene and pinene degradation 0.004 0.023 





Atrazine degradation 0.008 0.034 
Caprolactam degradation 0.003 0.020 
Chlorocyclohexane and chlorobenzene degradation 0.004 0.023 
Drug metabolism - cytochrome P450 0.005 0.025 
Fluorobenzoate degradation 0.001 0.013 
Metabolism of xenobiotics by cytochrome P450 0.001 0.016 













Circulatory System 0.004 0.027 Cardiac muscle contraction 0.004 0.023 
Endocrine System 0.093 0.292 Melanogenesis 0.013 0.049 
Environmental 
Adaptation 0.528 0.779 Circadian rhythm - plant 0.005 0.025 









Cellular Processes and 
Signaling 0.326 0.608 
Cell motility and secretion 0.002 0.020 
Electron transfer carriers 0.001 0.013 
Germination 0.001 0.017 
Inorganic ion transport and metabolism 0.001 0.013 
Membrane and intracellular structural molecules 0.005 0.023 
Pores ion channels 0.003 0.022 
Sporulation 0.006 0.026 
Genetic Information 
Processing 0.685 0.851 
Restriction enzyme 0.012 0.049 
Transcription related proteins 0.005 0.025 
Metabolism 0.351 0.626 
Glycan biosynthesis and metabolism 0.002 0.019 
Metabolism of cofactors and vitamins 0.000 0.013 





Table A-2. Medians and ranges of normalized peak areas for all detected named metabolites. 
Compounds identified only by comparison to published library spectra are marked with an 
asterisk. Note that relative peak areas cannot be used to compare relative quantities of two different 
metabolites. P and q values < 0.05 are shown in bold. 
Compound 
Healthy Chronic Enteropathy   
Median Range Median Range p-value q-value 
1,2-propanediol 0.4667 [0.2553-2.8892] 1.1693 [0.2553-8.8776] 0.0263 0.0929 
1,3-diaminopropane 0.2594 [0.2594-1.5561] 0.2594 [0.2594-39.101] 0.8545 0.9174 
1,5-anhydroglucitol (1,5-AG) 0.1785 [0.1221-1.1503] 1.7475 [0.3162-11.03] 0.0000 0.0016 
10-heptadecenoate (17:1n7) 0.8657 [0.3247-3.6391] 1.8169 [0.1717-17.8203] 0.2998 0.4805 
10-hydroxystearate 0.7473 [0.2144-2.6944] 2.8566 [0.2648-17.2784] 0.0062 0.0399 
10-nonadecenoate (19:1n9) 0.9752 [0.3434-2.9329] 1.5884 [0.2485-15.203] 0.5338 0.6876 
12,13-DiHOME 1.4844 [0.4996-3.03] 0.8188 [0.0698-5.1941] 0.1057 0.2391 
12-dehydrocholate 0.6052 [0.1986-33.2721] 0.5097 [0.1591-41.145] 0.1957 0.3641 
12-hydroxyoleate 0.4341 [0.2407-4.6698] 4.0735 [0.1492-37.2416] 0.0037 0.0269 
13-HODE + 9-HODE 0.8219 [0.3762-1.7473] 1.1002 [0.0084-5.7011] 0.5614 0.7115 
13-methylmyristic acid 1.6836 [0.1132-9.3985] 0.3864 [0.0845-4.7114] 0.0032 0.0254 
15-methylpalmitate (isobar with 2-methylpalmitate) 0.9914 [0.5009-2.3236] 1.0314 [0.4135-3.0176] 0.9339 0.9582 
17-methylstearate 0.9301 [0.5482-1.931] 1.3120 [0.2498-6.2635] 0.3615 0.5391 
19,20-DiHDPA 0.8868 [0.0363-4.756] 1.0202 [0.0401-4.0574] 0.7089 0.8229 
1-arachidonylglycerol 0.6680 [0.2263-2.4342] 1.7541 [0.2263-8.7227] 0.0796 0.1955 
1-docosahexaenoylglycerol 0.6631 [0.1582-3.1366] 0.1582 [0.1582-41.1925] 0.3242 0.5093 
1H-quinolin-2-one 0.8822 [0.1634-28.4684] 0.1634 [0.1634-0.1634] 0.0000 0.0014 
1-linolenoylglycerol 1.1211 [0.2121-53.1655] 0.3978 [0.0806-14.7761] 0.1844 0.3447 
1-linoleoylglycerol (1-monolinolein) 2.3704 [0.359-7.7933] 0.4910 [0.0843-38.8233] 0.0279 0.0947 
1-linoleoylglycerophosphocholine (18:2n6) 0.9217 [0.1581-6.9648] 0.5225 [0.1581-13.8959] 0.4637 0.6303 
1-linoleoylglycerophosphoethanolamine* 0.0909 [0.0909-1.2573] 0.0909 [0.0909-15.0424] 0.6211 0.7555 
1-margaroylglycerophosphocholine (17:0) 0.2529 [0.2529-0.3741] 0.2529 [0.2529-8.6859] 0.1418 0.2928 
1-margaroylglycerophosphoethanolamine* 0.4830 [0.3727-1.9014] 0.3727 [0.3727-1.4264] 0.1167 0.2601 
1-methyladenine 0.6844 [0.1849-1.9713] 1.4744 [0.3369-13.9368] 0.0079 0.0453 
1-methyl-beta-carboline-3-carboxylic acid 1.0000 [0.2997-2.7202] 0.7815 [0.0667-57.4431] 0.6482 0.7729 
1-methylimidazoleacetate 1.0752 [0.0613-12.6798] 0.2249 [0.0471-6.8776] 0.0614 0.1665 
1-methylnicotinamide 1.0580 [0.1062-3.5365] 0.6903 [0.1062-3.7644] 0.5067 0.6616 
1-methylurate 1.1291 [0.3126-6.3497] 0.5203 [0.1035-2.9213] 0.0181 0.0758 
1-methylxanthine 1.0171 [0.5129-1.8813] 0.9829 [0.0613-3.5209] 0.5614 0.7115 
1-myristoylglycerol (1-monomyristin) 1.9608 [0.4641-4.5369] 0.6474 [0.3122-21.6146] 0.1057 0.2391 
1-oleoylglycerol (1-monoolein) 1.3800 [0.2446-6.0364] 0.7736 [0.0648-12.7071] 0.0465 0.1370 
1-oleoylglycerophosphocholine (18:1) 1.0486 [0.0728-2.2969] 0.5123 [0.0728-9.8204] 0.9337 0.9582 
1-oleoylglycerophosphoethanolamine 0.3032 [0.3032-2.5759] 0.4447 [0.3032-61.6865] 0.3197 0.5032 
1-oleoylglycerophosphoglycerol* 0.2073 [0.2073-1.0651] 0.2073 [0.2073-33.5241] 0.1599 0.3130 
1-palmitoylglycerol (1-monopalmitin) 1.0991 [0.3657-2.8696] 0.8546 [0.2894-10.3596] 0.5614 0.7115 
1-palmitoylglycerophosphocholine (16:0) 0.9212 [0.0376-4.3477] 1.0677 [0.1428-16.1569] 0.4553 0.6205 
1-palmitoylglycerophosphoethanolamine 1.4794 [0.0345-6.611] 0.7012 [0.0345-53.5511] 0.8519 0.9159 
1-palmitoylglycerophosphoglycerol* 1.0000 [0.0838-3.4259] 0.7338 [0.0838-9.6563] 0.7241 0.8381 
1-palmitoylglycerophosphoinositol* 0.2801 [0.2801-8.914] 0.2801 [0.2801-23.6638] 0.7871 0.8788 
1-palmitoylplasmenylethanolamine* 0.5841 [0.0864-3.2301] 0.0864 [0.0864-34.1766] 0.3294 0.5154 
1-pentadecanoylglycerol (1-monopentadecanoin) 1.5973 [0.3488-7.2626] 0.3690 [0.1019-10.3443] 0.0070 0.0418 
1-stearoylglycerol (1-monostearin) 0.9049 [0.3718-7.0455] 1.1804 [0.5088-6.483] 0.0512 0.1472 
1-stearoylglycerophosphocholine (18:0) 0.3100 [0.0788-1.7794] 1.1974 [0.0788-18.8548] 0.0249 0.0894 
1-stearoylglycerophosphoethanolamine 0.5008 [0.0839-5.5339] 2.6153 [0.1518-76.6895] 0.0250 0.0894 
1-stearoylglycerophosphoglycerol 0.2552 [0.2552-1.2036] 0.2552 [0.2552-56.701] 0.5902 0.7349 
1-stearoylglycerophosphoinositol 0.0868 [0.0868-1.1211] 0.7037 [0.0868-28.8554] 0.0004 0.0074 
1-stearoylglycerophosphoserine* 0.0769 [0.0769-1.5421] 0.8583 [0.0769-89.0432] 0.0021 0.0203 
1-stearoylplasmenylethanolamine* 0.5504 [0.0263-3.8286] 1.2426 [0.0136-28.3806] 0.3195 0.5032 




Healthy Chronic Enteropathy   
Median Range Median Range p-value q-value 
2,3-dihydroxyisovalerate 1.0811 [0.2039-7.5345] 0.8839 [0.2369-29.4536] 0.8357 0.9047 
2,4,6-trihydroxybenzoate 1.0000 [0.0929-4.853] 0.8609 [0.0929-5.2584] 0.5755 0.7270 
2,8-quinolinediol  1.0046 [0.2049-1.7682] 0.3672 [0.0817-28.2229] 0.1834 0.3447 
2-[(2-methylbutanoyl)amino]-3-phenylpropanoic acid 0.6127 [0.0639-2.8015] 0.0639 [0.0639-13.0458] 0.0271 0.0947 
2-aminoadipate 0.9194 [0.5356-1.9858] 1.0411 [0.0545-8.5154] 0.4068 0.5810 
2-aminobutyrate 0.7071 [0.2038-3.4973] 1.0875 [0.0382-6.6831] 0.3615 0.5391 
2-aminoheptanoate 1.1035 [0.4323-2.1032] 0.7226 [0.3433-3.0276] 0.0677 0.1790 
2-aminophenol sulfate 0.2424 [0.2424-54.0926] 0.2424 [0.2424-0.3287] 0.2722 0.4656 
2-arachidonoylglycerophosphocholine* 0.1231 [0.1231-1.5822] 0.1231 [0.1231-3.1826] 0.1789 0.3400 
2'-deoxyadenosine 1.1742 [0.2473-3.9313] 0.8639 [0.1503-3.9407] 0.1711 0.3276 
2'-deoxycytidine 1.1410 [0.122-4.4011] 0.3400 [0.122-4.507] 0.0951 0.2254 
2'-deoxyguanosine 1.1882 [0.1992-6.4138] 0.5369 [0.1992-13.3477] 0.4296 0.5971 
2'-deoxyinosine 2.5708 [0.3025-5.4587] 0.3310 [0.0248-6.5178] 0.0251 0.0894 
2-deoxyribose 0.6832 [0.2466-2.7388] 0.9877 [0.2466-2.7266] 0.9668 0.9743 
2'-deoxyuridine 1.8333 [0.4815-3.6029] 0.7271 [0.0123-2.5173] 0.1844 0.3447 
2-hydroxy-3-methylvalerate 0.1679 [0.0267-2.3425] 1.8852 [0.5855-77.0248] 0.0001 0.0033 
2-hydroxyadipate 1.1766 [0.5869-4.0341] 0.5604 [0.1053-3.2367] 0.0225 0.0848 
2-hydroxybutyrate (AHB) 0.2178 [0.1112-10.714] 5.1633 [0.3311-15.1281] 0.0014 0.0165 
2-hydroxydecanoate 0.9990 [0.6786-1.1992] 1.0037 [0.435-12.5549] 0.9010 0.9379 
2-hydroxyglutarate 0.5101 [0.1666-2.0226] 1.9907 [0.276-8.3645] 0.0005 0.0076 
2-hydroxyhippurate (salicylurate) 0.6347 [0.177-1.3921] 1.2533 [0.177-10.0059] 0.0135 0.0651 
2-hydroxyoctanoate 1.2024 [0.5839-2.4701] 0.7938 [0.1323-1.8586] 0.1464 0.2981 
2-hydroxypalmitate 0.7100 [0.1929-2.9837] 2.0140 [0.0942-11.7271] 0.0225 0.0848 
2-hydroxystearate 0.8077 [0.2525-3.7748] 2.0375 [0.0022-12.5642] 0.0971 0.2254 
2-isopropylmalate 1.5852 [0.1903-7.2482] 0.8599 [0.0204-3.7352] 0.1710 0.3276 
2-linoleoylglycerol (2-monolinolein) 1.3878 [0.2864-6.0051] 0.6906 [0.1028-27.2382] 0.1057 0.2391 
2-linoleoylglycerophosphocholine* 0.1134 [0.1134-1.9952] 0.1134 [0.1134-4.0572] 0.4259 0.5971 
2-linoleoylglycerophosphoethanolamine* 0.3997 [0.3997-2.5343] 0.3997 [0.3997-1.9468] 0.3616 0.5391 
2-methylbutyrylcarnitine (C5) 0.5167 [0.362-1.9693] 1.0000 [0.362-15.4418] 0.0554 0.1563 
2-myristoylglycerol (2-monomyristin) 1.1125 [0.0019-4.6991] 0.5693 [0.0019-45.5701] 0.9669 0.9743 
2-oleoylglycerol (2-monoolein) 0.9976 [0.2832-5.2886] 1.0024 [0.0761-12.6461] 0.4068 0.5810 
2-oleoylglycerophosphocholine* 0.4633 [0.4633-2.0785] 0.4633 [0.4633-3.9899] 0.2300 0.4087 
2-oleoylglycerophosphoethanolamine* 0.2193 [0.2193-1.9934] 0.2193 [0.2193-4.4772] 0.2878 0.4779 
2-oxindole-3-acetate 7.2500 [1.7082-24.8117] 0.1157 [0.001-0.2918] 0.0000 0.0011 
2-palmitoylglycerol (2-monopalmitin) 0.8738 [0.0833-3.3348] 1.5686 [0.3164-9.2684] 0.3615 0.5391 
2-palmitoylglycerophosphocholine* 0.2394 [0.2394-1.1482] 0.7022 [0.2394-5.5209] 0.0791 0.1955 
2-palmitoylglycerophosphoethanolamine* 0.1158 [0.1158-1.5752] 0.1158 [0.1158-19.5806] 0.5060 0.6616 
2-pentanamido-3-phenylpropanoic acid 0.2951 [0.0584-3.3269] 0.0584 [0.0584-2.9738] 0.0437 0.1322 
2-piperidinone 1.1756 [0.1113-2.0532] 0.0389 [0.0093-2.5789] 0.0251 0.0894 
2-stearoylglycerol (2-monostearin) 0.9659 [0.1645-2.997] 1.0534 [0.2565-8.4386] 0.4306 0.5971 
2-stearoylglycerophosphocholine* 0.1529 [0.1529-1.3698] 0.5348 [0.1529-19.2919] 0.0133 0.0646 
2-stearoylglycerophosphoethanolamine* 0.3489 [0.3489-1] 0.3489 [0.3489-42.1489] 0.2989 0.4805 
3-(3-hydroxyphenyl)propionate 1.5807 [0.1228-7612.0503] 0.5119 [0.1228-12.3101] 0.0084 0.0470 
3-(4-hydroxyphenyl)lactate 0.7342 [0.0317-13.2026] 1.2227 [0.2201-27.1103] 0.0971 0.2254 
3-(4-hydroxyphenyl)propionate 1.5688 [0.9916-3.8932] 0.1288 [0.0228-1.3382] 0.0000 0.0014 
3,4-dihydroxybenzoate 1.5210 [0.0436-3.5905] 0.0436 [0.0436-1.9118] 0.0006 0.0087 
3,4-dihydroxyphenylacetate 0.4836 [0.0723-61.4618] 0.0723 [0.0723-5.1981] 0.2874 0.4779 
3,7-dimethylurate 0.0441 [0.0441-0.0441] 0.0441 [0.0441-18.8239] 0.0797 0.1955 
3-[3-(sulfooxy)phenyl]propanoic acid 0.3052 [0.3052-7.6935] 0.3052 [0.3052-0.3052] 0.0384 0.1195 
3-aminoisobutyrate 0.5899 [0.1493-1.6751] 0.1493 [0.1493-2.9389] 0.1392 0.2883 
3beta,7alpha-dihydroxy-5-cholestenoate 0.0418 [0.0418-1.857] 0.0418 [0.0418-11.5644] 0.6547 0.7784 
3beta,7beta-dihydroxy-5-cholestenoate 1.2262 [0.4758-3.2571] 0.6884 [0.1321-4.0307] 0.0815 0.1986 
3b-hydroxy-5-cholenoic acid 1.0979 [0.3965-4.0082] 0.5253 [0.0099-3.8849] 0.0744 0.1904 




Healthy Chronic Enteropathy   
Median Range Median Range p-value q-value 
3-hydroxy-2-ethylpropionate 1.3124 [0.3671-2.7351] 0.3265 [0.2214-2.5026] 0.0018 0.0197 
3-hydroxy-3-methylglutarate 1.0631 [0.2698-7.3912] 0.8577 [0.1474-4.947] 0.3837 0.5613 
3-hydroxybutyrate (BHBA) 1.5644 [0.2652-3.7018] 0.4424 [0.0933-10.4478] 0.0225 0.0848 
3-hydroxydecanoate 0.8091 [0.5669-1.7815] 1.1763 [0.6963-2.7713] 0.0144 0.0670 
3-hydroxyindolin-2-one 1.2202 [0.2767-2.2848] 0.4382 [0.0113-2.2775] 0.0279 0.0947 
3-hydroxyisobutyrate 0.8289 [0.1413-1.8225] 0.6354 [0.1413-6.1242] 0.4920 0.6552 
3-hydroxylaurate 0.8419 [0.2887-2.7577] 1.0058 [0.4425-4.9833] 0.3401 0.5248 
3-hydroxymyristate 1.0400 [0.5356-3.7634] 0.9634 [0.2134-3.608] 0.7089 0.8229 
3-hydroxyoctanoate 1.2300 [0.6242-2.0276] 0.7853 [0.4574-3.4191] 0.0344 0.1092 
3-hydroxypalmitate 2.1569 [0.12-3.4192] 0.3164 [0.1148-2.2036] 0.0016 0.0180 
3-hydroxypropanoate 0.8109 [0.3008-7.9955] 1.3533 [0.5799-33.5356] 0.0421 0.1285 
3-hydroxysebacate 1.1263 [0.4369-2.8894] 0.5529 [0.1464-5.4539] 0.0070 0.0418 
3-indoxyl sulfate 0.1367 [0.1367-3.4531] 0.1367 [0.1367-13.9539] 0.5325 0.6876 
3-methoxytyrosine 1.2356 [0.3982-5.6838] 0.6420 [0.0857-5.4367] 0.0511 0.1472 
3-methyl-2-oxobutyrate 0.7690 [0.2516-1.7975] 1.6847 [0.3051-56.5531] 0.0181 0.0758 
3-methyl-2-oxovalerate 1.2440 [0.0774-4.8045] 0.8750 [0.0042-4.1933] 0.5069 0.6616 
3-methylglutarylcarnitine (1) 0.1537 [0.1537-1.3381] 0.3098 [0.1537-23.8941] 0.0957 0.2254 
3-methylhistidine 1.0538 [0.0856-8.8067] 0.3392 [0.0856-4.4918] 0.1184 0.2632 
3-phenylpropionate (hydrocinnamate) 1.6446 [0.0348-2.5737] 0.2405 [0.0112-5.8583] 0.0224 0.0848 
3-ureidopropionate 2.0348 [0.0916-19.6466] 0.3691 [0.0144-6.6725] 0.0197 0.0811 
4-acetamidobutanoate 1.0000 [0.1997-2.4289] 0.1997 [0.1997-6.6954] 0.0384 0.1195 
4-acetylphenol sulfate 0.0797 [0.0797-1.4681] 0.0797 [0.0797-1.5755] 0.6093 0.7537 
4-guanidinobutanoate 2.1359 [0.5179-3.9682] 0.5253 [0.1113-4.2172] 0.0161 0.0702 
4-hydroxybenzoate 2.6652 [0.8558-6.9585] 0.2255 [0.0556-1.1442] 0.0000 0.0011 
4-hydroxybenzyl alcohol 0.5124 [0.5124-1.5488] 0.5124 [0.5124-2.9149] 0.4537 0.6205 
4-hydroxycinnamate 1.3574 [0.36-5.4185] 0.5290 [0.0752-7.6666] 0.0309 0.1009 
4-hydroxycyclohexylcarboxylic acid 0.4067 [0.4067-10.1202] 0.4067 [0.4067-1.9403] 0.9527 0.9724 
4-hydroxyphenylacetate 1.2103 [0.3351-4.1877] 0.1135 [0.0132-6.3263] 0.0310 0.1009 
4-hydroxyphenylacetyl glycine 0.2689 [0.0139-1.3309] 1.3631 [0.0139-88.07] 0.0025 0.0217 
4-hydroxyphenylpyruvate 1.3259 [0.1983-5.0466] 0.9298 [0.0334-6.7083] 0.8357 0.9047 
4-imidazoleacetate 1.0908 [0.488-1.7651] 0.5584 [0.0529-1.8206] 0.0344 0.1092 
4-methyl-2-oxopentanoate 1.0001 [0.1253-3.3018] 0.9999 [0.0162-5.4733] 0.8035 0.8856 
4-methylcatechol sulfate 0.2972 [0.2972-1] 0.2972 [0.2972-6.9609] 0.2925 0.4805 
4-methylthio-2-oxobutanoate 0.9324 [0.1239-3.7721] 0.7943 [0.1239-22.6672] 0.9004 0.9379 
4-ureidobutyrate 1.4711 [0.0809-4.6092] 0.0809 [0.0809-1] 0.0000 0.0026 
5-(2-Hydroxyethyl)-4-methylthiazole 1.6959 [0.4157-5.6302] 0.1111 [0.0242-8.6919] 0.0025 0.0217 
5-(galactosylhydroxy)-L-lysine 0.1089 [0.1089-0.1089] 0.1089 [0.1089-50.6784] 0.0036 0.0269 
5,6-DiHETrE 0.8475 [0.1113-2.4162] 1.0252 [0.1113-8.933] 0.4304 0.5971 
5,6-dihydrothymine 0.5825 [0.1096-2.165] 1.2970 [0.1096-5.2305] 0.0926 0.2222 
5,6-dihydrouracil 0.9335 [0.004-3.4577] 0.8348 [0.004-3.3564] 0.9338 0.9582 
5-aminovalerate 0.9328 [0.2694-2.2728] 1.0672 [0.0104-5.9787] 0.8035 0.8856 
5-dodecenoate (12:1n7) 1.0294 [0.3943-1.4453] 0.7226 [0.1102-2.8643] 0.9010 0.9379 
5-HETE 0.6935 [0.1095-2.5444] 0.8215 [0.1095-23.7421] 0.6165 0.7537 
5-hydroxydecanoate 0.8988 [0.1629-3.3894] 0.1629 [0.1629-143.2411] 0.0295 0.0993 
5-hydroxyindoleacetate 1.8408 [0.6563-4.3699] 0.4321 [0.1281-2.8119] 0.0005 0.0076 
5-hydroxylysine 0.7608 [0.0789-6.6019] 1.6444 [0.0376-7.1045] 0.3614 0.5391 
5-hydroxymethyluracil 0.8608 [0.0972-2.4976] 0.2652 [0.0972-3.0122] 0.3371 0.5248 
5-ketogluconate 0.5655 [0.2996-5.5536] 1.7324 [0.1767-61.2063] 0.0465 0.1370 
5-methyl-2'-deoxycytidine 1.1478 [0.5516-2.2823] 0.5796 [0.066-5.1624] 0.0462 0.1370 
5-methylthioadenosine (MTA) 0.3586 [0.3586-1.4354] 0.3586 [0.3586-5.9853] 0.0752 0.1908 
5-methyluridine (ribothymidine) 1.6743 [0.2146-3.2062] 0.0573 [0.029-9.9821] 0.0242 0.0894 
5-oxoproline 0.5854 [0.1273-1.7887] 2.4828 [0.5204-13.8445] 0.0001 0.0043 
6-hydroxydaidzein 0.9170 [0.0816-59.8135] 0.0816 [0.0816-16.9609] 0.0761 0.1913 




Healthy Chronic Enteropathy   
Median Range Median Range p-value q-value 
6-oxolithocholate 1.2730 [0.175-4.5981] 0.5368 [0.0128-29.0662] 0.1056 0.2391 
6-oxopiperidine-2-carboxylic acid 0.9707 [0.4274-1.6352] 1.1434 [0.4545-8.2232] 0.2998 0.4805 
7,12-diketolithocholate 2.0607 [0.0823-12.1295] 0.1203 [0.0823-14.6585] 0.0023 0.0217 
7-alpha-hydroxy-3-oxo-4-cholestenoate 0.7719 [0.0271-2.4202] 1.1176 [0.0271-46.277] 0.4296 0.5971 
7-ketodeoxycholate 0.6697 [0.2139-14.6467] 1.2832 [0.1494-23.5424] 0.2998 0.4805 
7-ketolithocholate 0.3737 [0.0793-3.1325] 1.1615 [0.0793-7.4681] 0.0739 0.1904 
7-methylguanine 1.1855 [0.642-2.7987] 0.7538 [0.1301-2.056] 0.0161 0.0702 
7-methylurate 0.5017 [0.0038-2.3183] 0.1540 [0.0038-11.8759] 0.2952 0.4805 
7-nonadecenoate (19:1n12) 0.7337 [0.3167-4.6204] 4.6224 [0.1465-39.7403] 0.0144 0.0670 
9,10-DiHOME 1.2797 [0.2969-2.9372] 0.7729 [0.3686-3.8945] 0.7400 0.8416 
acetoacetate 1.9505 [0.2873-4.6225] 0.5185 [0.2797-2.0231] 0.0016 0.0180 
acetylcarnitine 0.7844 [0.0533-4.9477] 1.4625 [0.018-16.7198] 0.4807 0.6423 
aconitate [cis or trans] 0.9766 [0.5228-1.6098] 1.4812 [0.3539-7.0654] 0.1248 0.2670 
adenine 1.0688 [0.4584-4.0017] 0.6487 [0.0928-3.0876] 0.2998 0.4805 
adenosine 1.8275 [0.5424-5.7513] 0.6632 [0.1033-6.5215] 0.0279 0.0947 
adenosine 5'-monophosphate (AMP) 0.0644 [0.0644-0.0644] 0.0644 [0.0644-16.2868] 0.0797 0.1955 
adrenate (22:4n6) 0.8896 [0.2378-1.655] 1.7575 [0.1088-13.9074] 0.1249 0.2670 
agmatine 0.4638 [0.0598-5.265] 1.5190 [0.0598-21.8349] 0.0278 0.0947 
alanine 0.7452 [0.3411-1.9062] 1.6500 [0.5119-7.642] 0.0128 0.0627 
alanylalanine 0.7819 [0.2022-2.9228] 1.0809 [0.1559-2.6833] 0.8682 0.9196 
alanylarginine 1.1765 [0.161-5.8734] 0.5514 [0.0937-8.6664] 0.1584 0.3118 
alanylisoleucine 1.1320 [0.1012-6.8725] 0.9949 [0.0363-5.5799] 0.8357 0.9047 
alanylleucine 1.2489 [0.1188-4.1307] 0.7110 [0.3163-4.1449] 0.6187 0.7537 
alanylmethionine 1.2418 [0.0819-4.5169] 0.6593 [0.0819-6.2978] 0.3725 0.5541 
alanylphenylalanine 1.0629 [0.1041-5.0153] 0.9371 [0.1472-5.8301] 0.7400 0.8416 
alanylproline 0.9006 [0.2998-3.4327] 1.0334 [0.4062-4.737] 0.2455 0.4265 
alanyltryptophan 1.2200 [0.0552-2.2381] 0.9809 [0.2614-3.9274] 0.3837 0.5613 
alanyltyrosine 0.9080 [0.1953-4.1517] 1.2009 [0.2141-5.7649] 0.9010 0.9379 
alanylvaline 0.9876 [0.2406-6.6118] 1.0105 [0.1114-6.3947] 0.7089 0.8229 
allantoic acid 0.0700 [0.07-2.2107] 0.1371 [0.07-17.1249] 0.0245 0.0894 
allantoin 0.0222 [0.0093-13.6238] 3.8543 [0.0093-23.6102] 0.0076 0.0447 
allo-isoleucine 0.3533 [0.1195-7.2377] 1.0221 [0.1195-8.5179] 0.2876 0.4779 
alpha-CEHC 1.9940 [0.0648-7.2444] 0.1096 [0.0186-3.9441] 0.0090 0.0487 
alpha-CEHC glucuronide* 0.0148 [0.0148-0.0148] 0.0148 [0.0148-16.0546] 0.0036 0.0269 
alpha-CEHC sulfate 0.3669 [0.0039-15.0232] 1.0797 [0.047-8.0483] 0.3195 0.5032 
alpha-glutamylglutamate 0.5179 [0.0856-3.2413] 1.6040 [0.4082-8.0655] 0.0054 0.0363 
alpha-glutamylthreonine 0.4609 [0.0841-2.9068] 1.4696 [0.0841-4.7593] 0.1842 0.3447 
alpha-glutamyltryptophan 0.8679 [0.0806-3.9572] 0.9608 [0.0806-2.8707] 0.9009 0.9379 
alpha-glutamyltyrosine 1.6394 [0.2667-4.4116] 0.9970 [0.0585-4.409] 0.4068 0.5810 
alpha-glutamylvaline 0.2909 [0.023-4.7125] 1.0616 [0.023-3.2814] 0.4304 0.5971 
alpha-hydroxyisocaproate 0.1060 [0.0118-2.5201] 2.1760 [0.2716-43.0681] 0.0002 0.0050 
alpha-hydroxyisovalerate 0.2204 [0.0027-3.445] 1.7462 [0.4065-29.6122] 0.0021 0.0203 
alpha-ketoglutarate 0.5729 [0.2152-1.6455] 3.0621 [0.4068-169.4707] 0.0002 0.0055 
alpha-muricholate 1.7248 [0.2885-5.5636] 0.3344 [0.007-8.721] 0.0225 0.0848 
alpha-tocopherol 1.5622 [0.2672-3.5291] 0.7414 [0.0309-5.2896] 0.0465 0.1370 
alpha-tocopherol acetate 1.2600 [0.3504-5.6863] 0.7870 [0.031-3.3294] 0.1585 0.3118 
anserine 1.2689 [0.2819-3.3222] 0.1062 [0.0038-5.326] 0.0344 0.1092 
anthranilate 0.9594 [0.14-2.1298] 1.0066 [0.5483-2.5014] 0.2808 0.4703 
apigenin 1.7438 [0.1027-11.2783] 0.4851 [0.0157-4.0591] 0.0225 0.0848 
arabinose 1.8066 [0.3971-8.5153] 0.5435 [0.0111-7.1108] 0.0090 0.0487 
arabitol 0.1112 [0.1112-0.7734] 1.0860 [0.1112-2.2283] 0.0101 0.0539 
arabonate 0.1011 [0.1011-0.5844] 0.9747 [0.1011-6.0083] 0.0025 0.0217 
arachidonate (20:4n6) 0.5657 [0.1873-2.4479] 1.7338 [0.0919-32.8549] 0.0079 0.0453 
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arginine 0.7144 [0.2792-3.8006] 1.5969 [0.3033-37.4299] 0.0971 0.2254 
arginylaspartate 0.2278 [0.0618-3.053] 0.9598 [0.0618-4.7195] 0.4168 0.5932 
arginylisoleucine 1.0973 [0.0606-6.3947] 0.7024 [0.0606-7.3343] 0.4798 0.6423 
arginylleucine 1.7484 [0.1105-7.4564] 0.6700 [0.1165-3.3575] 0.1711 0.3276 
arginylphenylalanine 1.3247 [0.102-3.2462] 0.3780 [0.0269-2.8748] 0.0251 0.0894 
arginylproline 0.8328 [0.0652-3.4103] 1.0838 [0.0652-3.7428] 0.4679 0.6349 
arginyltyrosine 0.8899 [0.1117-3.7668] 0.1117 [0.1117-3.6241] 0.0376 0.1184 
arginylvaline 1.1562 [0.0263-4.2257] 0.3493 [0.0263-2.8302] 0.1240 0.2670 
asparagine 0.3107 [0.0786-6.5284] 1.1592 [0.0995-23.5462] 0.1585 0.3118 
asparagylisoleucine 1.4277 [0.2456-7.2706] 0.8008 [0.0012-3.0265] 0.0620 0.1665 
asparagylleucine 1.4247 [0.1755-5.9738] 0.7208 [0.0416-5.075] 0.1249 0.2670 
asparagylvaline 1.2801 [0.219-5.493] 0.9692 [0.0142-4.2607] 0.9010 0.9379 
aspartate 0.5466 [0.1578-5.567] 3.3042 [0.0208-27.6348] 0.0070 0.0418 
aspartate-glutamate 0.1999 [0.0353-2.0599] 4.5822 [0.0353-114.1268] 0.0005 0.0076 
aspartylaspartate 0.0350 [0.035-2.0785] 1.3617 [0.0671-48.7688] 0.0003 0.0066 
aspartylglutamine 0.5411 [0.0396-2.0445] 2.5976 [0.2261-54.215] 0.0007 0.0098 
aspartylglycine 0.3104 [0.0837-1.743] 2.4142 [0.4214-51.1879] 0.0002 0.0050 
aspartylleucine 0.8578 [0.0664-3.1413] 1.3014 [0.203-3.3992] 0.0465 0.1370 
aspartylphenylalanine 0.5666 [0.0699-2.4851] 1.2184 [0.104-3.6034] 0.0161 0.0702 
aspartyltryptophan 0.3992 [0.1222-5.2437] 0.9635 [0.1222-26.2187] 0.1036 0.2376 
aspartylvaline 0.7006 [0.0275-8.0736] 1.1359 [0.0275-4.3693] 0.2806 0.4703 
assymetric dimethylarginine (ADMA) 0.1091 [0.0187-2.7263] 1.1957 [0.0187-3.9081] 0.0155 0.0702 
azelate (nonanedioate) 2.2805 [0.8211-4.6528] 0.6810 [0.2465-1.8503] 0.0004 0.0074 
benzoate 1.1494 [0.596-1.8453] 0.8195 [0.2756-1.8197] 0.0344 0.1092 
beta-alanine 2.5415 [0.5219-11.2159] 0.4525 [0.1067-2.2257] 0.0018 0.0197 
beta-hydroxyisovalerate 1.5632 [0.42-3.3714] 0.1332 [0.0276-1.2738] 0.0001 0.0032 
beta-hydroxyisovaleroylcarnitine 0.0390 [0.039-3.4351] 0.9237 [0.039-8.5661] 0.0008 0.0104 
betaine 0.5621 [0.2984-11.8053] 1.0844 [0.2984-34.9215] 0.0744 0.1904 
beta-muricholate 0.4508 [0.0449-6.2919] 2.2600 [0.0256-40.1661] 0.0381 0.1194 
beta-sitosterol 1.8184 [0.7775-2.4802] 0.6002 [0.1567-1.9787] 0.0001 0.0028 
beta-tocopherol 0.4461 [0.4461-1] 0.4461 [0.4461-4.9468] 0.3274 0.5133 
bilirubin (E,E)* 0.0424 [0.0424-1.1561] 0.0424 [0.0424-5.5441] 0.2061 0.3789 
bilirubin (Z,Z) 0.1129 [0.1129-1.1607] 0.8561 [0.1129-9.1417] 0.0065 0.0415 
biliverdin 1.0000 [0.094-3.2933] 0.7108 [0.094-3.0431] 0.8681 0.9196 
biocytin 0.8395 [0.0728-3.9601] 1.0000 [0.0728-5.4279] 0.7713 0.8650 
biopterin 0.7098 [0.0217-1.5828] 1.3140 [0.0217-3.8197] 0.0883 0.2138 
biotin 0.5099 [0.0447-26.3799] 2.2367 [0.0274-20.6366] 0.0114 0.0579 
butyrylcarnitine 0.0389 [0.0389-2.0284] 0.0389 [0.0389-3.5163] 0.7138 0.8273 
butyrylglycine 0.3418 [0.0791-2.251] 1.0561 [0.0791-6.905] 0.0643 0.1722 
cadaverine 0.4212 [0.0058-50.1027] 5.8839 [0.0606-80.8022] 0.0144 0.0670 
campesterol 1.1399 [0.6302-1.6244] 0.5878 [0.1136-3.6083] 0.0144 0.0670 
caprate (10:0) 0.9924 [0.5286-4.844] 1.0076 [0.4141-47.1251] 1.0000 1.0000 
caproate (6:0) 1.1306 [0.8842-1.579] 0.8333 [0.5517-1.6058] 0.0114 0.0579 
caprylate (8:0) 1.1683 [0.508-3.3773] 0.8797 [0.536-7.4669] 0.2134 0.3851 
carboxyethyl-GABA* 1.4271 [0.8138-3.0233] 0.7591 [0.1582-1.3938] 0.0005 0.0076 
carnitine 1.3973 [0.0797-4.747] 0.8425 [0.1365-3.0471] 0.3837 0.5613 
carnosine 0.8435 [0.1053-4.554] 0.9652 [0.1053-17.0716] 0.9667 0.9743 
catechin 0.3469 [0.3469-10.1136] 0.3469 [0.3469-1.3967] 0.1599 0.3130 
catechol sulfate 0.2463 [0.2463-4.1406] 0.2463 [0.2463-5.5278] 0.7079 0.8229 
C-glycosyltryptophan* 0.0486 [0.0486-0.3841] 0.7875 [0.0486-8.0044] 0.0039 0.0277 
chenodeoxycholate 0.1269 [0.1269-7.901] 0.9494 [0.1269-7.1643] 0.0101 0.0539 
chiro-inositol 0.0896 [0.0896-72.3084] 0.7064 [0.0896-49.155] 0.2874 0.4779 
chlorogenate 0.0888 [0.0888-0.0888] 0.0888 [0.0888-26.1041] 0.0797 0.1955 
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cholestanol 0.9656 [0.4888-1.4335] 1.0239 [0.3637-5.6793] 0.6185 0.7537 
cholesterol 0.9279 [0.4084-1.2679] 1.7093 [0.3399-4.8153] 0.0421 0.1285 
choline 0.8655 [0.2248-1.2195] 1.6657 [0.6872-7.9863] 0.0028 0.0234 
choline phosphate 0.5659 [0.1449-1.4237] 0.1449 [0.1449-322.7082] 0.7428 0.8436 
chrysoeriol 1.7540 [0.0158-10.4908] 0.6311 [0.0158-2.617] 0.2193 0.3940 
cinnamoylglycine 0.4628 [0.4628-0.471] 0.4628 [0.4628-16.5925] 0.2615 0.4503 
cis-Cyclo[L-ala-L-Pro] 0.8571 [0.4221-1.6806] 1.3242 [0.4221-4.0689] 0.0250 0.0894 
cis-urocanate 0.9969 [0.3184-4.6541] 1.0161 [0.2907-4.8037] 0.7400 0.8416 
cis-vaccenate (18:1n7) 0.9692 [0.2998-2.2746] 1.3536 [0.0455-6.2398] 0.1585 0.3118 
citramalate 0.8336 [0.2384-2.9241] 0.7080 [0.2384-15.1119] 0.8674 0.9196 
citrate 0.6492 [0.2852-2.3137] 2.3996 [0.2852-10.4133] 0.0848 0.2061 
citrulline 0.8165 [0.0413-3.2737] 1.1835 [0.0911-4.2169] 0.6482 0.7729 
coprostanol 0.6330 [0.2057-3.7535] 0.2057 [0.2057-1.8682] 0.0738 0.1904 
creatine 1.0259 [0.0024-2.0902] 0.9898 [0.1277-4.9274] 0.2998 0.4805 
creatinine 1.0125 [0.0196-3.5089] 0.7372 [0.2402-13.6339] 0.9339 0.9582 
cryptochlorogenic acid 0.0467 [0.0467-0.0467] 0.0467 [0.0467-30.2592] 0.0797 0.1955 
cyclo(gly-glu) 0.4902 [0.137-1.4029] 1.4576 [0.1385-17.4513] 0.0062 0.0399 
cyclo(leu-pro) 0.8631 [0.3057-1.5684] 1.5780 [0.8348-3.3178] 0.0016 0.0180 
cyclo(L-phe-D-pro)* 0.7827 [0.2018-2.1343] 0.2018 [0.2018-7.3197] 0.3457 0.5313 
cyclo(L-phe-L-pro) 0.7206 [0.1426-1.2121] 1.3444 [0.74-3.5132] 0.0004 0.0069 
cyclo(pro-tyr) 1.1284 [0.3243-2.0727] 0.5416 [0.0719-6.0035] 0.1150 0.2578 
cysteine 0.5919 [0.2732-1.4702] 3.1520 [0.1339-15.8029] 0.0028 0.0234 
cysteine s-sulfate 0.0917 [0.0917-1.4858] 0.5429 [0.0917-20.5032] 0.0141 0.0670 
cystine 0.0107 [0.0107-0.7625] 1.8062 [0.0107-10.6622] 0.0019 0.0197 
cytidine 1.0764 [0.4209-2.156] 0.9288 [0.2431-6.3155] 0.4306 0.5971 
cytosine 0.7841 [0.1705-2.2509] 1.0412 [0.0507-18.6288] 0.9337 0.9582 
daidzein 1.1912 [0.3435-55.4554] 0.5373 [0.0942-19.8957] 0.0971 0.2254 
daidzin 0.2928 [0.2928-1.6971] 0.2928 [0.2928-27.5209] 0.5772 0.7279 
decanoylcarnitine 0.7470 [0.4487-2.5299] 1.3312 [0.5576-13.4626] 0.0619 0.1665 
dehydrolithocholate 1.5589 [0.1106-7.6316] 0.0963 [0.0155-2.2566] 0.0002 0.0047 
delta-tocopherol 0.3344 [0.1716-5.3081] 0.6727 [0.1716-69.111] 0.5064 0.6616 
deoxycarnitine 1.6813 [0.0541-3.2022] 0.3664 [0.0115-4.7919] 0.0310 0.1009 
deoxycholate 1.1090 [0.3068-2.0284] 0.2000 [0.031-3.1216] 0.0077 0.0452 
dihomo-linoleate (20:2n6) 0.5791 [0.2649-9.4356] 3.1205 [0.088-30.7256] 0.0620 0.1665 
dihomo-linolenate (20:3n3 or n6) 0.7544 [0.269-3.8493] 1.6784 [0.042-23.9963] 0.2134 0.3851 
dihydrocaffeate 2.5192 [0.1268-26.9725] 0.0012 [0.0012-2.614] 0.0000 0.0026 
dihydroferulic acid 1.8901 [0.1218-49.341] 0.4231 [0.0415-4.4669] 0.0202 0.0811 
dihydrokaempferol 0.1938 [0.1938-2.7884] 0.2815 [0.1938-3.4983] 0.1917 0.3574 
dimethylmalonic acid 1.0350 [0.4145-5.0389] 0.7379 [0.3877-1.5797] 0.0276 0.0947 
docosadienoate (22:2n6) 0.5311 [0.1628-2.1075] 3.9325 [0.0778-37.4996] 0.0114 0.0579 
docosahexaenoate (DHA; 22:6n3) 0.5938 [0.0391-2.9426] 1.2485 [0.0152-9.9655] 0.1585 0.3118 
docosapentaenoate (n3 DPA; 22:5n3) 0.8682 [0.1141-2.5021] 1.6792 [0.0182-12.578] 0.0971 0.2254 
docosapentaenoate (n6 DPA; 22:5n6) 0.4811 [0.0689-3.2645] 2.0835 [0.0689-21.7583] 0.0121 0.0610 
docosatrienoate (22:3n3) 0.1470 [0.147-1.665] 0.7175 [0.147-21.5294] 0.0019 0.0197 
dodecanedioate 1.0566 [0.3575-19.9232] 0.7331 [0.3575-5.0465] 0.1298 0.2747 
D-urobilin 1.3001 [0.0653-3.7205] 0.4155 [0.0078-3.4049] 0.0202 0.0811 
ectoine 1.1464 [0.3234-5.9625] 0.3206 [0.1067-7.7068] 0.0503 0.1467 
eicosapentaenoate (EPA; 20:5n3) 0.9095 [0.1054-2.0784] 1.2148 [0.0363-12.0315] 0.2808 0.4703 
eicosenoate (20:1n9 or 11) 0.7824 [0.2421-1.7669] 1.8572 [0.2492-29.0449] 0.0225 0.0848 
enterodiol 0.0076 [0.0076-15.2125] 0.0076 [0.0076-4.0774] 0.6146 0.7537 
enterolactone 1.0797 [0.2382-2.9822] 0.4202 [0.0391-30.3657] 0.2444 0.4265 
equol 1.7696 [0.1072-7.7133] 0.2004 [0.0744-5.3247] 0.0201 0.0811 
equol sulfate 0.0867 [0.0867-9.771] 0.0867 [0.0867-5.1527] 0.9363 0.9595 
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ergothioneine 0.1203 [0.1203-1.2495] 1.5131 [0.1203-7.4744] 0.0020 0.0203 
eriodictyol 0.4981 [0.037-10.653] 0.0370 [0.037-0.037] 0.0001 0.0032 
erucate (22:1n9) 0.8662 [0.2359-3.0728] 1.9105 [0.3982-10.5099] 0.0070 0.0418 
erythritol 0.3989 [0.3161-3.179] 0.7876 [0.3161-2.8493] 0.2391 0.4210 
erythronate* 1.1314 [0.2299-3.2617] 0.8838 [0.2594-2.6643] 0.6482 0.7729 
ethanolamine 0.8655 [0.214-1.7854] 1.6988 [0.2618-13.5924] 0.0079 0.0453 
ethylmalonate 0.9881 [0.4826-2.1593] 1.0467 [0.3339-7.3547] 0.8035 0.8856 
famotidine 0.0005 [0.0005-0.0005] 0.0005 [0.0005-2.5878] 0.0797 0.1955 
ferulate 2.1360 [0.4241-7.6741] 0.2345 [0.0179-1.338] 0.0002 0.0047 
ferulic acid 4-sulfate 0.0014 [0.0014-15.6197] 0.6019 [0.0014-2.427] 0.0898 0.2162 
formiminoglutamate 0.7867 [0.167-3.8827] 3.2184 [0.0384-41.863] 0.2997 0.4805 
formononetin 0.0469 [0.0469-3.2028] 0.0469 [0.0469-5.1352] 0.4557 0.6205 
fructose 0.8215 [0.3416-1.8289] 1.1211 [0.2879-5.3781] 0.7400 0.8416 
fucose 0.4958 [0.0885-5.1006] 2.0993 [0.1529-19.6986] 0.0161 0.0702 
fucosterol 1.9011 [0.5899-3.413] 0.3822 [0.111-3.6991] 0.0002 0.0055 
fuculose 0.4687 [0.1667-4.6004] 0.9562 [0.1667-26.6826] 0.1785 0.3400 
fumarate 0.6252 [0.1852-1.5367] 1.2932 [0.0124-5.9547] 0.1844 0.3447 
galactonate 0.5963 [0.1025-5.7109] 5.0929 [0.2516-18.728] 0.0016 0.0180 
galactose 0.9608 [0.1496-1.8067] 1.0000 [0.0318-8.506] 0.4306 0.5971 
gallate 0.5614 [0.5614-1.4095] 0.5614 [0.5614-1.1622] 0.3894 0.5686 
gamma-aminobutyrate (GABA) 0.9001 [0.2594-35.9794] 2.6432 [0.0411-89.9461] 0.3615 0.5391 
gamma-CEHC 1.0398 [0.0305-10.8595] 0.3602 [0.0305-20.1215] 0.1701 0.3276 
gamma-glutamylisoleucine* 0.8122 [0.1304-1.7543] 1.9676 [0.1655-9.8498] 0.0279 0.0947 
gamma-glutamylleucine 0.0343 [0.0343-1.9551] 1.4741 [0.0343-18.2079] 0.0012 0.0147 
gamma-glutamyllysine 0.0281 [0.0281-0.1794] 3.1473 [0.0281-10.7836] 0.0008 0.0104 
gamma-glutamylmethionine 0.3542 [0.1115-1.8904] 0.3860 [0.1115-31.8463] 0.6970 0.8175 
gamma-glutamylphenylalanine 0.0613 [0.0368-3.5338] 2.6898 [0.0368-27.628] 0.0008 0.0106 
gamma-glutamylvaline 0.2540 [0.254-0.6744] 0.7013 [0.254-10.7623] 0.0008 0.0104 
gamma-tocopherol 0.8585 [0.1998-5.5337] 1.1157 [0.1998-61.8443] 0.3506 0.5348 
gamma-tocotrienol 0.5010 [0.501-1.5017] 0.5010 [0.501-0.501] 0.0036 0.0269 
genistein 1.7193 [0.3711-116.3805] 0.4665 [0.0526-57.0113] 0.0745 0.1904 
gentisate 1.3543 [0.2759-2.8249] 0.0918 [0.0321-3.6823] 0.0048 0.0325 
gluconate 0.4531 [0.1682-2.3834] 6.3580 [0.1682-35.3436] 0.0373 0.1180 
glucose 0.7219 [0.1612-3.7221] 2.0046 [0.1557-54.6435] 0.0421 0.1285 
glucuronate 0.6926 [0.2505-4.0529] 2.7871 [0.1578-28.0646] 0.0070 0.0418 
glutamate 0.7551 [0.2745-2.1437] 3.7114 [0.3543-12.9027] 0.0003 0.0059 
glutamate, gamma-methyl ester 0.7750 [0.0874-6.1946] 1.0030 [0.0874-7.259] 0.8518 0.9159 
glutamine 0.6706 [0.0854-3.028] 1.4101 [0.0103-5.7604] 0.3615 0.5391 
glutamine-isoleucine 0.9306 [0.0256-7.0585] 1.0694 [0.0643-4.0537] 0.8682 0.9196 
glutamine-leucine 1.6778 [0.0911-4.2214] 0.6344 [0.2356-3.6566] 0.2134 0.3851 
glutarate (pentanedioate) 1.0512 [0.4831-9.6505] 0.4954 [0.0507-10.1717] 0.2808 0.4703 
glutarylcarnitine (C5) 0.1982 [0.1576-2.1669] 1.3508 [0.1576-8.4783] 0.0190 0.0793 
glycerate 0.8269 [0.2641-1.6839] 1.0514 [0.3592-3.3561] 0.0745 0.1904 
glycerol 1.0368 [0.5434-2.6512] 0.8127 [0.0563-7.6995] 0.4553 0.6205 
glycerol 3-phosphate (G3P) 0.6084 [0.2317-3.181] 1.5685 [0.7428-8.6916] 0.0070 0.0418 
glycerophosphoethanolamine 1.0278 [0.1582-36.0789] 0.9722 [0.2461-18.9973] 0.7716 0.8650 
glycerophosphoinositol* 1.2784 [0.1855-5.3971] 0.5389 [0.1855-10.1725] 0.6782 0.7979 
glycerophosphorylcholine (GPC) 1.0630 [0.3007-38.2926] 0.9491 [0.1138-42.7964] 0.5067 0.6616 
glycine 0.5176 [0.1702-1.3632] 2.8586 [0.5056-21.2532] 0.0001 0.0032 
glycitein 1.0139 [0.0165-84.8169] 0.4969 [0.0165-18.8669] 0.3951 0.5758 
glycochenodeoxycholate 1.0147 [0.1856-2.0846] 0.2644 [0.1856-279.2771] 0.0654 0.1745 
glycocholate 0.5941 [0.0972-2.3384] 1.8127 [0.0972-16.2626] 0.2987 0.4805 
glycodeoxycholate 0.7217 [0.068-7.4286] 0.0680 [0.068-25.1657] 0.0034 0.0263 




Healthy Chronic Enteropathy   
Median Range Median Range p-value q-value 
glycohyodeoxycholate 0.7772 [0.1837-40.7114] 0.1837 [0.1837-480.5528] 0.0929 0.2222 
glycolithocholate 0.4590 [0.0459-2.5831] 0.0459 [0.0459-7.9551] 0.0151 0.0699 
glycoursodeoxycholate 0.3240 [0.324-5.4671] 0.3240 [0.324-13.5823] 0.3617 0.5391 
glycylglycine 0.7026 [0.1931-2.4905] 3.2186 [0.0703-7.4394] 0.1465 0.2981 
glycylisoleucine 0.6329 [0.1125-4.2771] 1.0405 [0.007-5.5439] 0.2998 0.4805 
glycylleucine 0.6638 [0.1363-3.7619] 1.1022 [0.0563-4.821] 0.4068 0.5810 
glycylmethionine 1.0000 [0.1945-4.4256] 0.6116 [0.0624-3.6352] 0.7089 0.8229 
glycylphenylalanine 0.9655 [0.2124-3.6308] 1.0324 [0.0899-4.0421] 0.4068 0.5810 
glycylproline 0.7459 [0.2382-2.9478] 1.7840 [0.2241-4.4342] 0.0128 0.0627 
glycylserine 0.7633 [0.1733-3.2348] 1.2659 [0.1176-7.0317] 0.2455 0.4265 
glycyltryptophan 0.7082 [0.1282-2.1002] 1.3007 [0.0718-2.9842] 0.1354 0.2811 
glycyltyrosine 1.1496 [0.174-5.0155] 0.9137 [0.07-3.0134] 0.9339 0.9582 
glycylvaline 0.4630 [0.1151-2.8342] 1.4732 [0.0118-6.7495] 0.0620 0.1665 
guanidinoacetate 0.5949 [0.3773-2.9214] 0.3773 [0.3773-1.6302] 0.1167 0.2601 
guanine 0.8369 [0.2131-2.7086] 1.3452 [0.0289-13.3948] 0.9669 0.9743 
guanosine 1.1604 [0.1224-4.2997] 0.8046 [0.0777-39.1072] 0.2806 0.4703 
gulonic acid* 0.1309 [0.0286-0.5437] 8.8565 [0.0286-28.1393] 0.0003 0.0069 
harmane 1.0208 [0.3991-2.3042] 0.9078 [0.1063-28.6321] 0.4067 0.5810 
heme 0.1166 [0.1166-0.1166] 0.1166 [0.1166-98.833] 0.0181 0.0758 
hesperetin 0.0589 [0.0589-3.7745] 0.0589 [0.0589-0.7284] 0.1458 0.2981 
hexadecanedioate 1.0214 [0.5147-2.0487] 0.9327 [0.317-3.0223] 0.3837 0.5613 
hexanoylcarnitine 0.4685 [0.0963-1.3768] 0.3351 [0.0963-8.0447] 0.8649 0.9196 
hippurate 0.1301 [0.1301-1] 0.1301 [0.1301-68.5918] 0.2075 0.3798 
histamine 0.9359 [0.0798-379.1795] 0.8375 [0.0798-201.148] 0.4063 0.5810 
histidine 0.4237 [0.1779-2.6708] 2.5225 [0.5924-20.0847] 0.0003 0.0059 
histidylisoleucine 1.1035 [0.2729-7.7476] 0.9492 [0.0308-4.2677] 0.4306 0.5971 
histidylleucine 1.6475 [0.1268-5.8465] 0.8589 [0.0463-3.875] 0.6482 0.7729 
histidylmethionine 0.6762 [0.236-6.8684] 0.2360 [0.236-3.7845] 0.0661 0.1758 
histidylphenylalanine 1.0631 [0.2379-5.815] 0.5872 [0.1733-5.0885] 0.1985 0.3659 
histidylproline 0.6647 [0.1688-3.2254] 1.2286 [0.1082-4.5712] 0.1585 0.3118 
histidyltryptophan 0.1865 [0.1865-2.7243] 0.8736 [0.1865-3.2765] 0.1336 0.2810 
homocitrulline 0.9910 [0.2864-2.5545] 1.0451 [0.0385-17.333] 0.6783 0.7979 
homoserine 1.2938 [0.2134-4.1918] 0.9081 [0.3028-7.7938] 0.5338 0.6876 
hydroquinone sulfate 0.2490 [0.1064-10.9813] 0.1064 [0.1064-7.2782] 0.8246 0.9047 
hydroxybutyrylcarnitine* 0.2415 [0.2415-1.6117] 0.4220 [0.2415-524.1505] 0.1258 0.2684 
hyocholate 0.8646 [0.2008-7.271] 1.1384 [0.0865-51.0266] 0.5614 0.7115 
hyodeoxycholate 2.0594 [0.063-13.5884] 0.5293 [0.0535-6.9848] 0.0619 0.1665 
hypoxanthine 1.0274 [0.1663-1.9701] 0.6523 [0.0355-7.0067] 0.4805 0.6423 
imidazole lactate 0.9784 [0.0315-2.6191] 1.0216 [0.0343-5.1134] 0.2808 0.4703 
imidazole propionate 2.0383 [0.0903-4.2588] 0.2984 [0.0008-3.2014] 0.0021 0.0203 
indole 1.5029 [0.0557-12.0477] 0.2013 [0.0149-31.9668] 0.2132 0.3851 
indole-3-carboxylic acid 1.0040 [0.1511-7.8426] 0.4706 [0.1511-4.2025] 0.5577 0.7115 
indoleacetate 2.2174 [0.3971-8.0187] 0.3226 [0.0124-3.9607] 0.0004 0.0074 
indoleacetylglutamine 0.0715 [0.0715-7.4572] 0.7234 [0.0715-18.5283] 0.0761 0.1913 
indolelactate 0.3349 [0.0095-5.732] 1.6964 [0.0876-27.606] 0.0465 0.1370 
indolepropionate 1.2305 [0.0046-3.109] 0.0080 [0.0046-2.2127] 0.0043 0.0296 
indolin-2-one 2.5225 [0.1104-206.8175] 0.1584 [0.0456-87.3051] 0.0062 0.0399 
inosine 1.2614 [0.0117-3.1333] 0.0308 [0.0117-4.1163] 0.0498 0.1457 
inositol 1-phosphate (I1P) 0.5902 [0.5902-2.2349] 0.5902 [0.5902-3.0773] 0.7254 0.8383 
isobutyrylcarnitine 1.0182 [0.6647-2.2435] 0.9737 [0.2239-2.5355] 0.5069 0.6616 
isobutyrylglycine 0.8090 [0.4577-2.301] 1.3991 [0.1442-14.8308] 0.1249 0.2670 
isocaproate 1.1368 [0.3209-12.7417] 0.6891 [0.1247-178.9493] 0.0890 0.2149 
isoferulate 1.6912 [0.6858-5.9585] 0.4961 [0.0114-2.1368] 0.0001 0.0033 
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isoleucylalanine 1.1012 [0.2031-4.4824] 0.7407 [0.1253-3.775] 0.4807 0.6423 
isoleucylarginine 0.9787 [0.0164-16.8003] 0.3365 [0.0164-36.644] 0.3613 0.5391 
isoleucylasparagine 1.9755 [0.228-7.6853] 0.8093 [0.2136-4.0345] 0.1844 0.3447 
isoleucylaspartate 1.0343 [0.2662-6.0087] 0.9103 [0.3595-4.7812] 0.6482 0.7729 
isoleucylglutamate 1.0370 [0.4558-3.4061] 0.7064 [0.2272-1.8801] 0.3195 0.5032 
isoleucylglutamine 1.0084 [0.2143-3.6505] 0.8351 [0.4444-4.5915] 0.6482 0.7729 
isoleucylglycine 1.5120 [0.4146-5.0287] 0.7535 [0.0913-3.7164] 0.1585 0.3118 
isoleucylisoleucine 1.0392 [0.1752-6.7627] 0.9608 [0.0519-4.233] 0.4807 0.6423 
isoleucylleucine 1.6319 [0.1532-5.1315] 0.5812 [0.2297-4.1468] 0.1466 0.2981 
isoleucylmethionine 1.3307 [0.1409-5.1803] 0.6464 [0.2048-3.8707] 0.1585 0.3118 
isoleucylphenylalanine 1.0124 [0.0534-4.8817] 0.8805 [0.1176-3.7995] 0.7400 0.8416 
isoleucylserine 1.3582 [0.4514-4.4033] 0.6987 [0.0729-3.2089] 0.2290 0.4078 
isoleucylthreonine 0.9950 [0.3617-5.6412] 1.0050 [0.4191-7.0337] 0.4807 0.6423 
isoleucyltyrosine 1.1486 [0.1181-3.4855] 0.5986 [0.1843-3.6997] 0.8357 0.9047 
isoleucylvaline 1.0767 [0.2609-6.2654] 0.9233 [0.1502-3.5187] 0.5897 0.7349 
isovalerate 1.2972 [0.814-3.3495] 0.2571 [0.051-4.3824] 0.0032 0.0254 
isovalerylcarnitine 0.1571 [0.0344-2.1643] 0.7689 [0.0344-19.8732] 0.1225 0.2670 
isovalerylglycine 0.7917 [0.4167-2.3484] 1.6994 [0.1556-21.9836] 0.1711 0.3276 
I-urobilinogen 1.3736 [0.0646-3.3286] 0.2769 [0.0103-8.0747] 0.1247 0.2670 
kaempferol 0.0565 [0.0565-2.4342] 0.1345 [0.0565-7.2782] 0.2332 0.4134 
kynurenate 0.6034 [0.0353-5.5782] 6.1762 [0.0246-149.7087] 0.1466 0.2981 
kynurenine 0.9338 [0.2531-1.7414] 1.1637 [0.2392-4.6628] 0.4068 0.5810 
lactate 0.4862 [0.073-9.0636] 10.2443 [0.4733-90.2055] 0.0000 0.0026 
lanthionine 0.4694 [0.4377-1.2892] 1.2289 [0.4377-27.3279] 0.0740 0.1904 
lathosterol 0.5720 [0.572-1.6202] 0.5720 [0.572-2.2804] 0.3375 0.5248 
laurate (12:0) 0.7866 [0.6073-6.558] 1.2449 [0.4754-117.2933] 0.1466 0.2981 
leucine 0.4169 [0.1763-1.9169] 1.2891 [0.479-4.5303] 0.0032 0.0254 
leucylalanine 1.0699 [0.114-5.9913] 0.7242 [0.042-4.6552] 0.5897 0.7349 
leucylarginine 0.8561 [0.0741-12.3698] 0.7490 [0.0741-29.6941] 0.6179 0.7537 
leucylasparagine 1.3524 [0.1645-5.8008] 0.5228 [0.3825-5.1318] 0.5614 0.7115 
leucylglutamate 0.9240 [0.2174-6.7874] 1.0207 [0.1875-5.4197] 0.6783 0.7979 
leucylglutamine* 1.1214 [0.137-3.5215] 0.8218 [0.1749-2.9412] 0.7400 0.8416 
leucylglycine 1.8423 [0.2973-5.397] 0.8515 [0.1027-3.7911] 0.3837 0.5613 
leucylisoleucine 1.0105 [0.0253-6.8219] 0.8324 [0.0252-7.4673] 0.6187 0.7537 
leucylleucine 1.9392 [0.1151-7.15] 0.8279 [0.2856-7.9803] 0.1249 0.2670 
leucylmethionine 1.3395 [0.091-6.7933] 0.4107 [0.0915-7.3713] 0.1985 0.3659 
leucylphenylalanine 1.7947 [0.0675-8.2906] 0.5895 [0.0845-8.6767] 0.1249 0.2670 
leucylserine 1.0094 [0.182-5.3546] 0.9906 [0.1273-6.2893] 0.9010 0.9379 
leucylthreonine 1.0054 [0.1902-6.533] 0.9718 [0.2391-6.9845] 0.9010 0.9379 
leucyltryptophan 1.0312 [0.0213-6.1123] 0.7694 [0.0055-11.5711] 0.6482 0.7729 
leucyltyrosine 1.6853 [0.0791-6.4241] 0.5889 [0.1591-9.273] 0.1585 0.3118 
leu-leu-leu 1.1672 [0.0104-5.4667] 0.8026 [0.0104-2.7716] 0.6333 0.7680 
levulinate (4-oxovalerate) 1.3258 [0.5905-2.1895] 0.5392 [0.1772-2.7713] 0.0037 0.0269 
linoleate (18:2n6) 0.9318 [0.3306-2.6735] 1.2443 [0.1265-8.5233] 0.8682 0.9196 
linolenate [alpha or gamma; (18:3n3 or 6)] 0.9875 [0.4298-15.8315] 1.0125 [0.1104-24.1062] 1.0000 1.0000 
lithocholate 1.6371 [0.3585-2.2675] 0.1353 [0.0004-2.6402] 0.0114 0.0579 
L-urobilin 0.0618 [0.0618-6.7862] 0.0618 [0.0618-3.971] 0.1016 0.2345 
lysine 1.0084 [0.1225-4.0209] 0.9916 [0.3226-7.8489] 0.9669 0.9743 
lysylisoleucine 0.9584 [0.1889-8.1558] 1.0416 [0.0136-3.8709] 0.4306 0.5971 
lysylleucine 1.1926 [0.1716-5.4699] 0.8108 [0.0667-2.9794] 0.2808 0.4703 
lysylmethionine 1.3352 [0.1229-6.2667] 0.1495 [0.1229-2.856] 0.0069 0.0418 
lysylphenylalanine 1.1220 [0.0949-6.6373] 0.5839 [0.0554-2.4102] 0.0251 0.0894 
lysylvaline 1.0795 [0.1627-7.9987] 0.7947 [0.0873-5.845] 0.3837 0.5613 
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maleate (cis-Butenedioate) 0.7797 [0.4116-4.1214] 1.0050 [0.7139-2.2136] 0.2998 0.4805 
malonate (propanedioate) 1.1799 [0.1998-5.2286] 0.6125 [0.4086-2.6032] 0.1354 0.2811 
maltol 1.9456 [0.4613-169.3159] 0.7783 [0.122-3.6488] 0.0564 0.1563 
maltose 1.1072 [0.1898-3.1553] 0.7753 [0.0223-23.7012] 0.4551 0.6205 
maltotriose 0.5475 [0.1601-2.6827] 1.2784 [0.1601-73.3269] 0.0808 0.1975 
mannitol 0.4358 [0.4358-1] 0.4358 [0.4358-5.648] 0.6894 0.8098 
mannose 1.0322 [0.1633-1.9984] 0.9678 [0.3113-4.3963] 0.5069 0.6616 
margarate (17:0) 0.8972 [0.6393-1.9519] 1.0306 [0.5941-4.4826] 0.4306 0.5971 
methionine 0.5587 [0.2609-2.2128] 1.5776 [0.3513-6.8466] 0.0161 0.0702 
methionine sulfone 0.3685 [0.2526-4.6328] 0.2526 [0.2526-137.5423] 0.7929 0.8839 
methionine sulfoxide 0.7986 [0.3646-1.7235] 1.0192 [0.3076-7.6077] 0.1844 0.3447 
methionylalanine 0.6625 [0.0787-10.9809] 0.2397 [0.0787-14.176] 0.3130 0.4966 
methionylglutamate 0.3073 [0.0921-4.3703] 0.0921 [0.0921-3.8855] 0.0989 0.2289 
methionylphenylalanine 0.9758 [0.1027-6.2819] 0.9005 [0.1027-15.4082] 0.9339 0.9582 
methionylserine 0.3122 [0.3122-1.6737] 0.3122 [0.3122-3.4606] 0.7293 0.8416 
methionylvaline 1.1352 [0.0579-12.5163] 0.8648 [0.2681-16.0681] 0.9010 0.9379 
methyl indole-3-acetate 1.1436 [0.4862-3.5905] 0.1987 [0.0378-10.5699] 0.0037 0.0269 
methylphosphate 0.6756 [0.1029-4.0833] 2.1897 [0.1029-8.0602] 0.0170 0.0733 
methylsuccinate 1.2118 [0.3609-4.1725] 0.5098 [0.0052-6.1487] 0.0680 0.1790 
mevalonate 0.3868 [0.0472-7.787] 4.2092 [0.0472-43.5754] 0.0114 0.0579 
mevalonolactone 0.4506 [0.1647-9.4323] 2.9927 [0.0526-38.4472] 0.0028 0.0234 
myo-inositol 0.7745 [0.2621-2.0393] 5.3074 [0.2857-10.8425] 0.0037 0.0269 
myristate (14:0) 0.9998 [0.6655-1.6573] 1.1191 [0.6353-7.2903] 0.4553 0.6205 
myristoleate (14:1n5) 1.0535 [0.6644-1.9179] 0.7954 [0.2162-4.8019] 0.3837 0.5613 
N(1)-acetylspermine 0.6589 [0.0105-9.1911] 0.6621 [0.0105-28.6884] 0.8679 0.9196 
N1-Methyl-2-pyridone-5-carboxamide 0.8981 [0.3304-2.2027] 0.6215 [0.3304-2.7688] 0.5011 0.6616 
N1-methylguanosine 0.8149 [0.0386-1.7804] 0.3059 [0.0386-2.8636] 0.6121 0.7537 
N2,N2-dimethylguanine 0.5976 [0.1282-1.7342] 4.9153 [0.127-43.9334] 0.0090 0.0487 
N2,N2-dimethylguanosine 0.3739 [0.3739-0.7571] 0.4611 [0.3739-58.8184] 0.0416 0.1285 
N2-acetyllysine 1.0586 [0.3844-2.3008] 0.9414 [0.0918-5.5017] 0.8357 0.9047 
N6-acetyllysine 0.8721 [0.6339-2.4104] 1.7057 [0.3792-8.769] 0.0564 0.1563 
N6-carbamoylthreonyladenosine 0.2621 [0.2621-1.6474] 0.2621 [0.2621-55.4916] 0.2492 0.4320 
N6-carboxyethyllysine 0.8715 [0.3417-2.5515] 1.3624 [0.0236-2.7891] 0.3837 0.5613 
N6-carboxymethyllysine 0.7880 [0.0861-2.5362] 1.1981 [0.065-12.459] 0.2998 0.4805 
N6-succinyladenosine 0.2829 [0.2829-3.1924] 0.2829 [0.2829-124.8342] 0.6545 0.7784 
N-6-trimethyllysine 0.9628 [0.1098-1.8317] 1.0372 [0.0635-1.9979] 0.3401 0.5248 
N-acetyl-1-methylhistidine* 0.9945 [0.4244-2.1494] 1.1791 [0.1765-4.9063] 0.5338 0.6876 
N-acetyl-3-methylhistidine* 1.5886 [0.0448-8.0379] 0.2304 [0.0448-1.9325] 0.0019 0.0197 
N-acetylalanine 0.4338 [0.0485-1.6109] 1.8869 [0.5046-6.7191] 0.0000 0.0026 
N-acetylarginine 0.7304 [0.3099-1.8675] 1.2235 [0.4105-5.7925] 0.0310 0.1009 
N-acetylaspartate (NAA) 0.8856 [0.0724-6.2627] 0.9280 [0.0724-31.0719] 0.5613 0.7115 
N-acetyl-aspartyl-glutamate (NAAG) 0.5251 [0.1299-1.7086] 2.4408 [0.1299-32.8893] 0.0581 0.1605 
N-acetyl-beta-alanine 1.4453 [0.5939-3.8111] 0.4648 [0.008-3.1774] 0.0009 0.0115 
N-acetyl-cadaverine 0.6898 [0.0797-11.6022] 1.2741 [0.0011-19.9897] 0.2134 0.3851 
N-acetylcarnosine 0.6155 [0.0781-6.0314] 1.2371 [0.0781-17.0273] 0.4543 0.6205 
N-acetylcysteine 0.7513 [0.0594-1.3467] 2.2476 [0.4351-10.4059] 0.0004 0.0069 
N-acetylgalactosamine 0.8668 [0.215-2.9456] 1.2963 [0.1801-58.9752] 0.1585 0.3118 
N-acetylglucosamine 1.4174 [0.2408-6.8372] 0.7807 [0.0906-37.8354] 0.5338 0.6876 
N-acetylglucosamine 6-phosphate 0.4755 [0.4755-0.4755] 0.4755 [0.4755-11.6402] 0.1644 0.3210 
N-acetylglucosamine 6-sulfate 0.0175 [0.0175-4.357] 0.4051 [0.0175-26.3133] 0.0040 0.0281 
N-acetylglutamate 0.9252 [0.3512-2.2829] 1.0891 [0.297-9.4748] 0.2808 0.4703 
N-acetylglutamine 0.7263 [0.2533-2.5408] 1.0294 [0.3521-10.5115] 0.0564 0.1563 
N-acetylglycine 0.5585 [0.047-4.7485] 1.4340 [0.1216-11.9025] 0.0344 0.1092 
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N-acetylisoleucine 0.6130 [0.0838-4.6842] 1.4465 [0.0336-5.1139] 0.2134 0.3851 
N-acetylleucine 0.8454 [0.2084-4.9104] 1.4998 [0.1126-4.519] 0.6187 0.7537 
N-acetylmannosamine 0.4952 [0.1401-2.0868] 1.2288 [0.1401-17.7335] 0.0774 0.1941 
N-acetylmethionine 0.3509 [0.1429-1.8227] 3.6530 [0.7346-16.4718] 0.0000 0.0020 
N-acetylmethionine sulfoxide 0.3287 [0.3287-0.3287] 0.5189 [0.3287-9.2601] 0.0001 0.0032 
N-acetylmuramate 1.4119 [0.3958-6.0812] 0.4223 [0.0532-2.9808] 0.0021 0.0203 
N-acetylneuraminate 0.8988 [0.2108-6.1778] 1.6429 [0.2444-21.1627] 0.1585 0.3118 
N-acetylphenylalanine 1.5671 [0.1504-5.0197] 0.9714 [0.1327-6.0393] 0.4306 0.5971 
N-acetylproline 1.3076 [0.7151-3.2558] 0.5273 [0.1873-4.5547] 0.0128 0.0627 
N-acetylputrescine 0.8990 [0.2833-4.0944] 1.1010 [0.1796-8.0225] 0.6187 0.7537 
N-acetylserine 0.2241 [0.1285-2.0652] 1.9534 [0.3055-15.6268] 0.0004 0.0074 
N-acetylsphingosine 0.9746 [0.0173-15.3395] 0.6240 [0.0157-142.5131] 0.5067 0.6616 
N-acetyltaurine 1.3918 [0.0132-3.1677] 0.8436 [0.0403-4.1067] 0.7715 0.8650 
N-acetylthreonine 0.2316 [0.0773-2.3719] 2.8786 [0.3868-6.6983] 0.0001 0.0033 
N-acetyltryptophan 0.8367 [0.0515-3.4033] 1.4351 [0.459-3.446] 0.0620 0.1665 
N-acetyltyrosine 1.2193 [0.4393-3.7936] 0.5510 [0.1352-2.2527] 0.0181 0.0758 
N-acetylvaline 0.7026 [0.1067-2.4609] 1.0214 [0.0944-2.9926] 0.2455 0.4265 
N-alpha-acetylornithine 1.3724 [0.517-5.8561] 0.3968 [0.0461-2.6473] 0.0008 0.0104 
naringenin 0.9020 [0.2039-32.9711] 1.0980 [0.2455-13.1332] 0.7716 0.8650 
N-carbamoylaspartate 0.2440 [0.244-2.0314] 0.3987 [0.244-104.9065] 0.3110 0.4945 
N-delta-acetylornithine 0.6438 [0.257-1.8602] 3.5042 [0.0527-31.8975] 0.0161 0.0702 
N-formylmethionine 0.7446 [0.2631-1.542] 2.6363 [0.4518-7.3884] 0.0012 0.0147 
N-glycolylneuraminate 1.0550 [0.0632-8.7076] 0.8406 [0.0632-15.7136] 0.7557 0.8557 
nicotianamine 0.9708 [0.0024-18.6832] 0.5751 [0.0024-21.8232] 0.4296 0.5971 
nicotinamide 0.8978 [0.0532-8.6049] 1.2054 [0.0532-12.2132] 0.3835 0.5613 
nicotinamide riboside 0.5659 [0.0793-38.1636] 1.0372 [0.0793-3.0988] 0.5896 0.7349 
nicotinate 1.3413 [0.4594-2.3664] 0.8065 [0.0439-1.9499] 0.0161 0.0702 
nicotinate ribonucleoside 1.5381 [0.0566-39.1645] 0.0698 [0.0566-1.213] 0.0232 0.0869 
N-linoleoylglycine 0.6803 [0.014-3.1316] 1.5579 [0.014-15.2812] 0.1329 0.2805 
N-methyl proline 0.8112 [0.1258-8.4904] 0.6071 [0.1258-1.9264] 0.1296 0.2747 
N-methylhydantoin 1.9446 [0.1037-20.325] 0.8849 [0.1005-19.2922] 0.5069 0.6616 
N-oleoyltaurine 0.2758 [0.0341-1.4989] 1.0549 [0.0341-28.0029] 0.0180 0.0758 
norvaline 1.0000 [0.0428-7.9614] 0.8858 [0.0428-8.0614] 0.7555 0.8557 
N-palmitoyl glycine 0.5228 [0.2135-3.2187] 1.8104 [0.0396-6.5977] 0.0251 0.0894 
N-palmitoyl-sphingosine* 0.6692 [0.2844-1.147] 1.3303 [0.2844-4.1936] 0.0327 0.1057 
N-palmitoyltaurine 0.5120 [0.1012-2.1372] 1.2683 [0.1012-5.6276] 0.0507 0.1472 
N-propionylalanine 1.5742 [0.3046-5.0823] 0.2766 [0.0389-5.8376] 0.0032 0.0254 
N-propionylmethionine 1.0713 [0.2505-11.3137] 0.3414 [0.1176-6.3423] 0.0617 0.1665 
N-stearoyltaurine 0.8310 [0.1628-2.3516] 1.4454 [0.1628-5.0012] 0.3090 0.4930 
O-acetylhomoserine 0.8254 [0.1321-3.368] 1.8185 [0.0943-14.0272] 0.5614 0.7115 
O-acetylserine 0.1962 [0.1962-1.4774] 0.3300 [0.1962-2.282] 0.1051 0.2391 
oleanolate 0.8285 [0.0399-6.1293] 0.0827 [0.0399-10.863] 0.2391 0.4210 
oleate (18:1n9) 0.9748 [0.4464-2.0824] 2.0593 [0.0577-7.5303] 0.5897 0.7349 
oleic ethanolamide 0.7977 [0.2461-2.9401] 1.9369 [0.0021-5.2536] 0.1150 0.2578 
oleoylcarnitine 0.2725 [0.2725-1.62] 0.2725 [0.2725-12.4497] 0.8587 0.9196 
oleoyl-linoleoyl-glycerol 1.3578 [0.1603-3.5371] 0.1110 [0.0169-6.896] 0.0225 0.0848 
oleoyl-linoleoyl-glycerophosphocholine (1)* 0.2789 [0.2789-1.2705] 0.2789 [0.2789-7.8669] 0.5331 0.6876 
oleoyl-linoleoyl-glycerophosphocholine (2)* 0.4134 [0.4134-1] 0.4134 [0.4134-9.4138] 0.9162 0.9525 
O-methylcatechol sulfate 0.4697 [0.4697-4.4151] 0.4697 [0.4697-1.4407] 0.3616 0.5391 
ornithine 0.3192 [0.049-4.9304] 1.9113 [0.1833-13.0951] 0.0055 0.0364 
orotate 0.4025 [0.0629-2.1987] 2.7536 [0.0316-34.3761] 0.0048 0.0325 
orotidine 0.0136 [0.0136-8.232] 0.5922 [0.0136-1.7869] 0.0024 0.0217 
O-sulfo-L-tyrosine 0.0558 [0.0558-1.7598] 0.7690 [0.0558-9.5363] 0.0107 0.0562 
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palmitate (16:0) 0.8738 [0.6445-1.4488] 1.1657 [0.6272-5.5555] 0.0564 0.1563 
palmitoleate (16:1n7) 0.7638 [0.2776-1.9332] 1.2307 [0.1351-23.6481] 0.4306 0.5971 
palmitoyl ethanolamide 0.6569 [0.2707-2.5249] 2.2235 [0.0162-4.8556] 0.0310 0.1009 
palmitoyl sphingomyelin 0.2987 [0.1834-1.5733] 1.3561 [0.1834-6.355] 0.0107 0.0562 
palmitoyl-arachidonoyl-glycerophosphocholine (1)* 0.3472 [0.3472-1.1809] 0.3472 [0.3472-7.603] 0.5331 0.6876 
palmitoyl-arachidonoyl-glycerophosphocholine (2)* 0.2188 [0.2188-1.4614] 0.2188 [0.2188-7.2173] 0.1249 0.2670 
palmitoylcarnitine 0.1719 [0.1144-5.5893] 0.5949 [0.1144-10.569] 0.4110 0.5860 
palmitoyl-linoleoyl-glycerophosphocholine (1)* 0.4384 [0.4384-1.2896] 0.4384 [0.4384-33.038] 0.7797 0.8729 
palmitoyl-linoleoyl-glycerophosphocholine (2)* 0.4885 [0.4885-1.5857] 0.4885 [0.4885-30.9862] 0.3416 0.5261 
palmitoyl-oleoyl-glycerophosphocholine (1)* 0.3145 [0.3145-1.1449] 0.3145 [0.3145-30.1359] 0.5736 0.7258 
p-aminobenzoate (PABA) 1.9048 [0.8011-4.3147] 0.0673 [0.0198-1.9903] 0.0000 0.0017 
pantothenate 1.5497 [0.3013-6.0816] 0.6014 [0.0994-2.2786] 0.0279 0.0947 
p-coumaroylserotonin 0.2771 [0.0537-33.7006] 0.0537 [0.0537-4.0689] 0.2677 0.4591 
p-cresol sulfate 0.3499 [0.3499-1] 0.3499 [0.3499-233.6838] 0.0750 0.1908 
pentadecanoate (15:0) 0.9112 [0.7594-2.1785] 1.0055 [0.48-2.64] 0.6783 0.7979 
phenethylamine 0.6548 [0.0883-8.9461] 1.3102 [0.0094-7.7202] 0.3615 0.5391 
phenol sulfate 0.4352 [0.0348-5.3274] 0.0348 [0.0348-7.171] 0.2509 0.4340 
phenylacetate 1.3037 [0.2174-5.3579] 0.5826 [0.0247-13.7593] 0.1349 0.2811 
phenylacetylglutamine 0.1065 [0.0327-8.4714] 1.0521 [0.0327-18.5244] 0.0528 0.1512 
phenylacetylglycine 0.4816 [0.0295-1.6398] 1.3304 [0.0295-23.6781] 0.0259 0.0918 
phenylalanine 0.5339 [0.1921-2.0425] 1.4257 [0.3072-4.2043] 0.0310 0.1009 
phenylalanylalanine 0.9739 [0.1111-6.7027] 1.0261 [0.1951-6.1052] 0.8357 0.9047 
phenylalanylarginine 0.9345 [0.1488-6.7595] 0.9617 [0.1488-32.3949] 0.7872 0.8788 
phenylalanylaspartate 0.6665 [0.1661-6.3828] 1.0012 [0.2662-5.4103] 0.5069 0.6616 
phenylalanylglutamate 0.5198 [0.1405-5.5148] 1.2352 [0.0283-4.0054] 0.6187 0.7537 
phenylalanylglycine 1.2705 [0.1302-4.3107] 0.9490 [0.2299-3.2324] 0.8682 0.9196 
phenylalanylhistidine 0.4872 [0.1342-4.2065] 0.2142 [0.1342-7.1927] 0.7620 0.8604 
phenylalanylisoleucine 1.3217 [0.0288-7.3781] 0.7816 [0.0159-6.5117] 0.1711 0.3276 
phenylalanylleucine 1.7420 [0.0093-8.5977] 0.8275 [0.1548-10.3683] 0.6187 0.7537 
phenylalanylmethionine 1.2140 [0.0078-8.8769] 0.5588 [0.0078-9.8138] 0.3506 0.5348 
phenylalanylphenylalanine 0.6430 [0.0636-4.8454] 0.8098 [0.0636-5.6553] 1.0000 1.0000 
phenylalanylproline 0.6644 [0.1628-2.9365] 1.6147 [0.4955-4.8604] 0.0202 0.0811 
phenylalanylserine 1.0212 [0.3605-4.198] 0.9327 [0.3684-4.0344] 0.9669 0.9743 
phenylalanyltryptophan 0.8775 [0.1285-8.9087] 0.5133 [0.1285-12.491] 0.7376 0.8416 
phenylalanyltyrosine 1.8015 [0.0223-7.8066] 0.7619 [0.0223-11.478] 0.2371 0.4193 
phenylalanylvaline 1.0759 [0.1015-5.7194] 0.8475 [0.2528-5.0676] 0.7400 0.8416 
phenyllactate (PLA) 0.3812 [0.0667-12.3408] 2.7132 [0.2201-19.4645] 0.0101 0.0539 
phenylpyruvate 1.0228 [0.1113-4.947] 0.6468 [0.0005-10.1771] 0.8682 0.9196 
phosphate 1.0724 [0.627-2.868] 0.7021 [0.1805-12.4677] 0.1985 0.3659 
phytosphingosine 1.1139 [0.0501-6.5097] 0.7563 [0.0561-37.6992] 0.9669 0.9743 
picolinate 1.1109 [0.2772-5.4655] 0.8785 [0.1903-1.5648] 0.0310 0.1009 
pimelate (heptanedioate) 2.3634 [0.3449-4.9568] 0.5551 [0.1773-2.3047] 0.0003 0.0065 
pinitol 0.2871 [0.2871-40.7924] 0.2871 [0.2871-2.1382] 0.1289 0.2741 
pipecolate 1.1938 [0.5257-2.0873] 0.4045 [0.0386-1.7485] 0.0009 0.0115 
piperidine 1.0000 [0.151-5.6826] 0.6844 [0.0111-21.027] 0.6783 0.7979 
piperine 0.1011 [0.1011-4.7398] 0.1011 [0.1011-1.9148] 0.9527 0.9724 
pro-hydroxy-pro 0.4754 [0.0557-4.6209] 2.0537 [0.1134-189.6809] 0.0070 0.0418 
proline 0.8310 [0.3493-2.092] 1.9242 [0.4733-15.9081] 0.0128 0.0627 
prolylalanine 0.7082 [0.2686-7.3193] 1.8303 [0.5473-16.7984] 0.0070 0.0418 
prolylglutamine 0.3993 [0.202-14.4046] 1.7645 [0.202-8.5347] 0.0220 0.0848 
prolylphenylalanine 0.7570 [0.3429-1.8096] 1.9169 [0.523-4.5023] 0.0062 0.0399 
prolylproline 0.6595 [0.3692-1.4203] 3.2255 [0.6759-108.767] 0.0003 0.0065 
prolyltyrosine 0.5422 [0.1614-1.422] 2.3739 [0.3817-7.1006] 0.0005 0.0076 
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propionylcarnitine 1.0526 [0.05-3.9265] 0.4648 [0.05-7.7325] 0.3090 0.4930 
propionylglycine 1.0636 [0.0878-8.2795] 0.9006 [0.0339-8.935] 0.4068 0.5810 
pseudouridine 1.4586 [0.0701-3.1938] 0.7967 [0.0394-3.8934] 0.2455 0.4265 
pterin 1.5053 [0.4021-3.0586] 0.2751 [0.0301-4.9594] 0.0021 0.0203 
putrescine 0.8324 [0.0288-12.5031] 2.0441 [0.0288-14.4983] 0.3095 0.4930 
pyridoxal 1.2049 [0.3797-2.7078] 0.4337 [0.0213-1.8149] 0.0128 0.0627 
pyridoxate 1.2419 [0.7619-1.8982] 0.2778 [0.0157-1.6155] 0.0001 0.0043 
pyridoxine (Vitamin B6) 0.5446 [0.0781-7.4113] 1.0378 [0.0781-4.7373] 0.2995 0.4805 
pyroglutamine* 1.1145 [0.0422-7.5981] 0.4273 [0.0616-4.4217] 0.4553 0.6205 
pyroglutamylglycine 0.6904 [0.1929-2.0462] 1.8585 [0.6691-12.4286] 0.0007 0.0098 
pyroglutamylvaline 0.8788 [0.2306-1.9954] 2.5757 [0.4433-10.6917] 0.0971 0.2254 
pyruvate 0.1485 [0.0248-8.1992] 1.5872 [0.0039-8.3821] 0.0202 0.0811 
quinate 0.8080 [0.3159-3.7971] 1.2756 [0.0628-66.104] 0.5897 0.7349 
quinolinate 0.6781 [0.1179-3.1273] 0.7877 [0.1179-22.9225] 0.4920 0.6552 
rhamnose 0.5895 [0.3459-7.8159] 0.9114 [0.3459-4.9648] 0.8514 0.9159 
ribitol 0.4744 [0.4744-1.412] 0.4744 [0.4744-2.0834] 0.8855 0.9367 
riboflavin (Vitamin B2) 2.5792 [0.2572-7.661] 0.3963 [0.0592-5.125] 0.0251 0.0894 
ribonate 0.8504 [0.1249-2.5194] 1.6296 [0.1902-5.9166] 0.0225 0.0848 
ribose 1.2090 [0.3361-2.8198] 0.5586 [0.0318-4.7704] 0.0181 0.0758 
ribulose 1.2708 [0.0608-5.6768] 0.6469 [0.0608-8.2404] 0.2778 0.4703 
R-mevalonate 5-diphosphate 0.2610 [0.1037-3.1183] 0.9092 [0.1037-70.3439] 0.1735 0.3314 
S-(3-hydroxypropyl)mercapturic acid (HPMA) 0.1304 [0.1304-9.2628] 1.0833 [0.1304-15.2403] 0.0037 0.0270 
saccharopine 0.2718 [0.2718-1.1167] 0.5019 [0.2718-5.9352] 0.0041 0.0291 
S-adenosylmethionine (SAM) 0.0779 [0.0779-1.4994] 0.2053 [0.0779-4.8184] 0.0490 0.1439 
salicylate 1.7308 [0.6189-3.9826] 0.3478 [0.1832-1.3077] 0.0000 0.0016 
sebacate (decanedioate) 1.8117 [0.7936-8.6909] 0.8071 [0.2274-4.2893] 0.0021 0.0203 
secoisolariciresinol 0.2646 [0.0762-231.7039] 0.0762 [0.0762-41.3022] 0.4310 0.5971 
secoisolariciresinol diglucoside 0.0395 [0.0395-14.8732] 0.0395 [0.0395-48.4019] 0.2184 0.3933 
serine 0.6361 [0.268-2.3248] 1.6584 [0.5586-6.4986] 0.0161 0.0702 
serotonin (5HT) 1.0000 [0.3561-3.1485] 0.9156 [0.0986-3.3409] 0.8357 0.9047 
serylisoleucine 1.0738 [0.1788-7.8245] 0.9806 [0.0509-4.8537] 0.7089 0.8229 
serylleucine 1.1194 [0.1626-4.808] 0.8806 [0.2988-3.8626] 0.8357 0.9047 
serylmethionine 1.1171 [0.1708-4.6912] 0.7480 [0.0957-6.0954] 0.3615 0.5391 
serylphenyalanine 0.8351 [0.089-4.4473] 1.1649 [0.073-4.974] 0.8357 0.9047 
serylproline 0.4696 [0.0625-2.0917] 1.1419 [0.2442-5.9571] 0.0202 0.0811 
seryltyrosine 0.8363 [0.0668-3.5505] 1.0391 [0.0486-3.9364] 0.9339 0.9582 
serylvaline 0.9201 [0.275-7.5363] 1.0799 [0.0432-4.6082] 0.6482 0.7729 
sinapate 1.3864 [0.3205-6.7161] 0.3201 [0.0252-2.0517] 0.0160 0.0702 
sitostanol  1.5717 [0.4157-2.3312] 0.1008 [0.0963-0.5215] 0.0000 0.0011 
solanidine 0.0350 [0.035-2.4356] 0.0350 [0.035-839.7977] 0.1028 0.2367 
spermidine 1.7785 [0.0132-6.4075] 0.5448 [0.0245-15.963] 0.0745 0.1904 
spermine 1.0000 [0.0928-10.5148] 0.2486 [0.0928-220.103] 0.7376 0.8416 
sphinganine 0.5691 [0.0145-3.8369] 1.8859 [0.0126-7.4785] 0.1249 0.2670 
sphingosine 0.5914 [0.0184-3.8582] 2.4597 [0.0088-10.4542] 0.2290 0.4078 
stachydrine 1.8420 [0.0392-3.9074] 0.2314 [0.0082-4.5176] 0.0564 0.1563 
stearate (18:0) 0.8805 [0.6107-1.1521] 1.3202 [0.6258-2.9426] 0.0025 0.0217 
stearidonate (18:4n3) 0.9717 [0.1105-5.1855] 1.4701 [0.042-33.8738] 0.8035 0.8856 
stearoyl ethanolamide 0.7504 [0.239-4.7974] 1.6622 [0.2024-24.373] 0.1354 0.2811 
stearoyl-arachidonoyl-glycerophosphocholine (1)* 0.4470 [0.447-0.447] 0.4470 [0.447-1.553] 0.3506 0.5348 
stearoyl-arachidonoyl-glycerophosphocholine (2)* 0.6880 [0.688-0.688] 0.6880 [0.688-1.312] 0.3506 0.5348 
stearoylcarnitine 0.1034 [0.1034-3.6945] 0.9726 [0.1034-7.5588] 0.0761 0.1913 
suberate (octanedioate) 1.3504 [0.6417-3.3989] 0.8038 [0.4233-1.947] 0.0090 0.0487 
succinate 0.1246 [0.0415-4.7919] 1.7903 [0.4471-10.7129] 0.0079 0.0453 




Healthy Chronic Enteropathy   
Median Range Median Range p-value q-value 
succinylcarnitine 0.8544 [0.0117-6.6029] 1.0745 [0.0329-23.3082] 0.3401 0.5248 
sulfate* 0.9941 [0.5677-2.5718] 1.0059 [0.0032-7.5965] 0.6482 0.7729 
symmetric dimethylarginine (SDMA) 0.4706 [0.0333-3.61] 0.9660 [0.0333-4.6147] 0.5862 0.7349 
syringic acid 2.2895 [0.4455-66.7552] 0.2637 [0.0763-1.4336] 0.0000 0.0018 
taurine 0.7111 [0.0609-3.6556] 1.0841 [0.2994-5.8539] 0.1249 0.2670 
tauro-alpha-muricholate 0.0263 [0.0263-6.9685] 1.1150 [0.0263-20.2105] 0.0216 0.0848 
tauro-beta-muricholate 0.7756 [0.072-17.6249] 0.4522 [0.072-21.957] 0.8505 0.9159 
taurochenodeoxycholate 0.5053 [0.0839-8.3797] 1.0000 [0.0839-80.9337] 0.8518 0.9159 
taurocholate 1.3417 [0.247-13.0527] 0.9403 [0.0556-15.285] 0.2998 0.4805 
taurodeoxycholate 1.4618 [0.2589-26.1331] 0.5325 [0.0286-20.4489] 0.1985 0.3659 
taurohyodeoxycholic acid 0.7659 [0.0276-13.2326] 0.6211 [0.0276-23.6901] 0.4510 0.6205 
taurolithocholate 0.6622 [0.0157-10.4824] 0.1251 [0.0157-33.1628] 0.5577 0.7115 
tauroursodeoxycholate 0.1261 [0.0367-8.255] 1.0025 [0.0367-71.4848] 0.0436 0.1322 
thiamin (Vitamin B1) 1.5225 [0.668-5.1574] 0.0932 [0.0063-6.2646] 0.0008 0.0104 
threitol 0.9548 [0.3853-2.2913] 0.8921 [0.3853-3.5623] 0.9337 0.9582 
threonate 1.1130 [0.31-3.4249] 0.7446 [0.1526-3.4797] 0.2290 0.4078 
threonine 0.6360 [0.3581-2.1626] 1.6459 [0.3514-9.0978] 0.0144 0.0670 
threonylalanine 1.0237 [0.2757-4.5588] 0.8852 [0.1425-4.876] 0.6482 0.7729 
threonylarginine 1.1587 [0.3798-3.9215] 0.2419 [0.0435-5.2722] 0.0032 0.0254 
threonylglutamate 0.7160 [0.1706-4.8473] 1.3970 [0.3686-2.4215] 0.1585 0.3118 
threonylisoleucine 1.3195 [0.2382-6.4691] 0.9655 [0.0273-3.2296] 0.2628 0.4515 
threonylleucine 1.1307 [0.12-4.7641] 0.6531 [0.3014-4.4628] 0.2808 0.4703 
threonylmethionine 1.4567 [0.0493-5.3704] 0.5121 [0.0826-4.3955] 0.0564 0.1563 
threonylphenylalanine 1.7825 [0.136-4.9575] 0.4680 [0.1889-4.3914] 0.1711 0.3276 
threonylproline 0.4778 [0.1063-3.3413] 1.8665 [0.4644-6.8027] 0.0465 0.1370 
threonylvaline 1.1681 [0.2944-6.6518] 0.9873 [0.0633-5.5623] 0.8357 0.9047 
thymidine 1.9487 [0.5523-3.6203] 0.5942 [0.0316-3.4646] 0.0225 0.0848 
thymine 1.0605 [0.203-1.8905] 0.6005 [0.1459-5.0098] 0.1249 0.2670 
trans-4-hydroxyproline 0.9616 [0.148-2.1927] 1.3823 [0.0517-10.3233] 0.5069 0.6616 
trans-urocanate 0.9326 [0.2668-8.6345] 1.2439 [0.0924-4.8684] 0.8357 0.9047 
trigonelline (N'-methylnicotinate) 1.0112 [0.534-1.8551] 0.8812 [0.0987-4.4939] 0.9010 0.9379 
tryptamine 1.0000 [0.1618-3.0142] 0.8686 [0.0003-9.7774] 0.7715 0.8650 
tryptophan 0.4425 [0.0862-2.5983] 1.3262 [0.0897-4.443] 0.0564 0.1563 
tryptophan betaine  0.0234 [0.0234-7.6442] 0.0234 [0.0234-2.9842] 0.0289 0.0977 
tryptophylalanine 0.9884 [0.0667-5.7616] 0.7126 [0.0667-8.518] 0.7086 0.8229 
tryptophylasparagine 1.1608 [0.046-4.8279] 0.7861 [0.046-9.588] 1.0000 1.0000 
tryptophylglutamate 1.0225 [0.0663-4.5107] 0.8325 [0.0663-3.7091] 0.6333 0.7680 
tryptophylglycine 0.8059 [0.0698-6.4736] 1.0143 [0.1256-4.7842] 0.6482 0.7729 
tryptophylisoleucine 1.0000 [0.0317-10.0961] 0.9629 [0.0317-19.7158] 0.6183 0.7537 
tryptophylleucine 1.1263 [0.0689-4.5726] 0.6669 [0.106-7.3649] 1.0000 1.0000 
tryptophylphenylalanine 0.8741 [0.0825-3.0225] 0.4682 [0.0825-4.0338] 0.8991 0.9379 
tryptophylproline 0.3306 [0.0494-2.1671] 1.3504 [0.3355-10.0309] 0.0048 0.0325 
tryptophylvaline 0.7843 [0.0175-4.3806] 1.1528 [0.0175-7.0999] 1.0000 1.0000 
tyramine 0.4440 [0.1364-17.5679] 11.9819 [0.0128-30.528] 0.0014 0.0165 
tyrosine 1.2134 [0.3966-4.9352] 0.6149 [0.1736-5.7459] 0.0680 0.1790 
tyrosol 1.0025 [0.3722-6.2362] 0.9790 [0.1503-4.4203] 0.4553 0.6205 
tyrosylalanine 0.9462 [0.0586-5.7727] 1.0122 [0.1629-8.0887] 0.4807 0.6423 
tyrosylarginine 0.7857 [0.2878-5.0722] 0.5556 [0.2878-30.2616] 0.8179 0.9002 
tyrosylglutamate 0.6056 [0.0874-4.0663] 1.1150 [0.0783-4.7509] 0.2998 0.4805 
tyrosylglutamine 0.9740 [0.0303-4.1567] 1.0000 [0.0303-5.2093] 0.6632 0.7872 
tyrosylglycine 1.0169 [0.1466-2.6642] 0.7521 [0.3542-3.5576] 0.8035 0.8856 
tyrosylisoleucine 1.1238 [0.1154-4.326] 0.8143 [0.0874-4.5415] 0.9669 0.9743 
tyrosylleucine 1.0555 [0.0445-5.8718] 0.8997 [0.0721-7.6498] 0.7400 0.8416 
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tyrosylphenylalanine 0.2831 [0.0318-5.3619] 0.1854 [0.0318-8.3315] 0.7620 0.8604 
tyrosyltyrosine 0.9059 [0.0732-5.4201] 0.7157 [0.0732-11.6181] 0.9502 0.9724 
tyrosylvaline 1.1316 [0.108-5.6607] 0.8476 [0.3471-5.1217] 0.9669 0.9743 
undecanedioate 1.8052 [0.8091-3.0282] 0.5537 [0.2821-2.2488] 0.0002 0.0050 
uracil 1.5127 [0.2511-4.4562] 0.5772 [0.0907-4.8754] 0.0421 0.1285 
urate 1.1064 [0.3069-3.8631] 0.7644 [0.1605-19.5307] 0.5338 0.6876 
uridine 1.4232 [0.2623-3.4162] 0.2316 [0.0451-5.9544] 0.0310 0.1009 
ursodeoxycholate 2.1302 [0.4259-7.3884] 0.5555 [0.0097-7.376] 0.0279 0.0947 
valerate 1.1264 [0.4982-4.3892] 0.1348 [0.0501-3.522] 0.0025 0.0217 
valine 0.4427 [0.1662-1.8432] 1.7055 [0.3998-6.5297] 0.0028 0.0234 
val-val-val 0.3744 [0.0071-3.9804] 1.0569 [0.0071-4.7791] 0.1583 0.3118 
valylalanine 1.0480 [0.3243-4.0153] 0.9695 [0.1738-4.7968] 0.9010 0.9379 
valylarginine 0.9471 [0.122-12.5435] 0.2081 [0.122-16.2534] 0.2072 0.3798 
valylasparagine 1.8367 [0.0482-7.2386] 0.7536 [0.126-2.9738] 0.2998 0.4805 
valylaspartate 0.7566 [0.2051-4.7998] 1.1461 [0.3955-3.146] 0.2454 0.4265 
valylglutamate 1.0157 [0.2464-2.399] 0.9843 [0.2725-2.5639] 0.5897 0.7349 
valylglutamine 0.6735 [0.1525-2.3502] 1.0667 [0.2987-3.2481] 0.3401 0.5248 
valylglycine 1.1147 [0.3569-2.8736] 0.8853 [0.2567-3.7152] 0.9339 0.9582 
valylhistidine 0.4528 [0.0235-2.9274] 1.0910 [0.0235-10.2651] 0.1701 0.3276 
valylisoleucine 1.1198 [0.1326-6.8543] 0.8119 [0.047-4.1109] 0.5614 0.7115 
valylleucine 1.2268 [0.1639-4.5565] 0.7119 [0.2188-3.3866] 0.2290 0.4078 
valyllysine 1.3923 [0.0875-7.3626] 0.7605 [0.0875-11.485] 0.2540 0.4383 
valylmethionine 1.3388 [0.1484-3.7028] 0.8947 [0.1219-4.6306] 0.3401 0.5248 
valylphenylalanine 1.1689 [0.0984-4.1062] 0.7379 [0.2-4.994] 0.8035 0.8856 
valylserine 0.9016 [0.2215-3.3537] 1.0984 [0.1228-3.9326] 0.8035 0.8856 
valylthreonine 0.8029 [0.1869-4.2412] 1.3239 [0.3871-8.4219] 0.0971 0.2254 
valyltryptophan 1.4044 [0.0875-4.1927] 0.8130 [0.3676-4.485] 0.8035 0.8856 
valyltyrosine 1.1025 [0.0229-5.0358] 0.6055 [0.0229-6.5121] 0.4805 0.6423 
valylvaline 1.0557 [0.307-6.458] 0.9230 [0.1713-3.9734] 0.6187 0.7537 
vanillate 1.3059 [0.3711-29.6286] 0.8183 [0.0808-2.2396] 0.0564 0.1563 
xanthine 0.9482 [0.1918-2.3439] 1.0382 [0.0238-4.5447] 0.9669 0.9743 
xanthosine 1.0384 [0.0172-7.2495] 0.0172 [0.0172-3.5994] 0.0153 0.0702 
xanthurenate 0.7430 [0.2069-11.0592] 5.4403 [0.1734-203.8674] 0.1349 0.2811 
xylitol 0.0734 [0.0734-2.2296] 0.7697 [0.0734-2.9365] 0.0511 0.1472 
xylonate 0.2347 [0.1608-1.3682] 2.5596 [0.1608-5.0613] 0.0083 0.0470 
xylose 3.2865 [0.5342-15.8302] 0.4246 [0.0779-1.4695] 0.0000 0.0016 
 
